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Abstract: 
Cardiac catheterizations are an essential procedure in the management of patients 
with congenital and acquired heart conditions. However, associated radiation doses 
are often high, raising concerns over potentially increased cancer risks. Neither the 
radiation doses, nor the associated risks, have been adequately investigated in 
young people undergoing these procedures.  
A cohort was established of around 13,500 patients aged under 22 years who have 
undergone cardiac catheterizations in England. Organ doses were estimated based 
on a dosimetry system utilising data from Monte Carlo simulations. Doses were 
highest for the lungs (median: 17.6 millisieverts, mSv) and heart (13.6 mSv), while 
doses to bone marrow (2.6 mSv) and the thyroid (0.7 mSv) were relatively low. 
Radiation doses have fallen by a factor of up to ten during the study period. The 
results were compared to equivalent figures derived from physical measurements. 
Uncertainties in dose estimates were calculated. These were around ±30%, though 
were potentially much higher for breast dose. 
The risk of cancer in relation to estimated doses was calculated using BEIR VII risk 
models. For examinations conducted using modern equipment, these risks are 
around 1 in 1700. A small epidemiological analysis was performed, suggesting a 
nearly threefold increased risk of cancer in the cohort, compared to the general UK 
population. There are a number of reasons to suggest that this increase was primarily 
not related to radiation exposure, most notably the large impact of transplantation and 
likely associated immunosuppressant use. Despite the high cancer incidence, the 
overall survival in the cohort was high, at around 91% after 30 years.  
Conclusion: The study provides the first large scale estimation of organ doses from 
cardiac catheterizations among this age group. Rates of cancer among this patient 
group are high, although this is appears to be mostly due to factors other than 
radiation exposure. 
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1: Introduction 
This study examines the radiation doses and associated risks from cardiac 
catheterizations. These are procedures used for diagnosing and treating congenital 
and acquired heart conditions using a wire-like tube threaded through blood vessels 
under the guidance of a type of x-ray imaging called fluoroscopy. The procedure is an 
essential part of the management of congenital heart disease [1, 2]. The ability to 
diagnose and treat various congenital heart conditions using cardiac catheterizations 
comes at the price of a relatively high radiation exposure, which is associated with an 
increased lifetime risk of developing cancer [3]. However, epidemiological evidence 
of the cancer risks from cardiac catheterizations is limited to a few small, inconclusive 
studies [4-6]. Risk estimates are currently based on age-adjusted models derived 
from studies of Japanese atomic bomb survivors [7], suggesting a lifetime risk of 
cancer mortality from paediatric cardiac catheterization procedures of around 0.08% 
[8] (1 in 1250). The recent findings of increased risk of leukaemia following CT scans 
in childhood [9] are compatible with these estimates. However, along with a large 
scope for dose variation from one procedure to the next [10, 11], cardiac 
catheterizations result in a unique energy deposition pattern, with a high dose being 
delivered to a small volume. The transferability of risk estimates derived from CT or 
atomic bomb survivors may, therefore, be unreliable.  
Faced with this uncertainty, researchers have turned to biodosimetric methods in 
which DNA damage is directly assessed from blood samples acquired following 
exposures [12-14]. These results indicate that the risks may be considerably higher 
than thought – around 0.4% [12]. This finding emphasises the need for a direct 
epidemiological assessment of the cancer risks specifically from cardiac 
catheterizations. Such an approach requires the following components; (1) 
establishing a well-characterised cohort of patients who have undergone cardiac 
catheterization procedures, (2) determination of the radiation doses these patients 
have received and (3) long-term follow-up of the cohort to assess cancer incidence 
and establish a dose/risk relationship. The rationale for focusing specifically on young 
patients is that the relatively low incidence of cancer in young people combined with 
the relative lack of confounding factors of cancer in this age range allows a greater 
statistical power in epidemiological analysis and longer follow-up time available for 
study. Furthermore, young patients with congenital heart conditions often undergo 
multiple procedures, resulting in potentially large cumulative doses. Information on 
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radiation doses from paediatric cardiac catheterizations is currently limited (previous 
research is reviewed in Chapter 2). 
The following sections introduce the basic principles of fluoroscopy, before describing 
the application of this type of x-ray imaging in cardiology. Finally, a brief summary of 
the current knowledge of the risks from low dose exposure to x-rays is provided. 
 
1.1: Fluoroscopy 
Fluoroscopy is an x-ray imaging system, developed soon after the discovery of x-rays 
by Röntgen in 1895 [15], that produces immediately viewable, dynamic, movie-like 
images [16]. This contrasts with general radiography (i.e. ‘normal’ x-ray imaging) in 
which a static image is recorded on film, which must be processed before viewing. As 
the dose per single image or ‘frame’ (akin to the frame of a movie reel) is relatively 
low, fluoroscopy is useful for situations in which simple verification of position is 
required without the need for high image quality. Such applications include 
orthopaedic surgery (alignment of screws and nails etc.), barium studies and the 
positioning of intravascular catheters. Most fluoroscopy systems also allow higher 
quality ‘cine acquisition’ imaging. The use of the word 'cine' harks back to the olden 
days where images were recorded on rolls of cine film for later viewing, although 
modern imaging systems record the images digitally. Acquisitions usually involve 
administration of iodine-based contrast agent (i.e. ‘x-ray dye’) which increases the 
attenuation properties of blood, increasing contrast between enhanced vessels and 
surrounding soft tissues. Other contrast agents, such as barium, may also be used, 
though not intravenously. Non-acquisition fluoroscopy is not usually permanently 
recorded, although modern equipment often features a ‘fluoro-grab’ function in which 
fluoroscopic images can be recorded. Despite this capability, the vast majority of 
recorded images are acquisitions and most fluoroscopic images are essentially lost 
forever once the procedure ends. 
Fluorescent materials absorb x-ray photons before re-emitting the absorbed energy 
as new photons at visible light wavelengths. Briefly, this process occurs when an 
orbiting electron of the fluorescent material is excited by a secondary electron 
liberated by an x-ray, elevating it to the conduction band. The electron becomes 
trapped in the forbidden gap, before returning to a lower energy level, emitting a 
photon of visible light [17]. These visible light emissions from the fluorescent layer 
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can be viewed by the human eye as an image, although under normal x-ray fluence 
the intensity of light emitted is still quite low, producing an unacceptably dim image 
[17]. Modern fluoroscopy systems (post 1950s) utilise a sort of night-vision scope 
called an image intensifier to amplify this signal (Figure 1.1). Light photons emitted by 
the fluorescent layer strike a photocathode releasing electrons, which are accelerated 
by a 25-30 kV electric field onto an output screen where they are again converted into 
photons of visible light. The efficiency of the photocathode is around 10% [18], with 
around 300 electrons being released for a 60 keV incident x-ray photon. Further 
intensity gain is achieved by the demagnification of the image [18], as the output 
screen is around ten times smaller than the input screen. Under ‘magnification mode’ 
a larger output window size is used, meaning greater x-ray fluence is required to 
maintain the same signal strength [19]. Output from the image intensifer can be 
recorded by a video camera and immediately displayed on a television monitor. 
Alternatively, images may be recorded digitally, or on x-ray film to produce a 
permanent record. 
The most commonly used fluorescent material is caesium iodide (CsI), arranged in 
closely packed needle-like crystal columns that function as ‘light pipes’ to channel 
fluorescence photons towards the photocathode without divergence [16]. This allows 
a relatively thick CsI crystal to be used without compromising spatial resolution. 
Furthermore, the k-edges of 36.0 keV (Cs) and 33.2 keV (I) correspond to typical 
photon energies used in diagnostic imaging [17], resulting in a high fractional 
absorption of x-rays (η≈0.85) [20] and high quantum detective efficiency (DQE). For 
each 60 keV x-ray photon absorbed, around 3000 violet light photos of 420 nm 
wavelength (≈ 3 eV) are emitted [16].  
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Figure 1.1: Main features of an image intensifier. Figure credit: author 
 
In recent years, image intensifiers have begun to be replaced by digital, or ‘flat panel’ 
detectors (FPD). FPDs have also replaced film-screen and (to a certain extent) 
computed radiography (CR) detection methods in general radiography. In this sense 
the distinction between fluoroscopy and general radiography has become somewhat 
blurred. There are two types of FPD; ‘Indirect conversion’ digital detectors are 
comprised of a CsI fluorescent layer backed by an integrated active matrix array 
(AMA) of hydrogenated amorphous silicon (a-Si:H) [18] (Figure 1.2). Light photons 
emitted by the CsI layer release charge carriers (electrons or holes) in the a-Si:H 
layer which are stored in local capacitors and in turn read sequentially [20]. In ‘direct 
conversion’ digital detectors, x-ray photons are converted to electrons by an 
amorphous selenium (a-Se) photoconductive layer, backed by an integrated a-Si 
AMA layer. Direct conversion detectors allow improved spatial resolution compared to 
indirect conversion detectors, as measured by the modulation transfer function 
(MTF). However, with a relatively low k-edge of 13 keV, a-Se detectors have a poorer 
fractional absorption of x-rays (η≈0.6), meaning the dose efficiency, defined by the 
DQE, is lower [20]. 
5 
 
 
Figure 1.2: Cross section of indirect conversion digital detectors. Figure credit: author 
 
FPDs have a more uniform response across the detector area than image intensifier-
based systems, with no distortion and minimal veiling glare [19, 21, 22]. The impact 
of FPDs on radiation doses is difficult to determine, with research suggesting no 
impact, reduced doses [21, 22] and increased doses, compared to image intensifiers. 
The methodology of such studies invariably involves comparison of entire systems, of 
which the detector is just one component. If the x-ray tube, collimator, table, filtration 
and generator are also different, changes to dose indicators, such as kerma area 
product (PKA, defined in Chapter 2) should not be attributed to the detector alone. 
Patient dose for a given value of PKA is strongly dependent on beam energy (see 
Chapter 4). Therefore a ‘dose reduction’, as represented by reduced PKA, may not 
indicate a true change to patient dose if beam energy has changed between systems.  
In most modern fluoroscopy systems, the detector and x-ray tube are joined together 
in a ‘C-arm’ configuration (actually it looks more like a ‘G’ or 'Ω') (Figure 1.3), with 
separate monitors providing real-time image display. Most systems have two such C-
arms; one frontal (anterior-posterior, or AP) and one lateral. This so-called ‘bi-plane’ 
arrangement allows rapid switching between frontal and lateral imaging without the 
need to rotate the C-arm. Each C-arm, whether single or bi-plane, can be rotated 
around the patient and angled in the cranial-caudal direction to provide an almost 
limitless range of imaging angles known as projections. A collimation device is 
attached to the x-ray tube. This allows the size of the x-ray field to be adjusted. In 
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most cases, the field is rectangular, though older machines have circular or octagonal 
collimation. An ionisation chamber may also be fitted to the x-ray tube. This collects 
charged produce from ionisation of air by the x-ray beam, allowing the calculation of 
kerma area product. This is described in more detail later. 
 
 
Figure 1.3: A biplane fluoroscopy machine (Siemens Axiom Artis BC). The device pointing in 
from the left is the lateral x-ray tube, while the device facing this, on the right, is the lateral 
image intensifier. The frontal x-ray tube is obscured from view, underneath the table. Photo 
credit: Author 
 
Fluoroscopic equipment is manufactured by a number of companies, including 
General Electric, Siemens, Philips, Toshiba and Shimadzu. In this study, the large 
majority of machines were made by Philips and Siemens, with the latter dominating in 
the last ten years. Various configurations of Siemens Axiom Artis equipment were 
used for a large proportion of more recently acquired data. The letters following the 
name ‘Artis’ provide more details on the equipment; d=digital (flat panel) detectors, 
F=floor mounted, B=Biplane, C=cardiology [23]. In all cases, an antiscatter grid is 
fitted to the entrance surface of the detector and can easily be removed.  
Fluoroscopic equipment has evolved considerably over recent decades. It is possible 
to define three generations of machines based on detector type, beam energy and 
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other factors. In this study, data on procedures carried out using different machines 
will be analysed separately to explore the impact of technological factors on doses. 
1st generation: Image intensifier detectors, fixed aluminium filtration, fixed antiscatter 
grid. Limited control of frame rates. E.g. Siemens BICOR and Angioscop.  
2nd generation: Image intensifier detectors, fixed aluminium and copper filtration, fixed 
grid. Limited control of frame rates. E.g. Siemens BICOR Plus, BICOR TOP, Philips 
Integris H3000/5000.  
3rd generation: Usually flat panel detectors, aluminium and variable copper filtration, 
removable grid, large range of frame rates and program settings. E.g. Siemens Axiom 
Artis/Artis Zee. 
 
1:2 Cardiac Fluoroscopy 
Cardiac catheterizations are a fluoroscopically guided procedure used for diagnosing 
and treating various congenital (i.e. those present at birth) or acquired heart 
conditions. Intravascular catheters are thin, wire-like tubes inserted into the body via 
blood vessels and used in the diagnosis and treatment of a range of conditions. The 
catheter is advanced from an entry point in a peripheral blood vessel - usually the 
femoral or radial artery - to the region of interest under fluoroscopic x-ray guidance. 
Once the heart has been catheterised, iodine based contrast agent can be directly 
injected into the heart. The relatively high atomic number of iodine (Z=53) increases 
attenuation (particularly by photoelectric absorption) of enhanced blood relative to 
surrounding tissues, thus increasing subject contrast. In fluoroscopy, the greyscale is 
usually reversed, with respect to radiography, meaning attenuating structures such as 
contrast enhanced vessels and bone appear relatively dark. 
Catheterization of the chambers or blood vessels of the heart, known as cardiac 
catheterization was first conducted by Werner Forßmann on himself in 1929 [22]. The 
procedure allows a range of diagnostic and therapeutic procedures to be carried out, 
including coronary angiography, physiological measurements, angioplasty, and 
closure of septal defects. An overview of the most common cardiac catheterization 
procedures is provided below: 
Coronary Angiography: Visualisation of the coronary circulation requires localised 
administration of contrast agent using a catheter. Pathology identified, such as 
vascular stenosis, may be treated by balloon inflation and/or stent insertion, known 
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collectively as percutaneous coronary intervention (PCI) [24]. Patients receiving a 
heart transplant are at risk of an accelerated form of coronary artery disease called 
coronary allograft vasculopathy, which can progress without clinical symptoms [25]. 
Consequently, transplant patients often undergo regular (i.e. yearly) coronary 
angiography. 
Heart Biopsy:  In endomyocardial heart biopsy (EMBx) procedures, a piece of tissue 
from the right ventricle of the heart is removed using a catheter with jaws called a 
bioptome [26]. EMBx procedures are usually carried out to assess for signs of 
rejection in recipients of heart transplants and are often combined with coronary 
angiography procedures. In contrast to most other procedures, the catheter is usually 
inserted via the jugular vein [26]. 
Patent Ductus Arteriosus (PDA) occlusion: The ductus arteriosus is a shortcut 
between the pulmonary artery and the arch of the aorta (Figure 1.4) that normally 
closes at birth. A failure of closure may be treated by trans-catheter delivery of a coil 
or mesh ‘Amplatzer’ device [27]. The procedure is highly effective, with few 
complications [28] 
Atrial Septal Defect (ASD) closure: An ASD is a shortcut between the right and left 
atria (Figure 1.4), allowing oxygenated blood to flow directly to the right side of heart, 
thus bypassing the systemic circulation. ASDs may lead to right ventricular 
hypertrophy, paradoxical emboli and heart failure. Closure of ASDs may be achieved 
by surgery or trans-catheter implantation of an umbrella-like occlusion device. This 
procedure was first carried out by King and Mills in 1976 [29] and has been shown to 
have a similar success rate to surgery, though with a lower complication rate (7.2% 
verses 24%) and shorter hospital stay [30]. Some ASDs are ‘fenestrated’ and 
comprised of several holes in the septum. ASDs may be created deliberately 
(iatrogenic) to relieve symptoms of transposition of the great arteries (TGA) [1]. This 
procedure, called an atrial septostomy, was first performed by Rashkind et al in 1966 
[31] and provides immediate relief from the symptoms of TGA until an switch 
operation is performed. 
Coarctation repair: A coarctation of the aorta (COA) is a narrowing of the aorta in the 
region of the ductus arteriosus (arch of aorta area). It may be treated by endovascular 
balloon inflation or stent insertion [32-35]. Coarctations sometimes return (re-
coarctation), requiring further treatment. The procedure is also used to treat 
coarctations developing post-operatively [1]. 
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Electrophysiology studies (EPS) and Radiofrequency ablation (RFA): EPS 
procedures are used to investigate the electrical conduction pathways in the heart 
and can be used to locate the source of cardiac arrhythmias. These arrhythmias, 
such as that caused by Wolff-Parkinson-White (WPW) syndrome, can then be treated 
using radiofrequency ablation, first used in the late 1980s [30].  A current is passed 
through a catheter placed in contact with a region of myocardium suspected as being 
the source of the arrhythmia, causing thermal damage of the tissue [24]. 
Valvuloplasty: In cases where the aortic valve (AV) or pulmonary valve (PV) is 
narrowed (stenosis), a balloon may be inflated to improve blood flow. Balloon 
valvotomy of pulmonary stenosis was first performed in 1982 by Kan and colleagues 
[36] and is considered a safe and effective method of relieving obstruction, with a 
single procedure providing relief for decades or even a lifetime [1]. Aortic 
valvuloplasty was first performed in 1984 by Lababidi et al [37]. The procedure is 
considered more dangerous and less effective than pulmonary valvuloplasty [1]. 
Pulmonary artery angioplasty: Narrowed pulmonary arteries can be made more 
patent through balloon inflation and stent insertion. The procedure was first 
performed by Lock and colleagues in 1981 on newborn lambs [38] before being used 
in humans in 1983 [39]. The procedure is commonly employed in patients with 
Tetralogy of Fallot (a condition involving four distinct pathologies of the heart), and 
while usually effective, may occasionally result in haemodynamic instability or 
vascular rupture. Mortality has been reported at 0.2% [1]. 
Pacemaker insertions:  
Not strictly a catheterization, fluoroscopy is also used to guide the implantation of the 
wires for pacemakers. Beginning in 1970, many patients were given plutonium (238Pu) 
powered pacemakers, designed to reduce or eliminate the need for power source 
replacement [40]. These pacemakers were cost effective and relatively free of 
complications [41, 42], though are now unnecessary due to improvements in battery 
life.  
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Figure 1.4: Catheterisation of the heart (left) and a schematic diagram of the heart (right). 
AV=aortic valve, PV=pulmonary valve. Figure credit: author 
 
1.3: Risks from x-rays 
X-rays are a form of electromagnetic radiation, sufficiently energetic to cause 
ionisation of atoms or molecules [43] (a more complete description can be found in 
Appendix 1). Ionisation within cells may lead to breakage of DNA, either directly or 
indirectly via hydrolysis and subsequent oxidative stressing by reactive oxygen 
species [16]. DNA damage may result in cell killing or cell mutation. The former is 
only significant when occurring to a sufficient extent to cause a noticeable tissue 
deficit known as a 'tissue reaction' [44]. A well-known tissue reaction, familiar to 
millions of British holidaymakers, is sunburn - a radiation injury caused by ultraviolet 
radiation. X-rays may also cause sunburn (or erythema), along with injuries to deeper 
lying tissues, although the doses required for these effects (>2 Gray) are much larger 
than those typical of diagnostic imaging (<50 milligray) [16]. 
In contrast to cell killing, a single mutated cell may, theoretically, undergo malignant 
transformation, leading to the later development of cancer [45, 46]. For over sixty 
years, the preferred model for describing the relationship between radiation dose and 
associated risk has remained the linear-no-threshold (LNT) model [3, 44, 47]. This 
assumes two things; firstly that there is no threshold dose below which there is no risk 
of developing cancer, and secondly that the risk increases in linear proportion to 
dose. The LNT model was originally ‘conceived’ to describe hereditary effects of 
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radiation following research by Muller and Mott-Smith on fruit flies in the 1920s [48]. 
Muller campaigned for decades for the LNT model to be adopted as the underlying 
principle of radiation protection, finally convincing the United States National 
Academy of Sciences in 1955 [49]. Although the early concerns of hereditary effects 
of radiation were later found to be overly pessimistic [50], the LNT model became the 
preferred choice to describe the induction of cancer in exposed individuals. 
An analogy for the LNT relationship is the lottery; a single ticket is all it takes to win 
the jackpot. This may be very unlikely but the ‘risk’ of winning increases linearly with 
the number of tickets bought (Figure 1.5). Also the size of the jackpot does not 
increase with the number of tickets bought (this isn’t strictly true as each ticket adds 
to the jackpot fund, but buying ten tickets instead of one certainly would not give you 
a ten times larger prize).  
 
Figure 1.5: The Linear-no-threshold model describing the relationship between radiation 
dose and cancer, and between lottery tickets and ‘risk’ of winning the jackpot. Figure credit: 
author 
 
The chances of winning the lottery jackpot seem trivially small – about 1:45 million. 
Yet since 1994 about 3700 people in Britain have struck it lucky [51], by virtue of the 
huge number of people playing. The same logic can be applied in radiation 
protection; Even though the risks of developing cancer from radiation exposures may 
appear trivially small to an individual (typically ranging from 1 in 1000 to 1 in 1 million 
for diagnostic dose levels [52]), a non-trivial cancer burden on society may be 
expected if sufficiently large numbers of people are exposed. In 2004, the number of 
excess cancer cases induced by diagnostic medical radiation procedures in the UK 
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was estimated to be around 700 [53]. This figure was based on the assumption that 
the LNT model correctly describes the dose-risk relationship between radiation and 
cancer. However, this assumption is difficult to prove. 
Radiation induced cancers are not histologically distinct from those associated with 
numerous other risk factors [3] – smoking, diet, lifestyle, genetic factors, viruses etc. 
Excess cancers in populations exposed to radiation can be difficult to detect above 
background variation. Currently, the best available evidence of the cancer risks from 
low doses of radiation – the cohort of survivors of the nuclear bombings of Hiroshima 
and Nagasaki – can only detect a significant excess risk above doses of around 100-
200 millisieverts (mSv) [7], where an approximately linear relationship is seen. The 
magnitude of excess risk at dose levels typical of medical diagnostic and 
interventional examinations (below around 50 mSv) can only be estimated by 
downward extrapolation, assuming a linear-no-threshold relationship. This practice 
remains controversial [46, 54-57] and other models have been advocated (Figure 
1.6). The ‘hormesis’ model, a popular subject of the journal Dose Response, 
assumes exposure to low doses decreases cancer incidence compared to 
background levels. The ‘bi-modal’ model proposed by Busby [58] relates more to 
internal exposures from radioactive substances and assumes that small doses are 
especially dangerous. The ‘threshold’ model, supported by the French Academy of 
Sciences [59] implies that cellular defence mechanisms successfully eliminate risk at 
low doses, meaning that radiation doses typical of normal background levels or 
diagnostic medical exposures carry no or negligible risk. 
 
Figure 1.6: Alternative models to LNT (solid line) include threshold (dot-dash), and hormesis 
(dashes). Figure credit: author 
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This uncertainty is unfortunate as the central principle of radiation protection – that of 
justification – involves weighing up the potential risks from radiation exposures 
against the diagnostic or therapeutic benefit for the patient [52, 60]. The uncertainty in 
the magnitude of risks from low dose exposures to ionising radiation is relevant to all 
forms of medical radiation exposures, including cardiac catheterizations.  
 
1.4: Study rationale 
Cardiac catheterizations undoubtedly play a vital role in the management of 
congenital and acquired heart conditions. Because these procedures involve often 
lengthy exposure to x-rays, there are concerns over the potential for long term health 
effects, most notably an excess risk of developing cancer. Currently, information on 
the radiation doses from cardiac catheterizations is limited and risks can only be 
estimated by extrapolation of the known risks at higher doses. Uncertainties in the 
magnitude of doses and associated risks result in difficulty in justification and 
optimisation of all medical radiation studies, including cardiac catheterizations. The 
study aim was to estimate radiation doses from these procedures based on data 
recorded at the time of the examination, then estimate the risks using existing risk 
models and epidemiological analysis.  
 
The aims of the PhD were as follows; 
1. Estimate the radiation doses from x-ray guided cardiac catheterizations 
conducted on children and young adults with congenital heart disease. 
2. Estimate the risk of cancer in relation to these doses. 
 
Objectives:  
 
1. Establish a cohort of people with congenital heart disease who have 
undergone cardiac catheterizations. 
2. Produce a dosimetry system capable of estimation of organ doses from details 
recorded at the time of examinations. 
3. Estimate radiation associated cancer risks using existing risk models. 
4. Conduct a direct epidemiological analysis of these risks by matching cohort 
members with cancer registry data. 
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1.5: Structure of thesis 
The following chapter will be a literature review of evidence of the effects of low 
doses of ionising radiation and the doses likely to be delivered from cardiac 
catheterizations. Later chapter will discuss the establishment of a retrospective 
cohort, dose estimation, risk estimation and epidemiological analysis. Each of these 
four chapters will be subdivided into methods, results and discussion, thus making 
them like self-contained studies. This organisation was an alternative to putting 
methods for each type of analysis in the same place, followed by the results for each 
type etc.  
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Chapter 2: Literature review 
A review was conducted of previously published research in two main areas; (1) 
existing knowledge of the radiation doses from cardiac catheterizations in children 
and young adults, including evaluations of various methodologies for estimating 
organ doses and effective dose, and (2) epidemiological studies assessing the 
potential cancer risks following exposures to ionising radiation. The search 
methodologies used are described separately for each of these areas. 
 
2.1: Dosimetry 
The following sections describe the various measures of radiation dose referred to in 
this study, before reviewing previously published data on doses specific to x-ray 
guided cardiac catheterizations. 
 
2.1.1: Measures of radiation dose 
Information was primarily obtained from the International Commission on Radiation 
Units and measurements (ICRU) [61, 62], along with textbooks on diagnostic imaging 
and radiotherapy physics [16, 43]. Measures of radiation dose include absorbed dose 
(D), equivalent dose (H), effective dose (E) and kerma (K). Different measures 
(particularly equivalent and effective) are often simply described as ‘dose’ or have the 
same units, which can lead to confusion [63]. Almost all previously published 
assessments of doses in cardiac catheterizations are based on kerma area product 
(PKA), also known as dose area product (DAP), and fluoroscopic screening time. Both 
should be regarded as ‘dose indicators’ rather than as a true measure of absorbed 
dose to patient organs.  
Absorbed dose: The fundamental measure of the biological effect of ionising radiation 
is the absorbed dose (D), which is defined as the mean energy imparted [by ionising 
radiation] (𝑑?̅?) to mass dm of material: 
𝐷 =
𝑑?̅?
𝑑𝑚
 
Equation 2.1 
The SI unit of absorbed dose is the gray (Gy) defined as one joule (J) of energy 
absorbed per kilogram of material. The older unit of the ‘rad’ represents 100 ergs per 
gram [43], therefore 1 Gy = 100 rad, or 1 rad = 10-2 Gy or 1 cGy. Absorbed dose can 
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be related to the average mass absorption coefficient (?̅?en/ρ) and the energy fluence 
(ψ): 
𝐷 =  ψ ∙ (
?̅?𝑒𝑛
ρ
) 
Equation 2.2 
Absorbed dose, as a point measurement (denoted by the derivative notation), is 
suitable for describing localised (i.e. partial organ or cell-level) exposures such as 
tumour dose in radiotherapy or in vitro experiments. It may be used to estimate 
stochastic risk provided the amount and type of tissue involved is defined. Localised 
diagnostic dose levels are typically in the 0-50 mGy range [64]. At a dose of 1 mGy, 
each cell nucleus is crossed by an average of 1 secondary electron track [65]. The 
mean dose (Dm) to a specific organ or tissue of mass mt can be defined as: 
𝐷𝑚 =
1
𝑚𝑡
∙ ∫ 𝐷 ∙ 𝑑𝑚
𝑚𝑡
 
Equation 2.3 
Equivalent dose: The absorbed dose required to produce a certain biological 
endpoint varies between different types of radiation, such as photons, neutrons or 
alpha particles [66]. This is taken into account by the equivalent dose (H), which is 
defined as the mean dose to organ T by radiation type R (DT,R), multiplied by a 
weighting factor wR designed to takes into account varying biological effectiveness of 
the radiation type. For photons and electrons, the value of wR is 1, while for protons it 
is 2 and for alpha particles or fission products it is 20. For exposures involving 
multiple radiation types, the equivalent dose is defined as the sum of each 
contribution: 
𝐻𝑇 = ∑𝑊𝑅 ∙ 𝐷𝑇,𝑅
𝑇
 
Equation 2.4 
Or, combined with equation 2.3, above: 
𝐻𝑇 = ∑𝑊𝑅 ∙ (
1
𝑚𝑇
∙ ∫ 𝐷 ∙ 𝑑𝑚
𝑚𝑇
)
𝑇,𝑅𝑇
 
Equation 2.5 
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Note that the earlier measure of ‘dose equivalent’ is not organ averaged. Equivalent 
dose is designed for estimation of stochastic risks from radiation exposures. As dose 
is averaged over the whole organ; equivalent dose is not suitable for evaluation of 
acute radiation effects or tumour dose in radiotherapy. In the case of estimation of 
stochastic effects, assuming a linear dose response, this averaging out should make 
no difference as the total energy imparted remains the same. Equivalent dose will be 
used to describe organ doses in this thesis, rather than ‘mean absorbed dose’ in 
gray. Although the units of equivalent dose (sieverts) are the same as for effective 
dose (described below), the distinction between these two measures will always be 
made clear.  
Effective dose: It is difficult to compare the stochastic risk from localised exposures of 
different parts of the body (e.g. a chest x-ray compared to a CT scan of the head), or 
to compare exposures of the same body part but with different exposure patterns 
(e.g. a cardiac CT scan with a cardiac nuclear medicine scan). One way to avoid this 
problem is to simply average out a localised dose over the whole body. The problem 
of the 'mean whole body dose' approach is that the stochastic risk of cancer induction 
varies from one tissue to another. The effective dose (E) is designed to account for 
this variation by the application of specific weighting factors for each tissue (WT). 
Effective dose is defined as the sum of the equivalent dose to each organ (HT) 
multiplied by its respective tissue weighting factor (wT). 
𝐸 = ∑𝐻𝑇 ∙ 𝑤𝑇 
Equation 2.6 
Weighting factors are calculated by the International Commission on Radiological 
Protection (ICRP) [44], based on the risk of cancer induction for each organ and 
adjusted for associated lethality, quality of life and years of life lost (Table 2.1). 
Organs that are remote from the site of irradiation will only receive a small equivalent 
dose (mainly due to scattering) and therefore contribute little to the effective dose, 
even if the weighting factor for that organ is high. Effective dose is used to estimate 
stochastic risks for populations, rather than individuals. 
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Organ/tissue 
ICRP 60 
[67] 
ICRP 103 
[44] 
Bone marrow 0.12 0.12 
Lungs 0.12 0.12 
Colon 0.12 0.12 
Stomach 0.12 0.12 
Breasts 0.05 0.12 
Thyroid 0.05 0.04 
Liver 0.05 0.04 
Oesophagus 0.05 0.04 
Bladder 0.05 0.04 
Salivary Glands - 0.01 
Brain - 0.01 
Skin 0.01 0.01 
Bone surface 0.01 0.01 
Remainder 0.05 0.12 
Gonads 0.20 0.08 
Total 1.0 1.0 
 
Table 2.1: Effective dose tissue weighting factors. 
 
Kerma: The kerma, or KERMA (Kinetic Energy Released per unit MAss), not to be 
confused with korma (a lightly spiced, coconut-based curry), is the sum of the initial 
kinetic energies of secondary electrons liberated by uncharged ionising radiation 
(dEtr) in material of mass dm [43].  
𝐾 =
𝑑𝐸𝑡𝑟
𝑑𝑚
 
Equation 2.7 
Like absorbed dose, kerma is measured in gray and the two measures can closely 
approximate each other. The energy transfer coefficient (?̅?tr) defines the fraction of 
photon energy transferred to secondary electrons, in the form of kinetic energy, per 
unit thickness of material [43]. Kerma can be calculated from this figure, divided by 
the material’s density (i.e. the mass energy transfer coefficient, ?̅?tr/ρ) and the photon 
energy fluence (ψ): 
𝐾 = ψ ∙ (
?̅?𝑡𝑟
ρ
) 
Equation 2.8 
Comparing this to the equivalent calculation for absorbed dose (Equation 2.2), it can 
be shown that: 
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(
?̅?𝑒𝑛
ρ
) = (
?̅?𝑡𝑟
ρ
) (1 − ?̅?) 
Equation 2.9 
Where g is the fraction of energy lost to radiative processes. For photon radiation 
under 1 MeV,  g is less than 0.4% [68], thus at diagnostic energy levels (usually <100 
keV), the numerical values of kerma and absorbed dose are approximately the same. 
Differences between kerma and absorbed dose are shown in Figure 2.1. 
 
Figure 2.1: X-rays (dashed lines) liberate secondary electrons (continuous lines) both inside 
and outside the volume of interest. The electron contributing track 1 is released outside the 
volume, thus does not contribute to the kerma, but imparts some of it’s energy within the 
volume, thus contributing to absorbed dose. Electron 3 is released inside the volume, thus 
does contribute to kerma, though imparts some of its energy outside the volume. Figure credit: 
author 
 
Kerma can be divided into collision kerma (Kcol) and radiative kerma (Krad). The 
former results from soft and hard collisions with atoms, while the latter includes 
losses due to Bremsstrahlung interactions and electron/positron pair annihilation [69]. 
The latter process cannot occur when photon energies are below 1.02 MeV (i.e. twice 
the rest mass of an electron/positron), while Bremsstrahlung emissions are relatively 
unimportant in materials with a low atomic number, being proportional to Z2 [43]. Thus 
at diagnostic photon energies, Kcol is the dominant component of total kerma. 
 
Dose indicators: 
All measures of dose thus far described are time consuming or impossible to 
measure in vivo, requiring some form of dose measuring device to be placed on or 
within the patient. None are routinely measured in clinical practice, or are readily 
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available for historic examinations. Kerma area product, given the symbol PKA  by 
ICRU [70] (or KAP), is approximately equal to absorbed dose in air multiplied by 
beam area in a plane perpendicular to the beam central axis. PKA is either measured 
by a large area transmission ionisation chamber fitted to the exit port of the x-ray 
tube, or alternatively, estimated based on exposure factors. PKA has the advantage of 
being routinely recorded for almost all general radiographic and fluoroscopic x-ray 
exposures. The following section describes the principles of physical acquisition of 
PKA, before outlining the relationship with patient dose. 
Ionisation of air molecules occurs along the tracks of electrons liberated by x-ray 
photons passing through the chamber. Positive and negative ions move toward their 
respective collecting plates, producing a current measured by an electrometer (Figure 
2.2). Under the assumption of electronic equilibrium (see figure 1), the exposure (X) 
can be calculated. This is defined by ICRU as dQ/dm, where dQ is the absolute value 
of the total charge of ions of one sign produced in [dry] air when all electrons and 
positrons liberated or created by photons in air of mass dm are completely stopped in 
air [62]. Exposure is measured in Coulombs per kilogram (C/kg), though the older unit 
of the Röntgen (R) is sometimes encountered, where 1 R = 2.58 x10-4 C/kg.  
 
Figure 2.2: Electrons liberated by x-ray photons generate ion pairs, which are collected by 
positively and negatively charged plates. For charged particle equilibrium to occur, collected 
ion pairs created by electrons liberated outside the volume (solid circle) must equal those not 
collected, created by electrons liberated within the volume (dashed circle). Figure credit: author 
 
The exposure area product (EAP), measured in R·cm2, is approximately equal to 
exposure multiplied by area irradiated (A) defined by the collimators. As beam 
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intensity is uneven (e.g. due to the anode heel effect), EAP is more properly defined 
as the integral of X with respect to area: 
𝐸𝐴𝑃 = ∬𝑋(𝑥, 𝑦)
𝐴
𝑑𝑥 𝑑𝑦 
≈ 𝑋 ∙ 𝐴 
Equation 2.10 
The most recent estimate of the mean energy required to produce a single ion pair in 
air (?̅?) is 33.97 electronvolts (eV) [71], or 5.442 x 10-18 J. The average energy to 
produce one unit of charge, in Coulombs, is defined as (?̅?/𝑒) 𝐽/𝐶, where e is the 
charge of a single electron (1.602 x 10-19 C). Therefore: 
(
?̅?
𝑒
) = (
33.97(𝑒𝑉/𝑖𝑜𝑛 𝑝𝑎𝑖𝑟) ∙ 1.602 x 10−19(𝐽/𝑒𝑉)
1.602 x 10−19 (𝐽/𝑖𝑜𝑛 𝑝𝑎𝑖𝑟)
) [8] 
= 33.97 J/C 
Equation 2.11 
By multiplying the exposure (in C/kg) by this figure, the energy released by the x-ray 
beam per unit mass of air (i.e the air kerma) can be determined. As radiative losses 
(i.e. due to Bremsstrahlung interactions) are not accounted for, the result is more 
accurately described as air collision kerma (Kcol,air): 
𝐾𝑐𝑜𝑙,𝑎𝑖𝑟 = 𝑋 ∙ (
?̅?
𝑒
) 
= 𝑋 ∙ 33.97 
Equation 2.12 
Kerma area product, or rather collision kerma area product, is the integral of air 
collision kerma with respect to area: 
𝑃𝐾𝐴 = ∬𝐾𝑐𝑜𝑙,𝑎𝑖𝑟(𝑥, 𝑦)𝑑𝑥 𝑑𝑦
𝐴
 
≈ 𝐾𝑎𝑖𝑟 ∙ 𝐴 
Equation 2.13 
The units of PKA are Gy·cm2. Smaller doses are often quoted as cGy·cm2, mGy·cm2, 
or μGy·m2. Some authors quote doses in R·cm2, which can be converted to Gy·cm2 
by multiplying by 8.764 x10-3 (i.e. the product of 2.58 x10-4 (C/kg)/R and 33.97 J/C). 
The absorbed dose in air (Dair) can be defined as follows: 
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𝐷𝑎𝑖𝑟 = 𝐾𝑐𝑜𝑙,𝑎𝑖𝑟 ∙ (1 − 𝑔) 
Equation 2.14 
As mentioned previously, g is the fraction of energy lost to radiative processes.  As 
this fraction is very small at diagnostic energy levels, collision air kerma can 
reasonably be considered approximately equal to absorbed dose in air. PKA and dose 
area product (DAP) are essentially the same thing, although in reality it is the former 
that is actually being measured. 
Kerma area product is almost independent of distance from the source. This can 
easily be appreciated by considering that area is proportional to the square of 
distance (d) from the source (A ∝ d2), while x-ray intensity (I) is inversely proportional 
to the square of distance (I ∝ 1/d2). The product of both should therefore be constant, 
though, in reality, scattered and extrafocal radiation result in a small level of distance 
dependence [72]. 
It is important to understand that PKA is an indicator or patient dose rather than an 
absolute measure in itself. The relationship between PKA and patient dose is strongly 
dependent on a range of parameters, in particular beam energy, projection angle and 
patient size (this relationship is explored in depth in the Chapter 4). Comparison of 
PKA figures acquired using different equipment, patient sizes or examination types 
requires caution. Still, useful observations can be made from such dose indicators 
that will have important implications for studies of doses and associated risks. 
 
Calibration and uncertainty: 
PKA meters must be regularly calibrated to national standards. Quoted allowable 
uncertainties range from 7% [73] to 35% [74]. The International Electrotechnical 
Commission (IEC) recommend a combined uncertainty of 25% for PKA and air kerma 
measurements [75]. The International Atomic Energy Agency (IAEA) [76] describe 
the following calibration process, consisting of two steps; (1) measuring the air kerma 
at a distance dr from the focus (i.e. the part of the anode acting as the x-ray source), 
and (2) moving the device to a second position, downstream from a circular or square 
lead aperture with a known diameter at a distance da from the focus. The calibration 
factor, NPKA,Q is then defined as: 
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𝑁𝑃𝐾𝐴,𝑄 = 
𝐾𝐴(𝑑𝑟/𝑑𝑎)
2
𝑀𝐾𝐴𝑃𝑘𝑇𝑃
𝐾𝐴𝑃  
Equation 2.15 
Where MKAP is the reading obtained by the meter [76]. An alternative ‘tandem’ method 
has been described by Pöyry et al [77] and Toroi et al [78] in which both the field PKA 
meter to be calibrated and the reference meter are placed in the beam together.  
 
Air Kerma: 
The air kerma (Kair) at a particular distance from the source can be calculated by 
simply dividing PKA by the beam area at that distance. This provides a method of 
estimating patient skin dose using PKA, without resorting to the placement of dose 
measuring devices on the patient’s skin. The location of the skin is estimated using 
the methodology of the IEC [79], who define the ‘international reference point’ as 
being at a location along the central axis of the x-ray beam 15 cm above (i.e. 
‘upstream’ from) the isocentre between source and detector [74]. However, to provide 
a true estimate of entrance skin dose (ESD), the backscattering of x-rays and 
secondary electrons from deeper lying tissues must be taken into account, in the form 
of a backscatter factor (BSF). The BSF, defined as the ratio of air kerma at the patient 
surface to the air kerma at the same distance in the absence of the patient, increases 
with beam quality, field size and (slightly) focus-skin distance [70], typically ranging 
from 1.3 to 1.5 for a 25 x 25 cm field [80]. 
Even if accounting for backscatter, skin dose estimates provide no information on the 
distribution of dose over the patient’s skin [74]. The beam is rarely in a fixed position 
throughout the procedure [81], meaning energy is imparted over a wider area of skin 
than suggested by the beam area.  
 
2.1.2: Previously published data on doses 
A previous review was published by Neofotistou in 2001 [10] of reported doses from 
adult and paediatric cardiac catheterizations. A large number of new studies have 
been published since this review and the figures quoted by Neofotistou can 
considered to be unreliable (for example, the author misquoted figures from two out 
of the three studies in which paediatric doses were reported). A new review of 
published doses was therefore required. This served a number of purposes; (1) 
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assess the magnitude and variation in doses, (2) identify factors affecting doses, and 
(3) evaluate the potential to estimate organ doses from the information likely to be 
obtainable from participating hospitals.  
Literature on doses was identified by searching Medline and Pubmed. Search terms 
were 'cardi*', 'catheteri*', 'fluoroscop*', 'dos*', 'paediatric', 'pediatric' and 'child*'. The 
reference list of identified papers was searched for further relevant publications. Most 
of these studies focus specifically on either childhood or adult exposures, with 
average age of patients in the latter group typically over 60 years. Some studies 
focus on all patients with congenital heart disease (CHD). These tend to be 
predominantly children, though studies may also include some patients followed into 
adulthood [82, 83]. Forty seven studies were initially identified as being relevant. Five 
studies reported methodologies for calculating organs doses or effective dose, rather 
than doses from clinical examinations [84-88]. Two studies focussed on risks but 
provided no information on doses [89, 90]. Forty studies were identified in which 
doses were reported.  
A summary of reported dose indicators is provided in table 2.2. A number of 
observations stand out. Firstly, average PKA is seen to vary with procedure type; 
figures were typically highest for right ventricular outflow tract (RVOT) dilatation and 
lowest for atrial septal defect (ASD) occlusions and endomyocardial heart biopsies. 
Secondly, there is a strong trend of increasing PKA with increasing patient size (either 
mass or age); this is unsurprising given the increased x-ray output required to 
maintain the same intensity at the detector as attenuator thickness increases, and 
also the increased beam area required to include the region of interest. Thirdly, an 
enormous variation in PKA is seen between different studies; for example, there is a 
more than 50-fold variation in median PKA for interventional procedures in studies by 
Ait Ali et al [13] and Smith et al [22].  
Regarding the third observation, there are a number of possible explanations. Firstly, 
the ages of patients vary between studies. Given the tenfold or more increase in 
examination PKA between newborns and young adults, a small difference in the 
average age of study subjects could explain a sizeable difference in average PKA. Yet 
large variations are seen even where data are stratified by patient age or mass. 
Interestingly, there is a tendency for PKA to explode upwards to very high values (over 
80 Gy·cm²) for larger patient sizes in some studies (e.g. Verghese [82], Glatz [91], 
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Ghelani [83]), but not in others (e.g. Barnaoui [92], McFadden [93], Martinez [94]), 
where the increases in PKA with patient size are relatively restrained. 
A second reason for variation in PKA is that studies may include a different mix of 
procedure types. If a particular hospital specialises in complex procedures such as 
valve replacements, this could result in an unusually high average PKA where data for 
all procedure types are presented together. However, large discrepancies remain, 
even where studies are stratified by procedure type. For example, a 10-60 fold 
variation in median PKA for ASD occlusions was seen between studies led by 
Barnaoui [92], and Verghese [82], depending on age group. The screening times of 
the latter study are longer, but to a much smaller extent than the increase in PKA.  
A third explanation for PKA variation relates to equipment differences. This includes 
not only the model of fluoroscopic equipment used, (e.g. Siemens Axiom Artis, Philips 
Integris etc.), but also includes the way the machine is set up, including frame rates, 
dose rate and antiscatter grid usage. Here, the desire to reduce radiation doses 
conflicts with the desire to obtain satisfactory image quality [95]. The signal-to-noise 
ratio (SNR) quantifies the ‘graininess’ of the image by relating useful signal to random 
quantum fluctuations in photon fluence [96]. Photon counting statistics conform to a 
Poisson distribution [95], meaning variance (σ²) is equal to the square root of photon 
count (N). Thus SNR is N/√N, which simplifies to √N [16]. At this superficial level, 
‘image quality’ is subject to a law of diminishing returns – to increase SNR by a factor 
of 2, photon fluence, and hence patient dose, would need to be increased by a factor 
of 22. This relationship does not take into account the ability of the imaging system to 
process useful signal and noise – a characteristic described by the system’s ‘detective 
quantum efficiency’ (DQE) – essentially a frequency dependent measure of image 
quality per unit dose [16, 97]. The DQE, and the related measure of ‘effective DQE’ 
(eDQE) take into account a range of other factors in addition to photon count, 
including handling of electronic noise, focal spot size and control of scattered 
radiation [97]. Post-acquisition image processing techniques, such as recursive 
filtering, may also improve image quality for a given dose [98, 99]. Thus, increased 
image quality does not necessarily come at the expense of increased dose [96].  
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Study (Collection date) Subjects 
Median 
age/weight 
Age/weight 
range 
Median FT (mins) 
[IQR] 
Median DAP (Gy·cm²) 
[IQR] Mean DAP (Gy·cm²) [SD] 
Median DAP per unit 
weight (Gy·cm²/kg) 
[IQR] 
Combined diagnostic               
Campbell (1997)(MD 1)* 18   
4m - 20y 
4.4 [R: 1.4-28.2] 5.22 [R: 0-22.84] 7.25 [7.75]   
Campbell (1997) (MD 2)* 26   5.4 [R: 2.4-42.2] 2.31 [R: 0.62-6.34] 2.64 [1.57]   
Schultz (published 2003) §§ 18       4.45   
Bacher (published 2005) (0.2 mm Cu) ** 15 2.4 y 0.1-8.8 y 4.9 [R: 0.5-14.5] 5.48 [R: 1.14-14.61]     
Bacher (published 2005) (0.4 mm Cu) ** 13 1.3 y 0.1-9.2 y 3.9 [R: 1.6-33.2] 3.37 [R: 0.96-13.99]     
Martinez (2007) 58 
  <1 y     1.9 [0.3] $$$   
  1-5 y     4.2 [0.9] $$$   
  5-10 y     4.2 [0.9] $$$   
  10-16 y     8.6 [2.7] $$$   
Al Haj (2000-2002) 60   0-12 y     7.77 [14.3]   
Dragusin (>2005) 
9   1–30 d 11 [ 18, 6] 2.7 [ 2.3, 4.1]     
27   1-12 m 6 [ 4, 11] 2.5 [ 1.2, 5.4]     
19   1-3 y 10 [ 8, 14] 5.1 [ 3.1, 8]     
24   3-5 y 8 [ 5.25, 14] 5.8 [ 2.9, 9.4]     
34   5-10 y 8 [ 5.75, 10.5] 7.1 [ 4.4, 12.3]     
13   10-15 y 5 [ 3, 16.5] 9.9 [ 3.5, 16.6]     
Beels (published 2009) 17 1.77 y 0-11.8 y 8.3 [R: 0.6-27.4] 5.55 [R: 0.7-16.6]     
Yakoumakis (published 2009) 42   1 d-14 y         
Karambatsakidou(1999-2004) 139 
  0-0.5 y     3.7 [2.6]   
  0.5-2.5 y     6.0 [5.8]   
  2.5-7.5 y     7.6 [9.5]   
  7.5-12.5 y     15.9 [12.9]   
  12.5-18 y     37.9 [52.3]   
Onnasch (1998-2003) 1106 11.0 kg 1.7-115 kg       0.28 [75%: 0.5] 
Ait Ali (2007) 13 0.7 y 0.4-11 y   14 [12, 28] 20.85 [16.9]   
Gherardi (2008-2009) 210   0-15.6 y 7.5 [R: 0.3-55] 3.2 [R: 0.2-21.0]     
Watson (2009-2010) 50   0-18 y 16 12.00 [R: 3-143]     
Watson (2009-2010) ## 23   <1 y         
El Sayed (published 2012) 46 4.17 y       3.78 [2.5]   
Verghese (2005-2009) 
242   <1 y 26 7.43 [4.33, 14.43]     
134   1-4 y 26 13.99 [8.52, 22.22]     
85   5-9 y 20 16.47 [9.04, 24.94]     
130   10-15 y 19 34.15 [15.84, 60.29]     
212   >16 y 25 82.84 [34.31, 184.02]     
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Ubeda (published 2012) 
76   <1 y   1.0 $$$ 1.1 $$$   
80   1-5 y   1.5 $$$ 1.8 $$$   
39   5-10 y   2.2 $$$ 2.8 $$$   
30   10-16 y   7.9 $$$ 9.0 $$$   
225   0-16 y   1.5 $$$ 2.7 $$$   
Ubeda (published 2012) (normal) 35         1.8 $$$   
Ubeda (published 2012) (complex) 45         3.5 $$$   
McFadden (published 2013) 159   0.1-15.3 y [4.6, 11.5] [1.40, 5.87] 2.94 $   
Glatz (2009-2013) 671 
  < 5 kg 15 [ 9, 23] 2.24 [ 1.16, 3.49]     
  5-12.5 kg 16 [ 11, 26] 4.18 [ 2.72, 6.63]     
  12.5-25 kg 13 [ 9, 20] 9.45 [ 5.75, 15.52]     
  25-45 kg 14 [ 8, 22] 27.22 [ 15.63, 42.90]     
  45-65 kg 14 [ 10, 25] 55.95 [ 34.32, 90.71)     
  >65 kg 16 [ 10, 21] 89.59 [ 49.19, 147.84]     
  All   15 [ 10, 23] 6.12 [ 2.72, 23.3]     
Barnaoui (2010-2011) 
93   <6.5 kg 7 [R: 0.3-45] 2 [R: 0.3-8.1] 2.7 [2]   
58   6.5-14.5 kg 6 [R: 0.3-25] 2 [R: 0.02-11.5] 2.9 [2.8]   
61   14.5-25.5 kg 4.5 [R: 1-23] 2.6 [R: 0.37-14.2] 3.9 [3.3]   
47   25.4-43.5 kg 5.4 [R: 1-25] 5.8 [R: 0.7-16.6] 6.3 [4.3]   
29   >43.5 kg 7.5 [R: 2.5-45] 12.8 [R: 3.4-37.5] 16.4 [10.8]   
Kobayashi (2008-2013) 
510 3.6 kg < 5 kg 14 [ 8, 22] 2.28 [ 1.22, 4.20]     
1429 9.5 kg 5-20 kg 14 [ 9, 20] 5.40 [ 2.86, 9.57]     
498 27.4 kg 20-45 kg 12 [ 7, 17] 14.49 [ 6.74, 26.74]     
314 58 kg 45-80 kg 11 [ 7, 18] 40.06 [ 15.69, 81.68]     
76 92 kg >80 kg 12 [ 7, 19] 103.47 [ 28.11, 158.74]     
2827   All <18 y 13 [75%: 20]     0.59 [75% 1.05] 
Borik (2007-2014) 1224   Children 11 [R: 0-181] 4.75 [R: 0.01-338.18]   0.39 [R: 0-92.98] 
Ubeda (2011-2013) 200 
  0-16 y 9.9 [75%: 15.8] 1.5 [75%: 2.9] $$$ 2.7 0.1 [75%: 0.16] $$$ 
  0-1 y [75%: 17.1] [75%: 1.17] $$$     
  1-5 y [75%: 14.9] [75%: 1.74] $$$     
  5-10 y [75%: 19.1] [75%: 2.83] $$$     
  10-16 y [75%: 17.4] [75%: 7.74] $$$     
Corredoira (2009-2013) ### 
34   0-1 y   1.80 [0.92, 4.10] 2.75   
47   1-5 y   4.67 [2.84, 10.44] 6.17   
25   5-10 y   6.03 [3.12, 14.48] 17.4   
45   10-16 y   15.56 [3.23, 29.56] 24.93   
21   16-20 y   25.44 [7.43, 53.34] 34.07   
172   All <20 y   5.26 [2.31, 16.16] 15.44   
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Heart biopsy  Subjects Med age/weight  Range  Median FT  Median PKA  Mean PKA  Median PKA/kg 
Verghese (2005-2009) 
30   <1 y 8 1.69 [ 0.99, 2.82]     
112   1-4 y 7 2.66 [ 1.45, 4.84]     
105   5-9 y 7 6.38 [ 2.89, 11.98]     
224   10-15 y 8 15.14 [ 8.39, 31.10]     
283   >16 y 8 18.53 [ 8.52, 39.05]     
Glatz (2009-2013) (Right Heart ± biopsy) 301 
  5-12.5 kg 9 [ 6, 18] 2.10 [ 0.89, 3.43]     
  12.5-25 kg 7 [ 5, 12] 4.84 [ 2.67, 9.90]     
  25-45 kg 7 [ 5, 15] 9.68 [ 4.64, 19.05]     
  45-65 kg 8 [ 5, 12] 17.71 [ 8.75, 32.04]     
  >65 kg 7 [ 5, 11] 30.02 [ 12.67, 49.21]     
  All < 22 y 7.8 [5-14] 9.00 [3.43, 20.87]     
Kobayashi (2008-2013) 
4 4.2 kg < 5 kg 7 [ 5: 10] 1.13 [ 0.51, 1.73]     
394 14.8 kg 5-20 kg 8 [ 4, 12] 3.91 [ 0.97, 10.63]     
425 31.1 kg 20-45 kg 7 [ 4, 12] 7.56 [ 1.66, 24.07]     
293 54.7 kg 45-80 kg 6 [ 3 :10] 13.41 [ 1.80, 48.96]     
56 91.3 kg >80 kg 4 [2, 8] 7.95 [ 3.12, 40.95]     
1172   All <18 y 7 [75%: 11]     0.26 [75%: 0.79] 
Borik (2007-2014) 710     5 [R: 2-28] 27.89 (sic) [R: 0.1-83.43]   0.1 [R: 0.01-1.08] 
Sutton (2011-2012) 45     3.7 [R: 1.2-9] 0.16 [R: 0.04–1.45]     
 
Coronary angiography  Subjects Med age/weight  Range  Median FT  Median PKA  Mean PKA  Median PKA/kg 
Tsapaki (2007) 
18 
  0-1 y 9.4 [R: 3.4-11.1] 1.9 [R: 0.1-3.2]     
  1-10 y 3.1 [R: 1.1-6.6] 1.15 [R: 0.1-10.7]     
  >10 y 4.1 [R: 2.4-21.1] 4.1 [R: 0.7-36.7]     
18   All 4.0 [R: 1.1-21.2] 2.1 [R: 0.1-36.7]     
Glatz (2009-2013) 179 
  12.5-25 kg 14 [ 11, 19] 12.35 [ 8.54, 24.43]     
  25-45 kg 15 [ 11, 20] 26.98 [ 17.59, 40.61]     
  45-65 kg 15 [ 11, 20] 54.76 [ 36.61, 80.82]     
  >65 kg 16 [ 13, 21] 89.77 [ 71.26, 112.43)     
  All 15 [ 11, 20] 31.80 [ 16.83, 63.50]     
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PDA occlusion  Subjects Med age/weight  Range  Median FT  Median PKA  Mean PKA  Median PKA/kg 
El Sayed (published 2012) 18         10   
Schultz (published 2003) §§ 12         18.8 
Verghese (2005-2009) 
61   1-4 y 17 8.00 [5.58, 14.30] 9 [8]   
20   >16 y 34 110.18 [56.51, 271.45]     
Al Haj (2000-2002) 41   0-13 y     23.21 [10.1]   
Glatz (2009-2013) 92 
  5-12.5 kg 10.5 [8, 13] 2.63 [1.78, 3.53]     
  12.5-25 kg 9 [8, 15] 5.56 [3.52, 9.85]     
  All 11 [9, 16] 3.52 [2.29, 7.09]     
Bacher (published 2005)               
Onnasch (1995-2003) 165           mean=0.35 [75%: 0.37] 
Smith (2005-2009) 140   <18 y 6 [ 4, 9] 1.52 [ 0.78, 2.52]     
Yakoumakis (published 2009) 10   4.8 m - 13 y         
Yakoumakis (published 2013) & 16   7-11 y   9.5 [R: 7.8-11.2] 9.5 [0.1]   
Barnaoui (2010-2011) 
23   <6.5 kg 6.5 [R: 2-23.4] 2.1 [R: 1-7.1] 2.8 [1.8]   
85   6.5-14.5 kg 3 [R: 0.5-20] 1.4 [R: 0.39-9.7] 1.9 [1.4]   
29   14.5-25.5 kg 3 [R: 1.3-17] 2.8 [R: 0.3-7.5] 3.1 [2]   
8   25.4-43.5 kg 3 [R: 2-9.3] 4.3 [R: 0.8-11.2] 5.3 [3.9]   
6   >43.5 kg 2 [R: 1-4.5] 10.8 [R: 0.6-20.1] 11.5 [7]   
98   All 3 [0.5, 23.4] 1.8 [R: 0.3-20.1] 2.8 [2.9]   
Ghelani (2009-2013) § 
130   <1 y 15 [75%: 21] 5 [75%: 8]     
294   1-4 y 10 [75%: 16] 7 [75%: 12]     
60   5-9 y 11 [75%: 15] 13 [75%: 22]     
38   10-15 y 12 [75%: 17] 33 [75%: 85]     
25   >15 y 24 [75%: 33] 96 [75%: 151]     
Kobayashi (2008-2013) (coils) 283   All <18 y 8 [75%: 13]     0.31 [75%: 0.53] 
Kobayashi (2008-2013) (device) 467   All <18 y 11 [75%: 16]     0.42 [75%: 0.71] 
Song (published 2014) 20 2.1 y  0.5-7 y 5.67 [R: 2.1-33.0] 6.47 [R: 1.29-90.01] 13.71 [20.21] Mean=0.62 
Borik (2007-2014) 
266   Children 8 [R: 3-92] 2.54 [R: 0.38-181.31]   0.18 [R: 0.04-2.51] 
87   0-10 kg   1.37 [R: 0.38-18.93]   0.19 [R: 0.05-2.08] 
122   10-20 kg   2.45 [0.48, 12.38]   0.17 [R: 0.04-0.86] 
34   20-30 kg   4.11 [R: 0.91-19.48]   0.17 [R: 0.04-0.91] 
25   >30 kg   20.87 [R: 2.94-181.31]   0.37 [R: 0.07-2.51] 
Keiller (2012-2013) 52         3.19 [R: 1.87-10.52]   
Ubeda (published 2012) (coils) 20         1.5 $$$   
Ubeda (published 2012) (device) 117         2.1 $$$   
Ubeda (2011-2013) (coils) 42     6.0 [75%: 9.1] 0.6 [75%: 1.2] $$$ 0.9 $$$   
Ubeda (2011-2013) (device) 84     9.8 [75%: 13.6] 1.0 [75%: 1.9] $$$ 1.7 $$$   
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ASD and PFO occlusion  Subjects Med age/weight  Range  Median FT  Median PKA  Mean PKA  Median PKA/kg 
Bacher (published 2005)               
Onnasch (1995-2003) (ASD) 259           mean=0.42 [75%: 0.50] 
Onnasch (1995-2003) (PFO) 21           mean=0.23 [75%: 0.30] 
Yakoumakis (published 2009) 15   1.5-18 y         
El Sayed (2012) 15         10 [10]   
Verghese (2005-2009) 
29   1-4 y 30 21.97 [ 16.14, 30.48]     
40   5-9 y 31 28.16 [ 14.31, 39.78]     
27   10-15 y 34 74.92 [ 44.19, 105.82]     
99   > 16 y 28 98.71 [60.97, 153.41]     
Smith (2005-2009)  49 (114?)   <18 y 8 [ 4, 14] 2.82 [ 1.28, 4.93]     
Yakoumakis (published 2013) & 19   6-11 y   40.3 [R: 17.3-58.3] 39.9 [1.2]   
Glatz (2009-2013) 97 
  5-12.5 kg 16 [ 11, 24] 5.03 [ 2.97, 6.61]     
  12.5-25 kg 14 [ 12, 22] 7.28 [ 4.80, 9.32]     
  25-45 kg 24 [ 12, 31] 16.21 [ 11.87, 24.33]     
  45-65 kg 18 [ 12, 27] 30.63 [ 14.33, 43.53]     
  >65 kg 17 [ 13, 27] 58.93 [ 33.79, 107.01]     
  All    15 [12, 25] 10.38 [6.29, 28.78]     
Barnaoui (2010-2011) 
4   6.5-14.5 kg 5.6 [R: 0.6-7] 1.8 [R: 0.1-3] 1.7 [1.2]   
25   14.5-25.5 kg 1 [R: 0.8-7] 0.7 [R: 0.1-2.9] 0.8 [0.6]   
13   25.4-43.5 kg 1.5 [R: 0.5-20] 1.1 [R: 0.4-6.8] 2 [2.2]   
12   >43.5 kg 2.5 [R: 1-11] 2.8 [R: 1-15] 4.5 [4.4]   
54   All 1.8 [0.5-20] 0.9 [0.1-15] 2 [2.7]   
Ghelani (2009-2013) § 
219   1-4 y 18 [75%: 27] 9 [75%: 17]     
180   5-9 y 16 [75%: 24] 14 [75%: 25]     
127   10-15 y 17 [75%: 27] 39 [75%: 67]     
194   >15 y 20 [75%: 31] 89 [75%: 204]     
Kobayashi (2008-2013) 568   All <18 y 15 [75%: 23]     0.41 [75: 0.71] 
Song (published 2014) 17 4.9 y 2.0-18 y 6.55 [R: 4.1-54.1] 4.85 [R: 1.70-21.21] 10.71 [8.35] Mean=0.33 
Borik (2007-2014) 
345   Children 8 [R: 2-95] 5.04 [R: 0.34-244.56]   0.21 [R: 0.02-3.67] 
6   0-10 kg   2.91 [R: 1.78-8.82]   0.31 [R: 0.22-0.89] 
141   10-20 kg   2.83 [R: 0.34-42.68]   0.16 [R: 0.02-2.13] 
80   20-30 kg   4.71 [R: 1.93-29.87]   0.22 [R: 0.08-1.36] 
118   >30 kg   12.70 [R: 1.93-244.56]   0.23 [R: 0.06-3.69] 
Ubeda (published 2012) 9         4.3 $$$   
Keiller (2012-2013) 19         4.95 [R: 2.08-33.23]   
Haas (2012-2013) 19 30 kg   6.9 [ 4.6, 9.0] 6.78 [ 3.52, 10.15] 10.48 [14.45] 0.16 [ 0.11, 0.39] 
Haas (2013) 31 26 kg   5.5 [ 3.8, 9.3] 1.12 [ 0.68, 3.67] 2.84 [3.51] 0.04 [ 0.03, 0.07] 
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Aorta dilatation / coarctation repair  Subjects Med age/weight  Range  Median FT  Median PKA  Mean PKA  Median PKA/kg 
Al Haj (2000-2002) 24   0-13 y     11.35 [24.3]   
Yakoumakis (published 2009) 10   2 m - 12 y         
El Sayed (published 2012) 6         42.5 [18.18]   
Smith (2005-2009) (balloon) 9     8 [ 5, 11] 2.37 [ 1.44, 5.42]     
Smith (2005-2009) (stent) 21     12 [ 9, 14] 27.10 [ 9.98, 50.12]     
Verghese (2005-2009) 
42   <1 y 34 12.98 [ 8.27, 22.92]     
34   >16 y 36 123.02 [78.54, 258.73]     
Glatz (2009-2013) 86 
  < 5 kg 18 [14, 20] 2.73 [ 2.02, 3.84]     
  5-12.5 kg 18 [14, 24] 4.34 [ 2.53, 6.90]     
  All   19 [14, 24] 4.84 [2.61, 17.70]     
Ghelani (2009-2013) § 
202   <1 y 21 [75%: 32] 7 [75%: 14]     
36   1-4 y 23 [75%: 35] 20 [75%: 30]     
38   5-9 y 22 [75%: 33] 41 [75%: 65]     
79   10-15 y 20 [75%: 26] 96 [75%: 170]     
93   >15 y 24 [75%: 36] 200 [75%: 340]     
Ubeda (published 2012) 70         2.2 $$$   
Kobayashi (2008-2013) (angioplasty) 182   All <18 y 15 [75%: 21]     0.66 [75%: 1.07] 
Kobayashi (2008-2013) (stent) 112   All <18 y 16 [75%: 23]     0.90 [75%: 1.59] 
Borik (2007-2014) (angioplasty) 120     11 [R: 4-66] 4.79 [R: 0.35-194.65]   0.43 [R: 0.07-4.47] 
Borik (2007-2014) (stent) 52     15 [R: 7-65] 32.92 [R: 1.49-291.54]   0.80 [R: 0.13-4.48] 
 
Aortic Valvuloplasty  Subjects Med age/weight  Range  Median FT  Median PKA  Mean PKA  Median PKA/kg 
Smith (2005-2009) 30     21 [ 16, 28] 2.35 [ 0.90, 7.28]     
Verghese (2005-2009) 43   <1 y 30 9.57 [6.29, 15.24]     
Glatz (2009-2013) 26   All 30 [ 22, 32] 11.18 [ 4.70, 63.42]     
Ghelani (2009-2013) § 
155   <1 y 25 [75%: 34] 7 [75%: 11]     
27   1-4 y 21 [75%: 33] 19 [75%: 37]     
22   5-9 y 22 [75%: 30] 21 [75%: 28]     
65   10-15 y 28 [75%: 36] 93 [75%: 137]     
27   >15 y 23 [75%: 39] 116 [75%: 187]     
Kobayashi (2008-2013) 138   All <18 y 18 [75%: 26]     0.80 [75%: 1.27] 
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Borik (2007-2014) 
138   Children 13 [R: 4-61] 3.4 [R: 0.14-110.91]   0.42 [R: 0.08-2.11] 
72   0-10 kg   1.45 [R: 0.14-7.09]   0.31 [R: 0.08-1.25] 
20   10-20 kg   0.48 [R: 0.05-19.55]   0.42 [R: 0.09-1.28] 
7   20-30 kg   14.72 [R: 7.38-32.22]   0.57 [R: 0.26-1.41] 
39   >30 kg   44.54 [R: 8.05-110.91]   0.77 [R: 0.24-2.11] 
Ubeda (published 2012) 30         2.0 $$$   
Ubeda (2011-2013) 13     11.0 [75%: 13.5] 0.6 [75%: 2.3] $$$ 2.6 $$$   
 
Pulmonary valvuloplasty  Subjects Med age/weight  Range  Median FT  Median PKA  Mean PKA  Median PKA/kg 
Al Haj (2000-2002) 44   0-13 y     9.96 [15.1]   
Yakoumakis (published 2009) 11   3.6 m - 8.5 y         
Smith (2005-2009) 63   <18 y 11 [ 8, 18] 1.23 [ 0.57, 2.03]     
Verghese (2005-2009) 86   <1 y 28 7.97 [4.59, 13.55]     
Glatz (2009-2013) 75 
  <5 kg 19 [ 12, 30] 2.41 [ 1.65, 3.10]     
  5-12.5 kg 24 [ 16, 32] 4.71 [ 3.13, 7.06]     
  All  19 [12, 30] 4.05 [2.33, 14.34]     
Ghelani (2009-2013) § 
303   <1 y 21 [75%: 35] 4 [75%: 9]     
64   1-4 y 19 [75%: 30] 10  [75%: 18]     
24   5-9 y 13 [75% 20] 16  [75%: 23]     
35   10-15 y 15 [75% 22] 44  [75%: 98]     
35   >15 y 28 [75% 42] 198  [75%: 448]     
Kobayashi (2008-2013) 342   All <18 y 14 [75%: 20]     0.56 [75%: 0.95] 
Borik (2007-2014) 
286   Children 15 [R: 1-131] 1.63 [R: 0.22-188.47]   0.28 [R: 0.01-3.45] 
216   0-10 kg   1.14 [R: 0.22-12.22]   0.27 [R: 0.06-3.44] 
40   10-20 kg   3.56 [R: 0.91-40.39]   0.24 [R: 0.08-3.11] 
9   20-30 kg   7.48 [R: 5.49-11.56]   0.34 [R: 0.22-0.42] 
22   >30 kg   50.90 [R: 0.87-188.47]   0.99 [R: 0.01-3.45] 
Song (published 2014) 16 4.8 y / 18 kg   9.8 [R: 5.1-21.0] 6.20 [R: 3.80-10.68] 7.11 [3.01]   
Ubeda (published 2012) 61         1.2 $$$   
Ubeda (2011-2013) 29     12.4 [75%: 17.0] 0.6 [75%: 0.9] $$$ 0.9 $$$   
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Combined interventional  Subjects Med age/weight  Range  Median FT  Median PKA  Mean PKA  Median PKA/kg 
Bacher (published 2005) (0.2 mm Cu) ** 16 2 y 0.2-10 y   4.72 [R: 2.82-20.44]     
Bacher (published 2005) (0.4 mm Cu) ** 16 2 y 0.3-7.8 y   2.72 [R: 0.41-18]     
Martinez (published 2007) 79 
  <1 y     2.4 [0.4] $$$   
  1-5 y     4.4 [0.8] $$$   
  5-10 y     8.6 [1.9] $$$   
  10-16 y     17.8 [3.7] $$$   
Dragusin (after 2005) 
12   1–30 d 16.5 [ 13.5, 24.3] 4.8 [ 2.5, 6.5]     
49   1-12 m 12 [ 9, 25] 5.9 [ 3.7, 9.2]     
29   1-3 y 16 [ 9.5, 24.5] 7.5 [ 5, 12.5]     
14   3-5 y 18 [ 10.75, 33.5] 9.5 [ 5, 22.2]     
31   5-10 y 21 [ 14, 26] 17.1 [ 9.7, 27]     
12   10-15 y 20 [ 16, 39.75] 46.8 [ 28.7, 74.4]     
Beels (published 2009) 32 0.69 y 0-10.8 y   2.7 [R: 0.1-31.7]     
Karambatsakidou (1999-2004) 110 
  0-0.5 y     3.2 [4.1]   
  0.5-2.5 y     2.6 [5.1]   
  2.5-7.5 y     7.8 [11.8]   
  7.5-12.5 y     10.0 [9.7]   
  12.5-18 y     34.2 [38.9]   
Onnasch (1998-2003) 883 13.8 kg 1.5-108 kg       0.35 [75%: 0.66] 
Ait Ali (2007) 5 14 y 0.3-16 y 24 [R: 13-26] 93 [64, 99] 109 [100.0]   
El Sayed (published 2012) 61 7.84 y 0–22 y     13.24 [15.4]   
Smith (2000-2005) (old) *** 444 2.19 y 0-17.9 y   8.0 [R: 0.1-156.0]     
Smith (2005-2009) (new) *** 312 2.06 y 0-17.9 y   1.76 [R: 0.03-125.15]     
McFadden (published 2013) 195   0-16 y [5.1, 15.4] [1.37, 7.15] 3.13 $   
Glatz (2009-2013) 816 
  < 5 kg 19 [ 12, 32] 2.58 [ 1.71, 3.67]     
  5-12.5 kg 26 [ 14.5, 41] 6.56 [ 3.46, 13.80)     
  12.5-25 kg 24 [ 13, 44] 12.96 [ 6.34, 31.28]     
  25-45 kg 38 [ 24, 59] 65.86 [ 2.43, 96.93)     
  45-65 kg 24 [ 16, 45] 85.14 [ 35.20–144.04)     
  >65 kg 36 [ 19, 51] 158.41 [ 87.58, 389.69)     
  All 25 [ 14–43] 10.51 [ 3.71, 43.15]     
Kobayashi (2008-2013) 
680   < 5 kg 18 [11,  31] 2.78 [ 1.18, 6.10]     
2231   5-20 kg 19 [ 11, 32] 7.37 [ 3.36, 15.41]     
767   20-45 kg 19 [ 11, 31] 19.22 [ 8.37, 37.80]     
500   45-80 kg 19 [ 12, 31] 54.62 [ 23.70, 104.18]     
90   >80 kg 20 [ 12, 34] 116.00 [ 65.09, 202.25)     
4268   All <18 y 19 [75%: 32]     0.72 [75%: 1.51] 
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Ubeda (published 2012) 
74   <1 y   0.9 $$$ 1.2 $$$   
123   1-5 y   1.4 $$$ 1.7 $$$   
58   5-10 y   1.9 $$$ 2.6 $$$   
64   10-16 y   4.5 $$$ 7.1 $$$   
319   0-16 y   1.7 $$$ 2.9 $$$   
Ubeda (2011-2013) 317 
  0-16 y 12.6 [75%: 20.6] 1.2 [75%: 2.5] $$$ 2.4 $$$ 0.09 [75%: 0.17] $$$ 
  0-1 y [75% 22.7] [75%: 1.11] $$$     
  1-5 y [75% 20.6] [75%: 1.90] $$$     
  5-10 y [75% 16.9] [75%: 3.22] $$$     
  10-16 y [75% 23.1] [75%: 8.68] $$$     
Corredoira (2009-2013) ### 
92   0-1 y   1.91 [1.19, 3.14] 3.19   
158   1-5 y   2.57 [0.86, 7.53] 4.92   
118   5-10 y   6.09 [2.25, 14.18] 11.52   
176   10-16 y   11.99 [3.77, 27.55] 21.94   
40   16-20 y   39.74 [17.87, 91.12] 57.06   
584   All <20 y   4.87 [1.60, 15.05] 14.68   
 
Table 2.1: Summary of dose indicators (kerma area product and screening time) for reviewed studies. 
 
Notes: * Results given for two different operators, ** study conducted using two different levels of copper filtration, *** data presented for two equipment 
types, $ geometric mean, $$$ figures reduced to account for table attenuation, # doses presented in chart form only, ## subset of above group, ### study 
included cone beam CT elements for 38 diagnostic and 71 interventional procedures, & Organ doses for PDA, VSD and ASD occlusions calculated using 0, 10 
and 10 year old phantoms, respectively, § Sample sizes are for DAP. The sample of examinations used for air kerma was smaller, presumably as not all 
procedures had an air kerma figure recorded, §§ It is not clear if the figures are median or mean.       
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Fryback and Thornbury [100] and Thornbury [101] propose six stages of efficacy of 
diagnostic imaging; these are (1) Technical capacity, (2) Diagnostic accuracy, (3) 
Diagnostic impact, (4) Therapeutic impact, (5) Patient outcomes, and (6) Societal 
outcomes. Barrett et al [95] state that the majority of research tends to focus on stage 
2. There is insufficient evidence to determine whether higher radiation doses are 
associated with improved patient or societal outcomes (e.g. survival, quality of life, 
employment or burden on healthcare services). Although most papers investigating 
radiation doses from cardiac catheterizations make some mention of image quality, 
there is little to suggest a conscious decision to increase radiation doses in order to 
improve patient outcome. Higher doses are rarely acknowledged, partly because 
‘comparison with previous research’ analyses tend to be limited to a handful of 
studies.  
Returning to the question of why PKA varies so much between different published 
studies, a fourth potential explanation is measurement uncertainty and careless 
recording or reporting of dose indicators. It was noted that around half of reviewed 
publications make no mention of calibration of dose measuring equipment. Recorded 
PKA figures are subject to a typical uncertainty of ±15%, even when regularly 
calibrated to national standards. For uncalibrated dosemeters, this uncertainty may 
be sizably higher, though never to the extent of explaining a tenfold variation in 
doses. Confusion between units, for example between μGy·m2 and mGy·cm2, could 
certainly explain a tenfold variation in doses. Smith et al [22] for example, quote PKA 
in the nonsensical units of “mGy/cm2”, giving the impression of extraordinarily low 
doses, assuming units should be mGy·cm². The correct units of measurement of 
μGy·m2 were obtained by consulting with medical physics staff at the same hospital 
(who were unaware the study had been conducted) (Ian Honey, 2013, personal 
communication). Borik et al [102] misquote the results of Smith by a factor of 10, 
leading to the incorrect conclusion that their own PKA figures were lower. 
There is no clear trend in PKA or screening time with study date. If anything, reported 
PKA figures are higher in more recently published data, although this observation 
involves comparison between studies rather than comparison of different eras at the 
same centre. Onnasch and colleagues [103] found a decrease in PKA per patient 
mass with the replacement of a Siemens Bicor/Digitron with a Philips Integris 
5000BH system (0.618 verses 0.278 Gy·cm2 kg-1). This change involved a reduction 
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in frame rate from 50 s-1 to 12.5-25 s-1 and the use of additional copper filtration. A 
greater than fourfold reduction in PKA was reported in the previously mentioned study 
by Smith et al [22] following the installation of new equipment.  Again, the newer 
machine was able to use a lower frame rate (typically 7.5-15 s-1). This reduction in 
the fluoroscopic or acquisition frame rate can be associated with a proportional 
reduction in dose [104], without sacrificing SNR. In many cases, frame rates are 
dictated by the heart rate of the individual undergoing the procedure, which for 
children can often exceed 100 beats per minute (BPM). Overall, there does appear to 
be a trend of reduced frame rates in more recent publications. Quoted fluoroscopic 
frame rates were typically 12.5 s-1, though rates of up to 50 s-1 were reported. 
From the above discussion it is apparent that a wide, and largely unacknowledged 
gulf in doses, as represented by PKA, exists between different centres. In particular, a 
number of large studies with sample sizes of several thousand examinations have 
reported unexpectedly large PKA figures in recent years. Most such studies are based 
in the United States, though it should be noted that other American studies have 
reported very low doses [105, 106], while some European studies have reported very 
high doses [13, 107]. A common mistake made by authors is to conduct only a 
limited comparison of their own data with previous research, often incorrectly 
reaching the conclusion that their doses are satisfyingly low. Studies reporting high 
PKA also tend to have large sample sizes, thus could argue that their figures 
represent a true picture of the radiation doses from these procedures, with lower 
doses being explainable by small sample sizes and publication bias (i.e. authors 
more likely to report doses if they are low). 
 
2.1.3: Derivation of organ doses and effective dose from PKA 
Kerma area product is a dose indicator, somewhat akin to the number of bullets fired 
from a gun. It provides no implicit information on how x-rays interact with the patient. 
This limitation is rarely acknowledged in publications, with PKA often simply referred 
to as 'dose'. PKA can however be used to provide estimates patient dose, including 
effective dose (E) and equivalent dose to individual organs (H). These are derived 
using E/PKA or H/PKA conversion factors calculated using either Monte Carlo (MC) 
computer simulations [86, 87, 108] or physical measurements in human tissue 
equivalent phantoms [84] (Figure 2.3). These phantoms are described in Chapters 4 
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and 7. Estimation of effective dose from entrance surface dose measurements has 
been found to be less reliable [109].  
 
 
Figure 2.3: An anthropomorphic phantom used for physical methods dosimetry, and a 
mathematical phantom used for Monte Carlo simulations (PCXMC 2.0). Photo credit: author 
 
A summary of E/PKA conversion factors is given in Tables 2.3 and 2.4. The most 
basic derivations of PKA are simple one-size-fits-all, age and mass independent 
conversion factors to relate total examination PKA to effective dose. Such simple 
estimates, used in both adult and paediatric studies [13, 110], should be avoided as it 
can be shown that effective dose is strongly dependent on patient age or mass [108]. 
In general, effective dose per unit PKA decreases with increasing patient age [86, 92], 
presumably due to a smaller proportion of patient tissues being close to the beam 
entrance. Consequently, where PKA values were converted to effective dose, the 
trend of increased ‘dose’ with age was less pronounced or even reversed, with the 
highest effective doses sometimes occurring in infants [111]. 
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Onnasch [103] 
PA+Lat 
combined $ * 
Barnaoui [92] 
PA/lateral $$  
Karambatsakidou 
[112] PA/PA+Lat 
combined $  
Schmidt [86] 
PA/Lat $ 
Axelsson  [84] 
PA/LAT $  
Beam energy 
65 kV,  
3.0 mm Al 
70 kV, 3.0 
mm Al, 0.3 
mm Cu 
60-85 kV, 
6 mm Al, 0.4/0.2 
mm Cu 
65 kV,  
3.0 mm Al ** 
58-70 kV, 
3.0 mm Al 
Methodology 
Derived from 
Schmidt [86] 
PCXMC v2.0 
Modified from 
Schmidt [86] 
PCXMC v1.3 
Physical 
measurements 
P
a
ti
e
n
t 
a
g
e
 (
y
e
a
rs
) 0 3.09 (3.4 kg) 3.5/3.5 3.7/3.7 2.05/2.34 - 
1 1.03 (9.2 kg) 2.1/1.6 1.9/1.9 0.82/1.16 1.8/1.4 
5 0.49 (19.0 kg) 1.05/1.3 1.0/1.0 0.42/0.64 0.9/.07 
10 0.29 (32.4 kg) 0.65/0.8 0.6/0.7 0.24/0.38 - 
15 0.17 (56.3 kg) 0.35/0.4 0.4/0.4 0.13/0.22 - 
30 0.13 (73.2 kg) - - 0.10/0.16 - 
 
Table 2.3: E/PKA conversion factors reported in different studies. Note: $ = ICRP 60 effective 
dose tissue weighting factors, $$ = ICRP 103. *The estimates for the Onnasch model are 
based on average weight at each age category, shown in brackets. 
 
 
 
 
Glatz [91] 
PA/lateral $$  
Onnasch PA+Lat 
combined $ * 
Beam energy Not stated 65 kV, 3mm Al 
Methodology PCXMC v2.0 
Derived from 
Schmidt [86] 
P
a
ti
e
n
t 
m
a
s
s
 
(k
g
) 
<5 2.07/2.25 3.09 (3.4 kg) 
5-12.5 0.91/1.04 1.06 (8.75 kg) 
12.5-25 0.68/0.89 0.49 (18.8 kg) 
25-45 0.47/0.60 0.26 (35 kg) 
45-65 0.21/0.24 0.17 (55 kg) 
>65 0.18/0.16 0.13 (73.2 kg) 
 
Table 2.4: E/PKA conversion factor stratified by mass. Note: $ = ICRP 60 effective dose 
tissue weighting factors, $$ = ICRP 103. *figures based on specified mass 
 
Dose estimates derived from PKA must therefore take patient size (age or mass) into 
account. This was done by Schmidt et al [86], who used Monte Carlo simulations 
(PCXMC v1.5) to produce tables of E/PKA conversion factors for individual projections 
and six different patient sizes, along with a separate table of relative adjustments to 
account for beam energy.  No conversion factors were calculated for estimation of 
individual organ doses. The paper, published in 2000, provides beam energy 
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corrections that, while appropriate for fluoroscopic equipment of that era, are 
inadequate for modern equipment in which a greater thickness of added filtration is 
generally used. The data calculated by Schmidt were used by Onnasch and 
colleagues [103] to calculate a remarkably simple E/PKA conversion factor of 9.26 * 
(PKA/kg). This figure, subsequently used by other studies [113, 114] is based on the 
mean of Schmidt’s conversion factors for frontal (PA) and left lateral projections, and 
beam energy defined by a tube potential of 65 kV and 3 mm Aluminium filtration. 
These parameters represent a much lower beam energy than is used for equipment 
used in the last 10 years. Consequently, the E/PKA conversion factor developed by 
Onnasch will result in underestimates of effective dose (this will be investigated in 
the Chapter 4). Karambatsakidou et al [112] also use the data calculated by Schmidt 
to produce their own set of E/PKA conversion factors based on the mean of seven 
different projections using the frontal x-ray tube. A separate conversion factor was 
used for the lateral tube output. A beam energy correction was applied, based on 
values recorded for clinical examinations. Effective dose estimates obtained using 
these conversion factors were compared with those obtained from reconstructions of 
examinations using Monte Carlo simulations and detailed, exam specific, beam 
angle and beam energy data. The agreement between these two methodologies was 
high, with variation less than 10% for 48 out of 52 examinations. This is encouraging 
as it suggests dose estimates based on limited data are comparable to those with 
detailed data.  
More recently, Barnaoui et al [92] used Monte Carlo simulations (PCXMC v2.0) to 
produce a set of E/PKA conversion factors for two beam projections (PA and left 
lateral), based on a beam energy more representative of modern equipment (70 kV, 
3 mm of Aluminium and 0.3 mm of Copper). These conversion factors are similar to 
those of Karambatsakidou et al [112]. It is noted that effective dose estimates by 
Barnaoui used the tissue weighting factors from ICRP 103, rather than ICRP 60. The 
weighting factor for the breasts was increased in the more recent report from 0.08 to 
0.12. Furthermore, the heart was included in the ‘other’ tissues category. 
Consequently, effective dose estimates using ICRP 103 weighting factors are greater 
than those using ICRP 60 by between 10 and 16% depending on patient size [112]. 
The previously mentioned study by Glatz et al [91] also estimated effective doses, 
again using PCXMC V2.0 Monte Carlo simulations. These E/PKA conversion factors 
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were lower than those calculated by other studies. The assumed beam energy and 
field sizes were not stated, making comparison difficult.  
Two studies led by Yakoumakis were reviewed [107, 115], with the latter study 
reporting considerably higher effective doses (almost ten times higher for ASD 
occlusions), despite the same equipment being used. It should be noted that the 
methodology of these studies was not the same, with the former estimating effective 
dose based on surface dose measurements and the latter using PKA. The latter study 
also estimated organ doses, although the actual conversion factors used were not 
stated. 
Conversion factors to relate equivalent PKA to organ doses (H/PKA) were developed 
by Axelsson et al [84] for a number of different projection angles. The methodology 
used by Axelsson was different to that used by the studies describe above, in that 
they used physical dose measurements in anthropomorphic phantoms rather than 
Monte Carlo computer simulations. Unfortunately, the range of beam angles (six) and 
phantom sizes (two) was very narrow, and no corrections for variable beam energy 
were investigated. A recent study by Kawasaki et al [116] calculated organ doses 
and effective dose for two beam angles (PA and lateral) and two patient sizes (0 and 
1 years). While the equipment was a modern, 3rd generation machine (Philips Allura 
9), the range of beam angles and patients sizes was overly limited. Other H/PKA 
conversion factors were developed by Stern et al [87] and Streulens et al [88] using 
MC simulations, though only for adult patients. 
None of the previously developed E/PKA or H/PKA conversion factors described above 
are adequate for the purposes of this study, due to (1) the narrow range of patient 
sizes studied, (2) the lack of organ dose estimates, and (3) the limited range of beam 
energies studied. A new dosimetry system needs to be developed in which organ 
doses can be rapidly estimated for a large number of cohort members based on 
limited data recorded at the time of the examination and held within hospital clinical 
records. Ideally, examination data can be fed directly into the dosimetry system, i.e. 
in the form of a spreadsheet, with dose estimates outputted in a readily analysable 
form. The dosimetry system needs to be able to estimate doses for a large range of 
patient sizes, from prematurely born babies to adults, and for a large range of beam 
energies. Information on examination type also needs to be incorporated, as this will 
affect the likely beam angles used.  
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2.1.4: Biodosimetry 
As an alternative to physical dose measurements, a number of studies have 
investigated the biological impact of medical radiation by measuring DNA damage 
itself. The initial response to a DNA double strand break is the phosphorylation of 
histone variant H2AX, to form ‘γ -H2AX’ [117, 118]. Foci of γ-H2AX can be detected 
using an antibody specific to this phosphorylated form of H2AX and 
immunofluorescence techniques. This technique has the advantage of allowing 
detection of DNA damage occurring at much lower doses than other techniques 
[118], including those relevant to diagnostic imaging. A number of studies have been 
conducted in which blood samples taken from patients following medical irradiation 
are analysed using γ-H2AX techniques. Beels and co-workers [12] compared risk 
estimates based on organ doses calculated using patient specific MC simulation with 
estimates based on γ-H2AX foci in peripheral blood T lymphocytes obtained before 
and immediately following diagnostic catheterization procedures of 48 paediatric 
subjects. In that study, a supralinear relationship between dose and γ-H2AX foci was 
found, implying the same dose response for DNA double strand break induction. 
This, the authors argued, suggests an under-estimation of the cancer risks by linear 
extrapolation using the linear no-threshold (LNT) model by a factor of four. A similar 
supralinear dose response was reported by Ojima et al [119] following in vitro 
irradiation of normal human fibroblasts to doses from 1.2 to 200 mGy. The authors 
attributed this pattern to the influence of gap-junction mediated bystander signalling 
between cells, as pre-treatment with lindane (an inhibiter of gap-junction 
communication) produced a linear dose response. 
Geisel and colleagues [14] found a significant increase in γ-H2AX foci (representing 
0.29±0.18 DSBs per lymphocyte) following adult diagnostic conventional coronary 
catheterizations (CCA) and cardiac CT procedures (n=56 for each modality). After 24 
hours however, DSB numbers had returned to background levels. A significant 
correlation was found between dose and γ-H2AX foci for both CCA (r=0.862, 
P<0.001) and CT (r=0.951, P<0.001). The authors estimated that this level of 
biological effect was 1.8 times greater than predicted from effective dose, though the 
dose-response did not appear to exhibit the supralinear relationship noted by Beels 
[12]. In another study by Ait-Ali et al [13], a significant increase in micronucleus levels 
compared to baseline levels was found following diagnostic (11‰ vs 7‰, n=13) and 
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therapeutic procedures (9‰ vs 5‰, n=5), though without any apparent relationship 
with DAP (r=0.1, p=0.74). 
While interesting, these findings need to be interpreted with caution. Beels’s finding 
of ‘hypersensitivity’ refers to the early endpoint of DSB induction, rather than later 
endpoints of cell-killing or cancer induction. The suggestion that a supralinear dose 
response for DSBs also implies the same relationship for diagnosable cancer may be 
overly pessimistic.  Research by Rothkamm [117] and later by Collis [120] and 
Grudzenski [121] suggests that DNA repair efficiency is reduced at low doses and 
possibly absent below around 5 mGy. When cultures were allowed to proliferate, 
damaged cells appeared to be eliminated. In this sense, ‘hypersensitivity’ may 
indicate excess cell-killing rather than cancer risk. Unfortunately Beels did not 
investigate persistence of γ-H2AX foci at later times following irradiation, thus 
allowing damage response to be assessed.  
The suggestion by Beels [12] and Andreassi [122] that cancer risks determined 
through direct analysis DNA damage were four times higher than 'expected' is also 
dubious, given that 'expected' risks are based on observational studies, albeit ones 
that lack statistical power at low doses. If, as Andreassi [122] suggests, the 
supralinear DNA damage relationship detected by Beels is due to the impact of 
'bystander' effects, in which irradiated cells influence their neighbours by means of 
the release of various genotoxic factors into the surrounding medium, why should 
such effects be specific to cardiac catheterizations? Surely if bystander effects do 
indeed play a role in cancer development following radiation exposure, such effects 
would have occurred following the exposures from which 'expected' risks are based, 
including studies of nuclear bombing survivors. There is currently no suggestion that 
bystander effects only occur at low doses, with some research even suggesting the 
reverse [123]. 
  
2.1.5: Summary of dosimetry review 
The published data on radiation doses from paediatric cardiac catheterizations 
suggests a wide variation, not only from one hospital or procedure type to the next, 
but also within individual hospitals and for the same procedure. This strongly 
suggests that the use of non-individualised ‘typical’ doses will be insufficient for an 
epidemiological analysis of the cancer risks. A patient and examination-type specific 
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system of dosimetry therefore needs to be attempted. Research suggests that an 
individualised estimation of organ doses based on limited examination data is 
plausible, though this needs to be investigated further. Biodosimetry studies have 
suggested that the risk from exposures may be higher than expected, but this is 
based on the early end-point of DNA damage and not cancer itself. To study this 
latter endpoint in relation to human exposures, epidemiological analysis is required. 
A review of relevant studies will be described next. 
 
2.2: Epidemiology 
Epidemiological analysis of populations exposed to elevated levels of ionising 
radiation have the advantage of allowing assessment of the final outcome of cancer 
rather than a single endpoint such as DSB induction. A large number of 
epidemiological studies have been conducted. However, none of these provide 
conclusive evidence of risks at dose levels below 50-100 mGy. Some could be 
interpreted as suggesting high risks at low doses [124], some low [125], while others 
are consistent with decreased risks compared to spontaneous incidence (hormesis) 
[126]. The results of the same studies can be shown to be consistent with seemingly 
opposing viewpoints. Doss [127], for example, uses the data from the atomic 
bombing survivors’ study (discussed below) to provide evidence of hormesis by 
adjusting background rates, while other authors have used the same study as 
evidence in support of the linear no threshold model [46]. 
Epidemiological analysis requires some form of dose estimation, although the 
standard of such estimates varies considerably, from individualised estimates to 
average doses applied across the whole study population or sub-groups (e.g. 
geographical areas) [128]. Studies with individualised dose estimated were 
preferred, to so-called ‘ecological’ studies with non-individualised estimates.   
The primary sources for the epidemiology literature review were the reports of the 
National Academy of Sciences Committee on the Biological Effects of Ionising 
Radiation (BEIR VII) [3], United Nations Scientific Committee on the Effects of 
Atomic Radiation (UNSCEAR) [45, 129] and International Commission for 
Radiological Protection (ICRP) [44]. The reference lists for these reports were 
searched for relevant publications. Papers identified using PubMed as citing and 
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cited by these papers were also obtained. Review papers investigating the risks from 
low dose exposures were also obtained [46, 54, 55, 130] and the reference lists 
searched.  
 
2.2.1: The Life Span Study 
The most informative study of the long-term cancer risk from exposures to ionising 
radiation remains the cohort of Japanese survivors of the nuclear bombings of 
Hiroshima and Nagasaki in 1945, known as the Life Span Study (LSS). The bombs 
dropped on both cities were fission weapons, but had different designs. The 
Nagasaki bomb, known as the “Fat Man”, used a sub-critical core of plutonium-239 
(239Pu) surrounded by conventional explosives, which when detonated produced an 
inward pressure on the core causing it to turn supercritical. The Hiroshima bomb, 
known as the “Little Boy”, used a sub critical hollow “bullet” of Uranium-235 (235U) 
which was propelled down an artillery barrel by conventional explosives into a 
second “target” of 235U, again causing super-criticality. The resulting fission process 
resulted in the conversion of around 1 g and 0.6 g of mass into energy by the 
Nagasaki and Hiroshima bombs respectively - equivalent to 21,000 and 16,000 tons 
of TNT [131]. This is easily appreciated using Einstein's relation, E=mc2, where 1 g of 
mass is shown to be equivalent to roughly 90 trillion joules. 
Radiation doses to inhabitants of the cities were largely due to release of a flash of 
so-called ‘prompt radiation’ - gamma photons and neutrons from the fission process 
itself. This was followed by around 5 seconds of ‘delayed’ radiation due to further 
fission of radioactive products in the fireball [132]. In both cases, the intensity of 
radiation decreased with distance from the epicentre due to divergence according to 
the inverse square law, and atmospheric scattering and absorption. Further, more 
minor, sources of radiation exposure were due to neutron activation of ground and 
building materials (absorbing neutrons and becoming radioactive) and ‘fallout’, i.e. 
unexploded uranium, plutonium or fission products settling to the Earth. Around 90% 
of radiation exposure was due to photons and 10% due to neutrons. 
The Lifespan study has the advantage of individualised dose estimates [133], 
although these have evolved considerably since 1945. The first meaningful estimates 
were calculated in 1957 and known as T57D (T standing for tentative), followed by a 
second in 1965 (T65D), a third in 1986 (DS86) and a fourth in 2002 (DS02) [132]. 
45 
 
Both the total dose at a given distance, and the relative proportions of this dose due 
to photons and neutrons have changed with successive iterations. Clearly, the 
situation of survivors had the potential to change considerably during the 5 seconds 
of primary radiation exposure. Once standing houses were blown down, thus altering 
the shielding characteristics for someone inside. People were knocked over or spun 
around, changing their orientation relative to the epicentre. To improve dose 
estimates, replicas of typical Japanese houses were exposed to nuclear explosions 
in the Nevada desert [132]. 
The LSS includes 86,611 individuals of both sexes and all ages exposed to a wide 
range of doses, with a mean whole body dose of 0.2 Gy [46], with 74,440 (79%) 
receiving less than 0.1 Gy [7]. Increased incidence has been detected for solid 
cancers (ERR=0.42 Sv-1 95% CI: 0.32, 0.53) and leukaemia (ERR=3.1 Sv-1 95% CI: 
1.8, 4.3). These estimates of risk per sievert (equivalent dose), based on the most 
recent dosimetry system (DS02) were around 8% lower than those based on the 
previous dosimetry system (DS86) [134]. The dose response for solid tumours is 
consistent with linearity without threshold, though Preston and colleagues [134] 
detected a significant upward curvature in the first report since the DS02 dosimetry 
was implemented. In the most recent analysis, the lowest dose range in which a 
significantly increased ERR for solid cancers was observed was 0 – 0.2 Sv [7], 
though an earlier report by Preston et al found a significant increase for cancer 
mortality in the 0-0.125 Sv range [135]. A linear-quadratic model provides the best fit 
for leukaemia incidence and mortality [130, 133]. 
In addition to the lack of statistical power to detect cancer risks below around 100-
200 mSv, there are a number of other limitations of the LSS. Firstly, as background 
incidence rates vary considerably between populations and ethnic groups, the ability 
to transfer risk estimates derived from a very homogenous Japanese sample to other 
populations is problematic [45]. As a large proportion of the male population of Japan 
was conscripted into the army at the time of the bombings, the populations of 
Hiroshima and Nagasaki had a relatively large proportion of females. Risk estimates 
per sievert are dependent on the radiobiological effectiveness (RBE) weighting factor 
applied to neutrons, which is set at 10. Suggestions have been made that the RBE 
should be higher [59], leading to correspondingly increased dose estimates and 
reduced risk per unit dose. For example, in an analysis of the LSS data, Kellerer et al 
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[136] detected a significantly increased risk estimate for organs located closer to the 
body surface with a neutron RBE of up to 100. Furthermore, the energy of gamma 
ray photons originating from the nuclear bomb blasts was relatively high compared to 
those of diagnostic x-rays (typically 30-100 keV). The radiobiological effectiveness of 
low energy photons is thought to be higher [137, 138], meaning risk per unit dose 
may be correspondingly higher also. 
 
2.2.2: Environmental and occupational exposures 
Populations and workforces exposed to elevated radiation levels represent an 
alternative opportunity to study cancer risks from exposures. Theoretically, a large 
dose protracted over a long period of time can be viewed as a succession of 
infinitesimally small exposures. If observed, elevated cancer risks in such 
populations would not be consistent with the concept of a low dose threshold below 
which there is no risk. 
Cardis et al [139] conducted a pooled analysis of mortality among 407,391 nuclear 
workers from 15 countries, exposed to an average cumulative dose of 19.4 mSv. A 
significantly raised ERR of 0.97 Sv-1 was found for all cancers except leukaemia 
(95% CI: 0.14, 1.97), while a non-significantly raised ERR for leukaemia was found 
(1.93 Sv-1, 95% CI: <0, 8.47). The study has drawn comment concerning the 
potential confounding effect of smoking and the unusually high ERR among 
Canadian workers [140, 141]. A reanalysis of the Canadian data was conducted by 
Zablotska et al [142], finding a much greater solid cancer ERR among workers 
employed between 1956 and 1964 (7.78 Sv-1, 95% CI: 1.88, 19.5) than for those 
employed after 1964 (-1.20 Sv-1, 95% CI: -1.47, 2.39). Excluding the Canadian data 
from the 15-country study, the ERR for solid cancers is reduced to 0.58 Sv-1 (95% CI: 
-01.0, 1.39) [143], which is reasonably close to the linear ERR mortality estimate 
from the LSS of 0.32 Sv-1 [130]. A significant increase in mortality for leukaemia was 
found by Muirhead and colleagues [144](ERR Sv-1 = 1.71, 95% CI: 0.06, 4.29) 
among 174,500 UK nuclear workers. The mortality ERR for all malignancies except 
leukaemia was also raised (0.28 Gy-1 95% CI: 0.02, 0.56). A more recent study was 
conducted by Leuraud et al [145] on a subset of the 15-country study, focusing on 
308,297 radiation-monitored workers in the UK, USA, France, receiving a mean 
yearly bone marrow dose of 1.1 mGy. Mortality was significantly raised for leukaemia 
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(ERR=2.96 Gy-1, 95 CI: 1.17, 5.21), but not for non-Hodgkin lymphoma (ERR=0.47 
Gy-1, 95% CI: -0.76, 2.03). This same group of workers was subject to a further study 
by Richardson et al [146] examining cancer mortality for all sites except leukaemia. A 
significantly elevated risk was found (ERR=0.48 Gy-1, 95% CI: 0.2, 0.79). This risk is 
50% lower than reported in the above-mentioned study by Cardis et al [143], though 
still a little higher than that of the LSS (0.32 Sv-1). These studies suggest an 
association between radiation and excess risk of cancer persisting at low doses, 
especially for leukaemia. However these studies all focused on adults, and may be 
biased to some extent by a ‘healthy worker effect’. The results may be more relevant 
to the cardiologists, nurses and radiographers conducting cardiac catheterizations, 
rather than the patients themselves. 
Residents of a number of areas exposed to elevated radiation levels as a result of 
natural radioactivity or industrial pollution have also been studied. A significantly 
increased ERR for solid cancer mortality of 0.61 Gy-1 (95% CI: 0.04, 1.27) was 
observed among people residing in the Techa River region of Russia between 1950 
and 1960 [147]. There was a suggestion that ERR increased with increasing age at 
first exposure (p=0.05) and attained age (p=0.10). A similar finding was reported in a 
study by Bauer et al [148] of residents of the Semipalatinsk region of Kazakhstan, 
who were exposed to radiation from nuclear weapons testing fallout. For all solid 
cancers, an ERR of 1.77 Sv-1 was reported (95% CI: 1.35, 2.27). Chen et al [126] 
studied residents of the Yangiang region in Southern China who receive an 
estimated yearly effective dose of 6.4 mSv from elevated background radiation 
levels. No increase in cancer mortality was detected, compared to a control area 
where residents received a mean yearly effective dose of 2.4 mSv (relative risk= 
0.99, 95% CI: 0.87, 1.14). In particular, relative risks were less than unity for a 
number of cancer sites previously linked to radiation exposure, including the lungs, 
stomach, breasts and thyroid.  
Kendall and colleagues [149] matched 27,447 children living in Great Britain who 
developed cancer with 36,793 cancer-free controls. Radiation doses were estimated 
based on the mother’s residence at the time of the child’s birth and a national survey 
of natural background radiation levels [150]. For leukaemia, a significantly raised 
relative risk of 1.12 per mSv cumulative bone marrow dose from gamma radiation 
was found (95% CI: 1.03, 1.22). Relative risk increased monotonically with 
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increasing bone marrow dose, becoming significantly raised above around 4 mGy. 
The trend was driven by lymphoid leukaemia (RR=1.13, 95% CI: 1.02, 1.24), with 
lower risks for myeloid leukaemia (RR=1.05, 95% CI: 0.87, 1.28). For all cancers 
except leukaemia, the ERR was non-significantly negative up to cumulative doses of 
around 12 mGy (Figure 2.4). Lest this be interpreted as evidence of hormesis, it 
should be noted that these doses were protracted, thus if a hormesis effect or low 
dose threshold does exist, it is likely to be in the region of a few nanosieverts. A 
similar study, based in Switzerland, was conducted by Spycher et al [151], involving 
2,093,660 children aged under 16 years. A significant increase in incidence was 
found for all cancers combined (hazard ratio (HR) = 1.64, 95% CI:1.13, 2.37) and 
leukaemia (HR= 2.04, 95% CI: 1.11, 3.74) for children residing in areas with 
background dose rates of greater than 200 nSv per hour (≈1.75 mSv per year) 
compared to less than 100 (≈0.88 mSv per year). The negative risks for moderate 
dose rates found in the UK study described above were not seen in the Swiss study. 
No corresponding increase was found for lymphoma (HR=0.91, 95% CI: 0.29, 2.86). 
Both the UK and Swiss studies are consistent with the ‘no-threshold’ component of 
the LNT model, at least for leukaemia.  
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Figure 2.4: Relative risk of leukaemia and all other cancers in relation to cumulative 
background dose. Reprinted by permission from Macmillan Publishers Ltd: Leukaemia, 
Kendall et al [146], copyright 2013 
 
 
2.2.3: Medical exposure studies 
Well over a hundred studies have been published investigating the cancer risk from 
radiation administered for medical diagnosis or treatment [3]. Such studies have the 
advantages of reasonably well defined exposure characteristics (i.e. dose, site of 
irradiation), relevance of low-energy and low linear energy transfer (LET) radiation, 
and medical records with long term follow-up. Medical exposures also typically 
produce a highly non-uniform dose distribution [130], in contrast to the whole-body 
doses from the Japanese atomic bomb exposures. The major disadvantage of 
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medical radiation studies is that of 'confounding by indication' [45]. Medical 
exposures should be carried out for a reason, such as illness or injury, which itself 
may be associated with increased long-term cancer risk. In other words, it is not clear 
if observed effects are due to the radiation itself or the need for radiation. 
Confounding by indication cannot be eliminated through large sample sizes. The 
association between the number of examinations of a particular type conducted and 
the number other examinations (e.g. fluoroscopy, nuclear medicine) or interventions 
including brain surgery could also influence results.    
A small number of studies have attempted to directly assess the cancer risks from 
cardiac catheterizations. Modan et al [6] reviewed 674 Israeli children who underwent 
these procedures between 1950 and 1970. Dose records were unavailable for 90% 
of cohort members. A standardised incidence ratio (SIR) of 2.3 (95% CI: 1.2, 4.1), 
based on 11 cases compared to 4.75 expected, including 4 lymphomas and 3 
melanomas. At least six of the tumours occurred in locations remote from the heart 
(testis, prostate, bladder, inguinal lymph nodes and melanomas of the groin and 
lower limb). The location of the others was not clear, either. A further interesting 
feature was that all cancers occurred in males, who represented 56% of the cohort. 
The results are unusual, though with such a small sample size, they could easily be 
attributed to chance. Spengler et al [4] conducted a retrospective cohort study on 
4861 children receiving cardiac catheterisations between 1946 and 1968 in Ontario, 
Canada. After 13 years of follow-up, 5 cancer deaths were observed compared to 4.8 
expected. A further study using the same cohort (reduced to 3915 members due 
exclusions of subjects living outside the study area) by McLaughlin et al [5] reported 
a standardised mortality ratio (SMR) of 1.2 (90% CI: 0.6, 2.3) based on 7 cancer 
deaths verses 5.7 expected, and SIR of 0.75 (0.3, 1.2) based on 13 cancer cases 
observed verses 17.3 expected. Again, a number of cancers were reported in sites 
remote from the heart including the tongue, testis (two cases), prostate, ovary, 
cervix, colon and brain. The small sample sizes, limited dosimetric information and 
lack of dose response analysis of these studies limits the ability to draw conclusions. 
Several studies have been conducted focusing on two cohorts of patients 
(Massachusetts, USA and Canada) treated with fluoroscopically guided 
pneumothorax therapy for tuberculosis (TB). These treatments were conducted 2 or 
3 times per month for around 2 years, resulting in mean cumulative doses of around 
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0.8 – 1 Gy to the lungs and 0.54 – 0.96 Gy to the breasts. Exposures were similar to 
cardiac fluoroscopy in terms of dose rate, photon energy and patient position 
(predominantly posterior-anterior). A significant increase in breast cancer incidence 
and mortality among both cohorts has been reported [152-155].  
Despite the lungs receiving a particularly high dose, lung cancer mortality was not 
raised for the exposed group in either Massachusetts (SMR = 0.8 for both male and 
female) [154] or Canada (Relative risk=1.00, 95% CI: 0.94, 1.07) [156] – findings 
grossly inconsistent with the seven-fold increase predicted by Gofman and Tamplin 
based on estimated doses [157]. There are a number of possible explanations for 
these findings; (1) bias due to smoking, (2) modification of risk by TB, or (3) 
fractionation of large doses reduces or eliminates risk. The final point is plausible, 
though inconsistent with evidence of nuclear workers [139] or underground miners in 
which increased lung cancer risk has been associated with chronic, highly 
fractionated exposures. In the former case, a significant increase in lung cancer 
mortality (ERR = 1.8 Sv-1 95% CI: 0.26, 4.01) was reported, though the authors state 
that a confounding effect due to smoking “may be partly but not entirely responsible” 
for the figure.  
The only study to evaluate all cancer sites among TB patients was conducted by 
Davis and colleagues using the Massachusetts cohort  [154]. No overall increase in 
cancer mortality was detected – the SMR was increased for some sites but not for 
others. These patterns are often reversed when male and female data are compared. 
The SMR was non-significantly raised for female leukaemia (1.4, based on 9 cases) 
but not for male (1.0, based on 8 cases). It is therefore extremely difficult to draw 
conclusions from the TB fluoroscopy data that are applicable to cardiac fluoroscopy. 
Patients suffering from the spinal deformity scoliosis are subjected to frequent 
radiological investigations to monitor curvature. Ronckers and colleagues [158] 
studied 3010 women examined an average of 26.8 times between 1912 and 1945, 
receiving a mean breast dose of 120 mGy (range = 0.05 – 1110 mGy).  Based on a 
median follow-up of 35.5 years, a borderline significant ERR of 2.86 (P= 0.058) for 
breast cancer was detected. A significantly higher risk was reported for women with 
first or second degree relatives diagnosed with breast cancer (ERR = 8.37 P=0.03). 
Raised risk was only apparent for patients receiving a cumulative breast dose of 
greater than 200 mGy (mean dose per fraction of 7.46 mGy). No other cancer sites 
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were investigated. This is unfortunate as the dose levels and site of irradiation are 
reasonably similar to cardiac catheterizations. 
Weiss and colleagues [125] studied 14,556 patients treated between 1935 and 1957 
with radiotherapy for ankylosing spondylitis (an inflammatory spinal disorder). The 
mean whole body dose was high (2.64 Gy), with the greatest localised doses to the 
spine. The average follow up was 25 years. Cancer mortality for all sites was 
significantly increased (ERR= 0.18 Gy-1) between 5 and 24.9 years after treatment, 
with risks decreasing beyond 25 years (ERR=0.11 Gy-1). A significant dose response 
was seen for cancers of the oesophagus, colon, pancreas, bones and connective 
tissues, prostate, bladder and kidney, along with non-Hodgkin’s lymphoma, multiple 
myeloma and leukaemia. A small increase in lung cancer mortality was detected 
(ERR=0.09 Gy-1, 95% CI: 0.03, 0.15), while stomach cancer mortality was non-
significantly decreased (ERR= -0.004, 95% CI: -0.05, 0.05). The lack of increased 
breast cancer risk (ERR=0.08 Gy-1 95% CI: -0.30, 0.65) may possibly be due to 
hormonal changes induced by the high dose to the ovaries [3]. The high doses limit 
the relevance of this study to cardiac catheterizations, although the limited effect on 
lung and stomach cancer is intriguing.  
Hildreth and co-workers [159] compared extrathyroid tumour risk in 2856 infants 
therapeutically irradiated for enlarged thymus between 1926 and 1957 with 5053 
unexposed siblings. A significant increase in incidence of malignant tumours of the 
skin and breast was noted (RR=2.0), along with benign tumours of the bone, nervous 
system, salivary glands, skin, and breast (RR=2.2). Further studies by Shore et al 
focused specifically on thyroid tumours among 2657 exposed individuals and 4833 
unexposed siblings [160-162]. Thyroid doses ranged from 0.03 to over 8 Gy, with 
62% receiving under 0.5 Gy. A significant increase was found for malignant tumours 
(ERR=10.0 Gy-1 95% CI: 5, 23) and benign adenomas (ERR=6.3 Gy-1 95% CI: 3.7, 
11.2), with excess risk persisting for at least 40-45 years post-irradiation. Dose 
response was linear for malignant tumours and for adenomas up to 6 Gy, after which 
a downward curvature was seen. Although the doses were relatively high and 
location of irradiation more superior, these findings have relevance to cardiac 
catheterizations and demonstrate the sensitivity of the thyroid to cancer induction in 
childhood. 
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2.2.4: Computed tomography studies 
Computed tomography (CT) is a diagnostic examination in which axial cross-
sectional images are produced by reconstruction of attenuation data obtained from 
multiple angles around the patient [163]. Based on existing knowledge, the effective 
dose for cardiac or chest CT (1-8 mSv [111, 164-167]) is similar, albeit somewhat 
lower, to that of cardiac catheterizations (2-12 mSv [91, 111, 164]), although the 
pattern of dose distribution is not the same. In CT, the beam rotates around the 
patient resulting in a relatively uniform dose distribution, while in cardiac 
catheterizations, exposures may involve only a single beam angle, focused in the 
same place, resulting in more uneven dose distribution to large organs such as the 
lungs. In addition, the peak tube potential used in CT (120 – 140 kVp) is higher than 
fluoroscopy (typically 60-80 kVp).  
To date, five epidemiological studies have been conducted examining the excess 
cancer risks following CT scans in young people. Pearce et al [9] conducted a 
retrospective observational study of nearly 180,000 children and adolescents 
scanned by CT between 1985 and 2002. After around 15 years of follow-up, a 
significant association between radiation dose and incidence of leukaemia (ERR=36 
Gy-1 95% CI: 5, 120) and brain tumours (ERR=23 Gy-1, 95% CI: 10, 49) was detected 
(in relation to red bone marrow and brain doses, respectively). The authors quote 
equivalent figures from the LSS of 45 Sv-1 for leukaemia (95% CI: 16, 188) and 6.1 
Sv-1 for brain tumours (95% CI: 0.1, 63.9) in the 0-19 years age group, suggesting 
the study findings are very similar to the LSS for leukaemia and four times higher for 
brain tumours. However the CT study ERR for leukaemia includes myelodysplastic 
syndrome (MDS), which is not generally regarded as a form of leukaemia [168] and 
not included in the LSS risk estimate. Excluding MDS from the CT study results, the 
ERR is reduced to less than half that of the LSS at 19 Sv-1 and no longer statistically 
significant. Even including MDS, risks for leukaemia were lower than reported in the 
previously mentioned study by Kendal et al [149] in relation to natural background 
radiation. Pearce et al found the risk of brain tumours to increase with increasing age 
at exposure, ranging from 5 Gy-1 at 0-5 years to 41 Gy-1 after 15 years. This finding, 
while not unprecedented, contrasts with the LSS [169] and studies of children 
irradiated for tinea capitis [170] and skin haemangioma [171] in which the reverse 
pattern was suggested. There was a suggestion that females were at a greater risk 
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than males of brain tumours following CT scans (ERR of 28, verses 16, p=0.085). 
Again, the reverse pattern was observed among the LSS cohort (p=0.02) [169]. 
As stated above, the ERR estimates derived by Pearce et al were higher than those 
of the LSS by a factor of around four. The LSS figures are themselves higher, by a 
factor of between five and ten, those derived from studies of brain tumours following 
radiotherapy for previous cancer in childhood [172]. These studies provide limited 
evidence of excess risk of brain tumours below doses of around 10 Gy [173-175]. A 
systematic review of benign second tumours by Kutsenko et al [176] found 
significantly raised incidence only where the primary tumour was of the brain, ‘other 
central nervous system’, thyroid and acute lymphoblastic leukaemia (all sites in 
which cranial radiotherapy is used). The association is stronger for meningioma, in 
which a reasonably linear dose response is seen, compared to glioma [129, 174]. 
Pearce et al [9] suggest a mean absorbed dose to the brain from CT scans of around 
60 mGy in childhood could triple the risk of brain tumours. This increase in risk is 
comparable to that following radiotherapy doses of over 10 Gy [172]. 
The UK CT study, and others following, was reviewed by Walsh et al [177] and Boice 
[178] who both raise concerns over the potential for confounding by indication, as 
well as the combining of MDS with leukaemia. No effort was made to identify 
subjects with diseases such as neurofibromatosis or tuberous sclerosis, both of 
which are an indication for CT and a major risk factor for brain tumour development 
[179, 180]. A recent study by Meulepas et al [181] estimated the confounding bias 
introduced by various cancer predisposing conditions. The study concludes that 
relative risks for leukaemia are not meaningfully confounded by such conditions, 
while brain tumour risks may be overestimated due to tuberous sclerosis.  
Following the UK CT study by Pearce et al [9], Mathews et al [124] conducted a data 
linkage analysis of 680,211 Australian patients receiving CT scans at ages 19 or 
under, between 1985 and 2005, compared to 10,259,569 unexposed individuals. 
With a mean follow-up duration of 9.3 years, cancer incidence in the exposed group 
was 24% greater than in the unexposed group (incidence rate ratio (IRR) = 1.24, 
95% CI: 1.20, 1.29 for all cancers). This increase, the authors state, is ‘mostly due to 
irradiation’. Increases in almost all sites of cancer were found, including those with 
limited previous association with radiation, such as Hodgkin's lymphoma and 
melanoma [182, 183], but no increase was found for breast cancer (IRR = 0.99) and 
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lymphoid leukaemia (0.96), both of which are strongly associated with radiation [45, 
178].  IRR figures were also calculated based on the number of years since first 
exposure. These were 1.35, 1.25, 1.14 and 1.24 for 1-4, 5-9, 10-14 and >15 years 
since the first scan respectively. This pattern of a large excess of cancers occurring 
soon after exposure, followed by a decrease is not consistent with the findings of the 
LSS or studies of second cancers following radiotherapy, in which a median latency 
between exposure and cancer diagnosis of around 20 is typically seen [184] [185]. 
The decision to use a latency period of only 1 year for solid tumours is not 
adequately justified and lacks biological plausibility. Again, no effort was made to 
remove potential confounding diseases. 
Huang and colleagues [186] studied cancer incidence ascertained from insurance 
records among 24,418 subjects undergoing CT scans of the head while aged under 
18 years between 1998 and 2006 in Taiwan, compared to 97,668 unexposed 
individuals. For all cancer types combined, no significant increase was seen among 
the exposed cohort (hazard ratio = 1.29, 95% CI 0.90-1.85). A significant increase in 
brain tumours was found (HR=2.56, 95% CI 1.44-4.54), based on 19 cases, of which 
14 were benign. A significant trend of increased brain tumour risk with scan 
frequency was noted, though based on an extremely limited number of cases (a 
single case in the 3 or more scans group). Radiation doses were not estimated. 
Furthermore, the authors did not include non-head CT exposures in their analysis. 
However, unlike the studies by Pearce and Mathews described above, the 
Taiwanese CT study team have at least attempted to address the issue of 
confounding by indication by excluding patients with certain conditions. The 
exclusions are somewhat inexhaustive though; not including tuberous sclerosis, 
ataxia telangiectasia or Li Fraumeni syndrome. This, combined with the small sample 
size and short latency period of 2 years (based on limited evidence not specific to 
brain tumours) renders the Huang study of limited value. 
Journy et al [187] investigated cancer incidence among 67,274 children who 
underwent CT scans before the age of 10 in France between 2000 and 2010. As with 
the Taiwanese study, Journy et al attempted to address the issue of confounding by 
indication by identifying patients with known cancer predisposing conditions. The 
study is limited by the very short median follow-up time of 4 years, though has the 
advantage over the Huang study [186] of providing dose estimates based on 
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examination protocols. The results presented by Journy are difficult to interpret. 
While apparently suggesting a decrease in ERR after adjusting for predisposing 
conditions, the ERR for children without such conditions appears to be higher than 
the unadjusted ERR for the whole cohort, while the ERR for children with 
predisposing conditions is close to zero. This, argue and Cardis and Bosch de Basea 
[188] and Muirhead [189] , implies the ERR is modified by predisposing factors rather 
than confounded. Furthermore, the study acquired data from specialist hospitals, 
where the rate of underlying predisposing conditions was relatively high [189]. 
Krille et al [190] conducted a study investigating cancer incidence among 44,584 
German children exposed to 71,073 CT scans between 1980 and 2010. Again, 
efforts were made to exclude subjects with conditions predisposing for cancer or 
those examined for suspected cancer. Non-significantly raised incidence of 
leukaemia (SIR = 1.72, 95 % CI: 0.89, 3.01) and CNS tumours (SIR=1.35, 95% CI: 
0.54, 2.78) was found. A significant risk for all cancers combined was observed 
(SIR=1.54, 95% CI: 1.05, 2.19), based on 31 observed cases verses 20.1 expected. 
This increase was driven to some extent by an increase in lymphoma (SIR=1.85, 
95% CI: 0.68, 4.02). A dose response was obtained by calculating the hazard ratio 
(HR). A significantly increased HR was found for brain tumours (1.008 per mGy, 95% 
CI: 1.004, 1.013), but not for leukaemia (HR=1.009 mGy-1, 95% CI: 0.981, 1.037) and 
for all tumours combined (HR=0.986 mGy-1, 95% CI: 0.944, 1.030). 
Most recently, a re-examination of the UK CT study was conducted by Berrington de 
González et al [191], who analysed pathology reports, radiologist reports and 
comments written in the radiology information system (RIS) to identify predisposing 
conditions and pre-existing tumours. Previously unreported cancers were found to 
have the largest impact, resulting in a reduction in ERR for brain tumours by 50% 
and for leukaemia by 15%. Pre-disposing conditions were not associated with a 
decrease in ERR as they did not appear to be related to CT exposure.  
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ERR per Gy (95% CI) 
Study Brain tumours Leukaemia 
Life Span study * 6 (0, 64) 45 (16, 188) 
Pearce [9] 23 (10, 49) 
19 (-12, 79)  
36 (5, 120) $ 
Berrington [191]  excluding 
previous cancers. 
10 (2, 26) 20 (-11, 29) $ 
Berrington [191]  excluding PFs 27 (10, 65) 34 (5, 129) 
Mathews [124] 21 (14, 29) 35 (0, 77) 
Journy [187] (unadjusted for PF) 22 (-16, 61) 57 (-79, 193) 
Journy [187] (adjusted for PF) 12 (-13, 37) 47 (-65, 159) 
 
Table 2.5: Summary of elevated relative risk (ERR) for brain tumours and leukaemia 
(excluding myelodysplastic syndrome) for 5 CT studies. * Figures reported by Pearce et al 
[9]. $ including myelodysplastic syndrome, PF=predisposing factor. 
 
2.2.5: In Utero exposures 
Prior to 1956, many pregnant mothers were examined by x-ray pelvimetry for 
obstetric planning purposes. This procedure was restricted following concerns of 
hereditary effects in the offspring of the irradiated foetus [192]. Although such risks 
appear to have been overly pessimistic, the abandonment of pelvimetry was later 
associated with a significant decrease in childhood cancer in the following years 
[193] in the Oxford Study of Childhood Cancers. Based on an estimation of doses per 
image and the total number of images acquired during pregnancy, the mortality ERR 
was estimated by Mole [192] as 0.038 per mGy (95% CI: 0.007, 0.079) and Bithell as 
0.051 mGy-1 (95% CI: 0.028, 0.076). The latter estimate is influenced by an upturn in 
RR beyond 1967, which Doll and Wakeford [193] argue is likely to be artificial.  The 
authors calculate an EAR of 6% Gy-1; though acknowledge uncertainty in the exact 
value. A later study by Wakeford and Little [194] revised this figure to 8% Gy-1. 
The results of the Oxford study have been used as evidence in support of linearity of 
dose response as low as 10 mGy [46], having the advantages of x-ray energies 
relevant to diagnostic imaging and the lack of confounding by indication issues (i.e. 
the unborn child was not being treated for a pre-existing condition). Nonetheless, the 
risk estimates are dependent on non-individualised reconstructions of doses 
delivered decades earlier, resulting in significant uncertainty. Furthermore, the 
findings are not consistent with those of the LSS in which no significant increase in 
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childhood cancer was detected among 753 subjects receiving in utero exposures of 
over 10 mGy [193]. A more recent study of 8000 offspring of pregnant workers of the 
Mayak nuclear weapons facility in Russia, receiving a mean dose of 54.5 mGy [195] 
found no significant increase in solid cancers (ERR= -0.1 Gy-1, 95% CI: <-0.1, 4.1) or 
leukaemia (ERR= -0.8 Gy-1, 95% CI: <-0.8, 46.9) in offspring. 
It is interesting that an increase in almost all cancer sites was detected in the Oxford 
study, including those cancers not normally induced by radiation [193]. The different 
level of cell proliferation, immune system development and level of gap-junction 
intercellular communication in embryonic tissues should limit the applicability of the 
Oxford findings to the wider population [59].  
 
2.2.6: The effect of age 
Age at exposure modifies the risk of radiation induced cancer and will have an 
important bearing on the current study. For all sites combined, a pattern of 
decreasing risk with increasing age at exposure is generally assumed [3, 44]. Such 
assumptions, while having reasonable evidential support, have become something of 
a cliché, forming part of the standard preamble of almost all published papers on 
paediatric imaging and radiation doses. In reality, evidence of the effect of age at 
exposure on radiation induced cancer risk is far from conclusive. More recent 
analysis of the LSS data suggests the possibility of a ‘U’-shaped relationship, with 
risks initially falling with age at exposure, before rising in middle age [169]. Analysis 
between individual cancer sites lacks statistical power [196], though there is a 
suggestion that for some sites, the risk of radiation induced cancer is higher among 
adults than previously supposed [197]. Confidence intervals are wide, however, and 
cannot be narrowed as data collection for individuals exposed in middle age is 
complete (i.e. all have now died) [198]. 
Other epidemiological studies, studies of nuclear industry workers have failed to find 
any modifying effect of age at exposure [9, 139, 148]. Analyses of cancer mortality 
among residents of the Techa River and Semipalatinsk regions suggests an increase 
in risk with increased age at exposure [147, 148]. The most recent analysis by the 
United Nations Scientific Committee on Atomic Radiation (UNSCEAR) [129] 
concludes that children are at a greater risk than adults for 25% of tumour types, 
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including thyroid cancer and leukaemia,  at the same risk as adults for 15% of tumour 
types, including liver cancer, and at a lower risk for 10% of tumour types, including 
lung cancer. For 20% of tumour types, including oesophageal cancer, the data are 
insufficient to draw conclusions [129].  
It appears that most radiation induced cancers develop at ages at which they would 
normally be expected to occur in the general population [132]. For example, where 
children receive radiotherapy for primary cancer, second cancers developing in the 
following years (i.e. where the patient is still a child or young adult) tend to be other 
‘childhood’ cancers, such as sarcomas, leukaemia and brain tumours [185, 199]. 
With longer follow-up, breast and colon second cancers develop [200, 201]. Only 
where follow-up times are sufficient to include cohort members who have reached 
around 40 years, are ‘adult’ second cancers such as lung and stomach found. 
Among the atomic bombing survivors, excess cases of lung, stomach, breast and 
liver cancer were close to zero at 35 years, rising to maximum levels at age 80 or 
above [135, 169]. While there is a suggestion that the latency period between 
exposure and cancer diagnosis is reduced at high doses [45], there is little evidence 
that radiation can somehow ‘force’ the early development in children of tumours 
normally associated with adulthood. Cancers of many of the most heavily irradiated 
sites from cardiac catheterizations (lungs, oesophagus, stomach and liver) are 
exceptionally rare before 30 years of age, with incidence rates generally less than 1 
case per 100,000, per year [202, 203]. This presents an important challenge for an 
epidemiological analysis; in order to detect the cancers most likely to be induced by 
cardiac catheterizations, the follow-up time would need to be long. With short follow-
up times (i.e. less than 20 years), observed cancers are all likely to be those normally 
occurring in childhood, notably leukaemia and lymphoma. 
 
2.2.7: Summary of epidemiology review 
Previous attempts at epidemiological assessment of the cancer risks from cardiac 
catheterizations lack sufficient statistical power and have limited or non-existent 
dosimetry. Currently, risks from these procedures can only be estimated based on 
the findings from studies of other exposures, most notably the Life Span Study. The 
applicability of these findings to cardiac catheterizations is debateable as the doses 
and exposure patterns are different. There is therefore a need for a direct 
60 
 
epidemiological analysis of radiation associated cancer risks among patients 
undergoing these procedures. There are however a number of significant challenges, 
in particular the issue of confounding by indication and the long follow-up time 
required to detect the cancers most likely to be induced. 
 
2.3: Conclusion 
Previously published assessments of the radiation doses from cardiac 
catheterizations in young people are inadequate, being mainly restricted to simple 
surveys of kerma area product, with little or no assessment of dose to the patient. 
Studies have suggested that estimation of patient dose using PKA is possible, though 
this needs to be explored in greater detail. Epidemiological evidence of the cancer 
risks at low doses remains inconclusive. The uncertainty in both the radiation doses 
and associated risks from cardiac catheterizations is problematic in terms of 
justification and optimisation. This necessitates further research. 
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Chapter 3: Analysis of Cohort Data: 
The following chapter describes the establishment of a retrospective cohort of 
children and young adults who have undergone x-ray guided cardiac catheterizations 
in the UK, along with an analysis of data received from participating hospitals. These 
data included kerma area product (PKA), fluoroscopic screening time (ST) and air 
kerma (skin dose estimates). Such dose indicators have limited usefulness in risk 
estimation or epidemiological analysis, though offer the opportunity for comparison 
with previously published research and can be used to evaluate and explain variation 
in doses between hospitals and to set so-called ‘reference doses’. The estimation of 
organ doses and associated cancer risks using these data will be covered in later 
chapters.  
 
3.1: Research Governance 
A favourable ethical opinion was gained for the study from the National Research 
Ethics Service (NRES) Committee North East - Newcastle & North Tyneside 2 ethics 
committee (10/H0907/47). In addition, Confidentiality Advisory Group (CAG) 
approval for obtaining patient identifiable data without individual patient consent was 
obtained (ECC 7-04(j)/2010). Each committee was provided with yearly updates of 
study status. Where data were obtained from hospitals, local Research and 
Development (R&D) department approval was also obtained. Cohort members were 
assigned an anonymous identification code. After these were assigned, the dataset 
containing patient names was stored in a relational database that could only be 
accessed from within the Sir James Spence Institute at Newcastle University. 
Analysis was conducted on anonymised data wherever possible. The study was 
retrospective in nature, extending from 2014 to as far back as data were recorded. 
Once data were acquired from a participating hospital, collection at that site was 
terminated.  
 
3.2: Data collection methodology 
The cohort was created by identifying all the hospitals in the UK carrying out cardiac 
catheterizations on children and young adults. These procedures are performed on 
adults at most hospitals throughout the United Kingdom. However, procedures on 
children and young adults are limited to 14 centres, carrying out between 100 and 
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500 procedures per year [2] (Table 3.1). Some of these are dedicated children’s 
hospitals while others are general hospitals. All hospitals were contacted by the 
author, except for two hospitals in which prior agreement to supply data had been 
obtained. Various strategies were used. A list of e-mail addresses of local medical 
physicists was obtained and these staff contacted. Job advertisements for 
catheterization laboratory staff were searched for possible contacts. Collaborators 
already involved in the study where in some cases able to identify staff at other 
hospitals who could help. R&D approval to obtain data was obtained from 7 
hospitals. At the time of writing, 6 hospitals had provided data. These were 
reasonably well distributed throughout England (Figure 3.1), giving representation for 
Southern, Midlands and Northern regions. One further hospital had agreed to 
participate but has not yet sent any data (though cooperation has been maintained). 
To be eligible for inclusion in the cohort, subjects needed to be aged under 22 years 
at the time of the first recorded examination. Procedures conducted after the patient 
reached 22 years were retained, though were not analysed in this study. Patients 
undergoing Hickman or PICC (Peripherally Inserted Central Catheter) line insertions 
or pericardial effusion drainage, in the absence of other cardiac catheterizations, 
were excluded. These procedures were not regarded as true cardiac 
catheterizations, and, in the case of PICC and Hickman insertions, often signify 
existing malignancy as they are used for chemotherapy administration or marrow 
transplants [204, 205]. Patients with congenital heart conditions who reach adulthood 
may continue to be cared for by paediatric cardiologists and may undergo 
catheterizations in children’s hospitals. Consequently, data obtained from paediatric 
hospitals often contained a small number of records for patients examined as adults.  
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Hospital: Contacted Replied 
R&D approval 
obtained 
Data 
obtained 
Great Ormond Street Hospital, London * Yes Yes Yes Yes 
Alder Hey Children’s Hospital, Liverpool* Yes Yes Yes Yes 
Glenfield Hospital, Leicester Yes Yes Yes Yes 
Evelina Children’s Hospital, London * Yes Yes Yes Yes 
Freeman Hospital, Newcastle-upon-Tyne Yes Yes Yes Yes 
John Radcliffe Hospital, Oxford  Yes Yes Yes Yes 
Birmingham Children's Hospital * Yes Yes Yes Awaiting 
Manchester Royal Infirmary Yes Yes Failed   
Leeds General Hospital Yes Yes - declined 
 
  
Glasgow Hospital for Sick Children * Yes Yes Applied   
Southampton General Hospital Yes No response     
The Bristol Royal Hospital for Children * Yes Yes Lost contact   
Royal Brompton and Harefield Hospital Yes No response     
Royal Belfast Hospital for Sick Children * Yes Yes Lost contact   
 
Table 3.1: Data acquisition status for 14 UK hospitals carrying out cardiac catheterizations in 
children and young adults. * Specialist children's hospitals. 
 
Figure 3.1: Location of hospitals providing data (yellow) and centres from which no data 
were obtained at the time of writing (red). Figure credit: author 
 
The data provided by participating hospitals were variable. Some centres recorded 
examination details in paper logbooks, while others recorded it electronically. A 
description of the data available at each participating hospital is provided below. A 
summary is provided in Table 3.2. Note that the total number of patients in the cohort 
is smaller than the sum of individual hospitals, as some patients underwent 
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procedures at more than one hospital. Table 3.3 shows details of equipment used at 
each hospital. All machines were biplane. These details will be explored in much 
greater detail in the ‘supporting information’ chapter. From the remainder of this 
thesis, all hospitals will be anonymized, and will be referred to as Hospitals 1-6. 
Fluoroscopic equipment was confirmed with local medical physics staff to have 
undergone at least yearly quality assurance (QA) testing, including PKA measuring 
device calibration. QA reports were obtained for machines, where available. 
 
Hospital 1 
Hospital 1 provided by far the largest amount of data in the study (36% of 
examinations). Data were recorded in paper form in multiple log books, which 
extended back as far as 1994. The logbooks were transcribed at Newcastle 
University. Procedures were carried out in several different laboratories, often with 
different equipment. Post 2002, recorded details were relatively extensive, including 
bi-plane PKA, estimated skin doses and clinical details including indications for the 
procedures (i.e. why it was being carried out). For examinations conducted in lab 1 
between 1994 and 2000, the recording of PKA was sporadic, quoted for 32% of 
procedures. Between 2000 and 2002, only screening time was recorded.  
Hospital 2 
Data were obtained for procedures carried out between 2004 and 2013. During this 
time period, two machines were used – a Philips Integris BH3000 up to 2008 and a 
Siemens Artis Zee after this date. Data were not available prior to 2004. Boxes of 
cine film from procedures as far back as the late 1960s were located, each 
containing the patient name and screening time, but no PKA or procedure type. These 
data were not acquired due to the limited information content and time required for 
gathering. More recent examinations up to 2004 were recorded on CDs, with dose 
information written on the CD packaging. Unfortunately, in a bid to save space, these 
CDs were transferred to large spools and all packaging was discarded without the 
information being recorded. Examination details were recorded in paper log books. 
On agreement with the named local collaborator and local R&D team, data from 
these were obtained by photographing each page of the book at Hospital 2 and 
transcribing these photographs at Newcastle University. The fluoroscopy equipment 
used at Hospital 2 reports doses as bi-plane PKA figures, but these were only 
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recorded in logbooks as total PKA (i.e. frontal and lateral beams combined). Hospital 
2 records the beam angles used for each examination along with short, free-text 
descriptions of procedure type and the clinical details of the patient.  
Hospital 3: 
Data were available from 2004 onwards and in electronic form. Doses were recorded 
as total PKA figures. Procedure types were recorded in good detail and secondary 
procedure types (i.e. a second exam done at the same time) were also recorded. 
Patient age, height and mass were also recorded.  
Hospital 4 
The data obtained from the Hospital 4 were unusual in that dose indicators were not 
recorded on the Radiology Information System (RIS). A download of RIS data for 
procedures carried out since 1991 was obtained, along with a separate file 
containing dose indicators recorded using a monitoring system developed by the 
local medical physics department from 1993 to 2014. PKA figures were adjusted by a 
calibration factor and for table attenuation. Unfortunately a large number of 
procedures recorded in the RIS data (n=4728) were not present in the dose file 
(n=1769). Dose details were only obtained for patients under age 16 years. 
Furthermore, the procedure types were found to be vague. Most procedures (75%) 
were simply listed in the dose file as ‘A.PAE’. It was observed that radiographers 
tended to use this procedure code for virtually all cardiac catheterizations, regardless 
of what the actual procedure type was. In the RIS file, most procedures were simply 
listed as an ‘angiocardiogram’. PKA, where recorded was in the form of biplane 
figures for 70% of procedures. The remainder were recorded as a single total figure.  
Dose data were recorded sporadically. In particular, between 2006 and 2011, PKA 
was recorded for only 26 out of 984 (2.6%) procedures. 
Hospital 5: 
Data were obtained from the Radiology Information System (RIS) in electronic form 
and included total examination PKA figures and screening time. Patient mass or 
height were not recorded. Procedure type was reasonably detailed, though lacked 
clinical details. There were 130 entries in which it appeared that the patient had 
undergone two identical examinations on the same day, both with the same 
screening time, but different PKA. Where dose figures were identical, the second 
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entry was assumed this was a duplicate entry and removed. Where the figures were 
different, they were combined to produce a single procedure. 
 
Hospital 6 
Data were recorded in log books at Hospital 6, but unfortunately these were 
discarded some years prior to the study. Procedures carried out after May 2006 were 
recorded electronically and details were obtained in an Excel file. Data included 
patient age, but not height or mass. Only the patient’s surname was included, which 
limited the usefulness of the Hospital 6 data for cancer registry matching. 
 
Hospital (date range) 
[laboratory number] 
No. of 
exams 
No. Of 
patients 
% with PKA 
 (with 
biplane PKA) 
% with  
ST 
% with 
Mass 
% with 
Height Age 
Exam 
type 
Clinical 
info 
Hospital 1 (1994-00) [1] 2067 
4753 
32% (30%) 98% 96% 0% Yes Yes Yes 
Hospital 1 (1999-02) [2] 1040 96% (96%) 97% 98% 95% Yes Yes Yes 
Hospital 1 (2000-02) [1] 183 0% (0%) 100% 71% 14% Yes Yes Yes 
Hospital 1 (2002-08) [1] 3196 97% (97%) 98% 98% 85% Yes Yes Yes 
Hospital 1 (2007-10) [4] 725  98% (98%) 99% 91% 68% Yes Yes Yes 
Hospital 2 (2004-08) 1640 
3655 
92% (0%) 91% 87% 0% Yes Yes Yes 
Hospital 2 (2008-13) 2012 90% (0%) 91% 93% 0% Yes Yes Yes 
Hospital 3 (2008-13) 1407 
1611 
94% (0%) 94% 99% 81% Yes Yes No 
Hospital 3 (2004-08) 842 94% (0%) 92% 100% 86% Yes Yes No 
Hospital 4 (1991-03) 2666 
2983 
46% (37%) 45% 41% 40% Yes Yes  No 
Hospital 4 (2003-14) 2863 19% (9%) 19% 17% 17% Yes Yes No 
Hospital 5 (2005-13) 737 674 97% (0%) 94% 0% 0% Yes Yes No 
Hospital 6 (2006-13) 356 313 58% (0%) 60% 13% 10% Yes Yes No 
Total: 19734 13,564 67% (33%) 
       
Table 3.2: Summary of data acquired from participating hospitals. Note that many hospitals 
replaced equipment during the data collection period at least once. These separate ‘eras’ are 
recorded as separate lines in the table. ST= screening time. 
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Hospital (date range) 
[laboratory number] 
Manufacturer and 
model 
Antiscatter 
Grid 
Tube 
potential 
(kVp) 
Filtration 
Frame 
rates (s-1) 
Detector 
type 
Hospital 1 (1994-2000) 
[lab 1] 
Siemens BICOR 
Biplane 
Fixed Unknown Al 
Cont (f) 
30-60 (a) 
II 
Hospital 1  (1999-2002) 
[lab 2] 
Toshiba Infinix CX 
Biplane 
Fixed 50-125 Al+? 
25-30 (f) 
25-30 (a) 
II 
Hospital 1  (2000-2002) 
[lab 1] 
Unknown Unknown Unknown Unknown Unknown Unknown 
Hospital 1  (2000-2008) 
[lab 1] 
Siemens Axiom 
Artis BC Biplane 
>10 kg 58-125 Al + Cu 
10-15 (f) 
15 (a) 
II 
Hospital 1  (2007-2010) 
[lab 4] 
Siemens Axiom 
Artis dBC Biplane 
>10 kg 58-125 Al + Cu 
10-15 (f) 
15 (a) 
FPD 
Hospital 2 (2004-2008) 
Philips Integris 
BH3000 
Always Unknown Al + Cu Unknown II 
Hospital 2 (2008-2013) 
Siemens Artis Zee 
Biplane 
Always 58-125 Al + Cu 
10-15 (f) 
30 (a) 
FPD 
Hospital 3 (2004 - 2013) 
Siemens HICOR 
Biplane 
Fixed Unknown Al + Cu 
10 (f) 
30 (a) 
II 
Hospital 3 (2004-2008) 
Siemens Axiom 
Artis dFC Biplane 
>10 kg 58-125 Al + Cu 
12.5 (f) 
30 (a) 
FPD 
Hospital 4 (1991-2003) 
Siemens  
Coroskop C Biplane 
Fixed Unknown Al Unknown II 
Hospital 4 (2003-2014) 
Siemens Axiom 
Artis BC Biplane 
>10 kg 58-125 Al + Cu 
7.5 (f) 
15-30 (a) 
II 
Hospital 5 (2005-2013) 
Siemens Axiom 
Artis Biplane 
Unknown 58-125 Al + Cu 
7.5-15 (f) 
? (a) 
FPD 
Hospital 6 (2006-2013) 
Siemens Axiom 
Artis dBC Biplane 
Unknown 58-125 Al + Cu Unknown FPD 
 
Table 3.3: Equipment used at participating hospitals. Note: II=image intensifier, FPD=flat 
panel detectors, Cu=copper, Al=aluminium, f=fluoroscopy, a=acquisitions. 
 
3.3: Data checking procedure 
For all cohort data, a systematic process was used to detect, and correct where 
appropriate, data entry errors. This process was especially important for data 
extracted from log books. 
1.  Where PKA was reported as biplane figures as well as a ‘total’ PKA, the frontal and 
lateral figures were added to check if it matched the ‘total’ quoted in log book. The 
radiographer calculates the total PKA figure through mental arithmetic. The sum of 
frontal and lateral figures was considered more reliable and used in cases of 
discrepancies (57 entries at Hospital 1). 
2. Estimated skin dose is calculated by dividing PKA by beam area. The PKA should 
always be higher than skin dose, otherwise the field size would be smaller than 1 
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cm2. Skin doses were higher than PKA in 41 cases (all at Hospital 1), where it was 
assumed the respective figures had been entered into the wrong columns. 
3. Body mass index (BMI) was calculated, where mass and height were recorded. 
This is defined as: 
𝑀𝑎𝑠𝑠 (𝑘𝑔)
𝐻𝑒𝑖𝑔ℎ𝑡2(𝑚)
 
Individuals with a BMI of over 35, defined by the World Health Organisation as being 
‘obese class II’ [206] (severely obese) were investigated. In most cases, a typing 
error was responsible, typically a missing decimal point. In 28 cases, the mass and 
height appeared to have been written the wrong way round. Units of height varied 
between centimetres and metres. After corrections, where possible, 19 patient mass 
entries were considered unreliable and deleted. A record of the quoted figure was 
recorded in the comments column. In all of these cases, a reliable patient age was 
recorded. 
4. Divide total PKA by screening time. A very high dose per unit screening time may 
be due to the patient being obese. The PKA/time figure was therefore divided by 
patient mass. In 13 cases, the PKA/min/kg was considered unusually high or low. 
5. Calculate age by subtracting date of birth from date of examination. Negative ages 
were investigated. After corrections, where possible, 5 patients had unresolved 
negative ages. 
6. Plot the date of examination against entry number as entered in the log book.  The 
examination dates should increase steadily. Any outliers suggest the date was 
entered incorrectly. Exams were always presented in chronological order. For 
missing examination dates, a date was assigned based on that of the previous 
examination. 
7. Where biplane PKA and skin doses are provided, calculate the ratio between PA 
and lateral PKA and between PA and lateral skin dose. The ratios should be 
approximately the same.   This process was not always possible for procedures with 
low doses. The skin dose from Hospital 1 was recorded in integer units of mGy, with 
doses less than 1 mGy being recorded as 0. 
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All discrepancies were first highlighted in red in the database and investigated 
further. In some cases, the problem could be corrected. The most common problems 
were transcription errors. In many cases, details had been written in the wrong 
columns (e.g. a height of 3 cm and a mass of 40 kg). These were corrected and a 
note made of the original data entry. Unresolved discrepancies were mostly due to 
illegible handwriting.   
 
3.4: Data analysis methodology 
Data were obtained for 20,078 procedures carried out for which a valid procedure 
type was available. Kerma area product was recorded for 13,654 of these 
procedures. Data obtained for procedures carried out at the same hospital but using 
different equipment were analysed separately (i.e. the same date ranges shown in 
Table 3.). These different ‘eras’ corresponded with the three generations of 
fluoroscopic equipment outlined in the Introduction chapter (section 1.1). All 
statistical analysis was carried out using MATLAB (versions 2011a and 2013a, 
Mathworks, Natick, USA) using anonymised data (only age, mass, dose indicators 
and anonymous ID number). A MATLAB function was written that automatically sorts 
the data into different procedure type categories, stratifies by patient age or mass 
and produces summary statistics. The results are automatically saved as an Excel 
file for viewing.  Each examination was numerically coded into four overall 
categories: 
1. Diagnostic: All procedures in which the aim was to find out what is wrong with 
the patient or to monitor a condition, but without any form of therapeutic 
intervention. 
2. Interventional: All procedures that involve “doing something” to the heart or 
surrounding vessels with the aim of changing heart function. This includes 
stent insertion, balloon dilatation, closure of anomalous ducts or vessels, or 
ablation. The interventional category includes procedures with both diagnostic 
and therapeutic elements and attempts at intervention that failed. 
3. Pacemaker procedures, including wire and battery replacements. 
4. Other: All other procedures involving cardiac fluoroscopy. This included 
biopsies and those procedures difficult to categorise as either diagnostic or 
interventional. 
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The above groups were then sub-divided into more specific procedure types:  
1. Atrial septal defect (ASD) occlusion 
2. Patent ductus arteriosus (PDA) occlusion 
3. Pulmonary valve (PV) angioplasty 
4. Aortic valve (AV) angioplasty 
5. Pulmonary artery (PA) angioplasty 
6. Coarctation (COA) angioplasty 
7. Electrophysiology studies (EPS) with or without radiofrequency ablation (RFA) 
8. Endomyocardial biopsy (EMBx) 
9. Coronary angiography 
10. Valve replacements 
11. Pulmonary vascular resistance (PVR) studies. 
12. Pacemaker procedures 
13. Atrial septostomy 
14. Unspecified valve angioplasty (PV or AV) 
15. Right ventricular outflow tract (RVOT) angioplasty 
0. Unspecified or other procedure types not listed above. 
Descriptions of these procedures can be found in the Introduction chapter. The final 
procedure type ‘0’ included procedures rarely carried out, such as collateral 
embolization or ventricular septal defect (VSD) occlusion. The procedure types 
provided by hospitals were sometimes too vague to categorize the procedure. This 
was the case for 1323 procedures carried out at the Hospital 4, listed simply as 
‘A.PAE’. These procedures were also classed as type 0. Note that certain 
procedures, such as valve replacements and heart biopsies are typically only carried 
out at certain specialist hospitals. 
The coding system also included a separate column to indicate multiple procedures 
being carried out during the same catheterization. In many cases these were 
relatively minor procedures such as insertion of a central venous catheter. These 
were coded as ‘1’ and included in the analysis of doses for individual procedure 
types. Where two distinct, non-minor procedure types were carried out, such as ASD 
occlusion and valve angioplasty, these were coded as ‘2’ and excluded from analysis 
of individual procedure types but included in the broader interventional or diagnostic 
groups.  
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Cohort data were analysed by total PKA, screening time, patient mass and age, PKA 
per kilogram (PKA/kg) and by broad exam category and specific procedure type. Bi-
plane PKA and skin dose figures were analysed where recorded. Data were stratified 
by mass using the same groups as Glatz et al [91]. Age was stratified using the same 
groups as Kobayashi et al [207] and Verghese et al [82] with the addition of an extra 
16-18 years group. Examinations with zero doses were excluded from the analysis, 
as were examinations in which data were considered unreliable, mostly due to 
difficult handwriting (n=29). A Lilliefors test [208] was applied to determine whether 
PKA data were normally distributed. Data were not found to be normally distributed for 
any of the hospitals from which data were acquired, and were always right skewed. 
Therefore median and interquartile range statistics were chosen as the primary 
representation of PKA data. 
 
3.5: Results 
Tables 3.4 to 3.6 present mean PKA, along with median PKA, screening time and 
(where available) skin doses and the percentage of total PKA originating from the 
frontal (PA) output, for all procedure types combined, stratified by age, presented for 
each hospital and equipment era separately. Skin dose is recorded in both frontal 
and lateral planes. The figures reported here are the median of whichever figure was 
the highest in each examination, rather than the median of both planes combined (a 
common, though ultimately unhelpful practice). Tables 3.7 and 3.8 show median PKA 
for different procedure types for all patient ages combined, again separately for 
different hospitals and eras. Categories in which fewer than ten procedures were 
carried out are not shown. More detailed tables with stratification by both mass and 
procedure type are provided in the appendix, along with equivalent tables stratified 
by mass. The following sections discuss various elements of the data separately. 
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Hospital, era 
Dose indicator 
Patient age range 
H
O
SP
IT
A
L 
1
 
 1
9
9
4
 -
 2
0
0
0
 
<1 y 1-5 y 5-10 y 10-16 y 16-18 y >18 y All 
Median PKA [IQR] 12.2 [7 : 18.7] 23.7 [14.9 : 35.9] 35.6 [21.1 : 61.8] 69.9 [28.1 : 117] 105 [64.3 : 179.7] 112.8 [77.6 : 150.3] 26.8 [13.1 : 61.9] 
Mean PKA [St Dev] 15.8 [14.1] 29.7 [23] 47.2 [40] 94.5 [101.5] 137.6 [107.7] 125.8 [91.1] 50.5 [67.9] 
Median PKA/kg [IQR] 2.35 [1.49 : 3.89] 2.02 [1.27 : 3.04] 1.7 [1.1 : 2.57] 1.8 [0.9 : 2.68] 2.19 [1.3 : 3.26] 1.82 [1.35 : 2.38] 2 [1.24 : 3.07] 
Median % PA [IQR] 71% [64 : 78] 67% [57 : 75] 62% [50 : 68] 61% [50 : 70] 60% [49 : 70] 62% [49 : 73] 66% [55 : 74] 
Median skin dose [IQR] n/a n/a n/a n/a n/a n/a n/a 
Screening time [IQR] 17.4 [11 : 25.9] 19.5 [12.4 : 29.7] 18.9 [11.9 : 29.7] 20.1 [9.8 : 34] 18.7 [13.3 : 30.6] 19.9 [12.6 : 25.7] 18.9 [11.6 : 29.7] 
n 166 179 124 111 32 29 641 
H
O
SP
IT
A
L 
1
 
 1
9
9
9
 -
 2
0
0
1
 
Median PKA [IQR] 4.4 [2.4 : 7.8] 9.1 [5.2 : 16.4] 13.7 [7.5 : 26.8] 26.6 [11.6 : 57.5] 43.2 [24.3 : 102.4] 95 [47.7 : 126.5] 10.3 [5 : 25.5] 
Mean PKA [St Dev] 7.3 [10] 15.7 [29.2] 20.5 [23.3] 45.2 [53.1] 63.9 [55.7] 89.5 [48.1] 23.9 [38.1] 
Median PKA/kg [IQR] 0.87 [0.44 : 1.55] 0.76 [0.41 : 1.34] 0.66 [0.34 : 1.11] 0.65 [0.31 : 1.24] 0.87 [0.46 : 1.7] 1.44 [1.01 : 1.92] 0.76 [0.39 : 1.32] 
Median % PA [IQR] 68% [56 : 78] 68% [53 : 81] 65% [49 : 81] 71% [50 : 100] 67% [56 : 85] 78% [52 : 82] 68% [53 : 82] 
Median skin dose [IQR] n/a n/a n/a n/a n/a n/a n/a 
Screening time [IQR] 10.9 [5.7 : 18.2] 12.9 [6.6 : 19.9] 10.2 [5.3 : 15.7] 10.8 [6.3 : 19.4] 12.9 [7.2 : 21.8] 17.5 [11.1 : 27] 11.3 [6.2 : 19.2] 
n 248 291 184 214 44 12 993 
H
O
SP
IT
A
L 
1
 
 2
0
0
2
-2
0
0
8
 
Median PKA [IQR] 0.8 [0.5 : 1.5] 1.2 [0.5 : 2.4] 2.2 [0.9 : 4.7] 5 [2 : 12.3] 7.8 [2.9 : 16.9] 8.2 [3.8 : 28.8] 2.1 [0.8 : 5.9] 
Mean PKA [St Dev] 1.2 [1.1] 1.9 [2] 3.8 [5.1] 9.7 [12.9] 12.8 [14.7] 23.1 [45.3] 5.8 [11.4] 
Median PKA/kg [IQR] 0.16 [0.09 : 0.29] 0.1 [0.04 : 0.21] 0.1 [0.04 : 0.2] 0.12 [0.05 : 0.26] 0.15 [0.06 : 0.29] 0.14 [0.08 : 0.46] 0.12 [0.05 : 0.25] 
Median % PA [IQR] 55% [41 : 68] 58% [38 : 80] 59% [37 : 88] 53% [35 : 83] 49% [32 : 79] 53% [38 : 82] 55% [37 : 79] 
Median skin dose [IQR] 15 [9 : 27] 16 [8 : 30] 24 [11 : 49] 46 [22 : 109] 75 [29 : 138] 72 [39 : 215] 26 [12 : 61] 
Screening time [IQR] 11.1 [7.3 : 18.5] 10.2 [6.1 : 18.3] 10.4 [6.2 : 19.4] 10.3 [6.1 : 18] 10.2 [5.4 : 17.3] 12.7 [7.5 : 22.7] 10.4 [6.2 : 18.4] 
n 502 737 549 969 233 49 3039 
H
O
SP
IT
A
L 
1
 
 2
0
0
7
-2
0
1
0
 
Median PKA [IQR] 0.6 [0.4 : 0.9] 1.2 [0.6 : 2.3] 2.3 [1 : 5.8] 9.8 [3.6 : 19.2] 10.1 [3.3 : 26.5] 10.8 [3.5 : 24.2] 2.1 [0.8 : 8.3] 
Mean PKA [St Dev] 1 [1.8] 1.9 [2.1] 6.5 [18.2] 17.7 [23.8] 18.5 [23.3] 17.6 [24.5] 8.7 [18.3] 
Median PKA/kg [IQR] 0.1 [0.06 : 0.18] 0.09 [0.05 : 0.2] 0.1 [0.05 : 0.24] 0.19 [0.09 : 0.38] 0.17 [0.06 : 0.44] 0.21 [0.07 : 0.59] 0.12 [0.06 : 0.26] 
Median % PA [IQR] 59% [45 : 69] 70% [49% : 83%] 65% [40 : 80] 57% [43 : 75] 68% [55 : 84] 85% [61 : 99] 62% [46 : 78] 
Median skin dose [IQR] 11 [7 : 18] 17 [9 : 31] 28 [12 : 64] 78 [38 : 161] 93 [27 : 186] 98 [32 : 176] 26 [11 : 79] 
Screening time [IQR] 8.3 [5.5 : 14.2] 10.1 [5.5 : 17] 10.5 [5.4 : 18.3] 10.6 [6.9 : 20.1] 10.1 [5.3 : 19.6] 10.6 [5.6 : 30] 10.1 [6.1 : 17.5] 
n 129 170 135 196 67 5 702 
 
Table 3.4: Summary statistics for all procedures combined at Hospital 1, for 4 eras of data collection. PKA is quoted in Gy·cm², skin doses are 
quoted in mGy. 
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Hospital, era Dose indicator 
Patient age range 
<1 y 1-5 y 5-10 y 10-16 y 16-18 y >18 y All 
H
o
sp
it
al
 3
  
2
0
0
4
-2
0
0
8
 Median PKA [IQR] 3 [1.7 : 5.3] 5.1 [2.9 : 8.5] 6.5 [2.7 : 13] 8.9 [3.6 : 19.4] 9.4 [4.8 : 19.2] 18.5 [5.3 : 33] 4.8 [2.4 : 9.9] 
Mean PKA [St Dev] 4.3 [4.4] 6.5 [5.5] 9.7 [9.7] 16.3 [20.8] 13 [13.1] 22.9 [21.1] 9.1 [12.7] 
Median PKA/kg [IQR] 0.52 [0.34 : 0.95] 0.39 [0.24 : 0.7] 0.26 [0.12 : 0.54] 0.19 [0.07 : 0.43] 0.15 [0.08 : 0.31] 0.26 [0.08 : 0.63] 0.36 [0.18 : 0.67] 
Screening time [IQR] 12.4 [7.4 : 18.9] 12.5 [8.1 : 20.6] 13.2 [7.1 : 23] 18.6 [12.8 : 28.7] 13.5 [6.2 : 20] 11.5 [6.8 : 21.5] 13.5 [7.9 : 22.1] 
n 245 193 97 122 40 40 737 
H
o
sp
it
al
 3
  
2
0
0
8
-2
0
1
3
 Median PKA [IQR] 0.8 [0.5 : 1.4] 1.6 [0.9 : 3.2] 2.7 [1.4 : 6.9] 7.5 [3 : 15.2] 6.9 [2.1 : 16.9] 19.1 [7 : 35.9] 2.1 [0.8 : 6.6] 
Mean PKA [St Dev] 1.3 [1.8] 2.7 [3.3] 7 [17.9] 12.2 [14.5] 15.3 [23.8] 34.6 [49.2] 7.4 [18] 
Median PKA/kg [IQR] 0.14 [0.08 : 0.25] 0.14 [0.08 : 0.25] 0.13 [0.06 : 0.26] 0.15 [0.07 : 0.33] 0.1 [0.04 : 0.29] 0.29 [0.1 : 0.51] 0.14 [0.07 : 0.29] 
Screening time [IQR] 10.8 [7.3 : 18.3] 10.7 [6.6 : 18.4] 12 [7.7 : 18.2] 14.7 [8.6 : 25] 12.9 [7.8 : 21.2] 14.3 [8.7 : 24] 11.8 [7.5 : 19.9] 
n 345 354 185 247 87 71 1289 
H
o
sp
it
al
 2
 
2
0
0
4
-2
0
0
8
 Median PKA [IQR] 3.6 [1.9 : 6.4] 6.2 [3.7 : 11.6] 9.1 [4.4 : 16.6] 16.4 [7.4 : 34.1] 23.2 [10.7 : 46.3] 5.6 [2.7 : 32.1] 6.7 [3.2 : 15.6] 
Mean PKA [St Dev] 6.7 [11.3] 9.7 [11.1] 13.7 [15] 25 [28.9] 54.3 [163.9] 16.8 [19.8] 14.8 [42] 
Median PKA/kg [IQR] 0.62 [0.37 : 1.3] 0.5 [0.31 : 0.95] 0.42 [0.2 : 0.8] 0.4 [0.19 : 0.73] 0.49 [0.23 : 0.75] 0.1 [0.04 : 0.56] 0.5 [0.28 : 0.95] 
Screening time [IQR] 9.2 [5.6 : 14.2] 9.1 [6.1 : 14.5] 10.1 [5.5 : 18.2] 10.1 [6 : 17.1] 12.5 [7.3 : 17.2] 2.4 [1.1 : 12.4] 9.6 [5.8 : 15.6] 
n 407 469 249 280 77 8 1490 
H
o
sp
it
al
 2
 
2
0
0
8
-2
0
1
3
 Median PKA [IQR] 2.3 [1 : 4.1] 3.8 [2.5 : 6.9] 6.5 [3.6 : 11.4] 14.7 [6.6 : 29.9] 14 [6.2 : 29.7] 7.4 [2.6 : 11.8] 4.7 [2.4 : 10.7] 
Mean PKA [St Dev] 3.3 [4] 5.6 [5.5] 9 [8.5] 21.6 [21.1] 23.4 [27.4] 11.4 [13.4] 9.6 [14.3] 
Median PKA/kg [IQR] 0.42 [0.24 : 0.79] 0.34 [0.21 : 0.57] 0.32 [0.17 : 0.51] 0.33 [0.16 : 0.62] 0.24 [0.11 : 0.54] 0.13 [0.04 : 0.19] 0.35 [0.19 : 0.61] 
Screening time [IQR] 8 [4.8 : 14.5] 7.1 [4.9 : 12.3] 7.6 [4.6 : 11.9] 10.3 [6.1 : 17.1] 9.9 [7 : 19.2] 5.4 [4 : 11.4] 8.2 [5 : 14] 
n 476 607 250 374 81 15 1803 
 
Table 3.5: Summary statistics for all procedures combined at Hospitals 2 and 3, for two eras of data collection. PKA is quoted in Gy·cm². 
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Hospital, era Dose indicator 
Patient age range 
<1 y 1-5 y 5-10 y 10-16 y 16-18 y >18 y All 
H
o
sp
it
al
 4
 
 1
9
9
3
-2
0
0
3
 
Median PKA [IQR] 3.2 [1.8 : 5.4] 5 [2.8 : 8.8] 8.4 [4.3 : 14.7] 16.2 [7.8 : 35.9] 18.4 [6.5 : 32.6] -  6.4 [3.1 : 13.7] 
Mean PKA [St Dev] 5.3 [8.5] 7.2 [7.6] 12.8 [15] 26.2 [27.4] 23.5 [19.5] -  12.5 [17.9] 
Median PKA/kg [IQR] 0.64 [0.39 : 1.07] 0.47 [0.24 : 0.79] 0.41 [0.21 : 0.68] 0.42 [0.22 : 0.8] 0.36 [0.14 : 0.63] -  0.49 [0.25 : 0.84] 
Median % PA [IQR] 0.71 [0.6 : 0.86] 0.69 [0.54 : 0.89] 0.68 [0.46 : 2] 0.66 [0.5 : 0.94] 0.71 [0.51 : 0.93]  - 0.69 [0.53 : 0.92] 
Screening time [IQR] 9.9 [5 : 16.3] 9.4 [5.6 : 16] 11 [5.8 : 20] 14.5 [7 : 26.2] 12.5 [5.1 : 24.1]  - 10.9 [5.9 : 19.2] 
n 275 394 255 271 30 0 1225 
H
o
sp
it
al
 4
 
 2
0
0
3
-2
0
1
4
 
Median PKA [IQR] 0.5 [0.3 : 1.1] 1.4 [0.7 : 2.5] 2.2 [1 : 4.7] 7.6 [4.3 : 11.6] 7.6 [4.9 : 9.6] -  1.7 [0.6 : 4.7] 
Mean PKA [St Dev] 1.4 [4.4] 2.3 [3.8] 4 [5.7] 10.9 [12.9] 7.1 [3.3] -  4.2 [7.9] 
Median PKA/kg [IQR] 0.1 [0.05 : 0.18] 0.11 [0.07 : 0.2] 0.11 [0.05 : 0.17] 0.16 [0.1 : 0.23] 0.16 [0.12 : 0.19] -  0.12 [0.07 : 0.2] 
Median % PA [IQR] 0.51 [0.44 : 0.65] 0.56 [0.38 : 0.68] 0.52 [0.41 : 0.65] 0.56 [0.43 : 0.91] 1 [1 : 1] -  0.54 [0.43 : 0.69] 
Screening time [IQR] 10.8 [5.2 : 18.6] 10.4 [6 : 18] 9.1 [6 : 13.7] 10 [7.3 : 16] 7.1 [5.3 : 13.7] -  10.1 [6 : 16.8] 
n 145 164 116 110 9 0 544 
H
o
sp
it
al
 5
 
 2
0
0
5
-2
0
1
3
 
Median PKA [IQR] 0.8 [0.4 : 1.5] 1.5 [0.7 : 3.8] 1.4 [0.4 : 5.7] 2 [0.6 : 11.3] 2.6 [0.9 : 10.4] 3.96 [0.98 : 48.77] 1.3 [0.5 : 3.9] 
Mean PKA [St Dev] 1.4 [2] 3.7 [5.5] 6.4 [16] 13.7 [45.9] 8.9 [17.8] 32.09 [46.08] 6.9 [24.9] 
Screening time [IQR] 11.5 [6.5 : 22.5] 8.6 [4.7 : 17.2] 10.1 [5.8 : 24.5] 15.5 [8.2 : 23.4] 16.8 [9.2 : 31.6] 15.4 [7.9 : 27.47] 11.7 [6.5 : 22.6] 
n 161 167 93 130 41 20 612 
H
o
sp
it
al
 6
 
2
0
0
6
-2
0
1
3
 
Median PKA [IQR] 0.7 [0.4 : 1.1] 0.9 [0.6 : 1.8] 1.5 [0.7 : 3] 3.4 [1.4 : 8.4] 1.2 [0.3 : 3.7] 3.53 [1.64 : 5.52] 1.2 [0.6 : 2.9] 
Mean PKA [St Dev] 0.9 [0.9] 1.5 [1.4] 2.2 [2] 9.8 [18.4] 7.4 [27.7] 7.39 [17.17] 3.5 [11.8] 
Screening time [IQR] 10.2 [6.2 : 17.2] 9.5 [7.3 : 15.9] 12.6 [8.7 : 16.5] 9.3 [3 : 18.1] 7.5 [3.2 : 10.1] 10.15 [6.44 : 14.11] 10.1 [6.4 : 16.2] 
n 91 116 41 39 26 47 360 
 
Table 3.6: Summary statistics for all procedures combined at Hospitals 4, 5 and 6. PKA is quoted in Gy·cm². 
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Procedure 
Hospital and data collection period 
Hospital 1 94-00 Hospital 1 99-01 Hospital 1 02-08 Hospital 1 07-10 Hospital 3 04-08 Hospital 3 08-13 
Other 26 [13 : 55.5] 14.3 [6 : 28.5] 1.5 [0.4 : 3.9] 1.4 [0.7 : 4.8] - - 
Interventional 27.1 [13.8 : 54.2] 7.6 [3.7 : 18.4] 1.7 [0.7 : 5.8] 2.2 [0.7 : 9.7] 4.7 [2.5 : 9.8] 2.2 [0.8 : 8.3] 
Diagnostic 68.9 [22.3 : 132.6] 11.6 [6.3 : 29.4] 3.2 [1.5 : 7.4] 2.8 [1 : 8.3] 5.1 [2.8 : 10] 1.9 [0.9 : 5] 
ASD occlusion - 6.3 [2.7 : 21.9] 0.8 [0.5 : 1.7] 1.3 [0.4 : 4.1] 5.3 [2.1 : 8] 3.2 [1.3 : 8.9] 
PDA occlusion 27.1 [14.4 : 45] 6.2 [3.4 : 12] 0.8 [0.5 : 1.3] 0.7 [0.5 : 1.3] 3.4 [2.5 : 5.3] 1.1 [0.6 : 2.2] 
PV plasty 16.9 [13.2 : 27.2] 6 [2.8 : 10.7] 1 [0.6 : 2] 0.8 [0.5 : 2] 3.4 [2.1 : 7.1] 0.7 [0.4 : 1.2] 
AV plasty - 6.9 [4.3 : 21.6] 1.2 [0.7 : 4.6] 4 [0.6 : 13.1] 5.2 [1.5 : 7.4] 2 [0.6 : 6.2] 
PA plasty 34.1 [26.9 : 154.9] 19.4 [8.3 : 40.6] 4.7 [2 : 9.2] 4.6 [1.8 : 8.8] 11.1 [8.3 : 28.5] 7.2 [3 : 13.8] 
COA repair - 7.8 [5.1 : 26.4] 1.7 [0.7 : 3.4] 3.7 [0.5 : 10.6] 3.5 [2 : 10.1] 6.4 [1.2 : 24.3] 
EPS/RFA 70.6 [46.8 : 147.4] 77.8 [24.1 : 144.8] 3.3 [1.2 : 7.3] 3.5 [1.6 : 9] 4.3 [2 : 9.2] 3.6 [1.7 : 7.1] 
Biopsy 5.5 [3 : 32.4] 5.4 [1.7 : 10.9] 0.7 [0.3 : 1.8] 1.2 [0.7 : 3.3] - - 
Coronaries 100.7 [62.9 : 149.2] 17.1 [9.7 : 33.6] 4.8 [2.5 : 11.1] 5.4 [1.9 : 11.9] - - 
PVR/Pressures - - 1.3 [0.4 : 3.7] 1.4 [0.6 : 5.4] - - 
Valve replace - - - 37.9 [27 : 77.4] - - 
Pacemaker 18.5 [8.8 : 51.8] - 1.6 [0.8 : 2.9] - 2.6 [1.4 : 11.8] 0.7 [0.3 : 2] 
Septostomy 3.5 [2.8 : 7] 2.1 [0.8 : 28.9] 2.1 [0.9 : 7.9] - - - 
 
Table 3.7: Median PKA [interquartile range] for individual procedure types for all patient sizes combined, for different eras at Hospitals 1 and 3. 
Note, ‘plasty’ can refer to ballooning and/or stent insertion. Only figures where at least 10 procedures were conducted are presented. 
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Procedure 
Hospital and data collection period 
Hospital 2 04-08 Hospital 2 08-13 Hospital 4 93-03 Hospital 4 03-14 Hospital 5 05-13 Hospital 6 06-13 
Other 6.6 [3.1 : 14.6] 5.5 [2.5 : 10.8] 6.3 [3.2 : 13.5] 1.3 [0.6 : 3.2] 0.6 [0.2 : 2] 0.9 [0.5 : 2.4] 
Interventional 7.2 [3.6 : 16.7] 4.3 [2.3 : 10.9] 6.8 [2.6 : 16.1] 1.1 [0.5 : 2.6] 1.3 [0.6 : 3.9] 1.2 [0.6 : 2.7] 
Diagnostic 5 [2.4 : 14] 5.8 [3 : 10.5] 8.3 [6.3 : 19.3] 4.8 [2.7 : 9.3] 2.6 [0.9 : 8.5] 1.5 [0.7 : 3.4] 
ASD occlusion 6.9 [4.8 : 14] 4.4 [2.7 : 8.4] - - 1.5 [0.7 : 3.8] 0.5 [0.5 : 1] 
PDA occlusion 6.2 [3.8 : 11.1] 3.2 [2.4 : 4.8] - - 1.1 [0.6 : 2.2] 0.4 [0.4 : 0.8] 
PV plasty 4.5 [2.5 : 8.6] 2.7 [1.7 : 4.7] - - - - 
AV plasty 7.9 [3.3 : 30.5] 2.1 [1.1 : 5] - - - - 
PA plasty 17.8 [7 : 28.8] 11.5 [5.9 : 21.8] - - - - 
COA repair 6.2 [2.9 : 16.4] 3.2 [2.5 : 6.2] - - 6.1 [1 : 27.7] - 
EPS/RFA 16.7 [9 : 30.5] 12 [5.3 : 27] 17.4 [7.7 : 42.7] - 1.1 [0.5 : 2.2] 1.6 [0.9 : 3.5] 
Biopsy - - - - - - 
Coronaries - - 9.8 [6.5 : 17.3] 4.8 [2.7 : 9.3] 2.3 [0.6 : 14.3] 2.1 [0.9 : 4.2] 
PVR/Pressures - 8.7 [3 : 11.4] - - - - 
Valve replace - - - - - - 
Pacemaker 3 [2.2 : 11.7] 2.2 [1 : 6.1] - - 0.3 [0.2 : 0.5] - 
Septostomy 1.2 [0.6 : 4.6] 0.4 [0.2 : 1] - - 0.3 [0.2 : 1.5] - 
 
Table 3.8: Median PKA [interquartile range] for individual procedure types for all patient sizes combined, for different eras at Hospitals 2, 4, 5 and 
6 Only figures where at least 10 procedures were conducted are presented. 
  
77 
 
3.5.1: Kerma area product 
PKA was generally in the range 0 to 20 Gy·cm², though occasionally reached 100 
Gy·cm² or higher, particularly for older procedures. Four procedures had a PKA of 
greater than 500 Gy·cm², with two being over 1000 Gy·cm². In one of these, the 
patient was a large 18 year old female (93 kg). The other was for an average sized 
17 year old female (51 kg) undergoing a procedure with 53.1 minutes of fluoroscopic 
screening. For the most recently conducted examinations using 3rd generation 
equipment, the median PKA across all patient sizes and procedure types ranged from 
1.2 to 4.7 Gy·cm² depending on the hospital - a near fourfold variation. Restricting to 
procedure conducted using Siemens Axiom Artis machines (all hospitals except 
Hospital 2), this range was reduced to 1.2 to 2.1 Gy·cm² – a less than two fold 
variation. PKA was almost always positively correlated with patient mass. Spearman's 
rank correlations are shown in Table 3.9 for most recent era procedures conducted at 
the four hospitals with the largest sample sizes. Exceptions tended to only occur 
where only a limited number of procedures were included in a particular category, 
such as ‘other’ procedures at Hospital 3, or if procedures were only carried out over a 
limited range of ages, such as electrophysiology studies (EPS) at Hospital 2. 
Median PKA varied between procedure types, tending to be highest for ballooning 
and/or stenting of the pulmonary arteries and (more recently) trans-catheter valve 
replacement. The lowest doses were for atrial septostomies and closures of patent 
ductus arteriosus (PDA) and atrial septal defect (ASD).  
The ranking of procedures by PKA was not the same at different hospitals, or even at 
the same hospitals for different eras. For example, among the most regularly 
conducted procedures, aortic valve (AV) angioplasty procedures had the lowest 
median PKA at Hospital 2 (2008-2013 data) but the highest at Hospital 1 (2007-2010). 
The exception in this variation in ranking was for pulmonary artery angioplasty 
procedures, which were consistently among the highest doses. Where carried out, 
endomyocardial biopsies were usually associated with low doses when carried out in 
isolation. At least 10% of coronary angiography procedures also included a heart 
biopsy as part of a yearly transplant review examination. Coronary angiography is 
increasingly performed with intravascular ultrasound (IVUS), which is regarded as 
the most sensitive imaging modality in the detection of coronary allograft 
vasculopathy [209]. 
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  Hospital 1, 2002-2008 Hospital 2, 2008-2013 Hospital 3, 2008-2013 Hospital 4, 2003-2011 
Procedure type: 
Mass and 
PKA 
Mass 
and ST 
PKA/kg 
and age 
Mass 
and PKA 
Mass 
and ST 
PKA/kg 
and age 
Mass 
and PKA 
Mass 
and ST 
PKA/kg 
and age 
Mass 
and PKA 
Mass 
and ST 
PKA/kg 
and age 
Other 
0.47 
p=<0.01 
-0.03 
p=0.38 
-0.02 
p=0.45 
0.43 
p=<0.01 
-0.10 
p=0.07 
-0.26 
p=<0.01 
0.03 
p=0.23 
-0.23 
p=0.05 
-0.21 
p=0.08    
Combined 
interventional 
0.64 
p=<0.01 
0.12 
p=<0.01 
0.06 
p=0.02 
0.63 
p=<0.01 
0.16 
p=<0.01 
-0.12 
p=<0.01 
0.76 
p=<0.01 
0.10 
p=0.01 
0.29 
p=<0.01 
0.45 
p=<0.01 
-0.07 
p=0.54 
-0.08 
p=0.48 
Combined diagnostic 
0.72 
p=<0.01 
-0.14 
p=<0.01 
-0.0 
p=0.85 
0.61 
p=<0.01 
-0.08 
p=0.16 
-0.15 
p=<0.01 
0.71 
p=<0.01 
0.00 
p=0.97 
0.14 
p=<0.01 
0.67 
p=<0.01 
-0.37 
p=<0.01 
-0.24 
p=<0.01 
ASD occlusion 
0.57 
p=<0.01 
0.04 
p=0.61 
0.12 
p=0.11 
0.51 
p=<0.01 
-0.02 
p=0.82 
-0.06 
p=0.56 
0.73 
p=<0.01 
0.10 
p=0.28 
0.37 
p=<0.01    
PDA occlusion 
0.39 
p=<0.01 
-0.01 
p=0.78 
-0.30 
p=<0.01 
0.31 
p=<0.01 
-0.09 
p=0.11 
-0.36 
p=<0.01 
0.61 
p=<0.01 
0.02 
p=0.77 
0.12 
p=0.13    
Pulmonary 
valvuloplasty 
0.67 
p=<0.01 
0.04 
p=0.63 
-0.08 
p=0.37 
0.34 
p=<0.01 
-0.26 
p=<0.01 
-0.36 
p=<0.01 
0.61 
p=<0.01 
-0.09 
p=0.46 
0.10 
p=0.40    
Aortic  
valvuloplasty 
0.81 
p=<0.01 
-0.00 
p=0.97 
-0.10 
p=0.44 
0.79 
p=<0.01 
0.28 
p=0.03 
0.14 
p=0.30 
0.92 
p=<0.01 
0.28 
p=0.05 
0.49 
p=<0.01    
Pulmonary artery 
angioplasty 
0.69 
p=<0.01 
-0.06 
p=49 
0.00 
p=0.94 
0.62 
p=<0.01 
0.13 
p=0.14 
-0.10 
p=0.23 
0.76 
p=<0.01 
-0.03 
p=0.78 
0.29 
p=<0.01    
Coarctation repair 
0.80 
p=<0.01 
0.00 
p=0.95 
-0.10 
p=0.46 
0.78 
p=<0.01 
0.07 
p=0.6 
-0.32 
p=0.02 
0.85 
p=<0.01 
0.05 
p=0.69 
0.53 
p=<0.01    
EPS ± ablation 
0.43 
p=<0.01 
-0.02 
p=0.75 
0.05 
p=0.45 
0.35 
p=<0.01 
0.10 
p=0.12 
-0.15 
p=0.01       
Heart biopsy 
0.67 
p=<0.01 
-0.07 
p=0.17 
0.15 
p=0.005          
Coronary angiography 
0.79 
p=<0.01 
0.07 
p=0.11 
0.25 
p=<0.01       
0.85 
p=<0.01 
-0.01 
p=0.93 
0.15 
p=0.21 
 
Table 3.9: Correlation between PKA and other parameters for most recent era data at four hospitals. Note the 2002-2008 data at Hospital1 were 
preferred to 2007-2010 data due to much larger sample size. ST=screening time 
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As mentioned previously, PKA was not normally distributed and exhibited a right-
skewed distribution, with a large number of procedures delivering a PKA and a small 
number of procedures delivering very high PKA (i.e. over 100 Gy·cm²). The 
distribution was investigated in greater detail for the 2002-2007 data collected at 
Hospital 1, by plotting percentiles in 1% intervals on a log scale (Figure 3.2). The 
relative ranking of PKA between procedure types was shown to be reasonably 
constant across the range of percentiles. 
 
 
Figure 3.2: Distribution of doses for various procedure types at Hospital 1 (2002-2008 data) 
 
The most striking feature of Tables 3.4 to 3.8 is the fall in PKA with successive ‘eras’, 
at hospitals where equipment was replaced during the study period. In all but one 
case, these falls were significant (Wilcoxon test for all procedure types combined 
p=<0.01). The exception was between 2002-2008 and 2007-2010 eras at Hospital 1 
(p=0.116). These represented two catheterization laboratories, both equipped with 
Siemens Axiom Artis machines. The machine in Lab 1 (02-08 data) was equipped 
with image intensifier (II) detectors, while Lab 4 (07-10 data) had flat panel detectors 
(FPDs). The median PKA for all procedure types combined is identical for the II and 
FPD machines (2.1 Gy·cm²), while the corresponding figures for interventional 
procedures were significantly higher in the FPD equipped Lab 4 (1.66 verses 2.40 
Gy·cm², Wilcoxon test: p=0.03). When this was analysed further, it was found that a 
large proportion of procedures carried out using the FPD equipped machine were 
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high-dose valve replacements. For 2007, 38% of interventional procedures in the 
FPD lab were valve replacements, while very few of these procedures were done in 
the II lab. Carrying out the same analysis, but excluding valve replacement 
procedures, the apparent increase in interventional PKA associated with the FPD 
machine disappeared and there was no significant difference in PKA associated with 
the transition between II and FPD (p=0.22).  
Further analysis of the fall in PKA with study date was conducted by calculating 
median PKA by year of procedure. This was conducted for all procedure types 
combined, as the number of individual procedure types carried out in a particular 
year was often small. These results suggest that PKA tended to fall suddenly upon 
installation of new equipment, though there was also some suggestion of a fall in PKA 
within eras as well. These patterns are shown in Figures 3.3 to 3.5 for Hospitals 1, 2 
and 3, respectively. Analysis of PKA by year was difficult for the Hospital 4 data due to 
the sporadic nature of data recording. New equipment was installed in 2003, but 
doses were recorded for hardly any procedures until 2011, while procedures carried 
out at Hospitals 5 and 6 were conducted on a single piece of equipment. PKA 
fluctuated quite wildly between 1994 and 1997 at Hospital 1, increasing from around 
21 Gy·cm² to nearly 40 Gy·cm² between 1995 and 1996, before falling. The reasons 
for this are unclear and there was no corresponding pattern for screening times (also 
shown in the same figure), though these figures unexpectedly increased themselves 
in 1999 before falling in 2000. 
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Figure 3.3: Median PKA and screening times (ST) for all procedures combined by year, at 
Hospital 1, between 1994 and 2010. Only years in which figures for more than 50 
procedures were carried out are shown. 
 
 
Figure 3.4: Median PKA and screening times (ST) for all procedures combined by year, at 
Hospital 2, between 2004 and 2013. 
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Figure 3.5: Median PKA and screening times (ST) for all procedures combined by year, at 
Hospital 3, between 2004 and 2013 
 
For all procedures, the percentage of PKA originating from the frontal (PA), x-ray tube, 
recorded at Hospital 1, was around 60%. This figure varied with data collection era, 
being 66% between 1994 and 2000 (lab 1), 68% between 1999 and 2001 (lab 2) and 
55% between 2002 and 2008 (lab 1). A similar fall in this proportion was seen at the 
Hospital 4 Hospital, from 69% between 1993 and 2003, to 54% after 2003. A small 
but statistically significant negative correlation was found between total dose and the 
percentage of this figure originating from the frontal x-ray tube (across all procedure 
types at Hospital 1, Spearman’s r= -0.12, p=<0.01). In other words, where doses are 
high, laterally orientated projections tend to be more responsible than frontally 
orientated projections. 
 
3.5.2: Fluoroscopic screening time 
As with PKA, the distribution of screening times was right skewed (Figure 3.6). The 
large majority of procedures had screening times below around 30 minutes, while a 
small number of procedures involved lengthy screening, extending to one hour or 
more. For the most recently acquired data, median screening times for all procedure 
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types and patient sizes combined occupied a reasonably narrow range, from 8.2 to 
11.8 minutes. As with PKA, there was a tendency for screening times to fall between 
successive eras. This pattern was found for all hospitals with different equipment 
eras and was seen for almost all individual procedure types. As seen in Figures 3.3 
to 3.5, screening time has tended to fall more steadily, without the pronounced falls 
occurring with the installation of new equipment, seen for PKA. At Hospital 1, a 
significant fall in screening time was seen between 2001 and 2002 corresponding to 
changing equipment (Wilcoxon test p=0.0001). An unexplained spike in median 
screening times was seen at Hospital 1 in 1999, before times fell in 2000 to below 
pre-1998 levels. 
In contrast to PKA, correlation between mass and screening time for individual 
procedure types tended to be weak (range was -0.37 to +0.28) though occasionally 
significant (Table 3.9), especially for overall procedure categories (diagnostic, 
interventional and other). These correlations were both positive and negative, and 
not consistent between hospitals. The overall impression was a lack of strong 
relationship between patient size and fluoroscopic screening time. Less variation in 
median screening times – generally by a factor of no more than two - was found 
between different hospitals than for PKA. Screening time was relatively poorly 
correlated with median doses at different hospitals. In fact, the hospital with the 
highest median doses for the most recent data (Hospital 2) had the shortest median 
screening times. 
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Figure 3.6: Histogram of screening times (all procedures combined), at Hospital 1, 2002-08 
 
3.5.3: Skin Dose estimates 
Estimated skin doses (i.e. air kerma) were available for 3640 examinations 
conducted at Hospital 1. These figures were generally in the range 0-200 mGy, with 
a median for all procedure types and patient ages combined of 26 mGy. Skin dose 
estimates in any one plane exceeded 1000 mGy in six examinations, and 2000 mGy 
in one examination. No skin doses were recorded for procedures conducted on older 
generation equipment, meaning it was not possible to assess trends with time. Like 
PKA, skin doses increased with patient mass/age (correlation coefficients were +0.89 
and +0.91 for interventional and diagnostic procedures respectively for 2002-2008 
data). This upward trend with age was smaller than that for PKA, increasing by a 
factor of around 10 from the smallest to the largest patient size groups for skin dose, 
compared to around 20 for PKA. 
 
3.5.4: PKA normalised by mass 
Patient mass was recorded for most examinations at Hospitals 1 to 4, but not 
Hospitals 5 or 6. Where PKA was divided by patient mass (PKA/kg), the median of this 
figure was found to vary with age/mass category. The nature of this pattern varied 
between hospitals or different eras at the same hospital. In some cases PKA/kg was 
seen to steadily increase or decrease, while in others a U-shaped or bimodal pattern 
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was observed (Figure 3.7). The correlation between PKA/kg and mass category 
tended to be either strongly negative or strongly positive, for example, -0.92 between 
2004 and 2008 for all procedures combined at Hospital 3, and +0.93 between 2008 
and 2013 at the same hospital. It was found that in addition to replacing fluoroscopic 
equipment in 2008, a new policy of omitting the antiscatter grid for patients less than 
10 kg was implemented. Similar patterns were observed for both procedure 
categories (diagnostic or interventional) and individual procedure types, although 
analysis of the latter is often hindered by small sample sizes. A similar situation was 
found for other hospitals. Where antiscatter grids were used for all patient sizes, 
PKA/m was highest in the 0-1 year age group and tended to be negatively correlated 
with patient age. Where antiscatter grids were omitted for small patients, PKA/m 
tended to increase with patient size or display a lop-sided ‘U’ or ‘J’ shaped pattern. 
Where PKA/kg figures were further normalised by screening time (Figure 3.8), i.e. 
(PKA/kg)/min, the above patterns become even more pronounced. A clear distinction 
was seen between datasets depending on grid usage.   
  
 
Figure 3.7: PKA normalised by mass for two different eras at three hospitals. 
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Figure 3.8: PKA/kg further normalised by screening time (per minute) 
 
3.3.5: Number of procedures per patient 
A function was written in MATLAB to identify patients undergoing multiple 
procedures on different dates (i.e. not including situations in which a patient has two 
or more procedure types during the same catheterizations on the same day). Across 
the whole cohort, the mean number of procedures per patient was 1.5 (median=1). 
As with PKA, the distribution was right skewed. The majority (75.8%) of patients 
underwent a single recorded examination during the study period, while 13.6% 
underwent two procedures. 79 patients (0.6%) underwent 10 or more procedures. All 
but one of these patients were examined at Hospitals 1 and 4, which are the two 
centres carrying out paediatric heart transplants in the UK [210]. The maximum 
number of procedures recorded for a single patient was 38. Figure 3.9 shows the 
percentage of patients undergoing a particular number of procedures, separated into 
transplant (Hospitals 1 and 4) and non-transplant hospitals (all others). The mean 
number of procedures per patient during the study period was 1.7 at transplant 
hospitals and 1.3 at non-transplant hospitals. For the latter group, a large majority of 
patients (82.4%) underwent a single recorded procedure. This analysis is limited by 
the follow-up period of the study, which was considerably longer for Hospital 4 and 
Hospital 1 than other hospitals. Calculations were repeated for patients born within 
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the study period, though the results were virtually unchanged, with a mean number of 
procedures per patient of 1.5 (1.6 and 1.3 for transplant and non-transplant hospitals 
respectively). 
 
 
Figure 3.9: Number of examinations per patient. Data are presented for the whole cohort. 
 
3.5.6: Clinical history and indication for procedure 
The reason for carrying out the cardiac catheterization procedure was recorded at 
Hospitals 1 and 2 (7973 examinations). Clinical information was searched for the 
following terms; transplant (Tx, HTx), Down’s syndrome (Trisomy 21), Tetralogy of 
Fallot (TOF, T4), transposition of the great arteries (TGA), hypoplastic left or right 
heart syndrome (HLH, HLHS, HRH, HRHS) Norwood procedure (surgery carried out 
for hypoplastic left heart), Fontan procedure (surgery for patients with a single 
ventricle) and valve atresias (pulmonary, aortic, tricuspid or mitral). The first two of 
these conditions are associated with known increased risk of cancer [211, 212], while 
the remainder (as well as transplantation) are associated with significantly decreased 
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survival [213-216]. These conditions are not mutually exclusive, with some patients 
suffering from more than one condition. The most common combinations were 
transplant and Tetralogy of Fallot (13 patients) and Tetralogy with Down syndrome (8 
patients). 
The percentage of examinations carried out on patients with these conditions differed 
between the two hospitals (Table 3.10). In particular, Hospital 1 carried out a much 
greater number of examinations on transplant patients (23% of total procedures). 
The mean number of procedures carried out for these indication groups was 
calculated. This figure was higher for transplant patients (4.1) compared to others 
(1.3 to 2.2). Patients with Down’s syndrome usually only underwent a single 
catheterization. It should be noted that there are a number of shortcomings of the 
above analysis. Firstly, only two participating hospitals record information on 
indications. Secondly, there is a reliance on the radiographer noting such details in 
examination records – the absence of the search terms in the comments column does 
not imply the patient does not have the conditions searched for, simply that they 
were not recorded. Consequently, the figures in Table 3.10 are likely underestimates 
of the presence of these conditions among cohort members. Again, this will have 
implications for epidemiological analysis. 
 
Hospital 1 Hospital 2 Both 
Condition n % patients n % patients n % patients 
Heart transplant 456 9.4% 14 0.5% 471 6.0% 
Tetralogy of Fallot 231 4.8% 121 4.0% 352 4.5% 
TGA 222 4.6% 242 8.0% 464 5.9% 
Down syndrome 26 0.5% 56 1.8% 82 1.0% 
Norwood procedure 25 0.5% 23 0.8% 48 0.6% 
Fontan procedure 47 1.0% 68 2.2% 115 1.5% 
Hypoplastic left heart 21 0.4% 25 0.8% 46 0.6% 
Hypoplastic right heart 9 0.2% 37 1.2% 46 0.6% 
Pulmonary atresia 141 2.9% 74 2.4% 215 2.7% 
Tricuspid atresia 19 0.4% 27 0.9% 46 0.6% 
Mitral atresia 5 0.1% 4 0.1% 9 0.1% 
Aortic atresia 1 0.0% 0 0.0% 1 0.0% 
Table 3.10: Indication for procedures at Hospital 1 and Hospital 2. Percentages represent 
the proportion of patients at the respective hospital with each condition. TGA = Transposition 
[of the] Great Arteries. 
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3.5.7: Imaging mode 
Fluoroscopic imaging may be in the form of high quality 'cine' acquisitions or non-
acquisition fluoroscopy. PKA is recorded separately for these imaging modes at 
Hospital 2 between 2004 and 2008, allowing the respective proportions to be 
analysed. This information was later utilised in the estimation of organ doses from 
PKA. Overall, the mean proportion of PKA from fluoroscopy was 0.82 (median = 0.85). 
This proportion was higher for interventional (median=0.86) rather than diagnostic 
procedures (0.68). Individual interventions, such as ASD or PDA occlusions tended 
to utilise reasonably similar proportions of acquisition imaging (Table 3.11). For RFA 
and EPS procedures, the total PKA was usually entirely from non-acquisition 
fluoroscopy. A small, but significant, positive correlation was found between total 
examination PKA and the percentage of this figure originating from fluoroscopy rather 
than cine acquisitions (Spearman’s r=0.17, p<0.01).  
 
 
Proportion of total PKA from 
fluoroscopy 
Procedure type: Median [IQR] Mean [SD] 
All interventional 0.86 [0.77-0.96] 0.84 [0.15] 
All diagnostic 0.68 [0.53-0.80] 0.68 [0.21] 
Other 0.67 [0.55-0.81] 0.67 [0.19] 
ASD occlusion 0.98 [0.94-1.00] 0.95 [0.08] 
PDA occlusion 0.83 [0.75-0.89] 0.80 [0.12] 
AV plasty 0.85 [0.78-0.91] 0.84 [0.10] 
PV plasty 0.85 [0.78-0.90] 0.81 [0.15] 
PA plasty 0.82 [0.71-0.86] 0.82 [0.13] 
COA procedures 0.78 [0.64-0.87] 0.74 [0.17] 
EPS ± RFA 1.00 [1.00-1.00] 0.97 [0.09] 
 
Table 3.11: Proportion of PKA from fluoroscopy at Hospital 2. IQR = interquartile range, SD = 
standard deviation. 
 
3.5.8: Beam angle 
Beam angles were also recorded at Hospital 2, for acquisitions only. These data will 
be utilised in greater detail in the ‘supporting information’ chapter and will be 
analysed here with respect to PKA. The majority of acquisitions were in the 
posteroanterior (48%) or lateral projections (35%), with the remainder made up 
mainly of left/right anterior oblique (both 3%) and other unspecified oblique views. 
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Table 3.12 shows the Spearman's rank correlation between PKA and the percentage 
of acquisitions in a particular projection, per examination. Analysis was carried out 
for both total PKA and that resulting from acquisition exposures only. In each case, 
PKA was normalised by mass to reduce (but not eliminate, see above) the impact of 
patient size. No strong correlations between usage of particular beam projections 
and PKA/kg were found (r ranged from -0.34 to +0.22). There was a tendency for 
usage of the PA projection to be negatively correlated with dose and oblique 
projections to be positively correlated, although neither of these observations was 
consistent between different procedure types. Also shown in Table 3.12, a positive 
correlation was always present between PKA/kg and the number of cine acquisitions. 
This was expected, though not inevitable as a single acquisition can still result in a 
large dose if lengthy. The direction of correlation was almost always consistent 
between acquisition PKA/kg and total PKA/kg verses number of acquisitions or 
percentage usage of different projections. In the former case, positive associations 
tended to be greater and more significant. 
 
  
No. of 
acquisitions 
% in 
PA 
% in 
Lateral 
% in 
RAO 
% in 
LAO 
% in 
RAO/CR 
% in 
LAO/CR 
% in 
Long 
Axis 
PDA 
occlusion 
Acquisition 
PKA/mass 
0.62** -0.20* -0.13 0.18** 0.07 
      
Total PKA/mass 0.49** -0.24** -0.02 0.22** 0.09       
ASD 
occlusion 
Acquisition 
PKA/mass 
0.38** -0.34** 0.12 0.2 0.1 
      
Total PKA/mass 0.16 -0.06 0.04 0.11 0.08       
Coarctation 
angioplasty 
Acquisition 
PKA/mass 
0.51** 0.09 -0.35* 0.01 0.05 
      
Total PKA/mass 0.43** 0.13 -0.18 0.06 -0.09       
Pulmonary 
artery 
angioplasty 
Acquisition 
PKA/mass 
0.57** 0.07 0.15 0.09 -0.15 0.08 0.05 
  
Total PKA/mass 0.49** 0.18 0.19 0.06 -0.07 0.10 0.03   
Pulmonary 
valve 
angioplasty 
Acquisition 
PKA/mass 
0.40** -0.1 -0.26** 0.22* 0.11 0.16 0.21* 
  
Total PKA/mass 0.23* -0.03 0 0.20* 0.08 -0.08 0.08   
Aortic valve 
angioplasty 
Acquisition 
PKA/mass 
0.44** -0.25 -0.13 0.15 
      
0.37* 
Total PKA/mass 0.21 0.02 -0.25 -0.04       0.24 
 
Table 3.12: Correlations between dose (either total or that arising from cine acquisitions 
only) and the number of acquisitions or proportion of acquisition PKA in different projections. 
** Significant to 0.01 level, * significant to 0.05 level. 
 
3.5.9: Operating cardiologist 
The cardiologists and radiographers conducting the examination were recorded at 
Hospital 1. Variation in PKA and screening time according to the involvement of 
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different staff was investigated using a Kruskal-Wallis test for five of the most 
common procedure types. A Spearman’s rank test was also performed to identify any 
correlation between dose/screening time and the number of procedures carried out 
for each operator. In both cases, PKA was normalised by mass to reduce the impact 
of variation in patient size on the results. For most examinations, more than one staff 
member was listed and it was not known who was actually at the controls. The 
results were characterised by mainly null findings. A significant difference in PKA was 
found for cardiologists for coronary angiography (p=0.03) and PDA occlusions 
(p=0.02), and for ASD occlusions for radiographers (p=0.03).  A significant negative 
correlation was found between the number of coronary angiography procedures 
carried out by each operator and PKA (Spearman’s r=-0.17, p=<0.01). No other 
significant correlations of this type were found. 
 
3.6: Discussion 
The most significant finding of the analysis of PKA and screening times was the fall in 
these dose indicators with time. For PKA, these falls tended to be associated with the 
installation of new equipment. The decrease was particularly pronounced at Hospital 
1 between the 1994-2000 and 2002-2008 eras, where a fall in median PKA by a factor 
of around 20 was seen for all procedures combined. A more moderate decrease was 
seen between the 2004-2008 and 2008-2013 eras at Hospital 2 (1.42 fold) and 
Hospital 3 (2.5), though older, pre-2000 data were not available at these hospitals. 
There was some suggestion of a decrease in PKA within individual eras, along with a 
more steady decrease in screening times, as might be expected due to increased 
experience and technique refinement. This variation was relatively small, however, 
and not monotonic. Only a limited analysis of the variation in dose indicators between 
operators at a given hospital was possible. These results suggest inter-operator 
variation has a relatively minor impact on doses. The overall impression was that 
technological factors were the driving force behind the decline in dose indicators with 
time. 
Technological factors include (1) improved detective quantum efficiency of detectors, 
(2) use of a different beam spectrum including the use of extra copper filtration, (3) 
ability to reduce frame rates for acquisitions and fluoroscopic imaging, (4) ability to 
remove antiscatter grids, (5) more dose efficient digital image processing techniques, 
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and (6) other features such as ‘last frame hold’ and lung shuttering. Referring to point 
2, while the use of extra copper filtration is an effective dose reduction technique 
without impacting image quality [8, 217-219], the patient dose per unit PKA is higher 
as beam quality is increased (see Monte Carlo results chapter for more details). 
Consequently, the magnitude of decrease in patient dose may be exaggerated where 
doses are represented by PKA only. Lung shuttering takes into account the reduced 
density of the lungs compared to the mediastinum, by inserting aluminium filters to 
modulate the intensity of the x-ray beam and reduce lung dose. The impact of lung 
shuttering on PKA is difficult to judge as usage is not recorded in examination details. 
Improved image processing includes techniques such as recursive filtering or 
‘temporal filtering’ [99], in which signal-to-noise ratio is improved by a weighted 
combination of the signal from previous frames. Alternatively, signals can be 
deconstructed into frequency bands called a ‘Laplacian Pyramid’ and filtered 
separately [99].  
The introduction of digital flat panel detectors (FPDs) is associated with a number of 
advantages, including reduced geometric distortion, greater dynamic range, smaller 
physical size and improved dose efficiency [98, 220]. The latter point is controversial, 
with some studies finding little or mixed evidence of any advantage [21, 221]. 
Comparison requires caution, as FPDs are usually installed as part of a complete 
replacement of fluoroscopic equipment, including x-ray tube, generator, control panel 
and image processing software. Thus the fall in doses between eras at Hospitals 2 
and 3, though associated with replacement of image intensifiers (IIs) with FPDs, 
should not be solely attributed to a difference in detectors. Median PKA was similar at 
Hospital 1 for ostensibly the same machine type, equipped with II detectors (2002-
2008) and FPDs (2007-2010). Hospital 4, while continuing to use image intensifiers 
(as of 2015), delivered doses that are very similar to those of hospitals using FPDs. 
The conclusion by Davies et al [221] that FPDs do not confer “an automatic 
improvement in image quality or dose efficiency” is supported by the current study, at 
least for doses. 
Antiscatter grids are used to reduce the impact of Compton scattering, and the 
associated reduction of image contrast, by selectively attenuating x-rays not traveling 
perpendicular to the grid septa [16]. This improvement in image quality comes at the 
expense of increased dose. As attenuator thickness increases, the amount of 
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material traversed by the beam, and thus opportunities for scattering, also increases. 
Conversely, for ‘small’ patients, the amount of scattering is often considered 
sufficiently minor to allow removal of the grid, resulting in a significant increase in 
dose efficiency [222, 223]. The definition of ‘small’ is open to debate. Partridge et al 
[224] recommend “that the gridless imaging should be the default technique for 
adults and children and in most installations”. This conclusion appears to have been 
reached based on a rather limited range of procedure types and a subjective 
assessment of image quality. Tapiovaara and colleagues [217] reported improved 
dose efficiency where the grid was removed for the smallest patient size studied (3 
years) but not for larger patients (10 and 15 years). The usage/omission of an 
antiscatter grid should only impact on doses for patients below 5 years of age (i.e. 
small patients where grids are removed), though lower PKA, PKA/kg and (PKA/kg)/min 
figures are seen beyond these ages. This suggests grid usage patterns are not solely 
responsible for variation in these figures between hospitals. Participating hospitals in 
this study tended to report grid removal for patients under ‘around 10 kg’, though 
admitted often omitting them for larger patients (McLaren C, personal communication 
2014). Thus the reduction in PKA and PKA/kg associated with grid removal may not be 
restricted only to the smallest patients. 
The variation in PKA between individual procedure types was expected as different 
procedures have different levels of complexity and involve the use of different beam 
angles. Furthermore, some procedures such as atrial septostomy and ASD closure 
involve the combined use of fluoroscopy and trans-oesophageal echo (TOE) 
ultrasound [225, 226], and tend to deliver lower doses. In fact, most atrial 
septostomies conducted at Hospital 3 where done entirely under TOE guidance with 
no x-ray exposure. The procedures associated with the highest doses were valve 
replacements, although this procedure is carried out infrequently. Despite the high 
doses, the procedure is a relatively complication-free alternative to surgery in 
patients with pulmonary valve regurgitation [227]. At most hospitals, median PKA 
figures for ‘interventional’ procedures were lower than those for ‘diagnostic’. In some 
previous studies, the reverse was found [91, 103, 113, 207]. However, while 
grouping procedures into such large categories is statistically convenient, it is 
ultimately arbitrary and unhelpful. For example, stenting of the coronary arteries 
would have a lot more in common with a purely diagnostic visualisation of the same 
vessels than with other interventional procedures such as ASD occlusion. 
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Furthermore, the individual procedure types included within each category are not 
the same at each hospital. Coronary angiography (diagnostic), for example, is 
usually only carried out at hospitals specialising in heart transplants. Valve 
replacements (interventional) were only regularly conducted at Hospital 1.  It might 
be expected that the relative ranking of procedure types by PKA would be fairly 
constant between centres, i.e. the procedures associated with the lowest doses at 
one hospital would be the lowest at all the others as well.  This pattern was not 
observed however - even at the same hospital over multiple eras. The reasons for 
this are not clear, though possibly related to local expertise and technique 
preferences.  
A trend of increasing average PKA with increased patient size or mass was seen for 
almost all procedure types at all hospitals. This finding was consistent with previous 
research [82, 91, 92, 207, 228]. The increase in PKA with patient size can be 
explained by (1) increased patient thickness requires a greater x-ray output to 
produce the same exposure at the detector, and (2) a larger beam area is required to 
cover the cardiac region as the patient grows.   
For all procedures combined, there was a near fourfold variation in median PKA 
between different hospitals. This variation is smaller than that suggested by previous 
research (see literature review), where a greater than tenfold variation was seen. The 
reasons why there is a smaller variation within the UK this are unclear. 
Standardisation of training for cardiologists is a potential factor, although concerns 
have been raised over the lack of formal training courses for these staff [229]. 
Monitoring of dose indicators is carried out by Public Health England, for the 
purposes of setting reference doses (discussed later). The sharing of such 
information could potentially help to standardise dose levels between centres, 
however, paediatric cardiac catheterizations are not included within published reports 
[230, 231]. Interestingly, no association between PKA and the number of procedures 
carried out at a particular hospital was found.  In fact the lowest doses were recorded 
at Hospital 6, which carried out the fewest procedures.  
Normalising PKA by patient mass has previously been advocated in several studies 
[103, 207] as a way a standardising dose reporting and setting of reference levels. 
Kobayashi et al [4] suggest that “growth dependent variation in PKA is successfully 
eliminated by normalizing PKA by body weight”. This conclusion appears to be based 
95 
 
on the lack of strong correlation between PKA/kg and patient age (r ranging from -
0.079 to 0.014). This finding was not replicated in the current study, where PKA/kg 
was found to vary with patient age in a number of distinctive patterns depending on 
equipment type and, it seems, antiscatter grid usage. It should be noted that the data 
described by Kobayashi were acquired from 16 hospitals, encompassing a range of 
equipment types. These were combined together to produce a single dataset of 8267 
procedures. Each machine type may respond to changes in patient size differently, 
while some hospitals may omit an antiscatter grid for small patients with others 
keeping it in. The lack of an overall pattern when data have been combined into a 
single sample is perhaps unsurprising. Combining data from multiple hospitals may 
produce large sample sizes, but an inevitable consequence is the blurring out of 
patterns and loss of useful information. Furthermore, in their claim that that 
normalising PKA by body weight eliminates variation in PKA with age, Kobayashi and 
colleagues [207] appear to have made the mistake of assuming the lack of 
correlation between two datasets implies there is no relationship. This is not 
necessarily true - a U-shaped relationship results in a correlation coefficient of zero, 
either for Spearman’s or Pearson’s methods. Correlation coefficients should not be 
used alone to determine if PKA/kg is somehow independent of patient size. The 
measure of PKA/kg is indeed a useful indicator of dose, reducing the impact of patient 
size but not eliminating it. The findings of the current study thus do not support the 
recommendation by Kobayashi et al that PKA/kg is suitable for establishing reference 
levels, at least not in isolation and not as single figure for all patient sizes. Further 
discussion of reference levels is provided below. 
The majority of patients in the cohort underwent a single procedure. This finding was 
replicated when analysis was restricted to patients born within the study period. This 
has positive implications for epidemiological analysis as it suggests the possibility of 
missing procedures is relatively small. Data on clinical conditions were limited to only 
two hospitals, although a certain degree of inferences can be made from the 
examination type alone. For example, a patient undergoing closure of a ventricular 
septal defect must be suffering from this anomaly. There is, however, no guarantee 
that this condition was isolated and not part of a wider disease pattern such as 
Tetralogy of Fallot. Information on clinical conditions will also have a significant 
bearing on future epidemiological analysis of this or similar cohorts. Patients with 
HLH or those undergoing transplants or Norwood procedures have reduced life 
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expectancies [89, 211, 232], while transplant and Down syndrome patients are at an 
increased risk of developing lymphoma and leukaemia, respectively [211, 212, 233]. 
The analysis of skin dose estimates was limited to examinations conducted at 
Hospital 1 after 2002. These figure suggest the risk of acute skin injuries, thought to 
occur following localised doses of above 2 Gray [16, 44, 234, 235], is extremely small 
for paediatric cardiac catheterizations carried out using modern equipment. Only a 
single patient received a skin dose in any one plane of greater than 2 Gy for a single 
procedure. Skin doses were not recorded for procedures conducted prior to 2002, for 
which PKA was higher by a factor of up to 20. The use of copper filtration in modern 
equipment has the effect of almost entirely removing low energy photons (<30 keV) 
from the x-ray beam and reducing skin dose by 58% (based on 0.35 mm Cu) [236]. 
Thus skin doses for older equipment in which no copper filtration is used may be 
higher than suggested by the ratio of PKA. Skin dose estimates are subject to 
considerable uncertainties relating to the distance from the source at which the 
patient’s entrance skin surface is expected to be found (i.e. the ‘international 
reference point’). The beam area varies according to the square of the distance from 
the source, thus a 10% error in estimation of the location of the reference point 
equates to a greater than 20% error in skin dose. 
 
3.6.1: Comparison with previous publications 
Previous publications reporting PKA and screening times from paediatric cardiac 
catheterizations were discussed in the literature review. These figures will now be re-
examined in the light of the data from the current study. It should be again 
emphasised that comparison of dose indicators with previous studies is difficult as 
each study involves a different equipment types, range of patient sizes and 
procedure types. Recent era data from Hospitals 1 (2002-2008), 2 and 3 were 
preferred in these comparisons, due to the large sample sizes and detailed 
examination type information (lest this be interpreted as ‘cherry picking’ in order to 
provide more favourable comparisons with other studies, it should be noted that 
doses at Hospitals 4, 5 and 6 Hospitals were lower – see Tables 3.7 and 3.8). 
The majority of previously published data are for procedures conducted in the last 10 
years with little data with which to compare early era doses at Hospital 1 and 
Hospital 4. The doses from between 1994 and 2001 at Hospital 1 were compatible 
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with those quoted by Boothroyd et al in 1997 [228] (presented for frontal tube output 
only) but much higher than those reported by Rassow et al [108] for data acquired 
from 1994 to 1996. For both diagnostic and interventional categories, recent era PKA 
figures were compatible with the results of studies led by Martinez  [94], Dragusin 
[237] and McFadden [93] when adjusted for age, and with Barnaoui et al [92] for 
diagnostic, ASD occlusion and PDA occlusion procedures. Where normalised by 
mass, PKA figures were higher than those presented by Ubeda et al [223] by a factor 
ranging from 1.3 to 3.5 (The PKA figures presented in Ubeda’s study, based in Chile, 
are exceptionally low, compared to almost all previous research). These 
investigations were relatively small, with sample sizes of no more than a few hundred 
procedures.   
A number of large studies have been recently published in which stratification of PKA 
by age or mass for individual procedure types was sufficient to allow meaningful 
comparisons. Firstly, Verghese et al [2] reported PKA and air kerma for 3365 
procedures conducted at Boston Children’s Hospital using Siemens Axiom Artis units 
with flat panel detectors. Given the modern equipment, one would expect the 
reported PKA figures to be comparable to those of the current study. Instead they are 
considerably higher. For diagnostic procedures, the median PKA reported by 
Verghese et al was higher than equivalent figures at Hospital 1 (2002-2008 data) by 
a factor of 5.1 to 8.8 depending on age range. For individual procedure types, the 
discrepancy is larger. For example, the median PKA quoted by Verghese et al for 
ASD occlusions is higher than that recorded at Hospital 1 by a factor of between 34 
and 40. It is noted that quoted doses also include those acquired before the 
implementation of the new radiation protection policy, where PKA was reduced by a 
factor ranging from 4 to 52%. Fluoroscopic screening times were longer than those of 
the current study by a factor of around 2; insufficient to explain the much greater PKA.  
Glatz and colleagues [1] reported PKA for 2265 procedures carried out at Philadelphia 
Children’s Hospital, using a Siemens Artis Zee unit between 2009 and 2011. Again, 
despite a range of effective dose reducing measures being implemented, including 
reduced frame rates and antiscatter grid removal where appropriate, the quoted PKA 
figures were much higher than those of the current study. For all procedure types 
combined, the median PKA quoted by Glatz et al was higher than equivalent figures 
for the most recent era in the current study by a factor of between 1.6 and 6.3 
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depending on hospital. For individual procedure types, the discrepancy in PKA was 
even greater, being higher for ASD occlusions by a factor of up 20 compared to the 
current study. As with Verghese, the screening times are longer, but by an 
insufficient extent to explain the discrepancy in doses.  
A recent study by Ghelani et al [83] in which data from 2713 examinations were 
acquired from 7 American centres, reported median PKA and air kerma levels higher 
still than Verghese or Glatz (two of the included centres were Philadelphia and 
Boston Children’s Hospitals). The median PKA for ASD occlusions in the 10-15 year 
age category was 93 Gycm2, compared to 2.0 at Hospital 1 between 2002 and 2008. 
For all ages, ASD doses were higher than those of the current study by a factor 
ranging from 4.7 to 24.7 depending on hospital. The discrepancies for other 
procedures were somewhat smaller, with median PKA figures reported by Ghelani 
being higher by a factor of 2.2 to 9.2 for PDA occlusions, 6.8 to 10.1 for aortic 
valvuloplasty, 5.0 to 16.8 for coarctation repair and 2.6 to 10.1 for pulmonary 
valvuloplasty, depending on hospital. Again, screening times were approximately 
twice as long as those of the current study. 
The previously mentioned study by Kobayashi et al [4] acquired data from 16 centres 
giving a sample of 8267 procedures. No analysis of variation between each of the 
participating centres or equipment types was performed. The procedure specific 
PKA/kg figures reported by in the study were higher than those of the current study 
using modern equipment by a factor of 2.2 to 6 for combined interventional 
procedures, 1.3 to 3.7 for diagnostic procedures, 2.0 to 10.3 for ASD occlusions, 2.5 
to 5.3 for aortic valvuloplasty and 1.3 to 4.7 for pulmonary valvuloplasty, depending 
on hospital. Another, more recent study by Borik et al [102], acquired data on 5196 
cases conducted at the Toronto Hospital for Sick Children. Doses, as represented by 
PKA and PKA/kg where closer to those of the current study, being broadly similar to 
figures recorded at Hospital 2 after 2008, but higher than equivalent figures at 
Hospitals 1 and 3.  
Few studies have been conducted with which skin dose estimates can be compared. 
Frustratingly, most authors have combined figures from both imaging planes into a 
single ‘cumulative air kerma’ figure. In such cases, it can be assumed that the 
maximum skin dose in any single plane can be no less than 50% of the cumulative 
figure. Skin doses reported in the previously mentioned study by Glatz et al [91] were 
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higher than those of the current study by a similar factor to their PKA figures. Single 
plane doses of greater than 2000 mGy occurred in 4.3% of interventional procedures 
overall. For patients over 65 kg, these levels were exceeded in 32.9% of all 
interventional procedures and 58% of PA angioplasty procedures. The skin doses 
reported by Verghese and colleagues [82] were also greater than those of the current 
study by a similar factor to PKA. For patients over age 16, the median cumulative skin 
doses for ‘distal R or L angioplasty or stent’, ‘RVOT dilatation and or stent’ and ‘Prox 
R or L angioplasty and or stent’ were 4.52 Gy (IQR: 2.94, 8.48), 4.55 (1.96, 5.54) and 
4.84 Gy (3.08, 5.51) respectively. For these procedures, the ‘median maximum’ dose 
(i.e. the median of whichever plane delivered the highest skin dose) must be at least 
2.25 Gy, thus over the supposed threshold for observable skin reactions [234]. The 
authors do not comment on the frequency of skin injuries at the study hospital. The 
skin doses reported by Sawdy et al [238] for 1310 procedures carried out over a 3 
year period are especially difficult to interpret. It is not clear what the units of 
measurement are – data presented in tables are written in the unit of ‘R’, which 
presumably means Roentgen (a unit of exposure often recorded by older 
equipment), while the text refers to the same figures in ‘mGy’. Nor is it clear if figures 
are combined for both planes, or are the maximum of both (as in this study). The 
authors report that 15 patients received radiation burns during the study period. Skin 
injuries were the first recorded adverse effects of exposure to ionising radiation, 
reported within 6 months of the discovery of x-rays in 1895 [16]. The findings of the 
current study suggest that acute skin reactions from cardiac catheterizations carried 
out using modern equipment are extremely unlikely in children, at least in the UK. 
Skin cancer, however, appears inducible by radiation, albeit mostly in less dangerous 
forms such as basal cell carcinoma, rather than malignant melanoma [45]. It is 
important, therefore, that epidemiological analyses of cancer risks following cardiac 
catheterizations include the identification of skin cancers. 
In the literature review, it was speculated that the high doses reported in recent 
studies led by Glatz [91], Verghese [82], Ghelani [83] and Kobayashi [207] could be a 
true representation of doses from modern cardiac catheterizations, and that the low 
doses of other studies could be explained by small sample sizes and publication bias 
(only publishing if doses are low). The findings of the current study, presented in this 
chapter, ought to suggest otherwise. While it is tempting to speculate that mistakes 
have been made in quoting PKA data, for example confusing mGy·cm² with µGy·m², it 
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is unlikely that four large studies could have made the same mistake. If the PKA 
figures quoted in the above mentioned studies were to be reduced by a factor of 10, 
they would become inexplicably low. The units of measurement were confirmed 
individually for all six hospitals in the current study and were consistent. The 
discrepancy in doses, as represented by PKA, is almost certainly real. However, it is 
not possible to claim that high doses are ‘too high’ – that would imply a proven net 
disadvantage, with the radiation-associated detriment (i.e. increased risk of cancer) 
outweighing the improved image quality associated with higher doses.  
 
3.7: Limitations and uncertainties 
The most important limitation of the data described in this chapter is the variable 
quality from one hospital to the next. Most notably, a large proportion of examinations 
conducted at the Hospital 4 lacked any form of dose indicator and lacked sufficient 
information on procedure type. This has implications for dose estimation as knowing 
the procedure type allows the likely beam angles used to be predicted. Procedure 
type information is also useful for epidemiological analysis as it allows inferences on 
confounding factors and survival rates.  
The number of patients without sufficient personal details to allow cancer registry 
matching (full name, date of birth, or NHS number) is also a concern. Much of the 
cohort (i.e. from Hospitals 1 and 2) was established from handwritten records, rather 
than computer-based RIS records. A number of spelling discrepancies were only 
identified because the patient had multiple entries. For patients examined only once, 
the risk of misspelled names is increased. Such cohort members, if they have indeed 
developed a tumour, may not be identified as such by the cancer registry. This could 
potentially lead to an under-ascertainment of cancer incidence in this patient group. 
Data obtained electronically may also include data entry errors – it is just as easy to 
enter data into the wrong column (e.g. mixing up PKA and ST) or to place a decimal 
point in the wrong place. 
Kerma area product is typically subject to an uncertainty of ±15% where regularly 
calibrated. All PKA meters were subjected to regular quality assurance (QA) testing. 
Calibration factors were applied to PKA data where provided. The spike in PKA in 1996 
at Hospital 1 (Figure 3.) could potentially be due to measurement error, although this 
is impossible to confirm or rule out. A calibration factor for the lateral tube (1.13) was 
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provided for 1995 but not 1996. The reliability of older data is an important concern 
for future epidemiological analysis. 
The automatic gathering of examination data for the purpose of national audits has 
been discussed [239, 240]. This is, in principle, a very attractive prospect, but 
requires rigorous attention to quality assurance. The automatic archiving of dose 
indicators, including 'structured dose reports' recorded by most modern fluoroscopic 
equipment, could be valuable in radiation protection and (providing sufficient details 
are recorded) epidemiological research, while also reducing the workload for 
radiographers. The latter point may not necessarily be a good thing though; manual 
recording of dose indicators may help to enforce a culture of awareness of radiation 
doses among radiography staff. 
3.8: Reference levels 
Mention must be made of so called ‘reference’ levels. These are often referred to as 
‘diagnostic reference levels’ (DRLs) [241], although their applicability need not be 
restricted to purely diagnostic procedures. Reference levels are supposed to 
represent typical doses for a particular procedure, usually defined using median or 
third quartile doses obtained from audits of PKA, skin dose, fluoroscopy time or (in 
CT), dose length product. In particular, reference levels should serve as an 
investigation level where these figures are being consistently exceeded. The above 
discussion of the large variation in PKA between published studies ought to illustrate 
the danger of failing to compare local dose indicators with those delivered elsewhere. 
Ironically, many of the studies reporting the highest PKA levels had the specific 
objective of setting reference levels themselves [83, 207]. This undermines the 
usefulness of the reference level concept. The setting of local reference doses that 
would be considered exceptionally high elsewhere provides little incentive for 
optimisation. 
Most reference levels are based on PKA, usually referred to in publications simply as 
‘dose’, with little or no appreciation for what this figure actually represents. As 
described in Chapter 2, PKA is derived from the charge produced in a known mass of 
air as the x-ray beam passes through, and thus represents dose (or more specifically 
collision air kerma) in air – not to the patient. Although PKA can indeed be related to 
patient dose (this will be exploited extensively in this study), this relationship is highly 
variable, depending on conditions including patient size, beam angle and beam 
102 
 
energy. Equal PKA figures may equate to greatly different patient doses. So what’s 
the use of reference levels based on something so tentatively related to patient dose 
as PKA? Without efforts to stratify PKA-based reference levels by patient size, exam 
type (and hence likely beam angles) and equipment type (defining beam energy) 
these figures are of limited usefulness. If such variables are accounted for, then the 
result will be a large number of different reference levels. This may be an unattractive 
prospect for those who like to keep radiation protection simple, but the alternative of 
one-size-fits-all reference levels for all procedure types combined would be of little 
value and could potentially be misleading. The use of PKA stratified by mass for 
reference levels is advocated as a solution by Kobayashi et al [207] and Onnasch et 
al [103], though as  demonstrated above, PKA/kg is not constant across the range of 
patient sizes studied. Therefore normalising PKA by mass does not eliminate the 
need for any form of patient size stratification of reference levels. The PKA data 
presented in this thesis may be used as the basis for the establishment of reference 
levels, but only in the fully stratified, procedure specific form presented in the 
appendix. Any form of ‘averaging out’ to produce simplified reference levels is not 
recommended.  
 
3.9: Conclusion 
A cohort was established from data on around 13,500 patients undergoing around 
20,000 procedures at six hospitals in the UK. The quality of these data were variable. 
In particular, a large number of procedures conducted at the Hospital 4 Hospital had 
no dose indicator recorded. 
Doses, as represented by PKA, screening times and skin doses have decreased over 
the timeframe of data collection. This appears to be mainly due to equipment related 
factors. The figures collected in this study were low compared to several recently 
published American surveys. Variation in PKA was seen between individual centres 
providing data, although the magnitude of this variation is somewhat less that 
suggested in previous publications.  
It should again be emphasised that PKA and screening time are only indicators of 
patient dose. For a more thorough analysis, including cumulative doses over multiple 
procedures and the associated risks, it is necessary to estimate organ doses. The 
following chapters describe the use of Monte Carlo computer simulations to establish 
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the relationship between PKA and organ doses over a range of beam angles and x-
ray energies, and the use of this information to construct a dosimetry system for rapid 
dose calculation for cohort members. Further chapters describe the use of estimated 
organ doses for assessment of long term risks of cancer. 
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Chapter 4: Computational Dosimetry: 
The following chapters describe the process of using kerma area product (PKA) 
(defined in Chapter 2), recorded for cardiac catheterizations, to estimate patient 
dose. The dosimetric modelling process was comprised of four components, each of 
which are covered in separate chapters: 
1. A systematic analysis of the relationship between kerma area product (PKA) 
and organ doses using Monte Carlo simulations, for a large range of beam 
angles, beam energies and patient sizes (this chapter) 
2. A process for utilising the above data for calculation of doses for cohort 
members based on available examination data (Chapter 5). 
3. Collection of supporting data on beam angles and beam energy used in 
clinical practice for use in dose models (Chapter 6). 
4. Verification of computer simulated doses using physical dosimetry (Chapter 
7). 
Monte Carlo (MC) computer simulations were chosen as the primary method of dose 
estimation due to the ability to rapidly calculate doses to multiple organs over a broad 
range of exposure conditions. Thousands of possible combinations of beam angle, 
patient size and x-ray energy were investigated, therefore accounting for each 
combination using physical measurements would be extremely time consuming.  
When estimating dose to organs based on limited data recorded at the time of the 
examination (i.e. procedure type, patient age/mass and PKA only), the uncertainty in 
dose estimates due to deviations from expected beam angles or energy needed to 
be estimated. Part of the dosimetric modelling process was to determine the 
sensitivity of organ doses to small changes to these factors. A further aim was to 
determine if correction factors to adjust organ doses could be applied as a single 
scaling factor or would need to be a continuous function of other factors (e.g. beam 
rotation).  
4.1: Monte Carlo Methodology 
Monte Carlo (MC) simulations are based on computer modelling of multiple random 
interactions between x-ray photons and matter [242], to produce the photon 
equivalent of flipping a coin a great many times (the name Monte Carlo refers to the 
region of Monaco and reflects the stochastical nature of gambling). Instead of heads 
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or tails, photon trajectories are modelled according to the known laws of physics, 
including photoelectric absorption, Compton scattering and Rayleigh scattering. The 
number of photon trajectories simulated can be variable, ranging from 103 to 108 [16]. 
In this study, the software used for Monte Carlo computer simulations was PCXMC 
version 2.0 [242]. This is a commercial code developed especially for calculating 
doses from diagnostic medical exposures with photon energies of 150 keV and 
below. PCXMC uses phantoms representing various ages (new born, 1, 5, 10, 15 
and 30 years (Figure 4.1), modified from the phantom originally reported by Cristy 
and Eckerman [243]. Modifications include the addition of an oesophagus and 
improved alignment of the head and neck region [242]. The phantoms are 
hermaphrodites. It is not possible to produce gender specific dose calculations (other 
than simply omitting breast dose). Characteristics of each phantom are given in 
Table 4.1. The crude nature of the Cristy phantom is widely acknowledged [244].  
 
 
Figure 4.1: 5-year old mathematical phantom used in PCXMC 2.0. The right hand image is 
displayed as if looking down from above, achieved by using maximum caudal beam 
angulation and removing head organs. Figure credit: author annotated PCXMC screengrab. 
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Phantom 
size 
Mass (kg) 
Height 
(cm) 
Trunk height 
(cm) 
Trunk 
thickness (cm) 
Newborn 3.0 50.9 21.6 9.8 
1 Year 9.2 74.4 30.7 13 
5 Years 19.0 109.1 40.8 15 
10 Years 32.4 139.8 50.8 16.8 
15 Years 56.3 168.1 63.1 19.6 
Adult 73.2 178.6 70 20 
 
Table 4.1: Phantom characteristics in PCXMC 2.0. Data obtained from Tapiovaara and 
Siiskonen [242] 
 
PCXMC has been used extensively in diagnostic medical radiation dosimetry, 
including for estimation of doses from cardiac catheterizations [85, 86, 91, 92, 107]. 
The results of such simulations in PCXMC show good agreement with the general 
purpose Monte Carlo code MCNP, while the former is considerably more convenient 
to use [85]. Good agreement has also been found between PCXMC and the results 
of Stern et al [87] for coronary angiography examinations [245], and with the results 
of Hart et al [246] for a range of x-ray energies and examinations, including chest 
imaging [245, 247]. Brady [248] found that agreement between computational and 
physical measurements of effective dose from CT scans was higher for PCXMC than 
for other programs, including those specifically designed for CT dose estimation. 
PCXMC calculates doses to 29 different organs and tissues along with effective dose 
using ICRP 60 [67] and ICRP 103 [44] weighting factors. Organ doses are presented 
as the mean dose to the whole tissue and are thus numerically identical to the 
equivalent dose (H) for that organ. This includes dose to the skin; it is not possible to 
calculate localised skin doses for the irradiated area in PCXMC, nor is it possible to 
calculate ‘partial’ organ doses, such as unilateral breast or lung doses. Only doses to 
active bone marrow, breasts, heart, lungs, lymph nodes, oesophagus, liver, stomach 
and thyroid were utilised in the dosimetry system, along with effective dose (ICRP 
103 factors) and mean absorbed dose to the whole body. Although other organs 
such as the bladder, colon and salivary glands are susceptible to radiation induced 
cancer [45], these organs are well outside the exposed area and thus receive little 
radiation dose. Other organs such as the uterus are of little interest in an 
epidemiological study of low radiation doses. Incorporating additional organs into the 
dosimetry system (described in Chapter 5) is especially time consuming, as each 
requires its own separate set of corrections for beam energy. These organs were not 
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analysed separately in this study, although the doses were incorporated into effective 
dose. 
Lymph nodes are not themselves simulated in PCXMC phantoms. Instead, lymph 
node dose is calculated by a weighted sum of doses to other tissues using the 
following relationship [242]: 
𝐷𝑙𝑦𝑚𝑝ℎ 𝑛𝑜𝑑𝑒 = 𝐷𝑠𝑚𝑎𝑙𝑙 𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒 + 0.13 ∙ 𝐷𝑒𝑥𝑡𝑟𝑎𝑡ℎ𝑜𝑟𝑎𝑐𝑖𝑐 𝑎𝑖𝑟𝑤𝑎𝑦𝑠 + 0.08 ∙ 𝐷𝑠𝑎𝑙𝑖𝑣𝑎𝑟𝑦 𝑔𝑙𝑎𝑛𝑑𝑠 + 0.05
∙ 𝐷𝑡ℎ𝑦𝑟𝑜𝑖𝑑 + 0.04 ∙ 𝐷𝑜𝑒𝑠𝑜𝑝ℎ𝑎𝑔𝑢𝑠 + 0.03 ∙ 𝐷𝑠𝑡𝑜𝑚𝑎𝑐ℎ + 0.15 ∙ 𝐷𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 + 0.10
∙ 𝐷𝑔𝑎𝑙𝑙 𝑏𝑙𝑎𝑑𝑑𝑒𝑟 + 0.07 ∙ 𝐷𝑙𝑢𝑛𝑔𝑠 + 0.05 ∙ 𝐷𝑡𝑜𝑡𝑎𝑙 𝑏𝑜𝑑𝑦 + 0.04 ∙ 𝐷ℎ𝑒𝑎𝑟𝑡 + 0.01
∙ 𝐷𝑡𝑒𝑠𝑡𝑒𝑠 
Equation 4.1 
 
Neither the thymus nor active bone marrow or the spleen are included in the above 
equation. Although not considered to be ‘nodes’, these tissues are regarded primary 
organs of the lymphatic system [249]. It is unclear what the impact of these 
assumptions in lymph node locations is. Currently, evidence of an association 
between lymphoma and radiation exposure is limited [7, 45]  and it is not possible to 
determine which tissues need to be irradiated to induce this disease (if indeed this is 
possible). 
PCXMC does not allow circular or irregularly shaped x-ray fields and cannot be used 
to assess the impact of beam equalising filters such as lung ‘shutters’ designed to 
adjust for the lower density of the lungs compared to the mediastinum. Nor does 
PCXMC allow organ density to be changed, meaning it is not possible to examine the 
impact of contrast enhancement on doses. This is not a trivial matter. Research 
suggests organ doses from CT scans can vary by 10-100% depending on contrast 
agent administration, due to the effect on tissue density [250, 251]. The issue of 
contrast agents is also discussed in the ‘Future Research’ chapter. 
Aside from featuring pre-set ‘standard’ phantoms representing different age groups, 
PCXMC allows the height and mass (i.e. weight) of these phantoms to be adjusted 
over a limitless range. To account for increased mass, the program adopts a 
cosmological inflation model in which all organs expand like balloons, visceral organs 
and bones alike (Figure 4.2). This approach is unsupported by evidence and has no 
basis in reality. Some level of pathological enlargement of some viscera can occur 
(e.g. cardiomegaly, hepatomegaly or emphysema) and rare conditions in which bone 
108 
 
enlargement occurs also exist (e.g. Paget’s disease), but never in the manner 
suggested by PCXMC. The primary reasons for altered mass for a given height are 
the variable deposition of adipose tissue (fat) and muscle size, neither of which is 
modelled in PCXMC. Given this limitation, the majority of analysis was restricted to 
the standard, pre-set phantom sizes based on average heights, weight and thickness 
of the general population. 
 
Figure 4.2: Standard 5 year old phantom (left), adjusted to have a greater and smaller mass 
for a given height. Note the unrealistic expansion or contraction of bones, especially the 
skull. Figure credit: author created screengrabs 
 
PCXMC can be operated automatically using a macro code in Microsoft Excel (2010 
edition, Microsoft Corporation, Redmond, Washington). The ‘Autocalc’ macro [252] 
allows relevant parameters such as patient and beam characteristics to be inputted 
in an Excel worksheet. A particular combination of parameters can simply be copied 
and pasted as multiple rows in the workbook to produce a large number of 
simulations in which a single parameter, such as beam angle or energy, is adjusted 
one step at a time. This is ideal for simulation of doses over a large range of beam 
angles and energies. The initial autocalc macro code restricts simulations to a 16° 
anode angle, copper and aluminium filtration and 20,000 photons per simulation, but 
these parameters can be changed by editing the macro script. 
For effective dose and equivalent dose to most organs, simulation errors were found 
to decrease with increasing phantom age (Figure 4.3). These errors were generally 
less than 3% for effective dose and doses to certain tissues such as bone marrow 
and lymph nodes and heart (Figure 4.4). Errors were much higher for tissues 
receiving relatively low doses due to being located well outside the irradiated field, 
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such as the thyroid (up to 80%) and testicles (up to 100%). Thyroid dose errors 
increased with increasing phantom age (Figure 4.5). This is most likely to be due to 
increased distance from the irradiated field and hence lower dose due to scattered 
radiation.  
Dose errors for tissues lying deep to the entrance surface, such as the breasts in 
postero-anterior (PA) beam projections, were higher than those for tissues lying 
close to the entrance surface. As these tissues are of interest in risk modelling and 
epidemiological analysis, measures to reduce large errors were investigated. It was 
found that increasing the input dose simply resulted in a linear scaling of calculated 
organ doses and did not affect estimated error. Increasing the number of simulated 
photon interactions does result in a decrease in error (Figures 4.3 to 4.6), but also 
increases the simulation time (2, 7, 15 and 150 seconds per simulation for 10, 50 and 
100 thousand and 1 million photons respectively). Figures 4.3 to 4.5 also show the 
doses for each photon count. These figures are almost identical at a given phantom 
size for the heart, in which errors are below 3%. However a large variation in breast 
and thyroid dose is apparent depending on the number of photons used in the 
simulation. 
The autocalc macro defaults to simulation for all photon energies, up to 150 keV. 
Simulation time can be reduced by editing the macro to restrict simulated photons to 
match the tube potentials being investigated. A maximum mean error of 3% for 
effective dose and 10% for breast dose could be achieved using 40,000 photons for 
phantoms adult, 15 and 10 year old patients, while 50,000 photons were sufficient for 
the 5 year and 1 year phantoms. For the neonate phantom, 100,000 photons were 
used. These simulations were used for initial investigations on the effects of changes 
to various parameters. For the final dosimetry system (described in Chapter 5), a set 
of ‘reference’ data based on single beam energy combination was used. For the 
reference data, a lower level of error was desired, and simulations were run using 1 
million photons (50 times the pre-set level). These simulations took over two weeks 
to complete, running day and night. The result was simulation errors being reduced 
to generally less than 1%. 
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Figure 4.3: Breast dose simulation errors at each phantom age for different number of 
simulated photons. 
 
 
 
Figure 4.4: Heart dose simulation errors at each phantom age for different number of 
simulated photons. 
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Figure 4.5: Thyroid dose simulation errors at each phantom age for different number of 
simulated photons. 
 
 
 
Figure 4.6: Thyroid dose as a function of beam angle for 0 year phantom at 70 kVp and 0.2 
mm Cu for simulations using 100,000 and 1 million photons (mean errors of 10.1 and 2.5%, 
respectively). The latter simulations were used as reference data. 
 
It is easy to accidently calculate and input doses calculated from previous 
simulations. To avoid this possibility, each simulation was given a unique 
identification number, and simulation files were deleted after doses were calculated 
and inputted into Excel spreadsheets. 
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The input dose for simulations was always in the form of kerma area product, set at 
1000 mGy·cm2 (1 Gy·cm2), meaning that the results were always presented as 
equivalent organ doses (in mSv) per unit PKA (PCXMC uses the units of ‘mean organ 
dose’ in mGy). Changes to the following parameters were investigated: 
 Beam angle in both rotational (around the patient) and cranio-caudal (head to 
foot) directions 
 Central ray location 
 Field size (collimation) 
 Focus-skin distance (FSD) – the distance between the x-ray source and the 
patient. 
 Beam energy (tube potential and filtration) 
 Patient size (the six phantom sizes in Table 4.1) 
Initially, the x, y and z beam coordinates were adjusted to ensure that the heart was 
in the centre of the irradiated field for all angles. Beam area was set to include the 
entire heart and a small surrounding region (Figure 4.7). The arms were omitted from 
the phantom for all projections (in clinical practice, the arms are elevated above the 
head to avoid obscuring the heart in the lateral projection). The focus-skin distance 
was initially set at 80 cm. PCXMC uses a default anode angle of 16°. This was 
changed to 12°, based on manufacturer’s specifications for fluoroscopy equipment 
from used equipment vendors [253]. In particular, an anode angle of 12° is used for 
Siemens Axiom Artis units, which were the most commonly used fluoroscopic 
machine at participating hospitals. The impact of using different anode angles was 
also investigated. 
For this thesis, the beam angle (or projection angle) terminology described in 
Appendix 1 will be used. A ‘posteroanterior’ (PA) beam projection is one that enters 
the back and exits the front, an ‘anteroposterior’ (AP) beam is the reverse of this. In 
bi-plane machine, both PA and AP projection utilise the frontal x-ray tube. A ‘left 
lateral’ beam enters the right hand side and exits the left. These correspond to 
rotational beam angles of 90°, 270° and 180° respectively in PCXMC. A distinction is 
made between ‘PA orientated projections’, meaning beam angles that are 
approximately in the PA projection, and ‘straight PA’ which means exactly PA and 
achieved with a vertical beam which the patient supine. A similar distinction is made 
between ‘laterally orientated’ and ‘straight lateral’ projections. It should also be noted 
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that cardiologists often refer to the PA projection as ‘AP’ [86]. This convention will not 
be used in this thesis.  
 
Figure 4.7: The exposed region for new-born child in PA projection (90°). The lungs are not 
shown. The dark green feature below the heart is the stomach, the white bars represent the 
ribs and spine, while the light green shape above the heart is the thymus. Figure credit: 
author created screengrab 
 
Rotational beam angle was investigated as a function of full 360° rotation around the 
patient in 5° intervals, resulting in a set of 72 Monte Carlo simulations. Each of these 
sets was repeated at different cranio-caudal beam angulations ranging from 55° 
caudal to 55° cranial (also in 5° intervals). Greater angulations in either direction 
were not calculated, as the head or pelvis is projected over the heart rendering the 
image clinically useless. The combination of rotation around the patient and cranio-
caudal angulations produced 1656 simulations representing a near complete range 
of possible beam angles. This ‘full projection set’ was the starting point from which all 
other changes to parameters were investigated.  
To investigate the impact of changes to beam energy, peak tube potential in kilovolts 
(kVp) was varied from 50 to 100 kVp at 10 kVp intervals. The typical range in clinical 
practice was around 58-90 kVp (see Chapter 6: Supporting Data). Aluminium 
filtration was kept constant at 2.5 mm, while copper (Cu) filtration was set at 0, 0.1, 
0.2, 0.3, 0.6 and 0.9 mm for each tube potential interval. Thus 36 different 
combinations of beam energy were investigated. The impact of beam energy on 
organ doses was calculated for all 1656 projection angles to determine whether 
conversion factors needed to be projection specific or could be applied as a single 
figure regardless of beam angle.  
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The effect of variation in patient size was investigated by calculating doses for the 6 
different pre-set phantoms listed in Table 4.1. For each of these phantom sizes, 
doses were calculated for the full set of 1656 projection angles and 36 different beam 
energy combinations. This resulted in a total of 1656 * 36 * 6 = 357,696 different MC 
simulations. Further investigation of the effect of patient size was difficult due to the 
unrealistic manner in which PCXMC handles changes to mass for a given height. If 
the mass is increased, the heart size is also increased, meaning the beam area must 
be adjusted to include the same region. Nonetheless, some separate simulations 
were carried out to assess the potential effect of under- or overweight patient 
characteristics on dose estimates. Phantom mass was adjusted to approximate 5th 
and 95th percentiles of body mass index (BMI) obtained from the Royal College of 
Paediatrics and Child Head (RCPCH) [254]. BMI is not used for children below 2 
years, so for phantoms representing new born and 1 year, the 5th and 95th percentiles 
of mass were used. The beam area was collimated to the heart border following each 
size adjustment. This process was repeated for both straight PA and left lateral beam 
projections. 
To investigate the effects of changes to focus-skin distance (FSD), central ray 
location and field size, a reduced set of beam angles were used, with intervals in the 
cranio-caudal direction increased to 10°. Beam energy was restricted to a central 
value of 70 kV and 0.2 mm Cu filtration, and extreme values of 50 kV/0.0 mm Cu and 
100 kV/0.9 mm Cu. All investigations were carried out using each of the 6 pre-set 
phantom sizes. 
Changes to field size were investigated by increasing or decreasing the height and 
width of the field in 1 cm intervals. The relative impact of this 1 cm increase would be 
larger for smaller patients (i.e. it would cover a greater proportion of the body), so 
extra simulations were run at ±0.5 cm for the new born phantom. In addition, a 
separate set of large field simulations were carried out designed to include most of 
the lungs. Such large field sizes are used in clinical practice to visualise the 
pulmonary circulation. In these cases, the central ray location was positioned slightly 
superior to the heart to include the aortic arch and avoid inclusion of the liver and 
stomach within the primary field. 
Focus-skin distance was adjusted over the range of 40-120 cm in 20 cm intervals 
using the standard field size. The impact of variation in the location of the x-ray beam 
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central ray was investigated by adjusting x, y and z coordinates in 2 cm intervals until 
the heart was no longer included within the primary field. This process was repeated 
for a limited range of beam angles. 
 
4.2: Results 
4.2.1: Beam angle 
The influence of beam angle on dose was seen to vary considerably between 
different organs, which are discussed individually below.  Note that situs solitis is 
assumed (organs in their normal positions). Some patients may have unusual organ 
arrangements including dextrocardia (right sided heart) [249] and situs inversus (all 
organs are on the opposite side of the body to normal).  
The figures showing the effect of beam angle throughout this chapter are presented 
for over the full range of rotational beam angles, but at a reduced range of cranio-
caudal angles to improve clarity. All figures are for a phantom representing a 15 year 
old individual (56.3 kg). The patterns shown are generally similar for other phantom 
sizes. Any significant differences are described. 
 
Bone Marrow: 
Active bone marrow (ABM) is contained within long bones (arms and legs) and the 
axial skeleton (spine, ribs, skull, and sternum) [255], which is predominantly 
posteriorly located. In the phantoms used in PCXMC, ABM is uniformly distributed 
through the matrix of bones [247], rather than being located in the medullary canal or 
sandwiched between two layers of compact bone as occurs in reality [255]. The 
distribution of ABM throughout the skeleton, according to data presented by Cristy  
[256], is taken into account. Equivalent dose to active bone marrow (ABM) (i.e. 
averaged over all ABM in the body) was found to be higher for PA orientated 
projections (Figure 4.8). Two peaks in ABM dose either side of the straight PA 
projection were noted in the results of simulations for phantoms representing 0, 1 
and 5 year old individuals (see Figure 4.31 later in chapter), and can be explained by 
greater inclusion of one scapula (shoulder blade) within the primary beam. These 
peaks are not seen for 10 year, 15 year and adult phantoms, because the scapulae 
are so widely spaced that they are not included within the primary beam unless the 
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field size is especially large (see field size results, later). Compared to other tissue 
types, ABM dose shows relatively little variation with beam angle in the cranio-caudal 
direction. 
 
 
Figure 4.8: Bone marrow dose per unit PKA as a function of beam angle. 
 
Breasts: 
Breast doses are calculated by PCXMC as the mean of both breasts and it is not 
possible to determine these doses individually. In contrast to ABM dose, breast dose 
was found to be much higher for AP orientated projections than PA, owing to the 
more anterior location of the breasts (Figure 4.9).  The large dip in breast dose 
occurring for straight AP projections occurs because the beam passes in between 
the right and left breasts, excluding both from the primary beam. The transition in 
breast dose between AP and PA projections is considerably more abrupt than is 
seen for ABM dose. This is particularly striking between rotational beam angles of 
165° and 195° and 345° to 15°, between which breast dose increases by a factor of 
13 (56 kg phantom). Breast dose is also sensitive to changes in cranio-caudal beam 
angulation, being highest where little such angulation is present. 
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Figure 4.9: Breast dose per unit PKA as a function of beam angle.  Note the pronounced ‘cliff’ 
in breast dose between around 170 to 190°. 
 
At certain ages, a pronounced ‘spike’ in breast dose was seen at rotational beam 
angles of around 195-210° (i.e. approximately laterally orientated with some rotation 
towards the anterior), with a smaller spike at around 350-355° (Figure 4.10). These 
features were present over the full range of beam angulations in the cranio-caudal 
direction. The spikes were only noted for simulations using 0 and 10 year old 
phantoms. Simulation errors were excluded as the cause because the spikes were 
still present when simulations were run at 1 million photons, where breast dose 
errors were less than 1% (i.e. a lot less than the size of the spike). It was noted that 
at the specified beam location coordinates, the irradiated field extended beyond the 
anterior chest wall. The coordinates of the x-ray beam were adjusted, decreasing the 
y coordinate so that the beam no longer included the anterior chest wall (Figure 
4.11). This was found to eliminate the dose spike. It should be noted, however, that 
beam angles orientated in the 195-210° range are never seen in clinical practice 
(these beam angles are described in the ‘Supporting Information’ chapter, later), 
therefore the ‘spike’ was of little consequence in dose estimations for clinical 
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examinations. The impact of inclusion of the chest wall in the primary beam will be 
explored further in section 4.2.4. 
 
 
Figure 4.10: Breast dose for 10 year phantom size (32.4 kg) as a function of beam angle, 
showing spikes. 
 
 
Figure 4.11: Anatomy inclusion at three different y coordinates by beam central ray. The thin 
blue line on the right hand side of each image delineates the beam edge. The projection of 
one breast outside the chest wall (blue circle) appears to be the cause of the dose spikes. 
Image credit: author screengrabs 
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Heart: 
The heart is an anterior lying organ, found slightly to the left of the midline. 
Consequently, heart dose is higher for AP orientated projections (between around 
220-300° in PCXMC) and higher for right lateral than left lateral projections (Figure 
4.12). In clinical practice, it is common to use beam projections in which the heart is 
closest to the detector to reduce magnification distortion and geometric unsharpness 
(i.e. PA and left lateral projections). This means the heart is shielded to some extent 
by other organs and dose is often lower than the lungs or breasts, despite the organ 
being located entirely within the irradiated field. For almost all rotational angles, dose 
to the heart was found to be greater where no cranial or caudal beam angulation was 
present. This is because cranio-caudal angulation increases the thickness of 
preceding tissue traversed by the beam before the heart is reached. 
 
 
Figure 4.12: Heart dose per unit PKA as a function of beam angle. 
 
Liver: 
The liver lies inferior to the heart and is predominantly located on the right hand side 
of the body [249]. Consequently, liver dose is highest in the left lateral projection. 
Liver dose was found to be especially sensitive to changes in cranio-caudal 
angulation compared to other organs (Figure 4.13). A particularly striking feature of 
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Figure 4.13 is the peak in liver dose occurring with cranial angulation and a rotational 
angle between 130-200°, in which case the beam passes through the liver before 
reaching the heart. Such beam angles are rarely used in clinical practice, however. 
 
Figure 4.13: Liver dose per unit PKA as a function of beam angle. 
 
Lymph nodes: 
As the organs used to estimate dose to this tissue are spread around the body, 
lymph node dose shows relatively little variation with beam angle compared to other 
tissues (Figure 4.14). Caudally orientated beam projections resulted in lower doses 
per unit PKA than cranially orientated beams. Dose per unit PKA is generally low and 
comparable to that for bone marrow. It was noted earlier that neither active bone 
marrow nor the thymus are included in lymph node dose calculations in PCXMC, 
despite both being regarded as principle organs of the lymphatic system [249]. The 
thymus is located in the anterior and superior mediastinum, close to the heart, 
though sometimes extending superiorly as far as the thyroid [249] (seen in Figure 4.1 
as the light green feature). The organ thus lies within the primary beam during 
cardiac catheterizations. The importance of the thymus in radiocarcinogenesis is 
currently unknown, however.  
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Figure 4.14: Lymph node dose per unit PKA as a function of beam angle. 
 
Lungs: 
Pronounced dips in lung dose per unit PKA were seen for straight PA and AP 
orientated projections in which exclusion of the lungs from the primary field is 
greatest (Figure 4.15). Overall, doses were higher in PA orientated projections, as a 
greater volume of the lungs is found in the posterior half of the body. Dose in left-
laterally orientated projections was higher than for right laterals as the right lung is 
larger due to the presence of the heart on the left.  Like the heart, doses were also 
higher for beams in which no cranial or caudal angulation was present. Lung doses 
were generally among the highest of all organ doses, regardless of projection angle.  
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Figure 4.15: Lung dose per unit PKA as a function of beam angle. 
 
Oesophagus: 
The oesophagus is fairly centrally located, found anterior to the spine and posterior 
to the heart. It is within or close to the primary beam in most projection angles, 
though is always shielded to some extent by other organs. This shielding effect 
increases where cranio-caudal beam angulation is applied (Figure 4.16). In PCXMC, 
the oesophagus is modelled as being exactly central and directly anterior to the 
spine. In reality, the oesophagus may deviate to one side [257], in which the 
shielding provided by the spine for PA-orientated projections would be less. Thus 
oesophagus dose may be underestimated by PCXMC. 
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Figure 4.16: Oesophagus dose per unit PKA as a function of beam angle. 
 
Stomach: 
Like the liver, the stomach is located inferior to the heart and thus receives greater 
doses in cranially orientated projections (Figure 4.17). In contrast to the liver, 
stomach dose is higher in right lateral projections, owing to its predominantly left 
sided location. The stomach is approximately ‘J’ shaped in humans, however its size 
and shape is highly variable, tending to increase in the cranio-caudal dimension and 
decrease in the anterior-posterior dimension with increasing ponderal index (a 
measure of how ‘lean’ a person is) [258]. Tall, thin people have tall, thin stomachs. 
This variation is not reflected in the PCXMC mathematical phantoms, in which the 
stomach is modelled as an ovoid (dark blue in Figure 4.1). However, the pattern of 
higher stomach doses with cranial beam angulation should still be valid.  
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Figure 4.17: Stomach dose per unit PKA as a function of beam angle. 
 
Thyroid: 
The thyroid gland is located anterior to the trachea and superior to the sternal notch 
and should not be included in the primary radiation field in normal practice (although 
one study found cases where this did sometimes occur [259]). Consequently, thyroid 
dose is low, and almost entirely due to scattered radiation (extrafocal and leakage 
radiation are not simulated in PCXMC but are accounted for in physical 
measurements, described in a later chapter). Doses were found to be highest with 
large levels of cranial beam angulation (Figure 4.18), where the thyroid is closest to 
the primary field. Where the beam is angled cranially, thyroid dose is highest in 
laterally orientated projections, while for caudal beam angles dose is highest in AP 
and right posterior oblique orientated projections (Figure 4.19) 
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Figure 4.18: Thyroid dose per unit PKA as a function of beam angle. 
 
 
 
Figure 4.19: Beam projections at which thyroid dose is highest (1 year old phantom). The 
position of the thyroid is shown (the green feature under the head). Image credit: author 
generated PCXMC screengrab 
 
Gonads: 
The testes and ovaries are located well outside the primary radiation field for cardiac 
catheterizations and receive minimal scattered dose. Where femoral catheterization 
is used, the pelvic area may be briefly imaged for catheter guidance, although this 
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should not be necessary for most patients [259]. Calculated doses were almost zero, 
even for the most caudally angulated beam projections (i.e. those in which the 
gonads would be closest to the primary field). 
 
Effective dose: 
The effective dose (E) is strongly influenced by breast dose, owing to the proximity of 
the breasts to the irradiated field and the high tissue weighting factor (0.12 in ICRP 
103 [44]). This can be appreciated by comparing Figure 4.9 and Figure 4.20 – the 
shape of the two curves is similar, though variation in effective dose with beam angle 
is less pronounced than for breast dose. Overall, there is a tendency for effective 
dose to be higher in more anteriorly orientated projections than posterior. As with the 
heart and lungs, effective dose per unit PKA is higher where no craniocaudal 
angulation is present. With large levels of cranial or caudal angulation, the variation 
in effective dose with rotational beam angle was found to be reduced. It should also 
be noted that effective dose is higher by around 20% for cardiac exposures where 
ICRP 103 [44] weighting factors are used as opposed to ICRP 60 [67]. This is 
principally due to the increased weighting for the breasts (0.12 instead of 0.05) and 
the inclusion of the heart into the ‘other’ tissue category. 
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Figure 4.20: Effective dose per unit PKA as a function of beam angle. Note the presence of 
the ‘cliff’ between170 to 190° and the dip between 220 and 290°, also seen for breast dose. 
 
Average absorbed dose: 
The average absorbed dose to the whole body was also calculated. This was done to 
allow comparison with effective dose (which could also be considered a form of 
‘whole body’ radiation dose measurement) and for use in risk models. Unlike 
effective dose or doses to individual organs, average absorbed dose was virtually 
independent of beam angle in either direction (Figure 4.21). Average absorbed dose 
was lower than effective dose by an average factor of around 1.8 across all beam 
angles and patient sizes. For beam angles commonly used in cardiac 
catheterizations, this factor is slightly reduced to around 1.7 (see Chapter 8). The 
difference between effective and average whole body dose illustrates the impact of 
the high density of radiosensitive organs in proximity to the heart. If such calculations 
are repeated for exposures of the extremities, the average absorbed dose is found to 
be higher than effective dose (for example, for a knee radiograph, the average 
absorbed dose calculated by PCXMC is higher than effective dose by a factor of 18). 
By multiplying the average absorbed dose by phantom mass, the total energy 
imparted to the body, in Joules (J) can be estimated. The energy imparted per unit 
PKA increases slightly as phantom size is increased from 3.4 to 73.2 kg (0 to 30 
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years), ranging from 8.0 to 13.1 mJ  at 70 kV and 0.2 mm Cu, as a greater proportion 
of the beam is attenuated with greater material thickness.  
 
 
Figure 4.21: Average absorbed dose per unit PKA as a function of beam angle 
 
4.2.2: Beam energy 
Doses to all organs per unit PKA were found to increase with increasing beam energy. 
This pattern can be characterised in different ways; by considering individual 
parameters affecting beam energy separately (i.e. tube potential, filtration and anode 
angle) or by using a single figure in which beam quality is characterised by the 
thickness of a given material required to reduce beam intensity by 50% - the so-
called half-value layer (HVL), usually given in millimetres of aluminium (Al). The 
former measure is more informative while the latter is more convenient. In this study, 
HVL was calculated using SpekCalc [260], a commercially available program utilising 
Monte Carlo data calculated by Poludniowski and Evans [261, 262]. This allows 
calculation of beam spectra and associated half value layer from a range of 
parameters including tube potential, anode angle and thickness filters of various 
materials including air, aluminium and copper. The HVL methodology has a number 
of limitations. The same HVL can be achieved using very different parameters 
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(Figure 4.22). For example, a 1st HVL of around 3.5 mm Al is achieved using a tube 
potential of 110 kV with 2.5 mm Al filtration, and also using 40 kV, 2.5 mm Al and 0.9 
mm copper filtration. The 2nd HVLs (i.e. the thickness reducing intensity by a further 
50%) for these two situations are very different, at 5.75 and 3.62 mm respectively. 
The low kV situation results in a beam spectrum lacking the high kV ‘tail’ and is 
entirely due to Bremsstrahlung, with no characteristic emissions. As the patient is not 
made from aluminium, the characterisation of x-ray beams according to their 
interactions with aluminium is an approximation and can lead to errors in dose 
estimation (see Section 5.2). 
When characterising by kV and filtration separately, the increase in organ dose with 
beam energy follows a pattern well described by a logarithmic or 3rd order polynomial 
(Figure 4.23). The rate of increase declines as beam energy is increased. The 
marginal increase in organ dose per unit PKA is especially large with initial addition of 
copper filtration (i.e. increased from zero to 0.1 or 0.2 mm). The effect of varying 
anode angle was generally small, with dose per unit PKA increasing by little more 
than 1% for each degree decrease in angle. The effect of beam energy on dose 
varied between organs (Figure 4.24), being greater for the thyroid, stomach and liver 
– tissues located mostly, or entirely, outside the primary field of irradiation - than for 
more evenly distributed organs such as bone marrow or the lungs. The implication of 
this finding is that corrections to adjust doses for beam energy must be organ 
specific. It was also found that the impact of changes to beam energy also increased 
with increasing phantom size. Examples of the ratio in dose between different beam 
energies are shown in Table 4.2. This implies that energy corrections must also take 
patient size into account.  
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Figure 4.22: Using half value layer (HVL) to describe beam energy. Colours represent HVL 
in millimetres of aluminium as a function of tube potential and added copper filtration 
(assuming 2.5 mm Al filtration). 
 
 
Figure 4.23: Bone marrow dose as a function of beam quality for various combinations of 
tube potential and added copper filtration. The phantom size is 10 years and beam angle is 
straight PA. Third order polynomial trend lines have been fitted. 
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Figure 4.24: The ratio in dose to different organs between high and low beam energy levels, 
represented by tube potential. Phantom size = 56 kg (15 years), beam angle is straight PA. 
 
 Dose ratio 
Phantom 
size (kg) 
Bone 
marrow 
Breasts Lungs 
3.4 1.89 1.30 1.18 
9.2 2.34 1.48 1.27 
19.0 2.35 1.90 1.35 
32.4 2.50 2.19 1.41 
56.3 2.49 2.32 1.59 
73.2 2.59 2.38 1.62 
 
Table 4.2: Ratio between dose at 100 kV/0.9 mm Cu and 70 kV/0.2 mm Cu for bone marrow, 
breasts and lungs for each phantom size. Beam angle is straight PA. 
 
The variation in dose with beam energy was also seen to be dependent on beam 
angle. This is best visualised by plotting the ratio between two beam quality values 
as a function of beam angle (Figure 4.25). The variation is greater for more unevenly 
distributed tissues (e.g. breasts and heart), i.e. these organs are found towards one 
side of the body (the anterior) rather than being evenly spread throughout the torso. 
In the case of characterising by HVL, the variation in dose can also be described by a 
polynomial equation, although the closeness of fit is not precise (Figure 4.26). The 
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data points appear to be scattered around the polynomial in a seemingly random 
way, albeit with greater deviation as HVL is reduced towards 1.7 mm Al 
(corresponding to 50 kV, 2.5 mm Al and 0.0 mm Cu filtration). This distribution was 
explored in greater detail by plotting dose against HVL, while labelling data points 
according to filtration level. This showed that the distribution followed a more 
predictable ‘saw-tooth’ pattern (Figure 4.27). It was also noted that deviation of data 
points from the polynomial increased with increasing phantom size.  
The average absorbed dose to the whole body increases with increasing beam 
energy, but the proportion of the beam absorbed correspondingly decreases (Figure 
4.28). The rates of these changes vary with patient size; the rate of increase in 
average absorbed dose with beam energy increases with increasing patient size 
(Figure 4.29), while the decrease in the fraction of beam energy absorbed by the 
patient decreases with increasing patient size (Figure 4.30). 
 
 
Figure 4.25: Ratio between dose at 100 kVp and 50 kVp (0.0 mm Cu filtration) as a function 
of beam angle for different tissues. Phantom size is 15 years. 
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Figure 4.26: Bone marrow dose as a function of half value layer for 6 phantom sizes. Third 
order polynomial trend lines have been fitted. 
 
Figure 4.27: Bone marrow dose as a function of HVL (10 year, 32.4 kg phantom) with 
different filtration levels displayed in different colours. Successive points for each colour 
represent different tube potentials, ranging from 50 to 100 kVp in 10 kVp intervals. 
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Figure 4.28: Variation in average absorbed dose to the whole body and the percentage of 
beam energy absorbed by the patient 
 
 
Figure 4.29: Variation in average absorbed dose to whole body with beam energy defined by 
tube potential, for 6 phantom sizes. Figures are presented relative to dose at 50 kV. Beam 
angle is 90°, with no cranio-caudal angulation applied (straight PA). 
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Figure 4.30: Variation in the fraction of beam energy absorbed with tube potential, for 6 
phantom sizes. 
 
4.2.3: Phantom size 
Dose per unit PKA was seen to decrease with increasing phantom size. This pattern 
was seen for all organs and beam angles. This is demonstrated in Figure 3.31, in 
which the variation in bone marrow dose with rotational beam angle is shown for 
each of the 6 simulated phantom sizes. Note that the shape of the curves for each 
patient size is approximately the same, although some details vary, such as the 
‘horns’ on the peak for smaller phantom sizes (described earlier) 
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Figure 4.31: Bone marrow dose as a function of beam angle at different simulated mass 
levels. 
 
There are a number of explanations for this pattern. X-rays are attenuated by tissues 
in a manner described by Beer’s law [16], in which intensity (I) is reduced 
exponentially with increasing thickness (t) of material traversed: 
𝐼 = 𝐼0𝑒
−𝜇𝑡 
Equation 4.16 
Where I0 is the initial intensity and µ is the linear attenuation coefficient. Thus, if a 
greater thickness of tissue is traversed before an organ is reached by the x-ray 
beam, the intensity will be lower. This can be seen in Figure 4.32 where distance A’ 
is shorter than distance A. Consequently, the intensity of radiation at tissues lying 
close to the surface are higher than those at greater depth. Effectively, for smaller 
patients, organs lie closer to the surface and thus receive a greater intensity of 
radiation. As organ size increases, the mean intensity of radiation traversing it 
decreases. For organs lying partially or wholly outside the irradiated field, such as the 
stomach or thyroid, the distance between the organ and the field edge decreases 
with decreasing patient/phantom size. This is demonstrated in Figure 4.32, in which 
distance between the field edge and the out-of-field organ (B) is greater than the 
equivalent distance for the smaller patient (B’). The intensity of scattered radiation 
137 
 
reaching such out-of-field tissues would decrease with increasing distance (though 
not strictly according to the inverse-square-law, due to anisotropy of scatter).  
 
 
 
 
 
 
 
 
 
Figure 4.32: Effect of patient size on organ doses. Entirely in-field (red), partially in-field 
(blue) and entirely out-of-field organs (green) are shown. Figure credit: author 
 
The relationship between dose and patient size was investigated by plotting effective 
dose and organ doses obtained at two different beam angles (90° and 180°, ie. PA 
and lateral) against mass using SPSS (Version 19, IBM).The beam energy was set 
at 70 kV and 0.2 mm Cu. Different curves were then fitted (figures 4.33 and 4.34). 
The closeness of fit for each curve varied between tissue types, although some 
general observations were apparent. It was found that an exponential curve provided 
a reasonable fit for masses greater than around 10 kg but tended to underestimate 
dose below this level. R2 varied from 0.79 to 0.96. A logarithmic curve provided better 
estimation of doses for low masses, but underestimated doses for masses above 
around 50 kg (even predicting negative doses in some cases). R2 ranged from 0.90 
to 0.95. A power law relationship was found to produce the best overall fit across the 
full range of masses and did not predict negative doses. R² ranged from 0.93 to 0.99. 
Despite all three curve fits being statistically significant for all organs and beam 
angles tested, for the purposes of this study the closeness of fit was often less than 
satisfactory. This was to cause difficulties later when an attempt at applying a 
correction factor for patient mass was made (see Section 5.3 in Chapter 5). 
B 
A 
A’ 
B’ 
Large patient 
Small patient 
X-ray beam 
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Figure 4.33: Simulated active bone marrow (ABM) dose, in millisieverts (y-axis), as a 
function of phantom mass with three models fitted (logarithmic, power and exponential). 
Beam angle = 180 degrees (straight left lateral). 
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Figure 4.34: Breast dose (y-axis) in mSv, as a function of mass with logarithmic, power law 
and exponential curves fitted. Beam angle = 180 degrees (straight left lateral). 
 
The values of the coefficient and exponent of the power law relationship describing 
variation in dose with patient mass were recorded as the beam quality was adjusted. 
Both were found to vary (Table 4.3) albeit in a well behaved manner and describable 
using a simple logarithmic relationship (Figure 4.35). In theory, this means that a 
conversion factor to adjust doses calculated at one patient size to any other size 
could be designed in which beam quality is accounted for. In general, the relative 
increase in organ dose with increased beam quality was greater as phantom size 
was increased. 
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Tube 
potential: 
0.0 mm Cu 0.1 mm Cu 0.2 mm Cu 0.3 mm Cu 0.6 mm Cu 0.9 mm Cu 
a b a b a b a b a b a b 
50 kVp 31.24 -1.04 28.52 -1.01 27.25 -0.99 26.38 -0.97 24.87 -0.95 24.05 -0.94 
60 kVp 28.51 -1.00 25.84 -0.97 24.51 -0.95 23.63 -0.94 22.12 -0.91 21.30 -0.90 
70 kVp 26.45 -0.98 23.87 -0.94 22.59 -0.92 21.76 -0.91 20.33 -0.89 19.57 -0.87 
80 kVp 24.71 -0.95 22.31 -0.92 21.13 -0.90 20.37 -0.89 19.09 -0.87 18.42 -0.85 
90 kVp 23.85 -0.94 21.18 -0.90 20.12 -0.88 19.44 -0.87 18.31 -0.85 17.72 -0.84 
100 kVp 22.37 -0.92 20.37 -0.89 19.42 -0.87 18.80 -0.86 16.42 -0.84 16.03 -0.83 
 
Table 4.3: Values of coefficient (a) and exponent (b) of conversion factor to adjust effective 
dose at 56 kg (15 years) to any other mass, as the level of copper (Cu) filtration and tube 
potential are adjusted. 
 
 
Figure 4.35: Plot of values from table 4.3 at 0.1 mm Cu filtration with log trend lines fitted. 
 
The fraction of total beam energy absorbed increases with phantom size, ranging 
from 44.7% for the new born phantom, to 68.7% for the 30 year old phantom (70 kV 
and 0.2 mm added Cu filtration). 
Analysis of the variation of dose due to changes in mass for a given height is 
hindered by the unrealistic phantom used in PCXMC. A few interesting observations 
could be made, however. In almost all cases, organ doses were seen to increase as 
phantom mass was reduced while height was kept constant, and decrease as mass 
was increased (Table 4.4). This variation in dose was generally around ±20% with 
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one standard deviation in BMI or mass. There was no clear relationship between this 
variation and phantom size. In some cases, thyroid dose was decreased for the 
smaller phantom BMI and increased for the larger BMI. Presumably this is because 
thyroid dose is entirely due to scatter originating from primary radiation field, 
therefore increasing the volume of material irradiated would increase opportunities 
for scatter.  
The implication is that obese patients would receive lower organ doses per unit PKA 
than asthenic patients. Due to the limitations of the computational phantoms used in 
PCXMC, these findings were not incorporated into central dose estimates or 
associated uncertainties. Further investigation is required, ideally using patient 
specific phantoms derived from cross sectional imaging. This would require different 
Monte Carlo software (e.g. MCNP or GEANT) as PCXMC can only utilise the inbuilt 
phantoms based on the Christy model. 
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Phantom 
age 
(mass) 
Projection Size change 
Effective 
dose 
Bone 
marrow 
Breasts Heart Lungs 
Lymph 
nodes 
Oesoph Thyroid Liver Stomach 
Mean 
Dose 
0
 y
e
a
rs
  
(3
.4
 k
g
) PA 
-1 SD # 20% 14% 53% 25% 18% 16% 16% 4% 11% 12% 16% 
+1 SD # -16% -13% -31% -23% -17% -15% -16% 4% -9% -5% -14% 
Lateral 
-1 SD # 41% 17% 69% 17% 17% 14% 48% -13% 1% 6% 15% 
+1 SD # -26% -14% -40% -19% -15% -14% -8% -4% -4% -8% -14% 
1
 y
e
a
r 
 
(9
.2
 k
g
) PA 
-1 SD # 21% 17% 21% 34% 22% 22% 26% 1% 14% 12% 19% 
+1 SD # -17% -12% -40% -23% -16% -15% -19% 13% -13% -14% -13% 
Lateral 
-1 SD # 36% 19% 77% 26% 20% 18% 12% 4% 5% 16% 18% 
+1 SD # -12% -43% 85% -59% -52% -56% -58% -62% -46% -59% -54% 
5
 y
e
a
rs
 
(1
9
.0
 k
g
) 
PA 
-1 SD 27% 18% 102% 33% 23% 21% 26% -12% 15% 17% 19% 
+1 SD -18% -10% -29% -22% -20% -17% -17% -26% -14% -13% -13% 
Lateral 
-1 SD 24% 18% 32% 30% 19% 20% 19% -16% 7% 21% 19% 
+1 SD 36% -11% 131% -20% -21% -19% -26% -13% -7% -12% -15% 
1
0
 y
e
a
rs
 
(3
2
.4
 k
g
) 
PA 
-1 SD 17% 13% 16% 24% 18% 18% 22% 9% 13% 11% 14% 
+1 SD -25% -18% -50% -34% -24% -24% -24% 6% -22% -25% -20% 
Lateral 
-1 SD 12% 13% 3% 23% 16% 17% 22% -12% 5% 25% 14% 
+1 SD -28% -20% -56% -31% -16% -17% 24% -32% -10% -24% -19% 
1
5
 y
e
a
rs
 
(5
6
.3
) PA 
-1 SD 20% 17% 38% 35% 18% 22% 26% -31% 19% 15% 17% 
+1 SD -23% -18% -41% -34% -25% -24% -24% -29% -21% -20% -19% 
Lateral 
-1 SD 17% 15% 17% 31% 17% 19% 13% -22% 7% 26% 17% 
+1 SD -26% -18% -41% -31% -18% -21% -12% 6% -9% -25% -19% 
 
Table 4.4: Percentage variation in dose associated with adjusting phantom body mass index (BMI) by 1 standard deviation. # for 1 year and 
new born phantoms, mass is used rather than BMI. 
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4.2.6: Field size 
PKA approximates the absorbed dose to air multiplied by beam area [70]. If PKA 
remains constant, an increase in field size must be matched by a decrease in dose. 
Most organs considered in this study are located partly within the irradiated field. For 
these organs, along with effective dose and average whole body dose, increasing 
field size increases the volume of the tissue within the field, but decreases dose to 
that volume. Theoretically, the result is invariance of organ dose per unit PKA with 
field size. In reality, due to the irregular shape of organs, organ doses do indeed vary 
with field size. This relationship was found to be complex, varying between different 
organs and beam angles. The overarching pattern is that increasing or decreasing 
field size depreciates or intensifies the variation in dose with beam angle, 
respectively. This can be seen in Figure 4.36, in which effective dose as a function of 
rotational beam angle is shown for three different field sizes (the 11x11 cm field is 
the same as that in Figure 4.20). Note that the variation is less pronounced for the 
largest field size – the ‘cliff’ between rotational angles of 160 and 190° has become a 
gentle hill. In this case, effective dose per unit PKA in the left lateral projection would 
be overestimated if the field size was underestimated.  
Of the organs considered in this study, only the heart is entirely included within the 
irradiated field. In this case, the situation is relatively straightforward - as field size is 
increased, heart dose per unit PKA decreases Figure 4.37. For tissues lying entirely 
outside the primary beam, increasing the field size has the effect of decreasing the 
distance between the tissue and the field edge, and thus increases dose. Of the 
organs of interest in this study, only the thyroid gland is entirely out-of-field. A clear 
increase in thyroid dose was only seen for the largest field size, with moderate 
increases in field size having a negligible effect (Figure 4.38). Overall, field size has 
an important impact on organ doses calculated from PKA and needs to be taken into 
account in dose estimations and associated uncertainty analysis. 
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Figure 4.36: Effect of variation in field size on effective dose (15 year phantom). 
 
 
 
Figure 4.37: Effect of field size on heart dose (15 year phantom). 
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Figure 4.38: Effect of field size on thyroid dose (new born phantom) 
 
4.2.4: Central ray location 
In clinical practice, variation in central ray location is generally in the superior-inferior 
direction. Procedures involving the pulmonary trunk or the arch of the aorta tend to 
be centred a little higher than other procedures. Left to right translation is very 
limited. Occasionally, imaging of the left upper lobe area of the lungs is carried out 
during pacemaker insertions to check box position. For the lateral projection the 
beam centring point is also determined by the height of the table in relation to the x-
ray beam central axis. Raising the table causes posterior translation of the central 
ray, while lowering the table results in anterior translation. Variation in organ doses 
as central ray location was adjusted was consistent with the anatomical distribution 
of respective tissues. Oesophageal dose was relatively insensitive to anterior-
superior translation, while thyroid dose was found to increase sharply with 
increasingly superior beam centring. Conversely, stomach and liver doses increased 
sharply as the central ray was shifted inferiorly.  
A fall of 89% in breast dose was seen in the lateral projection as the central ray was 
adjusted in the anterior-posterior direction, i.e. toward the front or back, defined by 
table height, relative to the patient, falling from around 5.5 to less than 1.0 mSv per 
unit PKA with a translation of only 2 cm (10 year phantom). This pattern is 
demonstrated in Figure 4.39 for two different field sizes. Where the field size was 
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increased, the variation in breast dose was smaller and the point of transition from 
high to low dose shifted in the positive y-axis direction (i.e. toward the back). 
According to these simulations, using an admittedly crude mathematical phantom, if 
the anterior chest wall is included within the primary field for laterally orientated 
projections, breast dose is very high. If it is excluded from the primary field, breast 
dose is close to that obtained in the PA projection. For other organs, the variation in 
dose with anterior-posterior translation in the lateral projection was reasonably small, 
generally varying by 20% or less. Images from a sample of 30 cardiac 
catheterizations conducted at Hospital 4 were reviewed and the level of inclusion of 
the anterior chest wall in the lateral projection was noted. In 20% of examinations, 
the anterior chest wall was entirely excluded from the exposed area, in 23% it was 
fully visible, while in the majority of cases (57%), the chest wall was partially visible. 
The exposed area in the majority of examinations was equivalent to positions 3 or 4 
in Figure 4.39 (y-axis positions of -3.5 and -1.5 cm), thus corresponding to high or 
low breast doses.  
Variation in breast dose in the lateral projection was further investigated by 
simulating the variation in dose with rotational beam angle with different 
combinations of field size and central ray position. In two cases, the field size was 
narrowed to completely exclude the anterior chest wall from the irradiated field. In 
one of these situations, the central ray was also translated posteriorly by 1 cm. This 
resulted in exclusion of a small part of the apex of the heart, though was still clinically 
plausible as the major vessels would be included within the field. In all four cases, 
the same pattern of a rapid rise in breast dose as the beam is rotated between into 
the lateral projection was seen (Figure 4.40). However, the angle at which breast 
dose begin to rise varied, occurring at greater angles for the ‘chest wall excluded’ 
situations. For an angle of 180° (i.e. a ‘straight left lateral’), this resulted in a greater 
than 3-fold difference in breast dose between these four situations. It can be seen 
from Figure 4.40 that breast dose in the left lateral projection can be as low at that in 
the straight PA projection, depending on the combination of central ray location and 
field size.  
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Figure 4.39: Variation in breast dose with central ray location. Simulated radiographs are 
shown for each corresponding position as beam is translated along the y-axis (anterior-
posterior direction) from front to back.  
 
 
 
Figure 4.40: Breast dose as a function of beam angle (15 year old phantom) for different field 
sizes and central ray positions. The grey bar represents the left lateral projection. The PA 
projection is at 90°. 
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4.2.5: Focus-skin distance 
Changes to the focus-skin distance (FSD), which is the distance between the x-ray 
source (i.e. the anode) and the patient’s entrance surface, had relatively little impact 
on organ doses per unit PKA. There was a small trend of reduced doses at shorter 
FSDs, although within the range of distances likely to be used in clinical practice (60-
100 cm), these differences were almost negligible. The same pattern was seen for 
both beam qualities extremes, though a slightly larger variation in dose with FSD was 
seen at 100 kV and 0.9 mm Cu compared to 50 kV and 0.0 mm Cu. For example, the 
mean variation between bone marrow dose at the shortest and longest FSDs was 
3.8% and 3.0% respectively. The variation in dose with FSD was lowest for the bone 
marrow (Figure 4.41) and highest for the heart (Figure 4.42). Increasing FSD is 
frequently listed among optimisation techniques in diagnostic imaging [263] and 
interventional fluoroscopy and can result in a modest reduction in effective dose 
[264]. The results described above should not be compared to such research as they 
represent dose per unit PKA, rather than per se. Overall, a central value of FSD (80 
cm) should suffice for dose estimations based on PKA.  
 
  
Figure 4.41: Bone marrow dose as a function of rotational beam angle at different focus-skin 
distances. 
149 
 
 
 
Figure 4.42: Heart dose as a function of rotational beam angle at different focus-skin 
distances. 
 
4.3: Comparison with previous research 
The previously published effective dose per unit PKA (E/PKA) conversion factors 
summarised in the literature review were compared to those of the current study 
(Table 4.5). Conversion factors were similar to those of Barnaoui et al [92] and 
Karambatsakidou et al [112], though higher by a factor of around 2 than those of 
Schmidt et al [86] and Onnasch et al [103]. This difference is consistent with the 
effect of beam energy on dose per unit PKA, as these latter two studies used relatively 
low energies for calculations. The E/PKA conversion factors quoted by Barnaoui et al 
are higher than those of the current study for the PA projection, but lower for the left 
lateral projection. The field sizes used by Barnaoui – a potential explanation for this 
variation - were not stated. It should be noted that four of the previous studies 
described here also used PCXMC Monte Carlo simulations to calculate E/PKA 
conversion factors. The figures reported by Kawasaki et al [116] were based on 
physical measurements. These figures are close to those of the current study for the 
1 year phantom, but lower for the new born. The lateral/PA E/PKA ratio is similar, 
albeit slightly higher, than calculated in the current study. 
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Onnasch et al 
PA+Lat 
combined $ 
Barnaoui et al 
PA/lateral $$ 
Karambat-sakidou 
et al PA+Lat 
combined $ 
Schmidt et al 
PA/lateral $ 
Kawasaki et al 
PA/Lateral $$ 
This study 
PA/lateral $$ 
Beam energy 65 kV, 3mm Al 
70 kV, 3.0 mm 
Al, 0.3 mm Cu 
 
65 kV, 3mm 
Al 
70-73 kV, 1 mm 
Al, 0.4 mm Cu 
70 kV, 3.0 mm 
Al, 0.3 mm Cu 
P
h
a
n
to
m
 a
g
e
 (
y
e
a
rs
) 0 3.09 3.5/3.5 3.7 2.05/2.34 2.2/4.0 3.5/5.28 
1 1.03 2.1/1.6 1.9 0.82/1.16 1.4/2.7 1.60/2.62 
5 0.49 1.05/1.3 1.0 0.42/0.64  0.84/1.69 
10 0.29 0.65/0.8 0.6 0.24/0.38  0.49/1.11 
15 0.17 0.35/0.4 0.4 0.13/0.22  0.26/0.48 
30 0.13 - - 0.10/0.16  0.20/0.39 
 
Table 4.5: Comparison of effective dose per unit PKA conversion factors, between this and 
previous publications. Note: $=ICRP 60 weighting factors, $$=ICRP 103. 
 
The only authors to use an alternative Monte Carlo code were Streulens et al [88], 
who used MCNP-X (v2.5.0), along with two voxel phantoms based on cross sectional 
images, known as ‘Laura’ and ‘Golem’ [265]. This allowed doses to be calculated 
separately for males and females (not possible using PCXMC). The analysis was 
restricted to adults, with no paediatric phantoms used. Simulations were conducted 
using a range of beam energies, represented by HVL, from 2.5 to 11.5 mm, allowing 
detailed comparison of the calculated effect of x-ray energy on doses. The overall 
pattern is the same for both studies, i.e. dose per unit PKA increases with increasing 
energy, tending to level off above around 9 mm Al. There is a close agreement in the 
magnitude of this variation in the PA projection (0-13%), though not for the left lateral 
projection, in which Streulen’s data suggest a 15-45% greater increase in dose per 
millimetre increase in HVL. Despite this, estimated effective dose for the lateral 
projection in the current study was higher by 38%, while for the PA projection, figures 
varied by around 2% (Figure 4.43). Streulens et al calculated doses to individual 
organs, as well as effective dose. There is no overall pattern of agreement between 
studies; heart dose per unit PKA was higher in Streulens’s paper, while breast dose 
was lower. The overall agreement was approximately ±30%.   
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Figure 4.43: Effective dose per unit PKA for two projections, calculated over a range of beam 
energies, by the current study and by Streulens et al. 
 
4.4: Conclusion 
The relationship between kerma area product and patient dose was found to vary 
sufficiently with beam angle, beam energy, phantom size and field size that these 
parameters need to be taken into account in dose estimations derived from PKA. 
Although a measure of patient size is usually recorded for clinical examinations (e.g. 
height, mass, age), details of beam angle and energy are not routinely recorded. 
These parameters must therefore be estimated, based on examination type and 
equipment type and uncertainty in these estimates must be taken into account. A 
somewhat smaller impact was found for changes in focus-skin distance, and anode 
angle. The largest variation in dose for a given value of PKA was for the breasts in the 
lateral projection. Even small changes to beam angle, field size or central ray 
location can result in a large difference in dose. 
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Chapter 5: Dosimetry system development 
The Monte Carlo simulation data described in Chapter 4 were represented in a large 
number of table matrices describing simulations done at 1656 discrete values of 
beam angle, 36 beam energy combinations and six different phantom sizes. 
Essentially, these are conversion factors, representing organ doses per unit PKA 
(H/PKA). Similar tabulated conversion factors have been previously published [84, 86, 
88], albeit over a more limited range of conditions. This chapter describes the 
incorporation of Monte Carlo data into a MATLAB-based dosimetry system, called 
‘Cardiodose’, capable of rapid estimation of individual organ doses for large cohorts 
by picking the right conversion factor. There are two reasons why this dosimetry 
system was developed, as opposed to running individual Monte Carlo simulations for 
each examination for cohort members: (1) MC simulations are slow to set up and 
execute, and (2) PCXMC is a relatively expensive piece of software that can only be 
installed on one computer. A dosimetry system that utilises MC data, but does not 
require doing new simulations would not require a PCXMC licence, improving 
accessibility. Future versions of the dosimetry system can be written as self-
executable files, not requiring MATLAB either. Ultimately, the development of 
Cardiodose paid dividends, as the dose estimation process needed to be repeated 
several times during the study as new data were obtained. 
The Cardiodose function was designed to be able to estimate organ doses for any 
specified projection angle, x-ray beam energy or patient size. If beam angle or 
energy data were not available, then some way of estimating these parameters 
based on examination and equipment type was needed. The gathering of data on 
beam energy and projection angles used in clinical practice is described in Chapter 
6: Supporting information.  
 
5.1: Beam angle 
Conversion factors to relate PKA to organ doses were stored in the form of tables with 
23 rows and 72 columns. The rows represented cranio-caudal angles from 55° 
caudal to 55° cranial, in 5° intervals, while the columns represented rotational angles, 
ranging from 0 to 360°, also in 5° intervals. A simple linear scaling approach was 
used to convert the specified beam angle to the correct table row/column number. 
For specified beam angles between the 5° intervals, a linear interpolation approach 
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was used. This is relatively straightforward and has the advantages of computational 
simplicity and fidelity to the original simulated data. The main disadvantages of linear 
interpolation are the large volume of data required (all of it) and the problem of high 
simulation errors for certain tissues resulting in noisy data. The latter problem could 
be addressed by running MC simulations with a greater photon count, although this 
is even more time consuming.  
An alternative to the above approach involved encoding the 23x72 tables as 
polynomial equations. A polynomial describes a function (i.e. organ dose as a 
function of beam angle) as the sum of a number of ‘building blocks’, each raised to a 
non-negative integer power and multiplied by a coefficient [266]. The degree of the 
polynomial (n) is represented by the building block raised to the highest power. 
𝐷 = 𝑐𝑛𝑥
𝑛 + 𝑐𝑛−1𝑥
𝑛−1 + ⋯+ 𝑐2𝑥
2 + 𝑐1𝑥
1 + 𝑐0𝑥
0 
Equation 5.17 
In theory, even complex functions can be described by a polynomial equation, 
although the number of degrees required may be large – in this case between 8 and 
20 (Figure 5.1). The polynomial method has the advantage of smoothing out noisy 
data, reducing the need to run lengthy simulations.  Additionally, even complicated 
polynomials require much less file-space than tables. Although the idea of describing 
a large table of numbers in a single equation is rather elegant, there are several 
significant problems with the polynomial approach. Firstly, the beam angle in two 
directions must be accounted for (rotational and cradio-caudal). It is possible to 
create a 2-dimensional surface polynomial, although this is significantly more 
complex and would require so many elements it would eliminate any advantages of 
reduced data storage. Secondly, the evaluation of polynomials is computationally 
slower than linear interpolation, increasing the time to estimate doses for a large 
number of examinations. A third problem was the difficulty in applying further 
correction factors to adjust for beam quality and patient size. It was principally for this 
latter problem that the polynomial method was abandoned in favour of linear 
interpolation. 
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Figure 5.1: Variation in dose with beam angle can be described using a polynomial 
equation. Circles represent data from Monte Carlo simulations at discrete beam 
angle intervals. 
 
For each examination type, the range of beam angles used was encoded in an n by 4 
matrix for incorporation into the dosimetry system, where n represents the number of 
different beam angles used. An example is shown below:  
[
90 0 0.5 𝑡
180 0 0.4 0
120 10 0.1 𝑡
] 
The first and second columns represent the rotational and cranio-caudal beam 
angles respectively. The third column represents the proportion of the total PKA spent 
in each projection. This could be adjusted to match projections used at different 
hospitals. The fourth column was added as a later modification and allows reduction 
of dose by a particular specified factor. This was used to correct for attenuation for 
the presence of the x-ray table (t). The estimation of this ‘table reduction factor’ is 
described in section 6.2.6. 
Each procedure type was given its own beam angle matrix. The values used in the 
matrix were based on data described in the following chapter on supporting 
information. The matrices are stored in the MATLAB function code and can easily be 
edited (see third page of appendix 4; matrices are written on a single line, with 
semicolons separating each row of the matrix, and commas separating the columns). 
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5.2: Beam energy 
The dosimetry system needed to take beam energy into account. As with projection 
angle, the simplest option would be to linearly interpolate between the simulated 
energy levels to produce a dose estimate at any specified beam quality. Again, this 
has the disadvantage of requiring a huge volume of data to be incorporated into the 
dosimetry system – 36 big tables of data, each about 60 kilobytes in size, for each 
phantom size and each organ type. A second approach involves starting with dose at 
a single ‘reference’ beam quality and applying a conversion factor to adjust for any 
other beam quality. The advantages of this approach include reduced data storage 
requirements, and that simulations at the ‘reference’ beam quality could be run using 
a very large number of photons, leading to reduced simulation errors and less noisy 
data. This approach also allows different field sizes to be incorporated as different 
sets of ‘reference’ data. A further advantage is that correction factors could be 
designed to account for other beam quality parameters (i.e. not just tube potential 
and copper filtration). A number of immediate questions arise: (1) how should beam 
quality be described?  (2) What should the ‘reference’ quality be? (3) Could a single 
conversion factor be applied for all beam angles, or would it need to vary with beam 
angle? These questions are addressed in the following sections. 
 
5.2.1: Half value layer encoding 
Even if inherent filtration is assumed to be fixed, accounting for both added filtration 
and kVp results in complicated conversions. For example, dose variation with added 
filtration is also dependent on kVp and vice versa. As with beam angle, the 
combination of kVp and filtration can be treated as a surface and described by a 
multi-variable polynomial equation. However, if other factors such as voltage ripple 
and inherent filtration were also taken into account, then these conversions would 
become extremely complex. As mentioned in the Computational Dosimetry chapter 
(section 4.2.2), beam energy can also be described by half value layer (HVL). This 
addresses the above problem by describing beam quality as a single figure that 
allows all influencing factors to be taken into account.  
The reference HVL was set at 4.8 mm Al, corresponding to 70 kV, 2.5 mm Al and 0.2 
mm Cu filtration. This ansatz was chosen simply because it represented a relatively 
central beam quality from which to convert to other beam energies (values seen in 
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clinical practice appeared to range from around 3 to 6.5 mm Al – see Chapter 6). The 
errors associated with correction to other beam energies were calculated as the 
reference HVL was adjusted from 1.78 to 9.99 mm Al (where errors were defined as 
a deviation from values obtained from doing an individual Monte Carlo simulation). 
Such errors were indeed minimal at 4.8 mm, though this is to some extent immaterial 
when beam angle specific energy conversions are applied, in which errors are 
consistently very small. The HVL conversion factor was applied in the form of a 4th 
order, single variable polynomial equation. 
 
5.2.2: Beam angle dependence 
As seen in the Computational Dosimetry chapter (section 4.2.2), the effect of beam 
energy varied quite strongly with phantom size and organ type, therefore correction 
factors needed to be specific to each. In previous Monte Carlo based attempts at 
dosimetry for cardiac catheterizations by Schmidt et al [86] and Streulens et al [88], 
different conversion factors were used to adjust for beam quality for each of the 
beam angles represented. In general, beam quality correction factors for organs that 
are fairly evenly or symmetrically distributed such as the lungs, lymph nodes or bone 
marrow, are relatively insensitive to changes to beam angle. For organs that are 
more localised on one aspect of the body such as the heart and breasts, the 
correction factor is considerably more sensitive to beam angle.  
Three approaches were investigated: 
1. A single conversion factor polynomial for all 1656 beam angles based on the 
mean value of conversion factors across these angles. 
2. A partially beam-angle-specific conversion factor, with a separate polynomial 
for each of the 23 different cranio-caudal beam angles, but each one of these 
averaged over the range of rotational beam angles (or vice versa). 
3. Fully beam angle specific conversion factors, with a separate polynomial for 
each of the 1655 different simulated beam angles. 
The first and second approaches were found to result in large deviations from the 
results of individual simulations with the specified beam energy, especially for the 
heart and breasts. The fully beam angle specific approach was considerably more 
accurate (Figure 5.2).  The computational time required to calculate dose to a 
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particular organ was found to be identical for all three methods (0.012 s). The size of 
the correction factor files was 1 kilobyte (kB) for the first approach, 6kB for approach 
two, and 367 kB for approach three. The files are much bigger, but there is no 
tremendous burden associated with having beam angle specific energy corrections. 
It would be desirable to have a simple dosimetry system, but ultimately accuracy (in 
terms of fidelity to the original Monte Carlo simulation data) is the most important 
consideration. Therefore the beam angle specific approach was adopted for all 
organs. 
As shown in Figure 5.2, the beam angle specific correction approach still results in a 
small level of ‘error’ in the sense of a difference between doses calculated by the 
dosimetry system and those obtained from doing individual MC simulations. This 
error is due to the use of half value layer to describe beam energy as opposed to 
using separate kV and filtration figures. Struelens et al [88] claim that dose estimates 
derived from the ‘HVL method’ deviate a maximum of 5% from those derived from 
the exact spectrum. This is encouraging, though a separate analysis was conducted 
to confirm this. 
 
Figure 5.2: Different approaches to beam energy correction for heart dose. 
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A function was written in MATLAB to compare doses calculated using each of the 36 
separate kVp and Cu combinations with those calculated using corresponding HVLs. 
This process was carried out across the full range of beam angles in the rotational 
direction (0-355° in 5 degree intervals) and 11 cranio-caudal beam angles (-50°, to 
+50° in 10° intervals) and for each phantom size and for each organ type. The errors 
resulting from the use of HVL as opposed to separate kV and Cu figures decreases 
with increasing HVL and increases with increasing phantom size. An example of 
these errors is shown in Figure 5.3, for bone marrow dose. The largest errors of over 
10% occur for high kV/low Cu combinations for 56.3 and 73.2 kg phantoms. For 
HVLs of greater than 5.5 mm, errors are generally less than 5%. Such errors were 
considered an acceptable price to pay for the computational simplicity and greater 
flexibility of the HVL approach. 
 
Figure 5.3: Dosimetry system ‘errors’ as a function of HVL for bone marrow dose 
(mean across all rotational beam angles, 0 degree cranio-caudal rotation). 
 
5.3: Patient size 
The dosimetry system also needed to be able to adjust for variable patient size. The 
relationship between dose and patient size can be assessed by age, mass (weight), 
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height, or body mass index (BMI). Age and mass data were available for nearly all 
patients in the cohort, but height information (and therefore ability to calculate BMI) 
was only recorded at a limited number of centres. Characterising patients by age 
would need to assume they were of ‘normal’ size (i.e. close to the 50th centile on 
growth charts) and not under or overweight. Secondly, problems arise when 
accounting for prematurely born patients who effectively have a negative age. This is 
not a problem when characterising by mass, which can be lower than 1 kg for 
extreme low birth weight (ELBW) neonates [254, 267, 268]. Clearly the same body 
mass can be achieved by being tall and asthenic or being short and sthenic, meaning 
mass characterisation could still be potentially inaccurate.  
As discussed in the Computational Dosimetry chapter (section 4.2.3), a power law 
was found to provide the best description of the relationship between dose and 
phantom size. It was found that the coefficient (a) and exponent (b) of this 
relationship varied with beam quality. In principle, a conversion factor (cfm) based on 
this power law could be applied to the dose estimate at a particular ‘reference mass’ 
to allow conversion to dose at any other specified mass, providing that a and b were 
themselves a function of beam quality, i.e. 𝑐𝑓𝑚 = 𝑎 ∙ 𝑚
𝑏. This beam quality adjusted 
power law correction factor was investigated by comparing actual simulated doses at 
a particular mass with those estimated using the correction factor. Large errors were 
found (Figure 5.4), principally because the values of a and b also varied with beam 
angle. Effectively, the curve representing dose as function of beam angle changes 
shape as mass is varied. To address this problem, separate power law conversion 
factors for each possible beam angle were calculated. This approach was also found 
to be inadequate, mostly due to the imperfect fit of the power law curve to actual 
data. A further modification of the power law, in the form 𝑐𝑓𝑚 = 𝑎 ∙ 𝑚
𝑏+𝑐 was also 
investigated but this tended to significantly underestimate doses at large masses. If 
mass is not available then patient age would need to be used to represent patient 
size. Using the power law correction, the dose tends to infinity as patient age 
approaches zero. 
Because of these errors, the conversion factor approach to adjusting for patient size 
was abandoned and replaced by interpolation between the discrete simulated mass 
levels. This approach has the advantages of simplicity and the avoidance of gross 
errors, though predictions of negative doses for larges masses still occur. Different 
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methods of interpolation were investigated; linear interpolation, power law 
interpolation, and a modified power law of the form 𝑎𝑏+𝑐. An example of these 
methods is shown in Figure 5.5 for bone marrow. Clearly the modified power law 
method provides a very poor fit to simulated values. The simple power law provides a 
good fit to simulated data below 30 kg, but begins to underestimate dose beyond this 
level. All size-adjustment models predict doses that continually fall, beyond the 
largest simulated patient size of 73.2 kg (30 years). This results in the prediction of 
negative doses for especially large patients (i.e. above 100 kg). To avoid this, no 
further adjustment for patient size was applied for patient masses of 80 kg or more. 
 
Figure 5.4: Actual simulated effective dose at 1 year (9 kg) (green) plotted against estimated 
effective dose calculated by conversion from dose polynomial at 10 years (32 kg) using 
beam quality specific power law (blue). 
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Figure 5.5: Various interpolation methods to obtain doses between simulated values. 
 
5.4: Field size 
Different field sizes were incorporated as different sets of ‘reference data’. This 
allowed more accurate dose estimation for examinations in which the pulmonary 
vessels need to be visualised (many examinations including pulmonary artery 
stenting, valvuloplasty, PDA occlusions and various diagnostic procedures). The only 
limitation of including extra field sizes was that energy corrections were calculated for 
the ‘standard’ field size, rather than for other sizes. Upon investigation, it was found 
that there is indeed a small field size dependence on energy corrections, though the 
errors associated with using a single energy correction for all field sizes was 
relatively small compared with not correcting for field size at all. Thus three extra field 
sizes were added, representing 1 cm and 2 cm larger fields and a ‘large’ field in 
which the whole thorax was included. 
 
5.5: Further modifications 
The Cardiodose function was modified several times during the study. The first 
version used the polynomial approach to selecting beam angles and non-beam-
angle-specific energy corrections. The second version replaced the polynomials with 
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linear interpolation, while the third added beam-angle-specific energy corrections. 
The ability to calculate doses based on age if no mass was recorded was added. 
Extra organs were gradually added during development as well as different field 
sizes. All field sizes use the same energy corrections as the ‘standard’ field size. A 
further modification was to utilise biplane PKA figures, where available. Initially, the 
Cardiodose function had a separate piece of code to calculate the dose to each 
organ. At first, the methods used for energy corrections were not the same for each 
organ (i.e. some were beam angle specific, others were not). Once these were 
standardised, a single for loop was created to calculate dose to all organs. This did 
not significantly affect the speed of the function (0.143, verses 0.148 seconds per 
line) but did reduce the length of code by around 50% and reduce the number of files 
needed. 
 
5.6: Summary of dosimetry system 
Cohort data is inputted in the form of an Excel file containing anonymous ID number, 
PKA (either total or separate frontal and lateral figures), mass (or age if not available), 
examination type, field size, beam energy (defined by HVL) and (if known) precise 
beam angles. The Cardiodose function estimates doses to organs through the 
following process: 
1. Dose per unit PKA at the desired beam angle is obtained by linear interpolation 
between conversion factors at 5° intervals. This process is done for each of the 
simulated patient sizes, to give 6 figures representing dose per unit PKA at the 
specified beam angle for a beam energy of 4.8 mm Al. If beam angles are not 
specified, these are estimated based on examination type. This process is covered in 
the next chapter. 
2. Apply the beam energy correction factor based on the HVL polynomial to each of 
the 6 figures calculated in step 1, to adjust for beam energies other than 4.8 mm Al. 
The process of determining the correct HVL to use is also described in the next 
chapter.  
3. Linear interpolation between doses at the 6 patient sizes to give dose per unit PKA 
at the specified mass. If mass isn’t specified, patient age is used instead (again, 
using linear interpolation). 
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4. Multiply this figure by the PKA for specified beam angle. If the beam passes 
through the table, a transmission factor is applied, unless this is already accounted 
for. 
5. Repeat for all beam angles used in the examination. The total examination dose is 
obtained as the sum of doses from different beam angles. 
6. Repeat steps 1-5 for each organ. 
The only ‘errors’ (in the sense that results differed from those obtained from running 
an individual PCXMC simulation using the same parameters) were due to the use of 
HVL to describe beam quality as opposed to the exact spectrum.  
 
5.7: Conclusion 
A dosimetry system was developed that utilises Monte Carlo simulations to provide 
rapid organ dose estimates based on limited data recorded at the time of the 
examination. The dosimetry system requires information on beam angles and beam 
energy used in clinical practice to be incorporated. The gathering of these data will 
be described in the next chapter.  
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Chapter 6: Supporting Data for Dosimetry System 
The dosimetry system described in the previous chapter requires information on 
projection angles and beam energy used for clinical examinations of cohort 
members. Unfortunately, such information is difficult to acquire and is rarely reported 
in published studies, or quoted too imprecisely. For example, Streulens et al [88] 
state that beam energy used in cardiac fluoroscopy, as represented by half value 
layer,  is between 2.5 and 11.5 mm Al – a range encompassing practically every 
possible combination of exposure factors. This chapter is concerned with the 
gathering of relevant information, estimating the central values of beam energy and 
projection angles, analysis of how reliable these estimates are, and analysis of how 
variation from expected values may affect calculated organ doses. The methodology, 
results and discussion of the beam energy analysis will be presented first, followed 
by the same for projection angles.  
 
6.1: Beam energy 
The energy of x-ray photons used in fluoroscopy (or any other form of x-ray imaging) 
is defined by a number of parameters described below:  
Peak tube potential: Measured in kilovolts (kV). Defines the maximum kinetic energy 
of electrons, in kiloelectronvolts (keV) arriving at the anode and thus available for 
conversion into radiant energy of x-ray photons [43]. All fluoroscopic equipment 
allows tube potential to be varied. Usually, the machine adjusts kV, along with tube 
current, automatically to reflect attenuator thickness in order to maintain an 
approximately constant signal-to-noise ratio [16]. 
Filtration: Both added and inherent filtration (i.e. the x-ray tube housing) is designed 
to selectively absorb low energy x-rays, resulting in a ‘hardening’ of the x-ray beam 
and an increase in mean photon energy. Aluminium filtration (Al, Z=13) is usually 
kept constant and designed to ensure a minimum thickness of 2.5 mm in order to 
remove very low energy photons. In modern machines, additional copper (Cu, Z=29) 
filtration is used. The thickness of copper is sometimes varied automatically, tending 
to decrease as tube potential is increased [269]. In other machines, added filtration is 
maintained at a constant level determined by program mode. For Siemens 
equipment, the capability of variable filtration, known as “CAREfilter” and first 
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introduced in 1994, is utilised for all “Artis” equipment (Axiom and Zee) [270].  Other 
filtration materials are employed by Toshiba and Shimadzu, including Gold (Au, 
Z=79) and Tantalum (Ta, Z=73) [271]. Older machines tend to lack the capability of 
variable filtration, though allow still tube potential to be adjusted. 
Voltage waveform: X-ray tubes utilise an alternating current. A rectifier is used to 
ensure voltage at the anode stays positive with respect to the cathode, avoiding 
electrons bombarding the cathode during the reverse cycle [43]. Voltage is never 
constant, however, tending to ‘ripple’ in a manner dependent on the method of 
rectification. Ripple ranges from 100% for a single phase, self-rectified generator, 
down to less than 10% for 3-phase/12 pulse or high frequency inverter generators 
[16]. All the equipment used for examinations in this study used high frequency 
generators. The impact of voltage ripple on beam energy was considered negligible.    
Anode angle: Average photon energy increases slightly as anode angle is 
decreased, presumably as photons generated within a narrow-angle anode must 
pass through a greater thickness of tungsten before exiting. For example, the HVL 
(half value layer) calculated using SpekCalc (described in section 4.2.2), was 2.13, 
2.07, 2.04, 2.01, and 1.98 mm Al at 8, 10, 12, 14 and 16° respectively (60 kV, 2.5 
mm Al). Where the beam is heavily filtered, the impact of anode angle on beam 
energy is negligible. Despite this, information on anode angle is readily available 
from manufacturers’ specifications, therefore can easily be incorporated into beam 
energy estimates. The impact of anode angle was briefly discussed in Chapter 4 
(section 4.2.2). 
A number of sources of information on the beam energies used in cardiac 
catheterizations were investigated. Firstly, patent applications [272], used equipment 
vendors such as medwow.com [253] and sales brochures [270] provide some details 
on the anode angle, generator type, tube potential range and filtration, though no 
details on the actual thickness of attenuator at which values change. Secondly, an 
American Association of Physics in Medicine task group (AAPM 125) [271] 
conducted a study investigating automatic fluoroscopic controls, though for a limited 
range of machines (one per manufacturer). The data provided on exposure 
conditions were insufficient and there is no guarantee that the machines tested by 
the AAPM group were set up in the same way as those used for examination of 
cohort members. The group did not investigate both acquisitions and fluoroscopic 
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exposures (in fact it is unclear which of these imaging modes was used). Likewise, a 
study by Li [269] provides some information concerning the operation of a single 
machine (Siemens Axiom Artis dBA) but no others. A third source of information was 
quality assurance (QA) reports, authored by local medical physics staff around the 
UK and obtained with the cohort data. These reports generally focus on 
characteristics such as threshold contrast detail, comparison of nominal and 
measured kV, image distortion and dose rate. Tests of the variation in output with 
attenuator thickness (usually sheets of copper), where reported, were insufficiently 
detailed. 
More information was required for the purposes of this study. Two approaches were 
used; (1) An experimental method in which machine response to variable 
thicknesses of water equivalent material was investigated, and (2) obtaining data 
recorded for clinical examinations, in the form of structured dose reports or image 
metadata. Analysis of variation of kV, Cu and associated HVL was carried out for 
both patient age and mass (structured dose reports) and PMMA thickness 
(experimental measurements). Information on older equipment was gathered from 
previously published research, especially that relating to paediatric cardiac 
catheterizations. 
It should be noted that even with these data, uncertainties still exist. The kVp and 
filtration values chosen by the machine depend on user-selected program mode 
(different settings designed to optimise for various examination types and patient 
sizes). These program modes may be changed by users or with software upgrades 
during the lifetime of the machine and were not always the same at different 
hospitals. Furthermore, x-ray output may vary over the lifetime of the tube with anode 
wear. 
 
6.1.1: Methodology 
The following sections describe the methodology for physical measurements and 
obtaining data from structured dose reports and image metadata. In both cases, 
filtration and tube potential were combined to produce a single HVL using Spekcalc. 
A description of this software, along with the advantages and limitations of the HVL 
method are given in Chapter 4. 
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1. Physical measurements: 
The response of fluoroscopic equipment to changing patient size was experimentally 
investigated using a methodology similar to the previously mentioned AAPM report 
[271] (Figure 6.1). Sheets of polymethylmethacrylate (PMMA, i.e. plexiglass) water 
equivalent material were used to simulate a patient of varying thickness (the density 
of PMMA is 1.18 g/cm3). The equipment types investigated were: 
1. Siemens Axiom Artis BC biplane unit with image intensifier detectors.  
2. Siemens Artis Zee biplane with flat panel detectors 
The c-arm was positioned in the vertical orientation with the x-ray tube pointing 
upwards (i.e. typical of a PA projection). The table top was positioned to be 15 cm 
below the isocentre of the beam. The table cushion was left in place. Slabs of PMMA 
material were added in 2 cm intervals up to a maximum of 26 cm. At each thickness, 
fluoroscopic, and then digital acquisition exposures were initiated and maintained 
until a steady value of tube potential and added filtration was reached (about 3 
seconds). The value of both figures was recorded. When the maximum thickness of 
PMMA was reached, the process was reversed, with slabs being removed one by 
one. This was to determine if the same filtration and tube potential values were used 
for the same PMMA thickness depending on whether the thickness had increased or 
decreased to that level. Anecdotal evidence suggested they would not be the same. 
Both gridded and non-gridded conditions were evaluated along with different field 
sizes and imaging modes.  
 
 
 
168 
 
 
Figure 6.1: Experimental set up for physical measurements. Figure credit: author 
 
2. Structured dose reports and PACS images: 
A second methodology involved obtaining details on tube potential and filtration 
recorded for cardiac catheterizations carried out in clinical practice. Since 2009, 
Siemens fluoroscopic equipment automatically records a ‘CAREreport’ [270], which 
includes details of dose (PKA and, sometimes, skin dose), beam angle, field size, 
frame rate, tube potential and added copper filtration for each digital acquisition. 
More limited details are recorded for fluoroscopy - doses are reported for each bi-
plane output but not for individual beam angles. The Axiom Artis records kV but not 
filtration, while the Artis Zee records neither, regrettably. Program mode is not 
recorded in dose reports. In addition to structured dose reports, information on tube 
potential and program mode could be obtained from images stored on the PACS 
network. This information was easier to obtain, but lacked details of added filtration 
used for examinations, and patient mass.  
 
6.1.2: Results 
Results are discussed below, first for the physical measurements (presented 
separately for the two machines studied), followed by the results of the dose report 
analysis. 
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Physical measurements - Axiom Artis: For acquisitions (Figure 6.2) an increase in 
tube potential with PMMA thickness was found. This increase was relatively steady 
and monotonic, ranging from 60 to over 90 kV. Added Cu filtration correspondingly 
decreased from 0.9 to 0.0 mm. For fluoroscopic exposures (Figure 6.3) this variation 
occurred in a more stepwise manner, with tube potential remaining below 60 kV up to 
a thickness of14 cm of PMMA before increasing to 66 kV at 16 cm. When the 
experiment was reversed, the 66 kV potential was maintained down to 12 cm PMMA 
thickness. Only three values of copper filtration were used for fluoroscopy - 0.3, 0.6 
and 0.9 mm. Again there was a mismatch between results obtained for increasing 
and decreasing PMMA thickness, with 0.9 mm Cu being maintained to a greater 
thickness during the increase phase. 
Where potential and filtration values were converted into a single HVL figure, a fall in 
HVL with increasing PMMA thickness was seen for acquisitions (Figure 6.4), but not 
for fluoroscopy. In the former case, the fall takes on a zigzag form, though could be 
reasonably approximated by a linear model. The highest value of HVL recorded was 
6.3 mm Al, which occurred for cine-acquisitions at the smallest PMMA thickness (60 
kV, 0.9 mm Cu) and for fluoroscopy between 14 and 20 cm of PMMA (66 kV, 0.6 mm 
Cu). The HVL for fluoroscopy remained above 6 mm Al up to a thickness of 22 cm 
and never dropped below 5.0 mm Al. The lowest HVL was 3.0 mm Al, which 
occurred for acquisitions at 22 cm of PMMA (82 kV, 0.0 mm Cu). The mean HVL 
across all thicknesses was 4.7 mm for acquisitions and 6.0 mm for fluoroscopy. 
A weighted sum of both fluoroscopy and acquisition exposures was also calculated 
(Figure 6.4). Where the proportion of fluoroscopy was high (over 90%), the HVL was 
almost constant at around 6 mm Al, from 2 to 20 cm of PMMA, before falling to 
around 5.0 mm. This change was associated with the machine switching from 0.6 to 
0.3 mm of Cu filtration for fluoroscopy. As the proportion of fluoroscopy is decreased, 
the HVL begins to fall with increased PMMA, though even for a fluoroscopy 
proportion of 70% the HVL did not fall below 5.6 mm for thicknesses less than 20 cm. 
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Figure 6.2: Copper filtration and tube potential as a function of PMMA thickness for 
acquisitions. Values acquired while increasing or decreasing PMMA thickness are shown 
 
 
Figure 6.3: Copper filtration and tube potential as a function of PMMA thickness for 
fluoroscopy. 
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Figure 6.4: Filtration and potential combined as single half value layer figure (increasing 
PMMA thickness) along with three different weighted sums of fluoroscopy and acquisitions. 
 
When the field size was decreased from 22 cm to 13 cm, tube potential and filtration 
changed more rapidly with increasing PMMA thickness (Figure 6.5), though the 
overall HVL was approximately the same between field sizes. When the antiscatter 
grid was omitted, the machine became relatively insensitive to changes in attenuator 
thickness, maintaining values of 58 kV and 0.9 mm Cu for most thicknesses of 
PMMA. 
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Figure 6.5: Variation in fluoroscopic tube potential and added filtration for two different field 
sizes. 
 
Physical measurements - Artis Zee: In contrast to the Axiom Artis, the Zee adjusts 
fluoroscopic tube potential while usually maintaining a constant value of added 
copper filtration, which depends on the imaging mode. Three imaging modes are 
available, “FL card”, “FL – card” and “FL + card”. At Hospital 2, these modes 
correspond to added copper filtration of 0.2, 0.3 (0.6 for patients above 70 kg) and 
0.1 mm respectively (D .Smith, Personal Communication). The machine defaults to 
“FL – card”, though the radiographer can switch to other modes to improve image 
quality if needed. At Hospital 4, these values were set at 0.6, 0.9 and 0.3 mm 
respectively.  
As with the Axiom Artis, the tube potential was found to increase with attenuator 
thickness, but reached a plateau after which it usually remained constant (Figure 
6.6). Where fluoroscopic kV and Cu values were converted into a single HVL figure, 
the pattern was the same as that for kV, reaching a plateau value and then remaining 
constant (Figure 6.7). Depending on imaging mode, HVL ranged from 3.1 to 8.6 mm 
Al, based on the Cu filtration at the Hospital 4. 
Changing frame rates for a given program did not impact the way in which the 
machine adjusts kV and Cu with attenuator thickness. Increasing magnification 
resulted in a slightly greater kV for a given thickness of PMMA, reaching the plateau 
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value at a lower thickness. This is an interesting finding given that the Zee uses flat 
panel detectors (FPDs), rather than image intensifiers. In the latter case, decreasing 
the field size results in decreased minification gain, meaning output must be adjusted 
to maintain signal-to-noise ratio [98]. For FPDs, magnification can be achieved 
without the need to adjust exposure factors, though as noted by Nickoloff, 
manufacturers do tend to utilise greater photon fluence for smaller field sizes to 
compensate for the perceived reduction in SNR [98]. 
Only tube potential was recorded for acquisitions. As with fluoroscopic exposures, kV 
increased with PMMA thickness up to a plateau value and then remained constant. 
The lack of data on filtration prevented the calculation of HVL for acquisitions.  
 
 
Figure 6.6: Variation in fluoroscopic tube potential with PMMA attenuator thickness for 
Siemens Artis Zee machine. 
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Figure 6.7: Variation in fluoroscopic HVL with PMMA thickness for three different imaging 
modes. Data for the ‘FL-card’ are shown with and without an antiscatter grid fitted. 
 
Results: Structured dose reports and PACS images 
For Hospital 4, dose reports from 49 examinations were obtained, comprising a total 
of 387 acquisitions. These reports are not automatically sent to PACS and could only 
be accessed from the machine console in the catheterization laboratory. In addition 
to these, information for 169 examinations comprising 1307 acquisitions and stored 
sequences of fluoroscopy (known as ‘fluoro grabs’) was obtained from images stored 
on the PACS network. This gave a total of 218 examinations comprising 1694 
acquisitions and fluoro grabs. These procedures were all conducted on the same 
Axiom Artis machine as used for the physical measurements described above. For 
Hospital 2 (Artis Zee, flat panel detectors), dose reports for 64 examinations 
comprising 324 acquisitions were obtained. Reports are sent to PACS and include 
patient age but not mass. Procedure type was recorded, but was found to be 
inaccurate.  
 
Axiom Artis machine at Hospital 4: For acquisitions, filtration (dose reports only) 
again ranged from 0.0 to 0.9 mm Cu, while tube potential ranged from 60 to 125 kV. 
Most acquisitions were at two frame rates – 15 and 30 per second. At Hospital 4, the 
latter frame rate was reserved almost exclusively for digital subtraction angiography 
(DSA) runs. Across all angles, the mean thickness of added copper filtration was a 
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little higher for DSA compared to non-DSA acquisitions (0.19 verses 0.14 mm, 
p<0.01), with tube potential being correspondingly lower (67.5 verses 72.0, p<0.01). 
A relatively large proportion of the non-DSA acquisitions were in oblique projections, 
however. Where tube potential was compared for the same projection, mean kV was 
almost identical (e.g. 66.5 verses 66.3 for PA). The relationship between tube 
potential and patient age was best analysed by considering different beam 
projections separately. In each case, a general trend of increased kV with increasing 
patient age was seen (Figure 6.8), although variation in kV was larger between 
different projection angles than between ages for the same angle. Data for patients 
above 15 years was limited, therefore were combined into a single group. 
 
 
Figure 6.8: Variation in mean tube potential with patient age for different beam angles. Error 
bars represent ± 1 standard deviation for the ‘all angles’ group. RAO/LAO = right/left anterior 
oblique. 
  
Analysis of HVL requires information on both tube potential and filtration. The latter 
figures were not recorded on PACS images, which greatly limits the sample of 
examinations from which overall beam energy can be analysed. To address this, the 
results of the experimental methodology previously described were combined with 
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the dose reports to provide estimates of filtration for examinations where it was not 
recorded. From the dose reports, a range of tube potential values were seen for each 
Cu thickness. A starting point for estimating the potential at which filtration changes 
was midway between the mean kV values for each Cu thickness (red markers in 
Figure 6.9. These figures were compared to corresponding figures derived from 
experimental methods, using the mean of both increasing and decreasing PMMA 
thickness phases (black markers in Figure 6.9). The agreement between these two 
methods was very high, with variation no greater than 1.3%. Taking the mean of the 
two methodologies yields estimated tube potentials above which added filtration of 
0.0, 0.1, 0.2, 0.3 and 0.6 mm Cu is selected as 80, 68, 66, 64 and 61 kV respectively. 
Tube potentials of less than 61 kV were assumed to be associated with 0.9 mm Cu. 
This allows filtration and HVL to be estimated in cases where only the tube potential 
was known and increases the sample of procedures from which beam energy can be 
inferred from 49 to 218 examinations. 
 
 
Figure 6.9: Tube potential ranges for different levels of added copper filtration derived from 
structured dose reports. Up/down bars represent the range of tube potentials at which a 
particular thickness of copper filtration was associated. 
 
The results of these estimates are shown in Figure 6.10. It is evident that there is 
less variation in HVL between different beam angle projections than was apparent for 
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tube potential (Figure 6.8). This is due to the corresponding decrease in added 
copper filtration at higher tube potentials, thus restraining overall HVL to a 
reasonably narrow range of values (4-5 mm Al). Interestingly, HVL for the PA 
projection tended to be higher than for other angles, despite the tube potential 
generally being lower. The lowest HVL recorded was 2.7 mm Al. This minimum 
occurred for an oblique projection during a coronary angiography examination of a 9 
year old patient. The highest value was 6.7 mm Al, occurring during a biopsy 
procedure on a 5-year old patient. 
 
 
Figure 6.10: Half value layer for different beam angles derived from tube potential recorded 
in dose reports and PACS images, and estimated added filtration. Error bars represent ± 1 
standard deviation for the ‘all beam angles’ data. RAO/LAO = right/left anterior oblique. 
 
Fluoroscopic exposures were usually found to be at 7.5 frames per second and in 
one of two modes; ‘fluoro low’ or ‘fluro normal’, with the latter offering greater image 
quality. Across all beam angles, the mean tube potential for fluoroscopy was 
significantly lower than for acquisitions (63.3 verses 70.0 kV, p<0.01). Analysis of 
fluoroscopic exposures by specific beam projection was limited to comparison 
between frontal and lateral biplane outputs, with tube potential being significantly 
higher for the latter (64.9 verses 62.0 kV, p<0.01). These mean kV figures are 
somewhat misleading however; the majority (75%) of fluoroscopic exposures for 
178 
 
patients under 15 years are at one of two values - 58 or 66 kV, with few values in 
between. These two potentials were combined with 0.9 and 0.6 mm added Cu 
filtration respectively, both yielding a similar HVL (6.1 and 6.3 mm Al). For patients 
older than 15 years, there is evidence of increased use of tube potentials of 68 kV, 
with either 0.3 or 0.6 mm Cu (corresponding HVLs of 5.4 and 6.5 mm Al 
respectively). Tube potentials of 70 kV or more were also recorded, though there is 
little data from which to determine the filtration thickness at these potentials.  
 
Siemens Artis Zee machine at Hospital 2: For most acquisitions, the Artis Zee was 
found to use 0.1, 0.2 or 0.3 mm of copper filtration. No acquisitions were found in 
which either less than 0.1 mm or greater than 0.6 mm was used. For all projection 
angles combined, tube potential generally ranged from 61 to 72 kV. There was a 
trend of increasing kV with increased patient age, though without the corresponding 
decrease in Cu seen with Axiom Artis equipment. Acquisitions were at three frame 
rates – 7.5, 15 and 30 per second. Across all ages and beam angles, the mean 
thickness of copper for these frame rates was 0.35, 0.25 and 0.13 mm respectively. 
When this pattern was explored in greater detail by stratifying by age, the same 
pattern was observed. Judging from the results of physical measurements, however, 
it is the imaging mode associated with the frame rate (which was not recorded in 
dose reports), rather than the frame rate per se that is responsible for this variation.  
Where kV and Cu figures were combined to produce a single HVL for acquisition 
data, the mean value across all beam angles and patient sizes was 4.5 mm Al, 
ranging from 3.6 to 7.1 mm. In contrast to the Axiom Artis, there was a tendency of 
HVL to rise with increasing patient beyond 10 years (Figure 6.11), presumably due to 
the maintenance of a single value of copper filtration thickness as tube potential is 
increased. There were insufficient data available to analyse variation in beam energy 
with projection angle beyond PA, lateral and combined oblique angles. As with the 
Axiom Artis, HVL tended to be higher in the PA projection than oblique or lateral 
projections. The apparent wide variation in HVL with beam angle for patients aged 
over 15 years should be interpreted with caution as the sample of acquisitions was 
small for this group (5 oblique. 7 PA and 11 lateral). Due to the maintenance of at 
least 0.1 mm added copper filtration, the Artis Zee tends to avoid HVLs of less than 
3.6 mm Al.  
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Figure 6.11: Siemens Artis Zee: Half value layer (mm Al) for acquisitions for different patient 
age ranges. Error bars represent ± one standard deviation for all angles. 
 
6.1.3: Beam energy for older equipment 
Although the majority of the examinations in the study were conducted using 
Siemens Axiom Artis or Artis Zee equipment, other, older machines were also used, 
such as the Philips Integris, Toshiba Infinix CB and Siemens BICOR (biomedical 
imaging core) or HIcor. These machines did not record structured dose reports and 
were not available for carrying out physical measurements on. Some technical 
details were found on websites selling used equipment, such as medwow.com [253]. 
Further information could be gathered from previous publications. A summary of 
these details is provided in Table 6.1 
In most cases, information on filtration and tube potential is very limited or entirely 
absent. The most detailed account of the latter is provided by Rassow et al [108] for 
a Siemens Angioskop biplane fluoroscopy system, in which kV values for different 
beam angles were recorded for both acquisitions and non-acquisition fluoroscopy, 
with and without zoom. An ‘effective voltage’ was calculated as a weighted average 
of these different modes for a range of different patient ages. For the frontal output, 
the effective voltage ranged from 54.5 kV (0-0.02 years) to 67.0 kV (15-21 years), 
while for the lateral output, the equivalent figures ranged from 63.6 to 83.5 kV. Using 
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the quoted total filtration of 2.5 mm Al, this range of 54.5 to 83.5 kV corresponds to a 
half-value-layer of 1.9 to 3.1 mm Al. 
The most commonly reported filtration values for Philips Integris machines (either 
3000 or 5000) is 1.5 mm Al plus either 0.2 or 0.4 mm Cu. Trianni et al [21] report the 
use of 0.1 mm Cu where fluoroscopy is restricted to 12.5 pulses s-1 and 0.0 mm for 
25 pulses s-1. Over a range of tube potentials 60 to 80 kV, this corresponds to a HVL 
of between 4.0 and 5.0 mm Al. The Siemens Coroskop TOP utilises the CAREfilter 
system of variable copper filtration, while the earlier Coroskop C Hicor does not 
[273]. The Bicor TOP is described by Yakoumakis et al [107] as using 3.5 mm Al plus 
0.22 mm Cu filtration, and a tube potential of between 55 and 70 kV. This 
corresponds to a HVL of between approximately 4.2 and 5.5 mm Al. The Bicor Plus 
machine is described by Al Haj et al (2008) as having an overall HVL of 3.5 mm Al, 
although it is unclear how this was measured.  
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Study (publication year) Equipment: Filtration: Tube potential (kV) 
Calkins (1991) [274] Siemens Angioscop D Not stated 70-109 
Schueler (1994) [275] GE Fluoricon 300 HVL=3.2 mm Al @ 80 kVp >60-70, up to 120 
Ross (1997) [276] Siemens HICOR Not stated Not stated 
Boothroyd (1997) [228] Siemens BICOR Biplane. Not stated Not stated 
Broadhead (1997) [277] 
Siemens Coroskop C 
Biplane 
3 mm (Al?) assumed 80 ± 4 assumed 
Philips Polydiagnost C2 
(monplane?) 
Axelsson (1999) [84] Philips Optimus 2000 3.00 mm Al 67 (a), 58-70 (f) 
Rassow (2000) [108] 
Siemens ANGIOSCOP bi-
plane and SIRECON II 
2.5 mm Al Not stated 
Kuon (2003) [278] Philips Integris H3000 1.5 mm Al, 0.4 mm Cu Not stated 
Bacher (2005) [8] 
Philips Integris BH5000 
biplane 
1.5 mm Al + 0.2 mm Cu Not stated 
1.5 mm Al + 0.4 mm Cu Not stated 
Trianni (2005) [21] Philips Integris 3000 
0.1 mm Cu (12.5 p/s), 0.0 mm 
(25 p/s) 
Not stated 
Onnasch (2007) [103] 
Siemens biplane 
BICOR/Digitron, 50 fps. 
Not stated Not stated 
Philips biplane DCI/LARC 
system. 
Not stated Not stated 
Dec 1997 Philips Integris 
5000BH, 12.5, 25 or 50 fps 
≈1.5 mm Al, 0.2/0.4 mm Cu Not stated 
Al Haj (2008) [279] 
Siemens BICOR plus 
biplane (COA dilitation, PV, 
PDA occlusion, diag). 
Not stated. Beam HVL=3.5 mm 
Al 
80 (f), 66 (a) 
GE bi-plane (septostomy, 
embolisation and RFA 
Not stated 80 (f), 70 (a) 
Beels (2009) [12] 
Philips Integris BH5000 
biplane 
1.5 mm Al, 0.4 mm Cu Not stated 
Karambatsakidou (2009 
and 2013) [112] [107] 
Philips Integris H 5000C 
6 mm Al + 0.4 mm Cu (f), and 6 
mm Al + 0.2/0.04 mm Cu (a) 
65-70 (f), 60-65 (a) 
Yakoumakis (2009) [115] Siemens BICOR TOP II 3.5 mmAl + 0.22 mm Cu 55-70 
Ait Ali (2010) [13] 
Philips Integris H5000C 
monoplane 
Not stated Not stated 
Chida (2010) [280] Siemens BICOR Plus. ? + auto 0.1/0.2 mm Cu 70 kVp 
Watson 2012 [167] 
Philips Integris BH5000 
biplane 
Not stated Not stated 
McFadden (2013) [281] 
Siemens BICOR TOP 
biplane 
2.5 mm Al Not stated 
 
Table 6.1: Tube potential and filtration details of older generation equipment quoted in 
previous publications of doses from cardiac catheterisations 
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6.1.4: Discussion (Beam energy) 
Beam energy was found to be variable, not only between different fluoroscopic 
equipment manufacturers and models, but for the same machine under different 
conditions, such as imaging mode, field size and frame rates. Some general patterns 
can be observed, although a degree of uncertainty will still exist. The most suitable 
approach was therefore to estimate a central beam energy value and set associated 
uncertainty limits. Structured dose reports were considered to provide the most 
reliable source of data on tube potential used for fluoroscopic imaging, and both tube 
potential and added filtration for acquisitions. Physical measurements were used as 
the source of information on fluoroscopic filtration. As the typical x-ray energies used 
in these two acquisition modes is different, the value (or values) of HVL used in 
organ dose estimates must take into account the proportion of total PKA as 
fluoroscopy and acquisitions. Hospital specific fluoroscopy proportions were used 
where such information was available (i.e. Hospitals 2 and 4). The beam energy 
values used for dose estimates are described below for different equipment types: 
 
Artis Zee: There was insufficient evidence of variation in x-ray energy with beam 
angle to warrant the definition of projection-specific HVL estimates. Based on 
structured dose reports from Hospital 2, the mean proportion of total PKA originating 
from fluoroscopy (pf) across all procedure types was 0.75 (this compares to 0.82 for 
2004-2008 data user older equipment). For diagnostic and interventional procedures, 
pf was 0.67 and 0.77 respectively. There are insufficient data to allow further 
stratification of pf by procedure type, though for electrophysiology studies (EPS) and 
pacemaker insertions, a pf of 0.95 was considered appropriate. The HVL values used 
for dose estimates at Hospital 2 are shown in Table 6.2,  and assume the use of “FL – 
card” mode with 0.3 mm Cu applied for all fluoroscopic imaging  and 0.6 mm Cu for 
patients over 70 kg. The lower and upper HVL limits, were based on 5th and 95th 
percentiles of values for acquisitions. The upper limit for patients over 10 years was 
fixed at 7.1 mm. 
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Patient size in 
years (kg) 
Intervention  
(pf = 0.77) 
Diagnostic  
(pf = 0.67) 
EPS, Pacemakers  
(pf = 0.95) 
<1 (<9.2) 5.2 [4.6 : 6.1] 5.1 [4.3 : 5.9] 5.4 
1-5 (9.2-19) 5.5 [5.0 : 6.5] 5.3 [4.5 : 6.1] 5.8 
5-10 (19-32.4) 5.7 [5.5 : 6.5] 5.5 [4.7 : 6.3] 6.1 
10-15 (32.4-56.3) 5.9 [5.5 : 7.1] 5.7 [5.3 : 7.1] 6.1 
>15 (>56.3) 6.0 [5.0 : 7.1] 5.9 [4.9 : 7.1] 6.2 
>70 y (>70 kg) 7.7 [5.2 : 8.2] 7.4 [5.1 : 8.2] 8.2 
Mean (all sizes) 5.7 5.5 5.9 
 
Table 6.2: Assumed half value layers (mm Al) used to estimate doses for procedures carried 
out using Siemens Artis Zee equipment at Hospital 2. 
 
Siemens Axiom Artis: Again, there appears to be little basis for beam angle specific 
HVL estimates. Values for all angles combined, with associated uncertainty limits 
were deemed sufficient. The majority of fluoroscopic exposures were at either 58 kV 
(0.9 mm Cu) or 66 kV (0.6 mm Cu), yielding HVLs of 6.0 and 6.2 mm Al respectively. 
The higher tube potentials seen for larger patients may yield a higher or lower HVL 
depending on the filtration applied, data on which was rather limited. There is 
reasonable justification in utilising a patient size independent HVL for fluoroscopy of 
6.1 mm Al, at least up to 15 years and probably beyond.  
Overall HVL figures calculated as a weighted sum of fluoroscopic and acquisition 
components are shown in Table 6.3 for proportions of fluoroscopy ranging from 0 (i.e. 
entirely acquisitions) to 1.0 (entirely fluoroscopy). Where hospital specific data on Pf 
was available, these were utilised. From structured dose reports at Hospital 4, the 
mean proportion of total examination PKA from fluoroscopy was 0.41 for all 
examination types combined, and 0.49 and 0.36 for interventional and diagnostic 
procedure categories respectively. For EPS, biopsy and pacemaker insertion 
procedures, the proportion PKA from fluoroscopy was set at 0.95. The assumed half 
value layers used for dose estimations using Siemens Axiom Artis machines, taking 
into account uncertainty in HVL for acquisitions and fluoroscopy, along with 
uncertainty in the proportions of total PKA in these two operating modes are given in 
Table 6.4. Uncertainties were based on 5th and 95th percentiles of HVL, calculated at 
-0.8 mm and +1.1 mm. The same values were used for all patient sizes as there was 
little suggestion of variation with age or mass.  
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Proportion of total output as fluoroscopy 
Patient size in years (kg) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
<1 (<9.2) 4.6 4.7 4.9 5.0 5.2 5.3 5.5 5.6 5.8 5.9 6.1 
1-5 (9.2-19) 4.4 4.5 4.7 4.9 5.1 5.2 5.4 5.6 5.8 5.9 6.1 
5-10 (19-32.4) 4.2 4.4 4.6 4.8 5.0 5.2 5.3 5.5 5.7 5.9 6.1 
10-15 (32.4-56.3) 4.0 4.2 4.4 4.6 4.9 5.1 5.3 5.5 5.7 5.9 6.1 
>15 (>56.3) 3.9 4.1 4.3 4.6 4.8 5.0 5.2 5.4 5.7 5.9 6.1 
 
Table 6.3: Central estimates of half value layer (mm Al) for different patient sizes and various 
proportions of fluoroscopy for Siemens Axiom Artis equipment. 
 
  Procedure type 
Patient size in years (kg) Interventional Diagnostic EPS, Pacemakers 
<1 (<9.2) 5.3 [4.5 : 6.3] 5.1 [4.3 : 6.2] 6 [4.6 : 6.3] 
1-5 (9.2-19) 5.2 [4.4 : 6.3] 5.0 [4.2 : 6.1] 6 [4.6 : 6.3] 
5-10 (19-32.4) 5.2 [4.4 : 6.3] 4.9 [4.1 : 6.0] 6 [4.4 : 6.3] 
10-15 (32.4-56.3) 5.1 [4.3 : 6.2] 4.8 [4.0 : 5.9] 6 [4.4 : 6.3] 
>15 (>56.3) 5.0 [4.2 : 6.1] 4.7 [3.9 : 5.8] 6 [4.4 : 6.3] 
 
Table 6.4: Assumed half value layers (mm Al) used to estimate doses for procedures carried 
out using Siemens Axiom Artis equipment. The figures in square brackets represent upper 
and lower uncertainty limits. 
 
The effect of the upper and lower beam energy uncertainty limits, expressed as 
percentages, are shown in Table 6.5 for each organ type and each patient. 
Uncertainty was seen to vary between organs, being highest for the stomach and 
thyroid, and lowest for the lungs and active bone marrow. Uncertainties also 
increased with increasing patient size and varied with beam angle. The figures in 
Table 6.6 represent the mean uncertainty over a range of beam angles from straight 
PA to left lateral in 30° intervals. The uncertainty for all organs and patient sizes was 
±12.5%. 
Siemens BICOR / BICOR Plus / HICOR/ Coroskop: A central HVL value of 4.8 mm 
was chosen, based on 65 kV and 0.22 mm Cu and 3.5 mm Al filtration. The lower 
uncertainty limit was set at 3.5 mm Al, based on the lowest reported tube potential of 
60 kV and no copper filtration. The upper limit was set at 5.9 mm Al, assuming 
maintenance of 0.22 mm Cu, and the maximum reported tube potential of 80 kV. 
There are few details available from which to estimate HVL for the older generation 
BICOR machine used at Hospital 1 prior to 2000 (i.e. not the more recent BICOR 
Plus or TOP machines), although copper filtration did not appear to be used.  The 
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central HVL was set at 3.0 mm Al, assuming a central tube potential of 75 kV, 3.5 
mm Al filtration and no copper. The lower limit of 2.0 mm Al assumed a reduced 
aluminium filtration of 2.5 mm and a potential of 60 kV. The upper limit was set at 4.0 
mm Al. The upper limit was based on a potential of 100 kV, with 3.5 mm Al filtration. 
A HVL of 3.0 mm was also used for the Siemens Coroskop C used at Hospital 4 until 
2003, based on the limited description of the machine in a paper by Broadhead et al 
[277]. For the purposes of effective dose estimation, the authors assumed 3 mm of 
aluminium filtration and a tube potential of around 80 kV. The same upper and lower 
HVL limits were used as for the BICOR machine described above.  
Percentage variations in dose due to HVL uncertainties for 2nd and 1st generation 
equipment are shown in Tables 6.6 and 6.7 respectively. 
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Patient age 
(mass) Uncertainty 
Effective 
dose ABM Breasts Heart Lungs Lymph Oesophagus Thyroid Liver Stomach 
Average 
dose 
<1 y (<9.2 
kg) 
Lower -8% -8% -9% -9% -6% -9% -10% -13% -9% -12% -7% 
Upper 8% 8% 10% 9% 5% 9% 10% 15% 9% 13% 7% 
1-5 y (9.2-
19 kg) 
Lower -9% -10% -8% -12% -8% -11% -12% -17% -11% -15% -9% 
Upper 10% 12% 7% 14% 8% 14% 15% 23% 13% 19% 10% 
5-10 y (19-
32 kg) 
Lower -10% -11% -8% -14% -9% -13% -14% -19% -13% -17% -10% 
Upper 12% 13% 10% 17% 10% 16% 18% 24% 16% 22% 11% 
10-15 y 
(32-56 kg) 
Lower -10% -12% -7% -15% -10% -15% -17% -20% -15% -18% -11% 
Upper 13% 15% 10% 19% 12% 19% 23% 28% 19% 25% 13% 
15-18 y 
(>56 kg) 
Lower -13% -13% -10% -18% -13% -16% -18% -24% -18% -22% -12% 
Upper 17% 16% 12% 24% 15% 22% 26% 38% 24% 33% 14% 
>18 y (>70 
kg) 
Upper -13% -13% -10% -18% -13% -17% -19% -23% -17% -21% -12% 
Lower 17% 17% 12% 25% 16% 23% 28% 39% 24% 31% 15% 
 
Table 6.5: Percentage uncertainties for Siemens Axiom Artis equipment, based on 5th and 95th percentiles of HVL. 
 
Patient age 
(mass) Uncertainty 
Effective 
dose ABM Breasts Heart Lungs Lymph Oesophagus Thyroid Liver Stomach 
Average 
dose 
<1 y (<9.2 
kg) 
Upper -30% -31% -27% -38% -27% -36% -39% -46% -37% -45% -29% 
Lower 11% 10% 13% 12% 7% 12% 13% 19% 12% 16% 9% 
1-5 y (9.2-
19 kg) 
Upper 12% 14% 9% 16% 10% 15% 17% 26% 15% 22% 11% 
Lower -35% -37% -29% -44% -33% -42% -45% -52% -42% -52% -35% 
5-10 y (19-
32 kg) 
Upper 13% 15% 11% 19% 11% 18% 20% 28% 18% 24% 13% 
Lower -39% -39% -34% -49% -36% -45% -50% -64% -46% -55% -37% 
10-15 y 
(32-56 kg) 
Upper 14% 16% 10% 21% 13% 20% 24% 30% 21% 27% 14% 
Lower -34% -41% -19% -50% -39% -48% -52% -60% -50% -58% -38% 
15-18 y 
(>56 kg) 
Upper 18% 17% 13% 25% 16% 23% 27% 40% 25% 34% 15% 
Lower -43% -41% -34% -54% -43% -50% -55% -64% -54% -60% -39% 
>18 y (>70 
kg) 
Upper 18% 18% 12% 26% 17% 24% 29% 40% 25% 32% 15% 
Lower -43% -42% -33% -54% -44% -51% -56% -62% -52% -59% -39% 
Table 6.6: Percentage uncertainties for 2nd generation equipment (Philips Integris, Toshiba Infinix CB, Siemens Bicor plus/Hicor) based on uncertainty in HVL 
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Patient age 
(mass) Uncertainty 
Effective 
dose ABM Breasts Heart Lungs Lymph Oesophagus Thyroid Liver Stomach 
Average 
dose 
<1 y (<9.2 
kg) 
Upper -20% -23% -12% -30% -20% -28% -31% -35% -29% -35% -22% 
Lower 17% 18% 16% 23% 15% 22% 24% 32% 23% 30% 17% 
1-5 y (9-19 
kg) 
Upper -24% -27% -15% -34% -25% -32% -36% -37% -32% -40% -26% 
Lower 21% 23% 17% 30% 19% 27% 30% 38% 27% 38% 21% 
5-10 y (19-
32 kg) 
Upper -30% -29% -28% -38% -28% -35% -39% -58% -35% -44% -27% 
Lower 24% 25% 20% 34% 22% 31% 36% 56% 32% 42% 23% 
10-15 y 
(32-56 kg) 
Upper -23% -30% -9% -39% -30% -36% -38% -48% -39% -48% -28% 
Lower 20% 27% 10% 36% 25% 33% 38% 50% 35% 46% 24% 
15-18 y 
(>56 kg) 
Upper -32% -30% -24% -42% -33% -38% -42% -47% -42% -46% -28% 
Lower 28% 26% 20% 40% 28% 36% 42% 56% 40% 49% 24% 
>18 y (>70 
kg) 
Upper -32% -31% -24% -42% -34% -39% -44% -57% -40% -47% -29% 
Lower 28% 27% 20% 41% 29% 37% 43% 49% 38% 47% 24% 
 
Table 6.7: Percentage uncertainties for 1st generation equipment (Siemens Bicor and Coroskop) based on uncertainty in HVL. 
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Philips Integris: Again, information is limited to a few previous publications (Table 
6.1). A central HVL of 4.8 mm Al was selected, corresponding to a tube potential of 
70 kV, fixed aluminium filtration of 1.5 mm Al and copper filtration of 0.3 mm (i.e. 
halfway between the commonly used values of 0.2 and 0.4 mm). A lower HVL 
uncertainty limit of 3.3 mm Al was used, based on 60 kV and 0.1 mm Cu. The upper 
HVL uncertainty was set at 6.3 mm Al, based on 0.4 mm of Cu and 80 kV. This range 
in HVL is thus the largest of all equipment types studied. 
Toshiba Infinix CB: Tube potential was recorded for 50 procedures conducted using 
this machine at Hospital 1 between 1999 and 2001. The mean potential was 76 kV 
(range: 70 to 88). The anode angle was stated to be 8° by a used equipment vendor 
[253], but the filtration was unknown. A central HVL of 4.8 mm was again used for 
this machine, being typical of equipment of this era, with the same uncertainty limits 
as the Philips Integris (3.3 to 6.3 mm). 
 
6.1.5: Limitations of beam energy analysis 
Only an image intensifier equipped Siemens Axiom Artis was studied, while in reality 
both image intensifier and flat panel equipped machines are used in practice. It is 
unclear if the beam energy characteristics differ between the two detector types. 
Irrespective of detector type, scope for variation in beam energy exists for otherwise 
identical machines depending on setup and software upgrades. This is illustrated by 
the large difference in copper filtration thickness used for Siemens Artis Zee 
machines at Hospitals 2 and 4. The sample of examinations for which structured 
dose reports were obtained was quite small. Unfortunately, obtaining these reports 
was very time consuming. Future research could make use of automatic recording of 
imaging metadata.   
Comparison of these findings with previous research is challenging. The previously 
mentioned AAPM report [271] provides limited details of imaging parameters, 
therefore it is difficult to determine equivalency of findings. A pattern of decreasing 
copper filtration and increasing tube potential with greater attenuator thickness was 
found in both the current and AAPM studies, although the thicknesses of PMMA at 
which these changes occur was not the same. The AAPM team noted an increase in 
tube potential from 58 to 66 kV with associated decrease in copper filtration from 0.9 
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to 0.6 at 7.6 cm of PMMA, while for the current study, this combination was not used 
until 16 cm was reached. The AAPM reports also suggests the use of 0.3 mm of 
copper occurs at a smaller thickness of PMMA (18 cm) than was found in the current 
study (22 cm). These variations support the comments above concerning uncertainty 
in beam energy due to differences in protocols and software upgrades. 
 
6.2: Beam angles 
As with beam energy, previously published information on the beam angles used for 
cardiac catheterizations is limited. The following sections describe attempts to gather 
information on beam angles used in clinical practice along with the impact of 
uncertainty in beam angle on dose estimates. A description of the terminology used 
for describing x-ray beam angles is given in the appendix.  
 
6.2.1: Methodology 
Four sources of information on beam angles were used: 
1. Projection angle questionnaire: 
The first investigation involved simply asking specialised cardiac radiographers 
which beam projections they used. A questionnaire was sent to radiographers 
working at participating hospitals, enquiring about typical beam angles used for 
various procedure types.  
2. Logbook records: 
The beam angles used for each procedure were recorded at Hospital 2 from 2004 
onwards. These were only recorded for acquisitions and not for non-acquisition 
fluoroscopy. In many cases, acquisitions are carried out in two beam angles 
simultaneously using the frontal and lateral x-ray tube. This allows iodinated contrast 
agent (which is osmotoxic and can cause renal damage and allergic reactions) to be 
injected as sparingly as possible. 
3. Structured dose reports and PACS images: 
As well as recording tube potential and added filtration, the structured dose reports 
recorded by Siemens equipment also records beam angles. As with the angles 
recorded in log books at Hospital 2, only acquisition beam angles are listed. Images 
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stored on the PACS network display the same beam angle information as dose 
reports. The procedure names listed on PACS are often rather vague - many are 
entered under the non-specific name of “congenital anomaly study” - meaning it was 
difficult to search the PACS archive for specific procedure types. Consequently, a 
greater sample of procedures was obtainable for some procedures than for others. 
4. Biplane kerma area product: 
Hospitals 1 and 4 record PKA as separate figures for frontal and lateral x-ray tube 
outputs. This allows some information on beam projections to be inferred, including 
the proportion of total PKA in each angle. 
Along with information on the beam angles used for different procedures, information 
on the proportion of the total examination dose originating from each of these angles 
is also required. This is relatively straightforward for examinations in which only 
straight PA and straight left lateral projections tend to be used; the proportions can 
be derived from the Biplane PKA data described above. The situation is more 
complex for examinations in which two or more projections involve the same x-ray 
tube (mainly pulmonary artery and coronary angiography procedures). Structured 
dose reports can help, but only provide information for acquisitions, not fluoroscopy.  
 
6.2.2: Results 
Data obtained on beam angles will now be presented separately for each of the four 
methodologies described above: 
Beam quality questionnaire. 
The compiled results of the beam angle questionnaire are shown in Table 6.8. 
Unfortunately, there are a lot of gaps. In some cases the hospitals sent their own 
departmental protocols for various imaging procedures rather than filling out the 
questionnaire. Although this information was still useful, comparison between 
hospitals was difficult. Reported projections for aortic and pulmonary valvuloplasty, 
pulmonary vascular resistance (PVR) studies and atrial septostomy procedures were 
consistent (PA and lateral), as were those for electrophysiology studies (EPS), 
although the level of left anterior oblique angulation varied from 30 to 50°. Other 
differences including reported usage of a small level of oblique angulation for 
coarctation repairs and PDA closures. Reported coronary angiography beam angles 
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have been colour coded for easier comparison. All hospitals reported use of a 30° 
right anterior oblique (RAO) projection, a left anterior oblique (LAO) beam and a LAO 
beam with caudal angulation. The lateral projection was reported at Hospitals 2 and 
3 but not at Hospital 4. The level of angulation varied between centres. It should be 
noted that coronary angiographies and endomyocardial heart biopsies are only 
regularly conducted at Hospitals 1 and 4, where transplant procedures are carried 
out.  
Hospital: 4 4 2 3 1 
Source: Radiographer Cardiologist Protocol Protocol Radiographer 
Coronary 
angiography 
RAO 20, 
CR 40,  
RAO 20/CAU 40,  
LAO 50/CAU 30,  
RAO 30,  
LAO 30 
 
LAO 30/CAU 
40,  
Lateral,  
RAO 30,  
LAO 60 
LAO 30/CAU 
40, RAO 30, 
RAO 30/CAU 
25, LAO 60/CR 
25, 
LAO 60 
Lateral 
PA 
AP Plane: 
RAO 30 
CAU 10 
 
Lateral plane: 
LAO 45 
CR 20 
LAO 60 
PDA closure 
PA,  
Lateral 
RAO 30,  
Lateral   
RAO 25, 
Lateral 
ASD closure 
PA,  
Lateral    
PA, 
Lateral 
AV angioplasty 
PA,  
Lateral    
PA, 
Lateral 
PV angioplasty 
PA,  
Lateral  
PA,  
Lateral  
PA, 
Lateral 
Heart biopsy PA 
   
PA, 
Lateral 
PA angioplasty 
 
PA,  
Lateral 
LAO 25/CR 25 
 
LAO 40/CR40 
Lateral/CAU 
10 
EPS 
RAO 30, 
LAO 50 
RAO 30, 
LAO 30  
RAO 30, 
LAO 45 
PA 
PVR 
PA,  
Lateral    
PA 
Lateral 
Atrial 
septostomy 
PA,  
Lateral    
PA, 
Lateral 
Pacemaker PA 
   
PA, RAO 30, 
LAO 30 
Coarctation 
repair 
PA,  
Lateral 
PA,  
Lateral   
LAO 15,  
Lateral 
Any others 
 
LAO 30, 
Lateral (arch 
aortogram) 
   
 
Table 6.8: Beam angles reported by staff at participating hospitals. Angles separated by a '/' 
represent both rotational and cranio-caudal angulation together for the same projection. 
 
192 
 
Logbook records of beam angles: 
Where all procedure types were analysed as a whole, 48% of acquisitions were listed 
as being in the PA projection, while 35% were in the left lateral projection. The 
remainder were various combinations of oblique beam angles, including right anterior 
oblique (3%) and left anterior oblique (3%). These proportions varied between 
procedure types (Figure 6.12). The majority of ASD occlusions, electrophysiology 
studies (EPS), radiofrequency ablations (RFA), and pacemaker procedures involved 
acquisitions only the PA projection. Procedures involving angioplasty of coarctations 
and pulmonary or aortic valve stenosis usually used PA and lateral projections only. 
More complex combinations of beam angles were used for angioplasty of the 
pulmonary arteries. These were usually anterior oblique angles with around 25° 
cranial angulation.  
 
 
Figure 6.12: Proportion usage of different imaging projections for acquisitions. CR=cranial, 
OBL=oblique, ‘Sit up’ and ‘Long Axis’ views are a combination of oblique and lateral 
projections 
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Structured dose reports and PACS images: 
Hospital 2: Details of 64 complete examinations comprising 324 acquisitions were 
recorded. Of all acquisitions, 85 were straight PA projections (26.2% of total), 147 
were left laterals (45.4%), while 77 were oblique (28.4%). The proportion of 
acquisitions recorded in structured dose reports as being in either PA or lateral 
projections (71.6%) was lower than recorded in the logbooks (83%). Of all complete 
examinations recorded, 25 (39%) involved only PA, left lateral or both PA and lateral 
projections only. A further 6 examinations (9%) involved a single acquisition in an 
oblique projection with all other acquisitions in PA or lateral. All other examinations 
involved at least 2 acquisitions in an oblique projection. Analysis of the beam angles 
used for different examination types is difficult as the sample size is relatively small 
for individual procedures. For all diagnostic procedures combined, (111 acquisitions 
in total), 36 projections were PA (32.4%), 48 were lateral (43.2%) and 27 were 
oblique (24.3%). For combined Interventional procedures (178 acquisitions), 43 were 
PA (24.7%), 83 were lateral (46.6%) and 52 were oblique (29.2%). For three 
examinations of the pulmonary arteries, 5% of acquisitions were in the PA, projection 
were 43% lateral and 52% were oblique projections, typically with around 25° cranial 
and 25° left anterior oblique angulation. These angles are consistent with those 
reported in the questionnaires, although the proportion of acquisition in the PA 
projection is lower than suggested by logbook records. 
 
Hospital 4: Dose reports for 49 examinations conducted using Siemens Axiom Artis 
machines were collected, along with details from 169 examinations stored on the 
PACS network. Figure 6.13 shows the proportion of acquisitions in various beam 
angles for nine of the most commonly conducted examinations, along with broad 
diagnostic, interventional and ‘other’ categories. There are a number of differences in 
these proportions to those shown in Figure 6.12, derived from logbook records of 
beam angles at Hospital 2. The main observation was the relatively lower use of the 
straight PA projection at the Hospital 4 and greater use of oblique projections. This 
was especially apparent for ASD occlusions in which PA projections were usually 
modified with a small right anterior oblique angle (around 10°), along with 
considerably greater usage of the left lateral projection. The use of the RAO and left 
lateral projections for PDA occlusions were consistent with the angles reported by 
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the cardiologist but not the radiographer (who stated PA and lateral). The projections 
used for aortic and pulmonary valvuloplasty were consistent with those of the 
questionnaire and Hospital 2 logbook records. 
In terms of beam angles, coronary angiographies are relatively unusual procedures 
and deserve special attention. Straight PA and lateral projections tend to be avoided 
in favour of various oblique projections. In most cases, the procedure is purely 
diagnostic, with only one acquisition carried out in each projection angle. This 
contrasts with most other examination types in which one or two projections are 
favoured for the whole examination. Beam angle data was analysed from PACS 
images and structured dose reports for 40 coronary angiography procedures 
conducted at the Hospital 4. Ten different projections were identified; these were 
various combinations of right or left anterior oblique angles, with or without cranial or 
caudal angulation, plus occasional use of straight PA and left lateral projections 
(Figure 6.14). The most common of these, used in 90% of examinations, was a left 
anterior oblique angle with no cranial or caudal angulation (Figure 6.15). The straight 
left lateral projection was avoided in all but one examination. Dose (as represented 
by PKA) was fairly evenly distributed between different projections. 
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Figure 6.13: Beam angles obtained from structured dose reports and PACS images at 
Hospital 4 
 
 
 
Figure 6.14: Percentage of examination PKA originating from different projections for 
coronary angiography at Hospital 4. 
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Figure 6.15: Percentage of coronary angiography examinations in which a particular 
projection is used. 
 
Biplane PKA 
Hospitals 1 and 4 record PKA as separate figures for frontal and lateral x-ray tube 
outputs. This allows some inferences to be made, particularly in regard to the 
proportions of total PKA in each projection, but provides little information on the actual 
beam angles used (i.e. output from the lateral tube does not necessarily imply the 
projection was a straight left lateral). The information is therefore more useful for 
examinations in which oblique projections tend to be avoided and most imaging is 
done in straight PA or lateral projections. 
Hospital 1: For all procedures combined between 1994 and 2010, the mean and 
median proportions of total PKA originating from the frontal tube were both 0.61. 
These figures varied considerably between different procedures (Figure 6.16). 
Almost all total PKA for ASD occlusions and pacemaker insertions originated from the 
frontal tube, while the majority of PKA was from the lateral tube for coronary 
angiography and PDA occlusions. The proportions also varied with era. The 
proportion of PKA from the frontal tube tended to be lower between 2002 and 2008 
(where the majority of data were acquired) than for other eras.  
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Figure 6.16: Proportion of total PKA from the frontal x-ray tube for different procedures at 
Hospital 1 from 1994 to 2010. Error bars represent one standard deviation. 
 
Hospital 4: Biplane PKA was recorded sporadically at Hospital 4. For 1126 procedures 
conducted from November1994 to May 2005, the mean and median proportions of 
PKA from the frontal tube were 0.61 and 0.62 respectively. These proportions are 
clearly very similar to those of Hospital 1 (mean and median were both 0.61), though 
the lack of detailed procedure type information prevents further analysis. Analysis of 
structured dose reports from Hospital 4 (which are considerably more reliable) 
demonstrated a proportion of total PKA from the frontal tube of 0.63. This could be 
analysed separately for fluoroscopy (0.73) and acquisitions (0.57).  
Hospital 2:  Only total PKA figures were recorded in logbooks at Hospital 2, though a 
crude approximation of the relative involvement of frontal and lateral x-ray tubes 
could be obtained from the number of acquisitions involving each output. In this case, 
the proportion of acquisitions involving the frontal tube was 0.59 for all procedures 
combined. For most procedures and categories, a reasonable level of agreement 
was found with the mean proportions of total PKA from the frontal x-ray tube at 
Hospital 1 (Figure 6.17). This is especially significant considering these data were 
obtained using two different methodologies at two different hospitals. The largest 
differences are for pressure studies and EPS procedures. Is these cases, the reason 
for the discrepancy appears to be that these procedure generally do not involve 
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acquisitions (the same logic would also apply to pacemaker insertions, although the 
agreement between acquisitions and total PKA is very high in this case).  
A further source of biplane information at Hospital 2 was the 64 structured dose 
reports obtained for procedures conducted between 2011 and 2014. Based on this 
source, the mean proportion of total PKA for all procedures combined from the frontal 
x-ray tube was 0.75 (0.88 for fluoroscopy and 0.53 for acquisitions). This proportion 
is higher than previously discussed figures derived from other sources, though the 
sample size was small and the procedure mix relatively limited. 
 
 
Figure 6.17: Proportion of total PKA from the frontal tube at Hospital 1 compared to proportion 
of the number of acquisitions using the frontal tube at Hospital 2 (2004-2008). Data are 
presented for 3 procedure categories, plus nine common individual procedures. 
 
6.2.3: Discussion (beam angles) 
The four methodologies used to establish projection angles each have their own 
strengths and limitations. Structured dose reports and PACS images provide details 
of the exact beam angles used for acquisitions and the relative proportions of such, 
but lack information on the angles used for fluoroscopic exposures. Biplane PKA 
figures include fluoroscopy, but provide little information on angles other than 
whether the frontal or lateral x-ray tube was used. Questionnaires provide some 
199 
 
information on the variation in projections between centres but provide no 
information on the relative proportions of different angles. Lastly, logbook records of 
acquisition beam angles have the advantage of offering a very large sample size, but 
provide only a crude approximation of relative proportions. 
A number of observations can be made. Firstly, the projections used vary between 
different procedure types. This was not unexpected as different beam angles are 
required to demonstrate different anatomical features such as heart chambers, 
vessels and valves. In some cases, more than one projection may be used to 
visualise a particular structure, giving scope for variation in beam angles between 
different hospitals or (potentially) between different cardiologists at the same 
hospital. As with beam energy, a degree of uncertainty in projection angles is 
unavoidable. This uncertainty will be quantified later in this chapter. 
Analysis of structured dose reports suggests that a greater proportion of acquisitions 
have some form of oblique angulation than is suggested by questionnaire results and 
angles recorded in logbooks. One explanation is that a PA projection with a small 
amount of oblique angulation may be casually referred to as ‘PA’. This appears to be 
the case for ASD occlusions, in which the use of a 15° LAO angulation was 
acknowledged as “pretty much standard practice to bring the atrial septum into 
profile” (S. Charlton, personal communication) by the same radiographer who listed 
the projections as being ‘PA and Lateral’ in the questionnaire. Both Hospitals 2 and 4 
reported the use of oblique beam angles for EPS and ablation procedures, even 
though the majority of these examinations appeared to only involve the PA projection 
according to information recorded in logbooks. This could be explained by the fact 
that these procedures rarely involve acquisitions, meaning the figures recorded in 
logbooks (which are for acquisitions only) may not represent the angles in which the 
majority of irradiation occurred. 
There was some scope for hospital specific beam angle combinations. This was 
more appropriate for hospitals in which good quality information on beam angles was 
obtained (Hospitals 1,2 and 4). In particular, the much greater use of the lateral 
projection for ASD occlusions at the Hospital 4 ought to be taken into account. 
Unfortunately, due to the limited examination type details recorded at this hospital, it 
was not possible to identify which procedures were ASD occlusions. Variation in 
coronary angiography beam angles was also seen between Hospitals 1 and 4. 
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However, this difference was based on radiographer reported angles, with no 
structured dose reports at Hospital 1 with which to compare.  
A further hospital specific modification was the use of a 15° LAO angulation for 
coarctation repairs at Hospital 1, rather than straight PA. It can also be implied from 
Figure 6.17 that the relative usage of PA and lateral projections in pulmonary/aortic 
valvuloplasty and coarctation repair procedures varies somewhat between Hospitals 
1 and 2. This may be true, although the methodologies used to determine the 
proportions shown in Figure 6. are different - biplane PKA for Hospital 1 and number 
of acquisitions for Hospital 2. The former may be considered more reliable as the 
number of acquisitions allow only limited inference of actual dose in any particular 
beam angle and does not include fluoroscopy.  
 
6.2.4: Beam angles used for dose estimation 
There are a number of cardiac catheterizations that are difficult to define as any 
particular procedure type. For these ‘unspecific cardiac catheterizations’,  the most 
realistic starting point when estimating likely beam angles would be a combination of 
straight PA and straight left lateral projections in proportions of 0.6 and 0.4 
respectively. These are by far the most commonly used projection angles and the 
proportions are consistent with data from biplane PKA records and acquisition beam 
angles recorded for individual examinations. This configuration can be encoded in 
the following matrix used in cardiodose: 
[
90 0 0.6 𝑡
180 0 0.4 0
] 
For example, for a total examination PKA of 2.0 Gy·cm², 1.2 Gy·cm² would be applied 
in a beam angle of 90° (straight PA) and 0.8 Gy·cm² would be applied in a beam 
angle of 180° (straight left lateral). The ‘t’ in the matrix means the table attenuation 
factor is applied for the first projection (PA) but not the second (lateral) Only the 
frontal output is modified by a table attenuation correction. The same beam angle 
matrix is also appropriate for coarctation angioplasty and pulmonary/aortic 
valvuloplasty procedures. Other examination types are listed below.  
Pulmonary artery angioplasty – aside from coronary angiography, these procedures 
involve the most complex arrangement of beam angles. The matrix used is based on 
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beam angles reported by radiographers in proportions suggested by structured dose 
reports. The proportion for the left lateral beam (180°) is based on biplane PKA data. 
[
90 0 0.25 𝑡
180 0 0.4 0
115 −25 0.25 𝑡
65 −25 0.1 𝑡
] 
ASD occlusion - these predominantly involve the PA projection, with or without 
around 10° of right or left anterior oblique angulation. A small contribution from the 
left lateral projections was added, based on biplane data and acquisition beam 
angles: 
[
90 0 0.93 𝑡
180 0 0.07 0
] 
ASD occlusion (Hospital 4): 
[
90 0 ? 𝑡
180 0 ? 0
] 
PDA occlusion – this procedure usually involves PA and left lateral projections, 
although the small use of a right anterior oblique projection is also taken into 
account: 
[
90 0 0.3 𝑡
180 0 0.6 0
60 0 0.1 𝑡
] 
Pulmonary and aortic valvuloplasty, coarctation repair – Almost all procedures utilised 
the PA and lateral projections only. The respective proportions of these angles were 
based on biplane PKA data recorded at Hospital 1. These proportions were different 
from those suggested by the analysis of beam angles recorded in Hospital 2 
logbooks (Figure 6.12) although these latter data were considered less reliable, 
being based solely on the number of acquisitions rather than PKA.  
Pulmonary valvuloplasty: 
[
90 0 0.60 𝑡
180 0 0.40 0
] 
Aortic valvuloplasty: 
[
90 0 0.65 𝑡
180 0 0.35 0
] 
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Coarctation repair: 
[
90 0 0.55 𝑡
180 0 0.45 0
] 
Coarctation repair (Hospital 4) – the use of a small left anterior oblique projection is 
accounted for: 
[
105 0 0.55 𝑡
180 0 0.45 0
] 
Coronary angiography:  Angles were based on structured dose reports at Hospital 4, 
for the 5 most commonly used angles: 
 
[
 
 
 
 
70 −40 0.2 𝑡
70 40 0.2 𝑡
140 30 0.2 𝑡
50 0 0.2 𝑡
130 0 0.2 𝑡]
 
 
 
 
 
Endomyocardial biopsy – Most imaging is done in the straight PA projection, though 
72% of these procedures involved a small contribution of PKA from the left lateral 
projection. The majority of biopsies were conducted at Hospital 4 in which biplane 
information was recorded. In these cases, the proportions in the PA and lateral 
projections were as given by biplane figures. The following matrix was used in the 
absence of these data: 
[
90 0 0.89 𝑡
180 0 0.11 0
] 
Electrophysiology study (EPS) - this matrix was largely based on radiographer 
reported beam angles and proportions based on biplane PKA data: 
[
60 0 0.5 𝑡
40 0 0.5 0
] 
Pressures and pulmonary vascular resistance studies and atrial septostomy – 
proportions based on biplane PKA data: 
[
90 0 0.75 𝑡
180 0 0.25 0
] 
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Trans-catheter pulmonary valve replacement: Based on radiographer reported beam 
angles. Proportions based on biplane PKA data: 
[
90 0 0.65 𝑡
180 0 0.35 0
] 
 
6.2.5: Errors and uncertainties 
Estimating the uncertainty in organ dose calculations based on variation in beam 
angles from those expected is challenging. The overall uncertainty encompasses 
variation in the angles themselves and their respective proportions. The situation is 
relatively simple for pulmonary and aortic valvuloplasty, valve replacement, 
coarctation repair, biopsies and pressure studies, which usually involve straight PA 
and straight left lateral projections. The usage of other beam angles in these 
procedures was considered negligible. Thus the uncertainty analysis needs only to 
focus on the variation in proportion between PA and lateral projections. Uncertainty 
in this proportion was initially based on two standard deviations, though this 
methodology was abandoned and replaced with 5th and 95th percentiles to allow 
calculation of separate upper and lower uncertainties and avoid situations in which 
lower uncertainty limits were greater than 100% (implying negative doses). PA/lateral 
proportions were obtained from bi-plane PKA figures recorded at Hospital 1 between 
1994 and 2010. Total examination doses were calculated with the PA/lateral 
proportions set at median, 5th and 95th percentile values. The difference in resulting 
dose to each organ between median and 5th/95th percentile proportions was 
calculated as a percentage figure. These figures are shown in Table 6.9 for 
pulmonary and aortic valvuloplasty, valve replacement, coarctation repair, biopsies 
and pressure studies combined. Uncertainties for individual procedures can be found 
in Appendix 4. As expected, uncertainties are highest for the breasts and relatively 
low for the lungs and lymph nodes. Uncertainties increase with increasing patient 
size and vary between the different procedure types. Where biplane PKA figures are 
recorded for a given procedure, the uncertainties in Table 6.9 are essentially reduced 
to zero. Thus the rather high beam angle uncertainties for endomyocardial biopsies 
are immaterial as these procedures were all conducted at hospitals in which biplane 
figures were recorded (Hospitals 1 and 4). 
204 
 
For other procedure types in which usage of more than two beam angles was 
recorded, a different process was used. Multiple procedures for each examination 
type were reconstructed using the beam angles recorded in structured dose reports 
and the doses calculated using cardiodose. All other parameters, including total 
examination PKA, patient size and beam energy were kept constant. Total 
examination doses for each organ were obtained by summing the doses from the 
individual beam angles comprising the reconstructed procedure. Any variation in 
these doses was due to variation in beam angles and their associated proportions. 
Uncertainties were defined using the 5th and 95th percentiles of these figures and 
expressed as a percentage variation from the median. This process was repeated for 
six different patient sizes. The uncertainties for ‘other’ or unspecified examinations 
were calculated from the mean values of uncertainties for all procedures for which 
uncertainties were calculated. These uncertainties are shown in Table 6.10, for 
coronary angiography, PDA/ASD occlusions and pulmonary angioplasty combined. 
Uncertainties for breast dose require special consideration.  In the Computational 
Dosimetry chapter, it was demonstrated that depending on the combination of beam 
angle, field size and central ray position, breast dose in the lateral projection may be 
as low as that in the PA projection, or several times higher. For central dose 
estimates, the latter situation has been assumed, while the former must be regarded 
as clinically plausible (and desirable) and needed to be accounted for in uncertainty 
limits. Thus the lower limit for breast dose was set to be no higher than would be 
obtained if the entire procedure was conducted in the PA projection. 
 
6.2.6: Table Reduction factor 
For many projections, the x-ray table and mattress attenuate the x-ray beam before it 
reaches the patient. The only hospital known to apply a correction factor to ‘raw’ PKA 
data (i.e. as quoted by the equipment) to account for table attenuation is Hospital 4. 
For all other hospitals, it was assumed that no such factor was applied. Previous 
studies by Ubeda et al [282] and Martinez et al [94] have quoted transmission factors 
due to table and mattress attenuation of 0.81 and 0.82, respectively, i.e. reduction in 
beam intensity by 19% and 18%. Used equipment vendors [253] usually quote table 
attenuation, in terms of aluminium equivalence, at 1 mm. Beer’s law was used to 
calculate the reduction in beam intensity, using quoted mass attenuation coefficients 
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of 0.37, 0.57 and 1.13 cm3/g at 50, 40 and 30 keV and a density of 2.7 g/cm3 [16] (i.e. 
linear attenuation coefficients of 1.0, 1.5 and 3.1 cm3, respectively). This yielded 
transmission factors of 0.90, 0.86 and 0.74 for 50, 40 and 30 keV beams, 
respectively. The mean of these three figures was 0.83, thus very close to the 
transmission factors quoted by Ubeda et al [282] and Martinez et al [94].  If the x-ray 
beam is angulated (i.e. not perpendicular to the table), the thickness of material 
traversed by the beam will be increased. The relative increase in thickness can be 
determined as 1 / cos θ, where θ is the angulation away from perpendicular. The 
maximum oblique angulation was 40° (2π/9). This results in an increase in thickness 
of material traversed of 31% and an increase in table attenuation by 5.4%. The 
average transmission factor for angles ranging from 0° (i.e. perpendicular to the 
table) to 40° for the three x-ray energies was 0.81. This figure was used for organ 
dose calculations for all projections except straight left lateral. Most table surfaces 
are flat. The table used in Siemens Artis Zee systems is slightly concave, though by 
an insufficient extent to influence the above calculations. 
 
6.3: Conclusion 
Information was gathered on the beam energy and projection angles used for cardiac 
catheterizations in clinical practice. Central values of these parameters were 
estimated from a range of sources, with structured dose reports being considered the 
most reliable. It is acknowledged that considerable uncertainty exists in these values. 
These uncertainties have been estimated from available data. The following chapter 
presents estimates of organ doses calculated using the ‘Cardiodose’ dosimetry 
system, utilising the information presented in this chapter. 
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Age range 
(mass) 
Uncertainty 
Effective 
dose 
Bone 
marrow Breasts Heart Lungs 
Lymph 
nodes Oesophagus Thyroid Liver Stomach 
Average 
dose 
<1 years 
(<9.2 kg) 
Upper 6% 14% 30% 11% 3% 0% 2% 5% 20% 3% 3% 
Lower -3% -20% -18% -7% -3% 0% -2% -4% -14% -3% -4% 
1-5 years 
(9.2-19 kg) 
Upper 11% 11% 39% 16% 1% 3% 7% 5% 30% 4% 1% 
Lower -7% -15% -24% -11% -1% -2% -5% -3% -19% -5% -2% 
5-10 years 
(19-32.4 kg) 
Upper 14% 10% 52% 10% 3% 1% 2% 10% 32% 8% 2% 
Lower -9% -15% -31% -7% -1% -1% -1% -7% -21% -11% -3% 
10-15 years 
(32.4-56.3 kg) 
Upper 18% 14% 67% 7% 2% 2% 1% 7% 31% 10% 4% 
Lower -11% -19% -40% -4% -1% -2% -2% -5% -20% -14% -6% 
15-18 years 
 (>56.3 kg) 
Upper 15% 14% 78% 4% 5% 3% 7% 13% 35% 14% 3% 
Lower -9% -20% -47% -2% -2% -3% -9% -8% -23% -19% -4% 
>18 years 
(>70 kg) 
Upper 16% 14% 86% 4% 6% 5% 12% 8% 35% 19% 4% 
Lower -10% -21% -51% -6% -3% -6% -16% -4% -23% -26% -5% 
 
Table 6.9: Upper and lower percentage uncertainties in organ dose due to variation in the proportion of PA and lateral projections. Figures are 
the average for Pulmonary/aortic valvuloplasty, coarctation repair, atrial septostomy, valve implantation and biospies.  
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Age range 
(mass) 
Uncertainty 
Effective 
dose 
Bone 
marrow 
Breasts Heart Lungs 
Lymph 
nodes 
Oesophagus Thyroid Liver Stomach 
Average 
dose 
<1 years 
(<9.2 kg) 
Upper 10% 19% 37% 9% 6% 5% 7% 10% 25% 15% 3% 
Lower -11% -22% -37% -13% -3% -4% -7% -9% -15% -15% -3% 
1-5 years 
(9.2-19 kg) 
Upper 12% 15% 47% 14% 7% 5% 7% 10% 29% 12% 1% 
Lower -13% -16% -38% -18% -6% -7% -8% -9% -20% -14% -1% 
5-10 years 
(19-32.4 kg) 
Upper 16% 14% 53% 11% 10% 5% 5% 11% 32% 15% 2% 
Lower -17% -15% -42% -17% -10% -8% -6% -12% -22% -16% -1% 
10-15 years 
(32.4-56.3 kg) 
Upper 18% 18% 49% 13% 9% 7% 8% 11% 35% 21% 4% 
Lower -18% -21% -44% -15% -11% -6% -7% -13% -23% -22% -3% 
15-18 years 
 (>56.3 kg) 
Upper 13% 19% 44% 15% 12% 8% 9% 16% 41% 28% 2% 
Lower -16% -21% -43% -16% -18% -10% -9% -18% -27% -27% -2% 
>18 years 
(>70 kg) 
Upper 13% 20% 44% 17% 13% 9% 13% 18% 40% 32% 3% 
Lower -15% -21% -44% -13% -17% -7% -14% -20% -27% -36% -2% 
 
Table 6.10: Upper and lower uncertainties for coronary angiography, PDA occlusions, ASD occlusions, and Pulmonary angioplasty 
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Chapter 7: Physical dosimetry 
This chapter describes the attempt to verify the findings of the previously described 
Monte Carlo simulations and Cardiodose dosimetry system using the alternative 
methodology of physical measurements conducted with anthropomorphic phantoms 
and thermoluminescent dosemeters (TLDs). Anthropomorphic phantoms are 
mannequins made from materials with similar x-ray interaction properties to human 
tissues [283]. They are designed to appear approximately similar to a living person 
when x-rayed, and usually have the capability to be disassembled to allow small 
dose measuring devices to be placed inside. A more detailed description of the 
phantoms used in this study, along with a description of thermoluminescent 
dosimetry is provided below. 
 
7.1: Methodology 
Physical measurements were conducted using ‘ATOM’ anthropomorphic phantoms 
manufactured by CIRS (Norfolk, Virginia, USA) [284] (Figure 7.1). Five different 
phantom sizes were available, representing new-born, 1 year, 5 year, 10 year and 15 
year old individuals. Conveniently, these are the same paediatric patient ages 
represented in PCXMC. ATOM phantoms are made from tissue equivalent epoxy 
resin, with no human remains [284] (some phantoms utilise a real human skeleton). 
The bone density varies with phantom size, from 1.41 to 1.6 g/cm3 (electron density; 
4.606 x1023 to 5.030 x 1023/cm3). Human bones comprise an outer layer of dense 
cortical bone surrounding an inner core of spongy, trabecular bone [255]. ATOM 
bones are solid with a uniform density equal to the average of trabecular and cortical 
bone to simplify calculations and eliminate air voids [284]. The density of the lungs is 
0.2 g/cm3. All other soft tissue organs were of identical density (1.055 g/cm3) [284]. 
This uniformity caused problems when positioning the phantoms as the heart was 
simply the space between the lungs and above the abdomen, and thus difficult to 
locate. Table 7.1 compares the characteristics of ATOM and PCXMC Monte Carlo 
phantoms. The phantoms are split into a number of 25 mm thick axial slices allowing 
them to be disassembled (Figure 7.1). Most slices are drilled with holes allowing 
dose measuring devices such as TLDs or metal oxide semiconductor field effect 
transistors (MOSFETs) to be placed inside. Most of the phantom sizes did not have 
holes drilled in positions representing the heart. Furthermore, only the new born and 
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1 year phantoms had arms and legs. The remaining phantoms only featured a torso 
(down to the proximal femora) and a head.  
 
 
Figure 7.1: Disassembled 1 year ATOM phantom, showing numbered holes in which TLDs 
can be placed. The arms can also be disassembled. Photo: author 
 
 
Characteristic Phantom New born 1 year 5 years 10 years 15 years 
Total height 
(cm) 
ATOM 51.0 75.0 110.0 140.0   
PCXMC 2.0 50.9 74.4 109.1 139.8 168.1 
Total body 
mass (kg) 
ATOM 3.5 10.0 19.0 32.0   
PCXMC 2.0 3.4 9.2 19.0 32.4 56.3 
Torso width 
(cm) 
ATOM 10.5 14.0 17.0 20.0   
PCXMC 2.0 10.9 15.1 19.6 23.8 29.7 
Torso thickness 
(cm) 
ATOM 9.0 12.0 14.0 17.0   
PCXMC 2.0 9.8 13.0 15.0 16.8 19.6 
Soft tissue 
Density (g/cm³) 
ATOM 1.06 1.06 1.06 1.06  1.06 
PCXMC 2.0 1.04 1.04 1.04 1.04 1.04 
Bone Density 
(g/cm³) 
ATOM 1.4 1.5 1.5 1.6  1.6 
PCXMC 2.0 1.22 1.4 1.4 1.4 1.4 
Lung Density 
(g/cm³) 
ATOM * 0.21 0.21 0.21 0.21  0.21 
PCXMC 2.0 0.30 0.30 0.30 0.30 0.30 
 
Table 7.1 Comparison of phantom characteristics for ATOM anthropomorphic phantoms and 
PCXMC Monte Carlo phantoms. * Lung density for ATOM phantoms is based on inhalation. 
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Thermoluminescent dosemeters are conceptually similar to the phosphor-based 
luminous paint on watch dials, in which radiant energy from visible light is absorbed, 
trapped, and re-emitted later as new visible light photons. TLDs used in x-ray 
dosimetry typically utilise a crystal of lithium fluoride (LiF) rather than phosphor. 
Incident x-ray photons provide energy to elevate electrons from the valance band to 
the forbidden gap whereupon they become stuck in ‘traps’ caused by the addition of 
impurities into the crystal. Excited electrons remain trapped until provided with 
sufficient energy in the form of heating (around 300°C) to escape the electron traps 
and reach the conduction band [43], after which they return to the valance band, 
accompanied by the emission of a visible light photon (direct transition from traps to 
the valance band is forbidden). The intensity of visible light photons emitted following 
heating is related to the absorbed dose to the TLD. The heating can be in the form of 
contact with a strip of hot metal, lasers/focused infrared bulbs or hot gas [285]. A 
controlled increase in heating during the reading process empties electron traps of 
increasing depth, producing a characteristic ‘glow curve’, measured using a 
photomultiplier tube [16]. 
The TLDs used were lithium fluoride, doped with magnesium and titanium 
(LiF:Mg,Ti) (Thermo Electron Corporation, Solon, OH). The effective atomic number 
of LiF (8.2) is comparable to that of soft tissue (7.4) [43], meaning x-ray interaction 
properties are reasonably similar. The electron traps are sufficiently deep to reduce 
spontaneous emptying at room temperatures to negligible levels [16]. TLDs have the 
advantages of small size, re-usability, low cost, and reasonably linear response to 
radiation at diagnostic dose levels and photon energies. TLDs are fiddly and 
extremely time consuming to use. The whole process of loading a phantom with 
TLDs, exposing, removing the TLDs and reading them can typically take 2 days. 
Before measurements could be made, the TLDs needed to be calibrated. The entire 
batch of TLDs were calibrated twice, once at the beginning of the study, and a 
second calibration after the first phase of exposures (see Exposures section below). 
The calibration procedure produces a conversion factor for each TLD to convert the 
measured signal to absorbed dose in milligray. To begin, all TLDs were annealed 
using a dedicated oven (Model TLD-28, Pickstone Ovens, Thetford, Norfolk, UK) set 
at 400°, for 12 hours after which they were allowed to cool, undisturbed, for a further 
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36 hours. The annealing process empties electron traps of residual signal from 
previous irradiations or background exposure [285].  
Following annealing, the TLDs were placed in individual heat sealed bags and 
attached to a jig designed to allow irradiation of TLDs equidistant from the radiation 
source (Figures 7.2 and 7.3). The source used to irradiate the TLDs was Caesium-
137 (137Cs), which decays by β- emission to barium-137 (137Ba). Around 90% of the 
time, 137Cs decays to a metastable state (137mBa), followed by the emission of a 
gamma-ray of 661.6 keV [16]. In the remainder, 137Cs decays directly to 137Ba with no 
metastable state. The source was handled with a set of special tongs to maintain 
distance from the handler, and the time spent with the source was kept to a minimum 
once it was unshielded. The source was placed in the centre of the calibration jig so 
as to be equidistant from the TLDs. For the first calibration, this achieved using tape 
stretched across the jig (Figure 7.). The TLDs were irradiated with the 137Cs source 
for 4 Hours 30 minutes, 42 seconds, giving a mean total dose to each TLD of 11.11 
mGy.  
 
 
Figure 7.2: Diagram of TLD calibration setup shown in Figure 7.3. Figure credit: author 
 
 
212 
 
 
Figure 7.3: TLD calibration jig as used for the first calibration. Note the tape method of 
finding the centre of the jig. Photo: author 
 
After exposure, TLDs were read to produce calibration factors. Each TLD chip 
responds slightly differently, therefore the calibration factor was specific to each 
numbered chip. Following calibration, all TLDs were annealed again before usage in 
dosimetry, using the same annealing protocol as the first time. Reading was carried 
out using a HARSHAW 5500 TLD reader (Thermo Electron Corporation, Solon, OH) 
[286], which uses hot nitrogen gas heating. The photomultiplier tubes of the reader 
are cooled, using cold liquid nitrogen. TLDs were read in batches of 50 at a time, with 
each batch taking around 35 minutes to read. 
Errors in the TLD calibration process came from a number of sources. Firstly, the 
TLDs were not exactly equidistant from the source. The vertical spread of TLDs on 
the calibration apparatus was around ±1.5 cm. This results in a variation in the 
distance from the source of ±0.12% (Pythagoras): 
𝐸𝑟𝑟𝑜𝑟 = (
√302 ± 1.52
30
) − 1 
Secondly, the site of the source was found to be not exactly in the centre of the 
circle, varying from 29 to 31 cm. As beam intensity from a point source is proportional 
to the inverse square of distance from that source, this small variation in distance 
from 30 cm would result in a variation in intensity of around ±6.7%. 
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For the second calibration, a number of changes were made to reduce these 
uncertainties. Firstly, the tape method of finding the centre of the calibration jig was 
replaced by an aluminium pole, which reduced variation in distance between the 
source and TLDs. Secondly, the vertical spread of TLDs on the calibration jig was 
reduced to around 1 cm. Where the results of the first and second calibrations were 
compared, the mean absolute variation in calibration factor was 5% (median = 4%), 
with 1% of calibration factors varying by greater than 20%, 8% varying by greater 
than 10%, 39% varying by greater than 5% and 87% varying by more than 1%. The 
largest variation was 268% although this TLD was never used in any phantom 
irradiations. The mean and median signed variation in calibration factor between first 
and second calibrations were +0.4 and +1.1% respectively, therefore there was little 
evidence of a systematic difference. 
 
7.1.1: Exposures 
TLDs were placed in all the holes representing the lungs, heart, stomach, liver, bone 
marrow, thyroid and breasts, using tweezers. A single TLD was placed in each hole. 
The organs represented by each hole in each phantom slice were determined from 
the manufacturers’ loading schemes. The number or holes representing each organ 
generally increased with phantom size, from new born to 15 years - Lungs (15-33 
holes), Bone marrow (49-67), oesophagus (2-4), liver (7-21), stomach (6-11), breasts 
(2 for all sizes), thyroid (2-4), heart (8-11). 
Phantom exposures were split into two phases. The first phase involved exposing 
each of the five phantoms, separately, in two projection angles - straight 
posteroanterior (PA) and straight left lateral. The second phase focused on a single 
phantom size (10 years) and involved exposures in 7 projection angles ranging from 
PA to lateral in 10 to 25° intervals, along with a further exposure in the PA projection 
at a lower beam energy. 
For the first phase, exposures were carried out using a Siemens Axiom Artis BC 
biplane unit at Hospital 4, with image intensifier detectors (Figure 7.4). The machine 
undergoes routine quality assurance (QA) testing every 12 months. A general use 
‘native’ cardiac paediatric imaging protocol was used (30 frames per second for 
acquisitions). An antiscatter grid was fitted. The c-arm was positioned and the beam 
collimated to the region of interest by a specialist cardiac radiographer. This is rather 
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difficult due to the crude anatomy of the ATOM phantoms. Finding the heart, which is 
simply the gap between the lungs, is challenging compared to PCXMC, in which 
organs have been thoughtfully colour coded. The positioning process was guided by 
fluoroscopy rather than cine-acquisitions. The dose from this initial positioning was 
generally less than 0.01 Gy·cm2 and regarded as negligible. The image intensifier 
was positioned as close as possible to the patient. The source-to-skin distance 
(SSD) was kept at approximately 80 cm. 
The phantom was exposed in a single beam projection to a particular value of PKA 
which depended on phantom size: 1, 2, 5, 10 and 15 Gy·cm2 for new born, 1, 5, 10 
and 15 year old phantoms respectively. These values were chosen based on the 
organ dose per unit PKA derived from Monte Carlo simulations and designed to 
ensure a mean dose to the lungs and heart of at least 10 mGy. A remainder of 10 
TLDs were saved to represent background exposures. The average doses recorded 
by these background TLDs were subtracted from the values recorded by TLDs 
placed in the phantoms. Following exposures, the phantoms were disassembled and 
the TLDs read (see below). The tube potential, added copper filtration and 
cumulative kerma area product were recorded.  
This process was repeated in the second beam projection. Dose estimations for 
complete examinations could be reconstructed from these data by adding doses from 
each projection in a particular combination. By obtaining results in individual 
projections separately, the results could easily be compared to the results of Monte 
Carlo simulations.  
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Figure 7.4: Position of new born phantom for the left lateral position. The arms are raised 
above the head as would be the case in clinical imaging. The bag over the x-ray tube is for 
infection control. An antiscatter grid (the black disk) is fitted to the image intensifier. Photo: 
author. 
 
For the second phase, exposures were carried out using a Philips BV300 mobile c-
arm fluoroscopy machine located in the regional medical physics department at the 
Hospital 4. This machine undergoes quality assurance testing every 12 months. 
Unlike the Siemens Axiom Artis, this Philips BV300 utilises circular x-ray fields. A 
PTW (Freiburg, Germany) M2 Diamentor was attached for PKA measurements and 
was calibrated at the time of the exposures. The c-arm had no proper attachment for 
a PKA meter, meaning the device needed to be strapped on (Figure 7.5). For these 
exposures, the phantom was stood vertically, supported by a table. The phantom 
itself was rotated for each projection angle rather than the c-arm, which was 
maintained in the same position. Exposures were carried out in seven projections 
ranging from straight PA to straight left lateral (rotational angles 90° to 180° in 
PCXMC terminology). Cranio-caudal angulation was fixed at 0°. A PKA of 10 Gy·cm2 
was delivered for each exposure. Unlike the Axiom Artis machine, tube potential 
could be set manually and was fixed at 70 kV for all exposures investigating the 
effect of beam angle. The overall HVL of 4.8 mm Al was obtained from QA reports for 
this machine. This figure is the same as the central value used in Cardiodose. 
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The process was extremely time consuming, therefore dose to a more limited range 
of organs was calculated. These were the lungs, heart, oesophagus, breasts and 
thyroid (i.e. organs in the thoracic region). A second exposure in the straight PA 
projection was carried out using a tube potential of 60 kV to investigate the impact of 
beam energy on dose per unit PKA.  
 
 
Figure 7.5: Setup for exposures using Philips BV300 mobile C-arm unit. Note the kerma area 
product meter strapped to the x-ray tube. Photo: author 
 
7.1.2: TLD reading 
The same HARSHAW 5500 TLD reader was used for TLD reading following 
exposures as was used following calibration. TLDs were read approximately the 
same length of time following exposures as they were following calibration exposures 
(as there were many TLDs to process, there was clearly a spread of reading times 
and there were numerous interruptions). Organ doses were calculated as the mean 
reading for all TLDs representing each tissue. For active bone marrow dose, a 
different approach was needed as the distribution of this tissue is uneven and varies 
with age. Information on age-specific bone marrow distribution was obtained from a 
paper by Cristy [256] (PCXMC Monte Carlo software uses the same approach). 
These proportions are summarised in Table 7.2. The mean TLD reading representing 
each of these regions of bone marrow was calculated before being multiplied by the 
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respective proportion from the Cristy data. The equivalent bone marrow dose (i.e. the 
average over the whole body) was calculated as the sum of these figures. Not all of 
the regions in Table 7.2 were simulated in the ATOM phantoms. The larger 
phantoms (5 years and above) did not have arms, or legs below the proximal femur. 
Dose values for these bones were assigned based on whichever bone containing 
TLDs was the closest (e.g. mandible = cervical vertebrae). 
 
 
Age (years) 
Region: 0 1 5 10 15 25 40 
Cranium 27 25.1 15.9 11.6 9.2 7.7 7.6 
Mandible 2.5 2.4 1.6 1.1 0.9 0.8 0.8 
Scapulae 2.7 2.7 2.7 2.9 3.3 2.9 2.8 
Clavicles 0.8 0.8  0.9 0.9 1 0.8 0.8 
Sternum 0 0.8 1.7 2.1 2.7 3 3.1 
Ribs 9.2 8.9 8.8 10.9 13.6 15.2 16.1 
Cervical vertebrae 3.4 2.8 2.2 2.7 3.3 3.7 3.9 
Thoracic vertebrae 8.3 8.4 8.9 10.9 13.7 15.3 16.1 
Lumbar vertebrae 2.4 4.3 6.8 8.4 10.5 11.7 12.3 
Sacrum 0.1 2.4 5.5 6.7 8.4 9.4 9.9 
Os coxae 9.2 11.1 13.1 15.6 18.5 19.5 17.5 
Femora, upper half 3.7 4.1 6.8 9.4 9.2 7.4 6.7 
Femora, lower half 3.7 3.9 6.3 6.1 2 0 0 
Tibiae, fibulae, patellae 8.0 8.7 9 5.5 0 0 0 
Ankle and foot bones 8.3 4.7 2.5 0 0 0 0 
Humeri, upper half 2.3 2.4 2.4 2.5 3.1 2.5 2.3 
Humeri, lower half 2.3 2.3 2.2 1.6 0.7 0 0 
Ulnae and radii 2.5 2.5 2 1.1 0 0 0 
Wrist and hand bones 3.6 1.9  0.9 0 0 0 0 
 
Table 7.2: Percentage distribution of active bone marrow as a function of age. Figures 
obtained from Cristy [253]. Note: ‘Os Coxae’ are the bones of the hip and pelvis. 
 
7.2 Results 
7.2.1: Phase 1 
The mean TLD readings per unit PKA for each organ are presented for PA and left 
lateral projections for each phantom size in Tables 7.3 and 7.4. In each case, 
equivalent figures calculated using Cardiodose are provided for comparison. Some 
218 
 
organ doses could not be calculated - on two occasions, the phantom’s head fell off 
during transporting resulting in the loss of TLDs representing the thyroid.    
The highest doses were for the lungs, oesophagus, heart and breasts. Doses to the 
thyroid, stomach and bone marrow were relatively low. Overall, organ doses 
calculated using physical measurements were higher than those estimated by Monte 
Carlo simulations. For the PA projection, the level of agreement between the two 
methodologies is reasonably high. Agreement was highest for the lungs, oesophagus 
and stomach and lowest for the liver and breasts. There is little suggestion of an 
association between phantom size and agreement between physical and Monte 
Carlo methods. For the left lateral projection, the doses calculated by physical 
measurements were higher than those of the Monte Carlo counterparts by an 
average factor of around 2.2. This discrepancy varied between organs, being highest 
for the liver and oesophagus and lowest for the breasts. Discrepancies were present 
across all ages – there is no suggestion of a closer match for smaller or larger 
phantom sizes. As with Monte Carlo simulations, organ doses per unit PKA decreased 
with increasing phantom size, except for the breasts in which the dose for the 1 year 
phantom was higher than for the new born. Again, a power law relationship tended to 
provide the best fit for this relationship. 
 
Phantom 
size (y) Methodology 
Organ 
ABM Breasts Heart Lungs Oesophagus Thyroid Liver Stomach 
0 
Physical 2.60 4.17 9.10 13.13 10.71 1.71 1.56 2.76 
Cardiodose 2.31 8.29 9.56 13.40 10.38 1.01 2.87 2.47 
1 
Physical 1.35 4.26 n/a 8.56 6.28 0.40 0.99 1.83 
Cardiodose 1.05 3.36 4.15 6.42 4.35 0.38 1.57 1.37 
5 
Physical 0.63 - n/a 4.03 2.67 - 0.30 0.30 
Cardiodose 0.53 1.37 2.12 3.32 2.14 0.12 0.69 0.59 
10 
Physical 0.43 1.23 1.66 2.35 1.20 0.07 0.83 0.34 
Cardiodose 0.46 0.82 1.49 2.17 1.19 0.05 0.41 0.33 
15 
Physical 0.44 0.51 n/a 1.49 0.81 0.05 0.42 0.15 
Cardiodose 0.35 0.25 0.77 1.33 0.80 0.02 0.22 0.15 
 
Table 7.3: Organ doses (in mSv) per unit PKA calculated for the PA projection by physical 
methods compared to those estimated using Monte Carlo computer simulations. 
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Phantom 
size (y) Methodology 
Organ 
ABM Breasts Heart Lungs Oesophagus Thyroid Liver Stomach 
0 
Physical 2.45 4.83 30.71 24.29 19.26 2.01 14.13 7.33 
Cardiodose 1.00 20.50 15.20 11.60 7.90 1.00 3.50 1.80 
1 
Physical 1.11 9.32 n/a 14.09 17.65 0.45 1.51 3.15 
Cardiodose 0.55 10.00 n/a 6.05 4.15 0.35 2.05 0.80 
5 
Physical 0.83 - n/a 8.15 6.99 0.20 1.29 0.64 
Cardiodose 0.30 7.30 n/a 3.98 2.66 0.14 1.36 0.39 
10 
Physical 0.78 5.81 3.99 3.78 2.22 0.16 2.34 0.26 
Cardiodose 0.22 5.27 2.46 2.34 1.18 0.07 0.76 0.21 
15 
Physical 0.38 0.46 n/a 2.37 1.23 0.06 1.94 0.14 
Cardiodose 0.15 1.77 n/a 1.30 0.52 0.02 0.52 0.06 
 
Table 7.4: Organ doses (mSv) per unit PKA calculated for the left lateral projection by 
physical methods compared to those estimated using Monte Carlo computer simulations. 
 
7.2.2: Phase 2 
Mean TLD readings for each projection angle and organ are given in Table 7.5 along 
with corresponding figures estimate using Cardiodose. A greater level of agreement 
was found between TLD readings and cardiodose estimates for phase 2 
measurements than phase 1. In particular, the discrepancy between doses in the left 
lateral projection was considerably smaller. The mean dose across all beam angles 
was higher for physical measurements by 22%, 8% and 12% for the lungs, heart and 
oesophagus respectively. A poor agreement was found across most beam angles for 
breast dose. The sharp rise in breast dose predicted to occur around the left lateral 
projection by Monte Carlo simulations was not seen for physical measurements. 
Thyroid dose was around 100% higher for physical measurements, although the 
absolute difference was not large (i.e. both methodologies yielded small doses).  
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Rotational beam angle (degrees) 
Organ Methodology 90 (PA) 115 130 145 155 170 180 (Lat) 
Lungs 
Physical 2.75 2.81 2.88 2.80 2.44 2.48 2.63 
Cardiodose 1.78 2.22 2.45 2.72 2.77 2.57 2.29 
Heart 
Physical 1.36 1.51 1.52 1.72 2.15 2.22 2.54 
Cardiodose 1.72 1.63 1.92 1.94 2.04 2.23 2.24 
Oesophagus 
Physical 1.17 0.90 1.17 1.42 1.21 1.32 1.37 
Cardiodose 1.22 1.32 1.32 1.40 1.31 1.14 1.06 
Breasts 
Physical 1.39 0.57 0.49 -  0.70 0.90 0.92 
Cardiodose 0.56 0.27 0.28 0.34 0.45 2.94 5.48 
Thyroid 
Physical 0.09 0.13 0.12  - 0.08 0.08 0.08 
Cardiodose 0.04 0.05 0.06 0.06 0.06 0.06 0.06 
 
Table 7.5: Doses per unit PKA for five organs (in mSv) and various projection angles obtained 
from physical measurements, compared to estimates obtained using the cardiodose function 
based on Monte Carlo simulations. 
 
Organ doses per unit PKA at 60 kV were lower than at 70 kV by 15%, 17%, 32%, 12% 
and 38% for the lungs, heart, oesophagus, breasts and thyroid respectively, 
compared to equivalent dose reductions of 9%, 13%, 14%, 12% and 16% calculated 
using Cardiodose.  
 
7.3: Discussion 
A number of discrepancies were found between physical measurements and Monte 
Carlo simulation based Cardiodose, although these varied between the two phases 
of measurements. Most notably, a large difference was found between cardiodose 
and physical measurements for the lateral projection where the Siemens Axiom Artis 
machine was used, but not when using the Philips BV300. There are a number of 
possible explanations; (1) differences in phantom density, (2) differences in phantom 
dimensions, i.e. width and thickness, (3) the discrete locations of TLDs within 
physical phantoms, and (4) measurement and calibration errors.  
The density of soft tissues and bones are similar for PCXMC and ATOM phantoms 
(see Table 7.1 at the beginning of the chapter), except for the new born model, in 
which bone density is around 13% lower in PCXMC. Lung density, however, is 
significantly different, being around 43% higher in PCXMC. The effect of this 
difference in density was investigated analytically, by considering the reduction in x-
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ray intensity (I) from its initial value (I0) as it passes through an attenuator of 
thickness x, approximated by Beer’s law: 
𝐼 = 𝐼0𝑒
−𝜇𝑥 
Where µ is the linear attenuation coefficient, which is dependent on material and 
photon energy. The mean intensity through an attenuator of thickness t is therefore: 
𝐼 ̅ =
1
𝑡
∫ 𝐼0𝑒
−𝜇𝑥
𝑡
0
𝑑𝑥 
= 𝐼0
1
𝑡
(
1
𝜇
−
𝑒−𝜇𝑡
𝜇
) 
Where µ is the linear attenuation coefficient, which is dependent on material and 
photon energy. A mass attenuation coefficient (µ/ρ)  for ICRU-44 lung tissue of 0.227 
cm2 g-1 at  50 keV, quoted by the Physical Measurement Laboratory [287] was used. 
The linear attenuation coefficient was therefore obtained by multiplying this by the 
respective lung density values. Three lung densities were analysed based on the 
values used in PCXMC (0.3 g cm-2), standard ATOM phantoms with inspiration lung 
density (0.21 g cm-2), and ATOM phantoms with expiration lung density (0.5 g cm-2). 
X-ray intensity relative to the initial unattenuated level as a function of lung thickness 
is shown in Figure 7.6, revealing a difference in attenuation patterns between 
different lung densities. Note that the attenuation curve for the PCXMC lung density 
lies approximately midway between the ATOM inspiration and expiration density 
curves. If the lung density is lower, then the x-ray beam will undergo less attenuation 
before reaching TLD locations in the lungs and other tissues. The resulting higher x-
ray intensity at TLD positions would result in higher recorded doses. However, to 
account for a 100% increase in dose, the beam would need to traverse around 30 cm 
of lung tissue. The thickness of lung tissue traversed in the phantoms considered in 
this study was considerably less than 30 cm, especially for the new born phantom, in 
which the heart may be reached by the beam following the traversal of only around 2-
3 cm of lung tissue. In this case, the intensity of radiation reaching the heart would be 
higher by little more than 10% for the low density lungs used in physical phantoms. 
Thus differences in lung density are unlikely to account for the large discrepancy in 
doses between MC and physical methodologies. 
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Figure 7.6: Attenuation of a mono-energetic (50 keV) x-ray beam through lung tissues of 
three different densities – 0.21, 0.3 and 0.5 g cm-3, representing different levels of inspiration. 
 
Aside from the difference in lung density, the ATOM phantoms, while having similar 
anterior-posterior thorax dimensions to the equivalent PCXMC mathematical 
phantoms, have somewhat narrower thoracic width (Table 7.1, again). This is 
especially the case for the 5 and 10 year old phantoms, in which the ATOM 
phantoms are 13% and 16% narrower respectively. The mean intensity to a given 
tissue decreases as the tissue thickness is increased. Based on the same Beer’s law 
relationship above, the difference in mean x-ray intensity between thicknesses t and 
t’ were calculated as follows: 
% 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
(
1
𝑡 ∫ 𝐼0𝑒
−𝜇𝑥𝑡
0
) − (
1
𝑡′
∫ 𝐼0𝑒
−𝜇𝑥𝑡′
0
)
(
1
𝑡′
∫ 𝐼0𝑒−𝜇𝑥
𝑡′
0
)
∗ 100 
=
𝐼0
1
𝑡 (
1
𝜇 −
𝑒−𝜇𝑡
𝜇 ) − 𝐼0
1
𝑡1
(
1
𝜇 −
𝑒−𝜇𝑡
1
𝜇 )
𝐼0
1
𝑡1
(
1
𝜇 −
𝑒−𝜇𝑡1
𝜇 )
∗ 100 
Based on the difference is phantom widths, mean x-ray intensity should be higher for 
the narrower ATOM phantoms by between 3% and 15% depending on phantom size.  
Variation in liver and stomach doses between physical and Monte Carlo 
methodologies may be related to the shape of the lungs represented in respective 
phantoms. In PCXMC, the diaphragm is flat (Figure 7.7). This happens to people 
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who have smoked for decades and have developed emphysema [288]. In normal, 
healthy individuals, the diaphragm is dome shaped, both in the sagittal and coronal 
planes [249]. The diaphragm does flatten during inspiration, but never to the extent 
shown in Figure 7.7. A more realistic lung shape is used in the ATOM 
anthropomorphic phantoms, with some TLD locations representing the liver and 
stomach being found superior to the lung bases. As the liver extends upwards to a 
greater degree in the ATOM phantoms, it would be expected that measured doses 
would be higher for cardiac imaging.  
 
 
Figure 7.7: The unrealistic relationship between the lungs and the liver in PCXMC 2.0. Image 
credit: author generated PCXMC screengrabs 
 
TLD calibration was only performed at a single energy (661 keV), and not repeated at 
photon energies more relevant to cardiac fluoroscopy (i.e. 30-100 keV). Brady [248] 
compared TLD calibration factors obtained using a linear accelerator at 6 MV with 
those obtained using a Therapax S3 SXRT superficial radiotherapy unit at 120 kV 
and 1.1 mm Al and 0.3 mm Cu filtration (HVL=8.1 mm Al). On average, the latter 
calibration factors were higher by 4.2%. Other general uncertainties in TLD dosimetry 
must also be considered. Nunn et al [289] found TLD response as a function of 
photon energy to differ from Monte Carlo simulations by up to 13%, due to 
complications in solid state physics of TLD materials. Harris et al [290] studied 
linearity of dose response for LiF:Mg:Ti (used in this study) and LiF:Mg:Cu:P TLD 
crystals. Although some departure from linearity was found, this occurred at large 
doses, approaching 5% at 400 cGy.  
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None of the variations in phantom dimensions and density and TLD calibration errors 
and uncertainties  discussed above offers a satisfactory explanation for differences in 
recorded dose between computational and physical methodologies, either in isolation 
or when combined. Nor do these variations explain the difference in agreement of 
physical measurements with Monte Carlo results between the two phases of 
phantom exposures. The two machines used for physical measurements differ in a 
number of ways, including beam energy (Axiom Artis is higher) and field shape 
(BV300 fields are circular), though neither of these factors explain why the large 
discrepancies were found in the lateral projection only. The Axiom Artis used in the 
first phase of physical measurements is a biplane machine, while the Philips BV300 
is not. Biplane machines have one capability not shared by single plane units – they 
can irradiate in two different projections at the same time. An unexpectedly large 
dose recorded for exposures in the lateral projection could be explained if the 
machine was also irradiating in the frontal plane. In fact, if the PA and lateral dose 
estimates derived using cardiodose are combined, the agreement with the lateral 
physical measurements using the Axiom Artis becomes close. The double-exposure 
problem would not have occurred for PA projection measurements as the lateral tube 
was always fully retracted. 
 
7.3.1: Comparison with previous research 
Three other studies using physical measurements were compared. Firstly, Axelsson 
and colleagues [84] calculated organ doses for two different paediatric phantom 
sizes (1 and 5 years) and for 10 different beam angles, including straight PA and left 
lateral. Exposures were carried out using relatively old equipment (Philips Optimus 
2000, Eindhoven, Netherlands), with a total filtration of 3.0 mm Al and a tube 
potential ranging from 58 to 70 kVp. Doses were measured using thermoluminescent 
dosemeters. In a second, more recent study, Barnaoui et al [92] calculated doses to 
the breasts, lungs, thyroid and oesophagus for 5 cardiac catheterizations, by 
reconstructing them using CIRS ATOM family phantoms. Doses were again 
measured using TLDs. For two of the reconstructions, multiple beam angles were 
used and it was not possible to determine the contribution to total organ dose from 
each projection. For the remaining three – two using the PA projection, and one using 
the left lateral projection, the results could be compared with those of the current 
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study. Finally, Kawasaki et al [116] calculated organ doses using 0 and 1 year CIRS 
ATOM phantoms, silver activated phosphate glass dosemeters and Philips Allura 9 
fluoroscopy equipment , in two projection (PA and lateral).   
The results of these studies, converted to organ dose per unit PKA, are presented in 
Table 7.6, along with equivalent physical measurements from the current study. 
There is a greater level of agreement between the figures presented by Axelsson et 
al and those of the current study for the PA projection. Differences in beam energy 
would explain the degree to which doses for the 1 year phantom are higher in the 
current study (50-100%), but not for the 5 year phantom, in which there is an 
unexpectedly close agreement between the two studies. Discrepancies in liver and 
stomach doses are presumably due to different levels of collimation and beam 
centring. Doses for the lateral projection were generally much higher in the current 
study, by a factor greater than could be explained by beam energy alone. Dose to the 
oesophagus was 3.7 and 4.7 times higher in the current study for the 1 and 5 years 
phantoms respectively. This discrepancy is consistent with the earlier theory that 
doses for the lateral projection in the current study are overestimates due to 
exposure in two planes. The figures calculated by Barnaoui et al [92] were based on 
the same equipment as used in the current study, thus ought be more comparable. 
Doses per unit PKA are generally lower than those of the current study, however, 
most notably for the breasts. Only Kawasaki et al calculated organ doses for the new 
born phantom size. With the exception of the thyroid, doses were lower than those of 
the current study for both projections. This is despite the involvement of higher beam 
energy (HVL=6.4-6.7 mm Al). The overall patterns of higher doses for the lateral 
projection and lower doses with increasing phantom size were consistent, however. 
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Posteroanterior Left lateral 
Age Organ Axelsson Barnauoi Kawasaki This study Axelsson Barnauoi Kawasaki This study 
0
 y
e
ar
s 
ABM     1.7 2.6     1.8 2.5 
Breasts   
 
4.0 4.7   
 
11.8 4.8 
Lungs   
 
6.0 13.1   
 
9.8 24.3 
Oesophagus   
 
6.0 10.7   
 
11.2 19.3 
Thyroid   
 
4.9 1.7   
 
4 2.0 
Liver   
 
0.9 1.6   
 
2.2 14.1 
Stomach     0.7 2.8     1.3 7.3 
1
 y
e
ar
 
ABM 0.8   0.9 1.4 1.1   1.1 1.1 
Breasts 1.6 1.7 2.9 4.3 3.8 
 
9.4 9.3 
Lungs 6.3 5.5 4.4 8.6 8.5 
 
6.6 14.1 
Oesophagus 3.1 4.4 3.6 6.3 3.7 
 
6.9 17.7 
Thyroid 0.2 0.5 1.9 0.4 0.3 
 
2.3 0.5 
Liver 0.7 
 
0.7 1.0 2.6 
 
0.9 1.5 
Stomach 2.6   0.6 1.8 4.1   0.6 3.2 
5
 y
e
ar
s 
ABM 0.8     0.6 0.4     0.8 
Breasts 1.8 
  
  3.7 1.3 
 
17.0 
Lungs 4.1 
  
4.3 2.3 4.7 
 
8.1 
Oesophagus 2.6 
  
2.7 1.9 3.2 
 
7.0 
Thyroid 0.3 
  
  0.3 0.6 
 
0.61 
Liver 0.4 
  
0.3 0.6 
  
1.3 
Stomach 0.2     0.3 0.1     0.6 
1
5
 y
e
ar
s 
ABM       0.4         
Breasts   0.1 
 
0.5   
  
  
Lungs   0.4 
 
1.5   
  
  
Oesophagus   0.6 
 
0.8   
  
  
Thyroid   0.1 
 
0.1   
  
  
Liver   
  
0.4   
  
  
Stomach       0.2         
 
Table 7.6: Organ doses, in mSv, per unit PKA calculated using physical measurements in 
three previous studies, compared to the current. 
 
7.4: Partial organ doses 
The organ doses presented in this chapter represent the mean for the whole organ. 
However, energy would not be expected to be imparted evenly within large organs; 
the heart is in the left lower portion of the chest, therefore the left lower lobe of the 
lungs would be expected to receive a higher dose than other lobes, the distal 
oesophagus would receive a higher dose than the proximal, and the fundus of the 
stomach would receive a higher dose than the pylorus. The results of Monte Carlo 
simulations in PCXMC are always presented as mean organ doses and cannot be 
expressed as partial organ doses. Physical measurements in phantoms do not have 
this restriction, thus allow doses to be characterised in greater detail. 
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According to the linear no threshold (LNT) model describing the supposed 
relationship between radiation dose and associated risk of cancer, uneven dose 
distribution is immaterial – one lung receiving a mean dose of 10 mGy would result in 
the same risk as both lungs receiving 5 mGy each (assuming they are of equal size). 
The introduction of the concept of a ‘dose and dose rate effectiveness factor’ 
(DDREF) – a reduction in risks, typically by a factor of 1.5 or 2.0 [3, 44], where doses 
are less than 200 mGy or delivered at a low dose rate – could be interpreted as an 
admission that some level of non-linearity exists. If the left lung receives a dose of 
250 mGy, while the right receives 50 mGy, then the equivalent lung dose would be 
150 mSv and no DDREF would be applied, despite the left lung receiving more than 
200 mGy. From an epidemiological perspective, partial organ dosimetry may allow 
alternative insights into the cancer risks from exposures. The uneven dose 
distribution within large organs should be matched by an uneven distribution of 
associated excess cancers. For example, if the dose to the left lower lobe of the 
lungs is consistently higher than for other lobes, then associated excess cases of 
lung cancer would be expected to occur more frequently in the left lower lobe than 
other lobes.  
ATOM phantoms do not have delineated ‘lobes’ of the lungs, though it is 
straightforward to analyse dose separately for left and right lungs, as well and left 
and right breasts. The results of this analysis (Table 7.7), for phase 1 figures, show 
that the left lung receives a higher dose than the right in the PA projection, while the 
situation is reversed for the left lateral projection with the right lung receiving a 
considerably higher dose. The right/left lung dose ratio increases with phantom size 
for the lateral projection, ranging from 2.2 at 0 years to 10.1 at 15 years. For 
examinations in which a 50/50 proportion of PA and lateral projections is used, the 
right lung would receive a higher dose than the left, by a factor ranging from 1.6 to 
5.4.  
These patterns were similar for breast dose. The right breast receives a considerably 
higher dose than the left in the lateral projection. Left and right breast doses were 
almost identical in the PA projection for the 1 and 15 year phantoms, while the left 
breast received almost twice the dose of the right for the 10 year phantom. 
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Lungs Breasts 
Phantom 
size 
Projection 
R/L 
ratio 
Mean R/L 
ratio 
R/L 
ratio 
Mean R/L 
ratio 
0 years 
PA 0.97 
1.59 
n/a 
n/a 
Lat 2.22 2.61 
1 year 
PA 0.92 
2.00 
0.99 
2.18 
Lat 3.08 3.37 
5 years 
PA 0.57 
1.93 
n/a 
n/a 
Lat 3.29 8.65 
10 years 
PA 0.63 
2.98 
0.57 
4.47 
Lat 5.33 8.36 
15 years 
PA 0.79 
5.43 
1.09 
3.19 
Lat 10.06 5.30 
 
Table 7.7: Comparison of doses to left and right lungs and breasts 
 
Dose to the lungs was also analysed on a slice-by-slice basis. As would be expected, 
given the inferior location of the heart in the chest, dose increases towards the lung 
bases and decreases towards the apices. The ratio between apical and basal lung 
dose tended to be greater for the lateral projection, reaching a value of more than 11 
in some cases (Figure 7.8). There was a small suggestion of a greater apex/base 
ratio with increasing phantom size, though the steepest gradient was found for the 10 
year phantom. 
 
Figure 7.8: Variation in lung dose with slice, relative to dose at the apex. 
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7.5: Conclusion 
The aim of this chapter was to verify the results of computational dosimetry (i.e. 
Monte Carlo simulations). This was only partially achieved. The results of the 
physical measurements were in reasonable agreement with MC-based Cardiodose 
in the PA projection, but were much higher in the lateral projection. A number of 
explanations are possible, including anatomical variation (differences in the size, 
shape and density of organs) and experimental error. The unusually high doses 
recorded for the left lateral projection using the biplane Siemens Axiom Artis were 
not replicated using the single plane Philips BV300. A likely explanation is that the 
phantoms were in fact irradiated using both imaging planes, resulting in 
approximately twice the anticipated dose. 
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Chapter 8: Organ doses 
With the ‘Cardiodose’ dosimetry system and supporting information on beam angles 
and x-ray energy in hand, organ doses could be estimated for cohort members using 
details recorded at the time of the examination. This chapter presents the results of 
such organ dose estimates, before comparing these figures to previous research and 
assessing uncertainties.  
 
8.1: Methodology 
Equivalent doses to the breasts, lungs, oesophagus, thyroid, stomach, liver, bone 
marrow and heart, along with effective dose and mean whole body dose were 
estimated for 14,934 examinations where patient age (n=14,775) or mass 
(n=13,382), dose indicators (kerma area product or screening time) and examination 
type were recorded. Only data obtained from Hospital 1 had usable biplane PKA 
figures. Those recorded at Hospital 4 were not considered reliable and only total PKA 
(e.g. frontal and lateral combined) was utilised. 
There were 1385 procedures conducted at Hospital 1 before 2000 where PKA was not 
recorded, but where screening time (ST) and patient mass or age were. Various 
methodologies for estimating PKA in these cases were investigated. Two linear 
models were calculated based on the median PKA, where it was recorded in this era, 
per minute screening time, per kilogram body mass (PKA/ST/kg), or per year of age 
(PKA/ST/age). These models were calculated for different age ranges (Figure 8.1) 
and polynomials fitted, to provide alternative models. The four models were applied 
to situations in which PKA was recorded, allowing the difference between actual and 
estimated PKA to be determined.  
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Figure 8.1: Relationship between PKA/ST/kg and PKA/ST/age and patient size. The age model 
was restricted to beyond 1 year. Below this age, the model rises rapidly, tending to infinity as 
age approaches zero. 
 
The median absolute errors were 39%, 47%, 35% and 41% for the linear mass, 
linear age, polynomial mass and polynomial age models, respectively. The 
respective 95th percentiles for these errors were 133%, 223%, 147% and 166%. Both 
age models resulted in extremely large errors below 1 year, while for the mass 
polynomial model, errors for patients below 10 kg were similar to other ages. The 
mass polynomial was the preferred approach, although for 27 examinations in which 
mass was not recorded, the age polynomial model was used. The estimation of 
doses from screening time results in the introduction of large uncertainties, though 
was still preferable to simply assigning average doses to these examinations. This 
approach was unavoidable for a large number of procedures conducted Hospital 4, 
and will be described in section 8.5 of this chapter. 
Cardiodose produces breast dose estimates for all patients, regardless of gender. All 
male patients in the cohort were identified and breast doses for these examinations 
were deleted. All breast doses were removed for patients examined at Hospital 6 as 
it was not possible to determine gender (neither sex nor Christian name were 
recorded). As with the raw PKA data, a MATLAB function was written to organise the 
output from Cardiodose to provide age, mass and procedure type stratification. 
Where patients underwent multiple procedures during the data collection period, 
these doses were added together to produce cumulative organ doses in addition to 
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individual examination doses. The total energy imparted to the patient, in millijoules 
(mJ), was calculated by multiplying the mean whole body dose by the patient mass. 
 
8.2: Results 
A summary of organ doses for all procedure types and from all hospitals combined is 
given in Table 8.1, stratified by both patient mass and age. More examinations are 
included in the age stratified data, and these figures are somewhat lower than where 
mass stratification is applied. These differences are due to the inclusion of 
examinations conducted at Hospitals 5 and 6, which not only lacked records of 
patient mass, but which also delivered generally low doses. Table 8.2 shows these 
data stratified by hospital and data collection era, but without mass stratification. 
More comprehensive tables with breakdown by procedure type and patient age are 
presented in appendix 3.  
Across the whole cohort, where patient age was recorded, and excluding procedures 
with zero dose, the median effective dose was 5.0 mSv. The median effective dose 
was a little higher for males (5.3 mSv) compared to females (4.7). As with PKA and 
screening times, organ doses were right skewed, with mean doses being almost 
twice as high as median (10.2 and 8.9 mSv for males and females respectively). The 
distribution of effective dose is shown in Figure 8.2, which is stratified by procedure 
type (unspecified procedures are not included). Figures 8.3 and 8.4 show this 
distribution in greater detail for low dose and high dose regions respectively. The 
median cumulative effective dose, for the whole cohort, was 6.2 mSv, and 8.2, 20.6, 
11.8, 8.8, 18.7, 19.2, 14.8 and 16.6 mSv for patients identified as having a history of 
transplantation, Tetralogy of Fallot, transposition of the great arteries, Down 
syndrome, Norwood procedure, Fontan procedure, hypoplastic ventricles and valve 
atresia, respectively. 
A more detailed analysis was conducted of the procedures with especially high or 
low doses. There were 279 procedures delivering an effective dose of less than 0.2 
mSv, of which 65 were pacemaker insertions/revisions, 50 were electrophysiology 
studies (EPS), 44 were heart biopsies and 80 were unspecified cardiac 
catheterizations. The large majority (91%) of these procedures were carried out 
using 3rd generation fluoroscopy machines. There were 898 procedures with an 
effective dose of less than 0.5 mSv; 105 pacemakers, 95 ASD occlusions, 156 
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EPS/ablations, 188 Biopsies and 213 unspecified. Again, 91% were carried out using 
3rd generation equipment. There were 100 procedures delivering an effective dose of 
more than 100 mSv, 95 of which involved 1st and 2nd generation equipment. The 
majority of these procedures (n=63) were unspecified cardiac catheterizations. 
Fourteen procedures delivered an estimated effective dose of over 200 mSv.  
The organs receiving the highest doses were the lungs (median for whole cohort 
=15.5 mSv), heart (11.8 mSv) and oesophagus (10.1 mSv). Estimated breast doses 
were high in examinations involving laterally orientated projections, but were low 
where these projections tended to be avoided. This was the case for a number of 
common procedure types including pacemaker insertions, biopsies (PA projection 
only), coronary angiography and EPS procedures. Doses to bone marrow and lymph 
nodes were relatively low at 2.3 and 3.0 mSv, respectively. For more recently 
acquired data, bone marrow doses were around 1 mSv. Thyroid doses were 
especially low and rarely exceeded 1 mSv for recent examinations.  
The relationship between dose and patient size (age or mass) varied between 
organs. In general, the relationship is similar to that for PKA normalised by mass, 
tending to display a lop-sided ‘U’ shaped pattern overall (Figure 8.5). For those 
hospitals that omit antiscatter grids for small patients, organ doses tended to 
increase with increasing patient size. Dose to the thyroid and breasts were almost 
always seen to decrease with increasing patient size (Figure 8.6). The average 
absorbed dose to the body was also found to decrease with increasing patient size, 
while the total energy imparted increased (Figure 8.7). On average, the effective 
dose was higher than the mean whole body dose by a factor of 1.73 (standard 
deviation = 0.22, 5th/95th percentiles = 1.16/2.17).  
Many of the patterns evident from analysis of organ doses are similar to those for 
PKA. A fall in organ doses between successive data collection eras is apparent, 
although the magnitude of organ dose reduction is somewhat less than that for PKA. 
For example, median effective dose was seen to fall by a factor of around 10 
between 1994-2000 and 2002-2008 eras at Hospital 1 (Table 8.2), compared to a 
reduction by a factor of around 20 for PKA.  
234 
 
 
Patient mass range (kg) 
 
<5 5-12.5 12.5-25 25-45 45-65 >65 All 
Effective dose 5.7 [2.1 : 15.3] 6.2 [2.5 : 14.3] 5.5 [2 : 13.3] 5 [1.7 : 12.3] 5 [1.9 : 12.2] 5 [1.9 : 13] 5.6 [2.1 : 13.5] 
Bone marrow 2.3 [0.9 : 6.2] 2.3 [0.9 : 5.4] 2.2 [0.9 : 5.1] 2.6 [1 : 6.4] 3.6 [1.4 : 8.3] 5 [1.9 : 11.3] 2.6 [1 : 6.2] 
Breasts 13.8 [5.3 : 37.3] 16 [6.3 : 36.6] 13.7 [4.5 : 33.5] 11.2 [2.2 : 33.9] 9.7 [1.6 : 28.3] 6.5 [1.3 : 26.2] 13.2 [4.1 : 33.6] 
Heart 13.7 [5.3 : 36.1] 14.4 [5.7 : 31.9] 12.3 [4.7 : 28.4] 11.5 [4.5 : 27.5] 12.1 [4.9 : 26.9] 13.3 [5.2 : 28.5] 13 [5.1 : 29.7] 
Lungs 16.9 [6.3 : 46.6] 18.2 [7.2 : 42.4] 16.6 [6.3 : 40.2] 15.3 [5.5 : 37.4] 17.3 [6.7 : 40.4] 16.9 [6.5 : 39.8] 17 [6.5 : 41.1] 
Lymph 3.5 [1.3 : 9] 3.8 [1.5 : 8.5] 3.3 [1.3 : 7.6] 2.8 [1.1 : 6.6] 2.9 [1.1 : 6.5] 3 [1.2 : 6.7] 3.3 [1.3 : 7.6] 
Oesophagus 13.3 [5.1 : 33.6] 13 [5.2 : 29] 10.8 [4.2 : 25] 8.7 [3.3 : 20.1] 9.5 [3.9 : 20.8] 10.6 [4.2 : 22.9] 11.1 [4.3 : 25.6] 
Thyroid 1.2 [0.5 : 3.1] 1.1 [0.4 : 2.3] 0.7 [0.3 : 1.5] 0.4 [0.2 : 0.9] 0.3 [0.1 : 0.7] 0.2 [0.1 : 0.4] 0.6 [0.2 : 1.5] 
Liver 4.9 [1.9 : 12.6] 6.2 [2.5 : 13.8] 5.5 [1.9 : 12.5] 4.1 [1.3 : 10.4] 4.1 [1.3 : 10.4] 4.4 [1.5 : 11.3] 5.2 [1.8 : 12.2] 
Stomach 2.8 [1.1 : 7.1] 3.1 [1.2 : 6.7] 2.5 [1 : 5.5] 1.9 [0.7 : 4.2] 1.5 [0.6 : 3.3] 1.6 [0.6 : 3.4] 2.3 [0.9 : 5.3] 
n 1453 3759 3327 2095 1772 777 13183 
 
 
Patient age range (years) 
 
<1 1-5 5-10 10-16 16-18 18-22 All 
Effective dose 5.5 [2.1 : 13.1] 5.3 [2.1 : 12.9] 5 [1.6 : 12.3] 4.5 [1.5 : 11.2] 4 [1.3 : 10.7] 5.2 [1.5 : 15.6] 5 [1.8 : 12.3] 
Bone marrow 2.1 [0.8 : 5.1] 2 [0.8 : 4.8] 2.1 [0.8 : 5.2] 3 [1.1 : 7.1] 3.3 [1.2 : 7.9] 4.7 [1.3 : 12.2] 2.3 [0.9 : 5.8] 
Breasts 13.4 [5.3 : 32.4] 13.8 [5.2 : 33.6] 11.6 [3.1 : 30.5] 9.1 [1.6 : 28.1] 6 [1 : 24.4] 6.4 [1.9 : 35.1] 11.8 [3.5 : 31.1] 
Heart 12.9 [5.1 : 30.5] 12.1 [4.9 : 28.2] 11.2 [4 : 26.8] 11 [4.2 : 25.3] 10.2 [3.6 : 23.5] 12.2 [3.9 : 32] 11.8 [4.5 : 27.7] 
Lungs 16.2 [6.1 : 38.9] 15.8 [6.2 : 38.5] 15.1 [5.2 : 37.2] 14.8 [5.4 : 35.9] 13.5 [4.7 : 34.3] 17.6 [5.2 : 51.1] 15.5 [5.7 : 37.7] 
Lymph 3.3 [1.3 : 7.8] 3.2 [1.3 : 7.6] 2.9 [1 : 7] 2.6 [1 : 6] 2.4 [0.9 : 5.7] 3 [0.9 : 8.3] 3 [1.1 : 7.1] 
Oesophagus 12.1 [4.7 : 28.5] 10.7 [4.3 : 25.2] 9.4 [3.3 : 22.4] 8.4 [3.2 : 19.3] 8.1 [2.9 : 18.3] 9.8 [3.2 : 26.8] 10.1 [3.9 : 23.7] 
Thyroid 1.1 [0.4 : 2.5] 0.8 [0.3 : 1.8] 0.5 [0.2 : 1.2] 0.3 [0.1 : 0.7] 0.2 [0.1 : 0.5] 0.2 [0.1 : 0.7] 0.6 [0.2 : 1.4] 
Liver 5 [1.9 : 11.6] 5.6 [2.1 : 12.9] 4.6 [1.4 : 11.2] 3.8 [1.2 : 9.6] 3.3 [0.9 : 9.5] 4.5 [1.1 : 13.3] 4.7 [1.6 : 11.3] 
Stomach 2.7 [1 : 6.2] 2.5 [1 : 5.9] 2.1 [0.8 : 4.9] 1.5 [0.6 : 3.5] 1.3 [0.5 : 2.9] 1.6 [0.5 : 4.3] 2.1 [0.8 : 4.9] 
n 3584 4164 2414 3261 819 375 14617 
 
Table 8.1: Median estimated organ doses, in millisieverts [interquartile range] for whole cohort and all procedure types combined. The upper 
table presents figures stratified by mass, while the lower table presents figures stratified by age. 
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Organ Hospital 1 94-00 Hospital 1 99-01 Hospital 1 02-08 Hospital 1 07-10 Hospital 2 04-08 Hospital 2 08-13 
Effective dose 22.3 [13.6 : 35.7] 11.9 [6.2 : 21.7] 1.9 [0.8 : 4.2] 2 [1 : 4.4] 8.2 [4.6 : 14] 6.5 [3.5 : 11.4] 
Bone marrow 10.3 [6.3 : 16.7] 5.8 [2.9 : 10.8] 1 [0.4 : 2.1] 1 [0.5 : 2.6] 3.5 [2 : 6.1] 2.7 [1.5 : 4.8] 
Breasts 56 [26.3 : 96.5] 26 [11.3 : 49.3] 3.2 [1 : 9.7] 3.6 [1.4 : 10.4] 21.7 [11.1 : 37.9] 17.2 [8.8 : 30.1] 
Heart 45.8 [28.4 : 73.3] 27.8 [14.4 : 49.3] 4.9 [2.2 : 10.3] 5 [2.5 : 10.9] 18.7 [10.7 : 31.3] 15.4 [8.4 : 26.8] 
Lungs 70.2 [43.4 : 112.1] 37.3 [19.7 : 67.7] 6.1 [2.6 : 13] 6.2 [3.1 : 14.1] 24.6 [14.2 : 41.9] 19.2 [10.5 : 33.6] 
Lymph 12.1 [7.4 : 19.7] 7.3 [3.9 : 13] 1.2 [0.5 : 2.6] 1.3 [0.6 : 2.6] 4.7 [2.7 : 7.9] 3.8 [2.1 : 6.6] 
Oesophagus 38.9 [23.5 : 64.1] 24.6 [12.9 : 42.9] 4.2 [1.8 : 8.6] 4.3 [2.2 : 8.8] 16 [9.3 : 27.1] 13.3 [7.2 : 22.9] 
Thyroid 2.1 [1 : 3.9] 1.5 [0.7 : 2.8] 0.2 [0.1 : 0.5] 0.3 [0.1 : 0.5] 1 [0.5 : 1.8] 0.9 [0.4 : 1.6] 
Liver 18.4 [10.5 : 30.4] 10.7 [5.3 : 19.8] 1.7 [0.7 : 3.8] 1.8 [0.8 : 4.1] 7.9 [4.3 : 13.5] 6.6 [3.4 : 11.3] 
Stomach 7.9 [4.6 : 13.4] 5.6 [2.9 : 10.1] 0.9 [0.4 : 1.9] 0.9 [0.5 : 1.9] 3.3 [1.9 : 5.8] 2.8 [1.4 : 4.9] 
n 2137 1039 3204 719 1615 1992 
       Organ Hospital 3 04-08 Hospital 3 08-13 Hospital 4 93-03 Hospital 4 03-13 Hospital 6 06-13 Hospital 5 05-13 
Effective dose 6 [3 : 11.1] 2.4 [1.3 : 4.9] 7.4 [4 : 12.7] 2.7 [1.5 : 5] 1.4 [0.7 : 2.6] 1.7 [0.6 : 4.6] 
Bone marrow 2.5 [1.4 : 4.7] 1.1 [0.6 : 2.4] 3.1 [1.7 : 5.6] 1.3 [0.6 : 2.3] 0.7 [0.3 : 1.1] 0.7 [0.3 : 2.1] 
Breasts 15.9 [6.4 : 30.1] 5.9 [2.3 : 12.8] 20.3 [10.9 : 35.4] 7 [3.9 : 12.9] 3.5 [1.9 : 6.8] 4.3 [1.5 : 11.8] 
Heart 14.2 [7.4 : 25.8] 6.2 [3.2 : 11.5] 15.2 [7.8 : 25.5] 6.4 [3.5 : 11.8] 3.2 [1.6 : 6] 4.1 [1.5 : 11.2] 
Lungs 18.2 [9.5 : 32.9] 7.6 [4 : 15.3] 23.2 [12.4 : 39.4] 8.3 [4.6 : 15.3] 4.1 [2.2 : 7.8] 5.1 [1.9 : 14.2] 
Lymph 3.5 [1.8 : 6.4] 1.5 [0.8 : 2.8] 4.1 [2.1 : 6.9] 1.6 [0.9 : 2.9] 0.8 [0.4 : 1.6] 1 [0.4 : 2.8] 
Oesophagus 12.5 [6.3 : 22] 5.2 [2.7 : 9.7] 13 [6.8 : 22] 5.4 [3.1 : 10] 2.8 [1.4 : 5.3] 3.6 [1.2 : 9.9] 
Thyroid 0.8 [0.3 : 1.6] 0.3 [0.1 : 0.6] 0.7 [0.3 : 1.4] 0.4 [0.2 : 0.7] 0.2 [0.1 : 0.4] 0.2 [0.1 : 0.7] 
Liver 5.9 [2.7 : 10.9] 2.4 [1.2 : 4.8] 6.3 [3.3 : 10.7] 2.5 [1.4 : 4.6] 1.3 [0.7 : 2.6] 1.6 [0.6 : 4.8] 
Stomach 2.7 [1.3 : 4.8] 1.1 [0.6 : 2] 2.7 [1.4 : 4.7] 1.1 [0.7 : 2.2] 0.6 [0.3 : 1.2] 0.7 [0.2 : 2] 
n 842 1407 817 496 354 738 
 
Table 8.2: Median organ doses in millisieverts [interquartile range] for all procedures and patient sizes combined, stratified by hospital and data 
collection era. 
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Figure 8.2: Distribution of effective doses, stratified by procedure type. 
 
 
Figure 8.3: Distribution of effective doses in the 0-3.0 mSv range 
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Figure 8.4: Distribution of effective doses between 20 and 100 mSv. 
 
 
 
Figure 8.5: Median and mean effective dose for all procedure types combined, as a function 
of patient mass, for examinations conducted using Siemens Axiom Artis or Artis Zee 
machines. 
 
238 
 
 
Figure 8.6: Median and mean thyroid dose for all procedure types combined, as a function of 
patient mass, for examinations conducted using Siemens Axiom Artis or Artis Zee machines. 
 
 
 
Figure 8.1: Total energy imparted in millijoules for all procedure types combined, as a 
function of patient mass, for examinations conducted using Siemens Axiom Artis or Artis Zee 
machines. 
 
8.3: Discussion 
The finding that the breasts, oesophagus, heart and lungs receive the highest doses 
from cardiac catheterizations is unsurprising considering the thoracic location of the 
field of primary irradiation. The doses to these organs were very high for procedures 
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conducted before 2000 at Hospital 1, though have fallen to reasonably low levels 
with the installation of new equipment. 
Cancers of the lungs and breasts have previously been strongly associated with 
radiation exposure [7, 139, 158, 291], with oesophageal cancer appearing to be more 
moderately inducible [7, 45]. While there is currently no evidence of the ability of 
radiation to induce cardiac tumours, there is evidence of an association between 
radiation exposure and other cardiovascular disease [3]. From an epidemiological 
perspective however, searching for evidence of heart disease among patients treated 
for heart disease is likely to be especially challenging. The relatively low doses to 
active bone marrow and the thyroid gland are significant findings as radiation 
exposure to both tissues is strongly associated with cancer development, especially 
in children [7, 292-294].  
The relationship between patient size and organ doses is noteworthy. In Chapter 3 
(section 3.5.1), it was noted that PKA is positively correlated with patient size (mass or 
age). The relationship between organ doses and patient size is more complex and 
was seen to vary between organs and the era in which the examination was 
conducted. The upturn in dose as patient size is reduced below around 10 kg 
(approximately 1 year) possibly suggests overexposure of small patients and a 
failure of equipment to properly adjust exposure factors to match attenuator 
thickness. The use of antiscatter grids for all patient ages was associated with a 
pattern of highest doses among the smallest patient sizes. Further research is 
warranted to determine if doses for these patients can be reduced without 
compromising image quality. The fall in thyroid dose with increasing patient size is 
most likely due to the increasing distance between the thyroid and the primary 
irradiation field. Effective dose was always higher than the average absorbed dose to 
the whole body. This is to be expected given the high density of organs with large 
effective dose tissue weighting factors in the chest region.   
The effective doses for paediatric cardiac catheterizations carried out in the last 10 
years were somewhat higher than those for cardiac computed tomography (CT) 
(Table 8.3). For example, Gherardi et al [111] estimate a median effective dose for 
paediatric cardiac CT of 1.7 mSv (IQR 0.8 : 2.4), while the equivalent figure 
calculated by Watson et al [167] was 0.74 mSv (range: 0.43–15.31). Doses from 
cardiac CT depend on the techniques used for gating (matching scan acquisition to 
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heart rhythm), tending to be lower for prospectively gated rather than retrospectively 
gated scans [165, 166]. Lee and co-workers [166] used a 1-year old ATOM 
anthropomorphic phantom and thermoluminescent dosemeters to calculate organ 
doses delivered by both 64 and 256 slice CT using different gating techniques (Table 
8.3). Typical effective doses for cardiac CT of 1-3, 2-6 and 0.2-1.0 mSv were 
reported by Goo [165] for high pitch dual source scanning, retrospective gating and 
prospective gating protocols respectively. Thus there is a sizeable variation in quoted 
doses for cardiac CT depending on equipment and imaging protocol, although this 
variation appears smaller than that evidence for cardiac catheterization doses. As 
with fluoroscopy, there has been a fall in CT doses over the last two decades. 
Reasons for this include improved detectors, more dose efficient reconstruction 
algorithms and slice-by-slice exposure modulation (varying x-ray output to match 
local anatomy). Despite the potential to deliver lower doses, CT provides limited 
capability to conduct therapeutic intervention such as ballooning, stenting or duct 
closure.  
 
64 slice scanner 256 slice scanner 
Organ NG RGH NG RGH PGA 
ABM 1.67 5.27 2.4 7.5 1.17 
Breast 2.34 7.35 3.6 10.74 2.04 
Lung 2.26 7.5 3.16 10.66 1.8 
Oesophagus 2.18 7.21 3.13 11.29 1.96 
Thyroid 2.54 7.76 4 13.5 2.03 
Liver 1.37 4.28 2.47 5.6 0.52 
Stomach 2.15 6.47 2.6 9.95 1.39 
Effective 1.49 4.66 2.15 6.87 1.12 
 
Table 8.3: Organ doses (in mSv) for cardiac CT reported by Lee et al [166]. NG = non-gated, 
RGH = retrospective gated helical, PGH = prospectively gated helical. Both 64 and 256 slice 
machines are models of Philips Brilliance scanner (Philips Healthcare, Cleveland, OH, USA). 
 
 
8.3.1: Comparison with previous research 
At the time of writing, very few assessments of organ doses from paediatric cardiac 
catheterizations have been carried out. A larger number of studies have estimated 
effective dose [8, 12, 13, 91, 92, 103, 108, 113], though, as noted in the literature 
review, many of these assessments were based on highly simplistic E/PKA 
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conversion factors with little or no x-ray energy or beam angle adjustment. The often 
quoted E/PKA conversion factor calculated by Onnasch et al in 2007 [103] based on 
PKA normalised by mass, of 9.26 * (PKA/kg) was re-examined in the light of the 
estimated effective doses calculated in the current study. For examinations 
conducted using 3rd generation equipment (Siemens Axiom Artis or Artis Zee), the 
effective dose per PKA per kilogram was calculated for 7202 examinations of all 
types. The mean E per PKA/kg conversion factor was calculated as 20.7 (standard 
deviation = ±3.2) – more than twice the value of the coefficient reported by Onnasch. 
This difference is consistent with the use of higher beam energies than were 
assumed in the 2007 study. Although simplistic, the E/PKA conversion factor quoted 
by Onnasch offers the opportunity to provide rapid estimates of doses for a sample of 
examinations of mixed type where variation in beam angles is averaged out. The 
methodology was easily expanded to include figures for individual organs. These 
conversion factors are given in Table 8.4. They should be regarded as being 
unsuitable for dose estimation for individual procedures in which particular beam 
angle combinations are used. 
 
Conversion factor 
Organ Mean [SD] Median [IQR] 
Bone marrow 11.0 [4.9] 9.0 [7.7 : 14.0] 
Breasts 46.1 [15.8] 48.5 [35.7 : 56.4] 
Heart 53.7 [19.2] 48.9 [44.2 : 56.6] 
Lungs 65.2 [14.7] 65.0 [57.6 : 70.9] 
Lymph nodes 13 [2.8] 12.8 [11.8 : 14.0] 
Oesophagus 43.2 [8.2] 42.7 [39.5 : 45.9] 
Thyroid 2.6 [0.9] 2.7 [1.8 : 3.3] 
Liver 17.3 [5.3] 17.9 [12.9 : 21.6] 
Stomach 11.1 [4.4] 10.2 [8.5 : 11.4] 
Effective dose 20.7 [3.2] 21.1 [19.3 : 22.9] 
Mean Dose 11.9 [2.2] 11.9 [10.8 : 13.1] 
 
Table 8.4: Conversion factors in the form of effective dose or organ dose (in mSv) per PKA 
per kilogram body mass. Note: SD=standard deviation, IQR=interquartile range. 
 
Organ doses for three procedure types (occlusion of ASD, PDA and ventricular-
septal defect, VSD) were estimated by Yakoumakis and colleagues [107], using 
PCXMC V2.0. Very high mean effective doses of 40, 22 and 17 mSv were reported 
for ASD, PDA and VSD occlusions respectively. Where age matched, these doses 
are higher than those of the earliest data in the current study and higher than recent 
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era doses by a factor of almost 60. To further investigate, the doses for each 
procedure type were calculated in Cardiodose using the same patient size and total 
examination PKA reported by Yakoumakis et al, with beam angles, field size and x-ray 
energy being set at the same values as used in this study. VSD occlusions are not 
modelled in this study (the procedure is rarely carried out in the UK), therefore the 
‘unspecified’ examination category was applied. This results of this comparison are 
shown in Table 8.5. There are a number of surprisingly large discrepancies between 
the two sets of figures, most notably for thyroid dose. Organ doses calculated by 
cardiodose were higher than those of Yakoumakis for PDA occlusions, and generally 
lower for ASD or VSD occlusions. The difference in dose estimates between 
Cardiodose and Yakoumakis are difficult to explain. The field sizes are similar 
between studies, as are the x-ray energies. The projection angles reported by 
Yakoumakis are difficult to interpret, though any variation is unlikely to be sufficient to 
explain the variation in doses. The study by Yakoumakis is the only one to provide 
breast dose estimates higher than those of the current study. 
 
   
Organ   
Procedure Study PKA ABM Breasts Heart Liver Lungs Stomach Thyroid Effective 
ASD 
occlusion 
(10 years) 
Yakoumakis 
39.9 
9.9 141.1 146.8 40.8 63.7 50.6 4.1 40.0 
Cardiodose 16.8 38.8 55.7 16.4 81.4 11.4 1.9 22.7 
VSD 
occlusion 
(10 years) 
Yakoumakis 
17.5 
5.2 61.7 67.6 24.2 35.7 29.9 5.6 22.0 
Cardiodose 6.0 35.7 26.2 10.3 35.8 4.2 0.9 12.0 
PDA 
occlusion 
(new 
born) 
Yakoumakis 
9.5 
4.3 60.7 57.0 19.0 26.6 23.8 1.5 17.0 
Cardiodose 13.8 106.0 101.9 35.8 108.1 19.4 8.9 39.1 
 
Table 8.5: Organ doses (in mSv) calculated by Yakoumakis et al, compared to those 
calculated using Cardiodose for the same examination type, patient size and total 
examination PKA. 
 
Doses to the lungs, oesophagus, thyroid and breasts were estimated by Barnaoui et 
al [92]  for 5 examinations by reconstructing the procedures using CIRS ATOM 
anthropomorphic phantoms. These results were compared to the physical 
measurements obtained in the current study in the preceding chapter. Further 
comparison was made by calculating doses for each of the 5 examinations 
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reconstructed by Barnaoui et al, using Cardiodose. The results of this comparison 
are presented in Table 8.6 and show a number of striking discrepancies. There is 
little suggestion of a systematic difference, except for thyroid dose, which is higher 
for all procedures in the Barnaoui study. The largest discrepancies were for the PDA 
occlusion procedure, particularly for the breasts and lungs which were 1217% and 
357% higher, respectively, in the current study. For one procedure – a pulmonary 
valvuloplasty on a new born baby - the recorded thyroid dose was especially high (37 
mSv), based on a PKA of 6.09 Gy·cm2. This could only have occurred if the beam was 
collimated such that the thyroid was entirely within the primary field. Another unusual 
finding was a higher dose to the oesophagus for a PDA occlusion, than for the lungs 
(3.7 verses 2.2 mGy).  
 
  
Organ 
Examination Study Breasts Lungs Oesophagus Thyroid 
PA angioplasty?  
(10 kg) 
Cardiodose 9.0 9.0 6.2 0.5 
Barnaoui 4.2 13.3 10.6 1.3 
Coronaries and 
biopsy (32 kg) 
Cardiodose 2.6 19.7 12.1 0.9 
Barnaoui 21.0 42.7 26.0 1.0 
PV plasty and 
VSD occlusion 
(3.5 kg) 
Cardiodose 60.1 72.7 57.3 5.5 
Barnaoui 33.0 61.0 53.8 37.0 
ASD occlusion  
(55 kg) 
Cardiodose 2.1 7.4 4.1 0.1 
Barnaoui 4.0 14.6 10.0 2.0 
PDA occlusion  
(19 kg) 
Cardiodose 10.5 10.0 6.6 0.4 
Barnaoui 0.8 2.2 3.7 0.7 
 
Table 8.6: Organ doses (in mSv) calculated by Barnaoui et al [91] for five examinations, 
compared to doses calculated using Cardiodose using the same reported PKA, patient mass 
and examination type. 
 
Keiller and Martin [295] estimated dose to the heart from 250 cardiac catheterization 
procedures (PDA and ASD occlusions, Radiofrequency ablations, ‘balloon 
angioplasty’ and ‘cardiac catheter and angiography’) conducted between 2012 and 
2013 on patients aged 1 to 11 years. Heart dose was calculated from PKA using 
PCXMC V2.0 for ‘typical procedures’ and for the ‘highest dose’ for each examination 
type. It appears therefore that dose was not calculated for each individual procedure, 
but rather single simulations were conducted using average and maximum PKA. 
Table 8.7 compares Keiller and Martin’s results with those of the current study 
(Hospital 1 2002-2008). The former doses are considerably higher.   This is primarily 
due to the higher PKA, though heart dose per unit PKA is also higher, especially for 
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ASD occlusions. The main reasons for this difference appear to be a lower mean 
patient mass in the Keiller and Martin study and different beam energy (a Philips 
Allura Xper was used, with relatively heavy filtration and high kV, giving a half value 
layer of around 6.8 mm Al). The beam angles used are generally similar to those of 
the current study. Comparisons were not made for the ‘cardiac catheter and 
angiography’ and ‘balloon angioplasty’ procedures as it is not clear what these 
procedures actually are (many disparate procedures involve balloon angioplasty of 
some sort, and virtually all procedures involve angiography). 
 
Procedure type Study 
Mean PKA 
(Gy cm²) 
Heart dose 
(mGy) 
Mass 
(kg) 
H/PKA 
CC + 
Angiography 
Keiller and Martin 5.7 43 8.2 7.5 
Hospital 1 (02-08) - - - - 
PDA occlusion 
Keiller and Martin 3.2 31 11.8 9.7 
Hospital 1 (02-08) 1.8 6.7 14.1 5.6 
Radiofrequency 
ablation 
Keiller and Martin 4.3 13 46 3.0 
Hospital 1 (02-08) 10.1 19.9 53.0 2.5 
Balloon 
angioplasty 
Keiller and Martin 10.6 43 18.4 4.1 
Hospital 1 (02-08) - - - - 
ASD occlusion 
Keiller and Martin 5.0 23 21 4.6 
Hospital 1 (02-08) 4.4 7.4 28.6 2.3 
 
Table 8.7: Mean heart doses estimated by Keiller and Martin, compared to equivalent figures 
for the current study at Hospital 1 2002-2008. Note: CC+A is ‘cardiac catheter + 
angiography’. 
 
The above comparison with previous studies reveals large differences in dose 
estimates, though these are not systematic, i.e. doses from the current study are not 
consistently higher or lower. Variation in dose estimates reaffirms the need for 
uncertainties stemming from variation in beam energy, projection angle and other 
factors from expected values to be incorporated into dose estimates and subsequent 
risk modelling. This process is described below. 
 
8.4: Uncertainty modelling 
An assessment of the uncertainty in dose estimates is essential, especially in the 
case of estimating cardiac catheterization doses using limited data recorded at the 
time of the examination. Estimated doses are calculated from the product of PKA and 
a conversion factor to relate this figure to organ doses (CFT). The overall uncertainty 
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in dose estimates (δD) can be calculated by adding in quadrature the uncertainty of 
PKA measurements (δPKA) and uncertainty in the conversion factor (δCFT): 
𝛿𝐷 =  |𝐷|√(
𝛿𝑃𝐾𝐴
𝑃𝐾𝐴
)
2
+ (
𝛿𝐶𝐹𝑇
𝐶𝐹𝑇
)
2
 
The denominators in the above equation represent the recorded value of PKA and the 
central estimate of the conversion factor, whereas the numerators are the uncertainty 
of each. The value of δPKA was assumed to be fixed at ±15%: 
𝛿𝐷 =  |𝐷|√(15%)2 + (
𝛿𝐶𝐹𝑇
𝐶𝐹𝑇
)
2
 
By adding in quadrature, the total uncertainty is dominated by the largest individual 
component (which is usually δCFT), meaning δPKA makes little contribution. The 
uncertainty in CFT (the T stands for total) comprises the uncertainty in projection 
angle (δp) beam energy (δE), field size (δfs) and ‘anatomical variation’ (δa):  
𝛿𝐶𝐹𝑇 = |𝐶𝐹𝑇|√(
𝛿𝑝
𝑎
)
2
+ (
𝛿𝐸
𝐸
)
2
+ (
𝛿𝑓𝑠
𝑓𝑠
)
2
+ (
𝛿𝑎
𝑚
)
2
 
The value of δE and δp are based on the 5th and 95th percentiles of dose per unit PKA 
over the range of energies and projection angles seen in clinical practice. These 
figures were defined in the supporting information chapter. As stated previously, 
where biplane PKA figures are recorded, δp is effectively reduced to zero for 
procedures involving only two projection angles such as valvuloplasty or pressure 
studies. The field size uncertainty was obtained by calculating doses using each of 
the 3 simulated field sizes used in cardiodose. In many cases, the field size used in 
dose estimations resulted in either the highest or lowest dose of the three sizes 
available. Consequently, the field size uncertainty usually only affected either the 
upper or lower uncertainty limit in isolation, rather than both. 
The value of δa – the uncertainty due to ‘anatomical variation’ is not only potentially 
the largest but also the most difficult uncertainty to quantify. It encompasses variation 
in the size, shape and density of cohort members from the PCXMC phantoms used 
in dose calculations. This includes variation in lung density due to different levels of 
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inspiration and the potential change in organ density due to contrast agent 
administration.  
The potential impact of lung density was apparent in the results of physical 
measurements, in which doses were higher than predicted by Monte Carlo 
simulations. Obtaining estimates of human lung density values is difficult as few 
published data exist. Woodard [296] quotes a single figure of 260 kg m-3 (0.26 g cm-
3) for inspiratory lung density. Van Dyk et al [297] used computed tomography 
images to calculate mean inspiratory and expiratory lung densities of 0.36 and 0.20 g 
cm-3 respectively at 5 years of age. The mean of these two values is 0.28 g cm-3. The 
authors found an inverse linear relationship between age and lung density, with 
respective values at 80 years being 0.22 and 0.16 g cm-3. A similar finding of 
decreased lung density with age was reached by Long and colleagues [298], who 
found an approximately 35% difference in mean Hounsfield Unit between inspiratory 
and expiratory breathing phases in children (-835 and -616 HU respectively).  Further 
research by Brown et al [299] suggests that following termination of primary growth 
of new alveoli between 2 and 8 years of age, further ‘growth’ of the lungs is achieved 
by enlarging existing alveoli, leading to a gradual decline in lung density with age. 
Lung density in both Monte Carlo and physical phantoms is fixed. Larger lungs are 
simply modelled by more lung tissue, rather than the same amount of lung tissue 
expanded to fill a larger volume, as seems to occur in reality [299]. PCXMC V2.0 
assumes a single lung density of 0.3 g cm-3, which appears to be designed to reflect 
a central level of inspiration. Adult ‘RANDO’ phantoms (The Phantom Laboratory, 
Salem, New York) have lung density of 0.32 g cm-3 designed to “closely [mimic] the 
density of lungs in a median respiratory state” [300], while ICRU-44 lung tissue 
substitute has a density of 0.26 g cm-3 [301]. As previously stated, ATOM phantoms 
are based on an inspiration density of 0.21 g cm-3, with expiration lung densities of 
0.50 g cm-3 being available on special request. 
Usually, cardiac catheterizations in children are carried out under general 
anaesthetic, with breathing controlled via a ventilator through an endotracheal tube 
[302]. During fluoroscopic exposures, the patient is allowed to breathe normally, 
therefore radiation exposures would be distributed over a range of lung densities 
from full inspiration to full expiration. During acquisitions, the anaesthetist can switch 
the ventilator off to reduce movement and improve image quality (S. Charlton, 
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personal communication). Thus for fluoroscopy at least, the ‘central’ lung density 
value of PCXMC appears more appropriate than the inspiration lung density of 
ATOM phantoms. 
Even where patient age and breathing phase are fixed, lung density varies with 
location, being higher towards the posterior or hilum (location of the primary 
pulmonary arteries and veins) [298]. Blood makes up around 43% of lung mass 
[296]. If iodinated contrast agent has been administered, the density, and hence 
attenuating property of lung tissue will correspondingly increase. The impact of 
contrast agents on organ density and calculated doses has been studied with respect 
to radiotherapy [303-305], though little research has been carried out on the impact 
of dose estimation for diagnostic imaging. There is, therefore, insufficient information 
available to account for the impact of contrast agent administration in organ dose 
uncertainties. 
Other research has focussed on the impact of more general changes in phantom size 
and shape between phantoms and organ doses.  Zanki and colleagues [306] 
compared doses calculated using seven different adult phantom models (Adam, Eva, 
Golem, Donna, Helga, Irene, Frank, Visible Human and Voxelman) incorporated into 
Monte Carlo simulations. Variation in calculated doses for the breasts, lungs, 
oesophagus, thyroid, stomach and bone marrow were up to 30% “for those directions 
of photon incidence where the organ is located at a shallower depth” and 30-100% 
for “photon beam directions from which the organs are averted” [306]. Variation 
between models was related to photon energy, being highest below 30 keV and 
relatively low beyond 200 keV. A further study by Johnson et al [307] assessed 
variation in organ doses from adult cardiac catheterizations, calculated by Monte 
Carlo simulations (MCNPX 2.6.0) for 27 phantoms constructed using contour 
mapped CT images of real patients, compared to size-matched UF reference 
phantoms. The authors estimate a variability in dose calculations due to variation in 
organ size and location of 35-45%. Such errors can be reduced through the 
incorporation of contour mapped patient specific phantoms, especially in the case of 
organ attenuation, in which errors can be reduced by 20-60% [307]. However this 
approach is unthinkable for dose estimation in a cohort of thousands of patients. 
Obtaining cross sectional images is exceptionally time consuming and requires 
considerable cooperation from collaborating hospitals. Furthermore, such images 
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would need to be acquired at a similar age as cardiac catheterizations were carried 
out.  
As such, dose estimation errors due to ‘anatomical variation’ ought to be accepted as 
unavoidable uncertainties and combined with uncertainties from other sources. 
Central dose estimates could be improved through more realistic phantom anatomy. 
Based on the previously discussed findings of Johnson et al [307], a potential value 
for δa is around 50%, which when combined with other uncertainties results in a total 
figure for δD of around ±60%, rising to ±80% where only screening time is recorded. 
These uncertainties are large, though considerably smaller than would be present 
without any form of examination specific dose indicator being incorporated, i.e. 
simply assigning an average dose for each procedure type. The figure for δa was 
considered too speculative to incorporate into dose estimates for the current study, 
however. Consequently, the doses presented in this thesis include all uncertainties 
except for those owing to anatomical variation. Examples are given in Table 8.8 for 
the ‘unspecified’ procedure category, in which errors represent the mean of those for 
all defined procedure types. Across all patient sizes, these errors are approximately 
±25%. Combined uncertainties, stratified by patient size and procedure type are 
shown in Appendix 4. 
In this discussion, individual sources or error have been largely treated as being 
independent of each other. This can be partly justified by the relatively small impact 
of projection angle on overall beam energy represented by HVL (Section 6.1.2, 
Figures 6.10 and 6.11). In reality, it is likely that the variation in beam energy is 
principally due to anatomical variation, i.e. differences in organ size, shape and 
density affect the level of beam attenuation, causing the machine to respond by 
adjusting tube potential and filtration accordingly. Furthermore, PKA measurement 
uncertainties may be influenced, to some extent, by beam energy. Uncertainty in the 
table transmission factor should also be considered. In particular, a single figure was 
used, rather than equipment/vendor specific factors. Some level of variation would be 
expected. The transmission factor is dependent on beam angle, though this variation 
was found to be quite small (see section 6.2.6). A more detailed analysis of the 
relationship between uncertainties is beyond the capabilities of the PCXMC Monte 
Carlo code and its crude phantoms and will be left as the subject of future research.  
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Patient age 
(mass) Limit 
Effective 
dose ABM Breasts Heart Lungs Lymph Oesophagus Thyroid Liver Stomach 
Average 
dose 
<1 y (<9.2 kg) 
Upper 19% 24% 41% 34% 17% 17% 18% 20% 32% 22% 17% 
Lower -18% -24% -35% -20% -16% -17% -19% -21% -32% -27% -17% 
1-5 y (9.2-19 
kg) 
Upper 21% 22% 42% 30% 17% 19% 23% 25% 40% 24% 17% 
Lower -20% -22% -40% -24% -17% -19% -20% -25% -28% -26% -17% 
5-10 y (19-32.4 
kg) 
Upper 25% 23% 59% 41% 18% 20% 24% 24% 44% 27% 19% 
Lower -22% -22% -47% -24% -18% -20% -21% -24% -34% -31% -18% 
10-15 y (32.4-
56.3 kg) 
Upper 26% 26% 64% 37% 19% 21% 24% 27% 49% 31% 19% 
Lower -23% -26% -56% -24% -19% -21% -22% -27% -37% -35% -19% 
15-18 y (>56.3 
kg) 
Upper 24% 28% 66% 42% 20% 22% 28% 31% 58% 37% 20% 
Lower -24% -26% -63% -26% -22% -23% -25% -33% -47% -42% -19% 
>18 y (>70 kg) 
Upper 25% 28% 70% 41% 21% 23% 28% 30% 61% 40% 20% 
Lower -24% -26% -65% -26% -22% -23% -28% -32% -42% -47% -19% 
 
Table 8.8: Overall uncertainties (not including those due to anatomical variation) for ‘unspecified’ procedures. ABM = active bone marrow. 
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8.4.1: Comparison of dose estimates based on detailed and limited data 
To further investigate the accuracy of dose estimations, figures produced using 
Cardiodose and limited data (mass, single-plane PKA and examination type only) 
were compared to those produced by reconstructing 44 examinations conducted at 
Hospital 4 for which structure dose reports, containing beam angles, tube potential 
and added filtration, were available. Fluoroscopic exposures are only recorded in 
structured dose reports as the total PKA from frontal and lateral tubes, rather than in 
the form of individual beam angles. The beam angles used for fluoroscopy were 
assumed to be the same as those used for acquisitions. The proportion of 
fluoroscopic PKA in each beam angle was estimated from the respective proportions 
for acquisitions. Thus dose estimated obtained from ‘detailed’ data are still subject to 
uncertainties.  
This analysis reveals reasonably good agreement between dose estimates obtained 
from limited and detailed examination data (Figure 8.8). The latter figures generally 
are within the upper and lower uncertainty limits for the former. For some organs, the 
detailed dose estimate is marginally outside the upper uncertainty limit. The median 
absolute error was 11%, while the median signed error was -8%, indicating a small 
systematic underestimation of doses by Cardiodose. The largest error in effective 
dose for a single examination was -37%. This finding that dose estimates obtained 
using limited examination data can be reasonable approximations of those using 
detailed data is consistent with that of Karambatsakidou et al [112], where the mean 
deviation in estimated effective dose between detailed and limited data 
methodologies was 5%. 
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Figure 8.8: Comparison of doses calculated using detailed beam angle data from structured 
dose reports with estimates derived from limited data using Cardiodose. Figures for each 
organ represent the mean dose for the sample of 44 examinations. 
 
8.5: Estimation of missing doses 
As noted in chapter 3, around 70% of procedures conducted at Hospital 4 had no 
recorded dose indicator (neither PKA nor even screening time). This presented a 
problem for the epidemiological analysis, considering patients examined at the 
Hospital 4 contributed around 23% of the total cohort (i.e. approximately 16% of the 
cohort had no dose estimates based on recorded data). The only option available 
was to estimate these missing doses from data where PKA was recorded. This is 
unsatisfactory, given the potential for enormous variation in doses from one 
procedure to the next. However, there was no alternative, other than to exclude these 
patients from the study. Comparable studies investigating the risks from CT scans 
have adopted a similar approach, using average doses for groups of scan types, 
adjusted for patient age and exposure era [9, 124, 187, 190]. 
The only individual procedure types in which a sufficiently large sample of 
examinations was available was for coronary angiographies (both 1993-2003 and 
>2003), and PDA occlusions (>2003 only). Missing doses were estimated based on 
the median figures for these groups. For all other procedures, estimated doses were 
based on the figures in Table 8.2, for each era. No patient size stratification was 
252 
 
applied, as there was little suggestion of a variation in organ doses with age at 
Hospital 4 (see age stratified organ dose tables in Appendix 3). There is a suggestion 
of an increase in coronary angiography dose with patient size, although this was not 
found to be significant (p=0.39) and the number of procedures in each size category 
was quite small. 
 All procedures Coronary angiography PDA occlusion 
Organ 93-03 Mar-13 93-03 Mar-13 Mar-13 
Effective dose 7.4 [4 : 12.7] 2.7 [1.5 : 5] 8.5 [4.8 : 12.2] 3.4 [2 : 5.2] 2.7 [1.9 : 4.2] 
Bone marrow 3.1 [1.7 : 5.6] 1.3 [0.6 : 2.3] 3.8 [2.6 : 7.9] 2 [1.2 : 3] 0.9 [0.7 : 1.4] 
Breasts 20.3 [10.9 : 35.4] 7 [3.9 : 12.9] 21.3 [14.8 : 32.5] 9.3 [5.2 : 14.7] 7.4 [5.2 : 12.3] 
Heart 15.2 [7.8 : 25.5] 6.4 [3.5 : 11.8] 17.4 [9.8 : 26.6] 8.6 [4.8 : 13.2] 6.3 [4.8 : 9.7] 
Lungs 23.2 [12.4 : 39.4] 8.3 [4.6 : 15.3] 24 [14.1 : 41.8] 10.6 [5.8 : 15.9] 7.6 [5.4 : 12.1] 
Lymph 4.1 [2.1 : 6.9] 1.6 [0.9 : 2.9] 3.8 [2.1 : 6.1] 1.8 [1 : 2.9] 1.6 [1.1 : 2.4] 
Oesophagus 13 [6.8 : 22] 5.4 [3.1 : 10] 12 [7.1 : 20.5] 6.7 [3.8 : 9.9] 5.4 [3.8 : 7.9] 
Thyroid 0.7 [0.3 : 1.4] 0.4 [0.2 : 0.7] 0.4 [0.2 : 0.7] 0.3 [0.2 : 0.4] 0.4 [0.2 : 0.6] 
Liver 6.3 [3.3 : 10.7] 2.5 [1.4 : 4.6] 5.6 [3.1 : 9.1] 2.7 [1.6 : 4.3] 3 [1.9 : 4.6] 
Stomach 2.7 [1.4 : 4.7] 1.1 [0.7 : 2.2] 1.5 [0.7 : 2.5] 0.9 [0.5 : 1.5] 1.3 [0.8 : 1.9] 
n 817 496 19 69 18 
 
Table 8.8: Estimated organ doses (in mSv) for examinations at the Hospital 4, where PKA 
was not recorded. 
 
8.6: Conclusion 
Organ doses have been estimated for around 14,500 procedures. The organs 
receiving the highest doses are the lungs, heart, oesophagus and breasts. Doses to 
bone marrow, lymph nodes and the thyroid gland are relatively low. Organ doses 
have fallen significantly during the period of data collection, in a similar manner to the 
dose indicators presented in Chapter 3. The doses from cardiac catheterizations are 
similar to those for computed tomography, albeit slightly higher. The estimates 
presented in this chapter are subject to uncertainties due to variation in beam angle 
and x-ray energy from expected values. Further uncertainties are introduced by 
‘anatomical variation’ – differences in organ size, shape and arrangement from that 
assumed in the phantoms used in Monte Carlo simulations and physical 
measurements. While the former uncertainties can be quantified and used to 
produce upper and lower uncertainty limits on dose estimates, uncertainties due to 
anatomical variation are difficult to determine without using patient specific 
phantoms. Based on previous research, however, such uncertainties may be around 
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±50%. The following chapter utilises organ doses to estimate excess cancer risks 
using existing risk models, derived mainly from survivors of the nuclear bombings of 
Hiroshima and Nagasaki. 
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Chapter 9: Risk projection 
The organ doses presented in the previous chapter can be used to estimate the 
lifetime risk of radiation induced cancer using models derived from previous studies 
of radiation exposures. The projection approach has the advantage of allowing risk 
estimation for small cohort sizes where epidemiological analysis would lack sufficient 
statistical power, or where follow-up time is limited. The largest source of data for risk 
models remains the cohort of survivors of the nuclear bombings of Hiroshima and 
Nagasaki [135, 308], though models may also incorporate data from other studies 
including pooled analyses of studies of thyroid [294] and breast cancer [309]. As 
discussed in the literature review, most epidemiological studies to date lack sufficient 
statistical power to detect excess cancer risks below doses of around 100 mSv, 
meaning risk estimation below this level can only be achieved through downwards 
extrapolation, assuming a linear-no-threshold (LNT) relationship between dose and 
risk.  
The process of risk estimation has two stages: (1) calculation of excess relative risk 
(ERR) or excess absolute risk (EAR) in relation to a given dose, age at exposure, sex 
and attained age in the ‘study’ population, then (2) to transport these risks to a 
‘reference’ population in terms of the lifetime attributable risk (LAR) of disease in 
relation to dose [310]. The ERR is equal to the rate of disease in the exposed 
population divided by the rate in the unexposed population, minus 1 [3]. Thus the 
ERR assumes cancer increases in proportion to the baseline rate [16]. However, the 
baseline rate varies from one population to another, depending on geographical 
location and ethnic group. Stomach cancer, for example, is more common in Japan 
than in America or Europe, while lung and breast cancer are less common in Japan 
[133]. Thus the application of ERR models derived from exposures in one such 
population (i.e. Japan) to other populations (i.e. UK) requires caution. The EAR 
represents the rate of incidence or mortality of the disease in the exposed population 
minus the corresponding rate in the unexposed population. This model assumes 
excess cancer is independent of baseline levels [16] and is thus better suited to 
application in populations differing from that from which the model was calculated 
[49] (e.g. European instead of Japanese). 
A modification to the LNT model known as a ‘dose and dose rate effectiveness factor’ 
(DDREF) has been recommended by a number of organisations [3, 44, 45]. This 
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reduction in risks by a variable factor is applied where dose rates are below 0.1 
mGy/min (regardless of total dose) or where the total dose is less than 200 mGy [45]. 
Such requirements were met for around 98% of examinations in the current study. 
Application of a DDREF effectively results in two linear slopes, one for low doses and 
one for high doses, and has remained unpopular with authors arguing for threshold 
or hormesis models [311]. Calculated values of DDREF have ranged from 1 to 35 
depending on biological end points [49], though values in the range 1.5 to 2.0 are 
typical in cancer risk estimation from low doses [3, 44]. 
 
9.1: Risk projection theory 
The simplest approach to risk estimation is to use sex- and age-at-exposure 
averaged ‘nominal risk coefficients’, calculated by the International Commission for 
Radiological Protection (ICRP). For the general population, these are 5.5% per 
sievert for cancer and 0.2% for heritable effects [44]. For example, for an effective 
dose of 10 mSv, the cancer risk would be 0.0055% or approximately 1 in 2000. This 
risk model is for a ‘reference person’ – a hermaphrodite of no particular age. It is not 
designed to be applied to real patients of defined age and sex [312, 313], rather 
being designed for use in optimisation and radiation protection planning purposes 
(e.g. shielding requirements). There are a number of reasons why this is the case. 
Firstly, the tissue weighting factors used to calculate effective dose are age 
independent, despite the risk of cancer induction varying with age in a different 
manor for different tissues [196, 197]. Secondly, risk estimates and weighting factors 
are sex-averaged, despite the risk of radiation induced cancer being strongly sex 
dependent (risks are higher for females) [44]. Thirdly, the effective dose for a male 
patient would assume he had breasts. This is especially significant for cardiac 
imaging as breast dose has such a large impact on effective dose. Removing the 
impact of the breasts from calculated effective dose for males would require all the 
remaining weighting factors to be re-calculated. Effective dose should not be used for 
individualised risk modelling, although various authors have done this [8, 13, 89]. 
These studies will be discussed later in this chapter. 
Appropriate risk estimation for individuals utilises age, sex and organ specific risk 
models. The Committee to Assess Health Risks from Exposure to Low Levels of 
Ionizing Radiation report on the Biological Effects of Ionizing Radiation (BEIR) 2006 
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report (BEIR VII phase 2) [3] describes models for estimating the ERR and EAR of 
cancer for a person of a given age following exposure to a given dose of radiation. 
Risks can be calculated for all solid cancers combined, or for certain individual 
cancer sites. Separate models are provided for leukaemia, in which a linear-
quadratic dose response is assumed, based on epidemiological data [7]. 
The ‘all solid cancers’ model is based on the concept of ‘mean colon dose’ as a 
measure of radiation dose to the body. This is based on the whole-body nature of 
exposure following the nuclear bombings, as opposed to the highly localised 
exposures from cardiac catheterizations, where mean colon dose is lower than the 
mean whole body dose by a factor of around 5. Using mean colon dose as the 
primary measure of radiation dose from these procedures would result in large 
underestimates of risk. 
For solid cancer sites, including lung, stomach and liver, the general form of the 
model for a given equivalent dose D, in Sieverts (Sv) is the following: 
𝐸𝑅𝑅 = 𝛽𝑆 ∙ 𝐷 ∙ exp (𝛾 ∙ 𝑒
∗) ∙ (
𝑎
60
)
𝜂
 
Equation 9.18 
The variable βS is the ERR for exposure at age 30 years and attained age of 60 
years, and is organ and sex-dependent. The parameters to the right of D are 
designed to adjust this figure to other exposure ages and to adjust for attained age. 
The parameter e represents age at exposure, 𝑒∗is (e-30)/10 for ages below 30 and 
zero above this age, while a represents the attained age. Organ-specific values of βS 
for males and females along with those of the age at exposure adjustment coefficient 
γ and attained age exponent η are given in table 9.1.   
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Cancer Site β male (95% CI) β female (95% CI) γ η  
Stomach 0.21 (0.11, 0.40) 0.48 (0.31, 0.73) -0.30 -1.4 
Colon 0.63 (0.37, 1.1) 0.43 (0.19, 0.96) -0.30 -1.4 
Liver 0.32 (0.16, 0.64) 0.32 (0.10, 1.0) -0.30 -1.4 
Lung 0.32 (0.15, 0.70) 1.40 (0.94, 2.1) -0.30 -1.4 
Breast - 0.51 (0.28, 0.83) 0 -2 
Prostate 0.12 (<0, 0.69) - -0.30 -1.4 
Uterus - 0.055 (<0, 0.22) -0.30 -1.4 
Ovary - 0.38 (0.10, 1.4) -0.30 -1.4 
Bladder 0.50 (0.18, 1.4) 1.65 (0.69, 4.0) -0.30 -1.4 
Other solid 0.27 (0.15, 0.50) 0.45 (0.27, 0.75) -0.30 -2.8 (-4.1, -1.5) 
Thyroid 0.53 (0.14, 2.0) 1.05 (0.28, 3.9) -0.83 0 
All solid cancers 0.33 (0.24, 0.47) 0.57 (0.44, 0.74) -0.30 1.4 (-2.2, -0.7) 
 
Table 9.1: Parameter values for incidence ERR model defined by the BEIR VII committee 
 
The effect of the negative value of γ in the exponential term is that ERR estimates 
decrease with increasing age at exposure. The factor 𝑒∗causes risk estimates to 
decrease until age 30, at which point they become constant. The evidential support 
for this feature of the model is limited. For all cancer sites combined, the risk does 
appear to decrease with increasing age at exposure [169, 314]. However, it is 
unclear if this pattern applies to individual sites. Most notably, there is reasonably 
strong evidence that the risk of lung cancer does not fall with age and may in fact 
increase [197, 314]. For this reason, the modelling process for lung cancer was 
repeated with the exponential term removed, meaning risks for all ages at exposure 
were equal to those at age 30 years. The same approach could be applied to other 
sites, although the evidence of the modifying effect of age on oesophageal and 
stomach cancer risks is inconclusive [129]. 
The negative value of the exponent of attained age (relative to age 60), η, results in 
decreasing ERR estimates with increasing attained age, consistent with 
epidemiological data [7]. For thyroid cancer, the zero value of η means that the ERR 
is dependent only on age at exposure and not attained age [315] (i.e. the attained 
age term remains constant at 1). The model for the elevated absolute risk (EAR) 
takes the same form as the ERR model and is based on absolute risk per 10,000 
person years at age 30 [3]. Values for the various parameters for the EAR model are 
given in Table 9.2. 
The BEIR VII committee prefer a separate model for breast cancer, based on that 
developed by Preston and colleagues [309], defined for the relative risk model as: 
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𝐸𝑅𝑅 𝑝𝑒𝑟 𝑆𝑣 = 𝛽(
𝑎
60
)2 
Equation 9.19 
While the absolute risk model is defined as: 
𝐸𝐴𝑅 𝑝𝑒𝑟 𝑆𝑣 = 9.9 exp (−0.05 ∙ (𝑒 − 25)) ∙ (𝑎/50)𝜂 
Equation 9.20 
Where a is the attained age and e is the age at exposure. The exponent η is equal to 
3.5 for attained ages of less than 50, and 1.0 thereafter.  
There is no EAR model for thyroid cancer. The ERR model for this site is based on a 
pooled analysis conducted by Ron et al [294], and is defined as: 
𝐸𝑅𝑅 𝑝𝑒𝑟 𝑆𝑣 = 𝛽 ∙ exp [−0.083(𝑒 − 30)] 
Equation 9.21 
Where β is 0.53 for males and 1.05 for females.  
The model for leukaemia was obtained from the BEIR VII report [3] as follows: 
𝐸𝐴𝑅 𝑜𝑟 𝐸𝑅𝑅 𝑝𝑒𝑟 𝑆𝑣 =  𝛽𝑆(𝐷 + 𝜃 ∙ 𝐷
2) ∙ 𝑒𝑥𝑝[𝛾 ∙ 𝑒∗ + 𝛿 ∙ 𝑙𝑜𝑔(𝑡/25) + 𝜙 ∙ 𝑒∗ ∙ 𝑙𝑜𝑔(𝑡/25)] 
Equation 9.22 
Where ϕ, δ and θ are fitting parameters. This model has a linear quadratic form, as 
opposed to purely linear for other sites. The quadratic term is omitted for chronic 
exposures [315] (i.e. a purely linear dose response is assumed), though was kept in 
for this analysis as all exposures were considered acute. 
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Cancer Site β male (95% CI) β female (95% CI γ η 
Stomach 4.9 (2.7, 8.9) 4.9 (3.2, 7.3) -0.41 2.8 
Colon 3.2 (1.8, 5.6) 1.6 (0.8, 3.2) -0.41 2.8 
Liver 2.2 (1.9, 5.3) 1.0 (0.4, 2.5) -0.41 4.1 (1,9, 6.4) 
Lung 2.3 (1.1, 5.0) 3.4 (2.3, 4.9) -0.41 5.2 (3.8, 6.6) 
Breast - 9.9 (7.1, 14)* -0.41 
3.5 (<30 years) 
1.1 (>30 years) 
Prostate 0.11 (<0, 1.0) - -0.41 2.8 
Uterus - 1.2 (<0, 2.6) -0.41 2.8 
Ovary - 0.70 (0.2, 2.1) -0.41 2.8 
Bladder 1.2 (0.4, 3.7) 0.75 (0.3, 1.7) -0.41 6.0 (3.1, 9.0) 
Other solid 6.2 (3.8, 10.0) 4.8 (3.2, 10.0) -0.41 2.8 
Thyroid - - -0.41 - 
All solid cancers 22 (15, 30) 28 (22, 36) -0.41 2.8 (2.15, 3.41) 
 
Table 9.2: Parameter values for incidence EAR model defined by BEIR VII committee.           
* Figures based on an erratum after publication of report. 
 
These BEIR VII risk models have been extensively critiqued by Calabrese and 
O’Connor [49], in particular highlighting the considerable difference in risk estimates 
derived using ERR and EAR methods. Kellerer et al [310] note that “radiation-risk 
estimates tend to be scrutinized to a level that is out of balance with their inherent 
degree of uncertainty”, though noting later that such uncertainties should not justify a 
lack of rigour in risk modelling.  
 
9.1.1: Risk Transport 
The ERR or EAR figures described above can be used to estimate the 'lifetime 
attributable risk' (LAR) of cancer from radiation exposure. Such estimates must take 
into account the probability of reaching a particular age, and, for ERR transport, 
background cancer rates. The LAR based on relative risk transport is defined by 
Kellerer et al [310] as:  
𝐿𝐴𝑅(𝐷, 𝑒, 𝑠) = ∫ 𝐸𝑅𝑅(𝐷, 𝑎, 𝑒, 𝑠) ∙ 𝑚(𝑎, 𝑠) ∙
𝑆(𝑎, 𝑠)
𝑆(𝑒, 𝑠)
𝑑𝑎
𝑎𝑚𝑎𝑥
𝑒+𝐿
 
Equation 9.23 
This represents the sum of age-specific risks taking into account the probability of 
surviving to that age [315]. The parameter m(a,s) represents the sex specific 
spontaneous incidence rate as a function of age. S(a,s) represents the “survival 
function”, which is the probability at birth, to reach age a, while the ratio S(a,s)/S(e,s) 
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represents the conditional probability of someone alive at age e of reaching age a 
[310]. Thus, at the time of exposure, the ratio S(a,s)/S(e,s) is equal to 1 and 
decreases with each successive year. In the case of LAR, S(a,s) represents the 
survival of an unexposed rather than exposed population, unlike the otherwise 
similar risk transport concept of ‘risk of exposure influenced death’ (REID), favoured 
by UNSCEAR. For doses below 0.1 Sv, the LAR and REID methods yield virtually 
the same results [3], while at 1 Sv, REID yields figures around 10% lower [310]. As 
doses in this study were almost always below 0.2 Sv, either figure could be used, 
although LAR was adopted as it is computationally simpler. The parameter L in the 
lower limit of integration represents the latency period for cancer development 
following radiation exposure. A value of L of five years was used in this study for 
solid cancers, and 2 years for leukaemia. These values are consistent with 
epidemiological studies [45], including the Life Span study.  
In reality, each parameter is obtained at discrete intervals (i.e. per year or per 
decade), thus the integral form of this calculation reduces to a simple summation: 
𝐿𝐴𝑅(𝑒) ≈ ∑ 𝐸𝑅𝑅𝑖 ∙ 𝑚𝑖 ∙
𝑆𝑖
𝑆𝑒
100
𝑖=𝑒+𝐿
 
Equation 9.24 
The second form of LAR is based on absolute risk transport and uses EAR rather 
than ERR. The absolute risk transport LAR can be defined by the BEIR VII 
committee [3] as: 
𝐿𝐴𝑅(𝐷, 𝑒, 𝑎) = 𝑀(𝐷, 𝑒, 𝑎, 𝑠) ∙
𝑆(𝑎, 𝑠)
𝑆(𝑒, 𝑠)
 
Equation 9.25 
Where M(D,e,a,s) is the EAR resulting from dose D at age a exposure age e and sex 
s. Integrating this between the exposure age (plus the latency period, L) and amax 
(taken to be 100 years, as before), yields the overall lifetime attributable risk: 
𝐿𝐴𝑅(𝑒) = ∫ 𝑀(𝐷, 𝑒, 𝑎, 𝑠) ∙
𝑆(𝑎, 𝑠)
𝑆(𝑒, 𝑠)
𝑎𝑚𝑎𝑥
𝑒+𝐿
𝑑𝑎 
Equation 9.26 
Again, this reduces to a simple summation: 
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𝐿𝐴𝑅(𝑒) ≈ ∑ 𝐸𝐴𝑅𝑖 ∙
𝑆𝑖
𝑆𝑒
100
𝑖=𝑒+𝐿
 
Equation 9.27  
The key difference between this and the relative risk transport of LAR is the absence 
of the background rate, m(a,s), in calculations, thus avoiding the problem of 
sensitivity of risk estimates on regional variation in background rates. 
 
9.2: Methodology 
Lifetime attributable risk of cancer incidence was calculated for all examinations for 
which organ dose estimates, based on recorded dose indicators, were available. 
LAR was not calculated for examinations conducted at Hospital 4 for which no dose 
indicators were recorded. A function was written in MATLAB that allows rapid 
calculation of LAR using data outputted by the Cardiodose dosimetry system. 
Estimates for EAR and ERR for cancers of the lungs, stomach, liver, breast, thyroid 
(ERR only) and all solid cancers combined, excluding thyroid and non-melanoma 
skin cancer, were based on the previously described models presented in the BEIR 
VII report [3] (Tables 9.1 and 9.2, earlier in this chapter). Fitting parameters for 
oesophageal cancer (not included in the BEIR VII report) were obtained from a paper 
by Berrington de González et al [315] describing ‘RadRat’ - a non-commercial web-
based risk estimation tool developed by the US National Cancer Institute (NCI). This 
program allows cancer risks to be estimated from a given dose at a given age, using 
BEIR VII models. For both ERR and EAR methodologies, a DDREF of 1.5 was 
applied in all cases where organ doses were less than 200 mSv. A DDREF was not 
applied for leukaemia risk estimates as the reduced risk at low doses is already 
accounted for in the linear-quadratic model used for that site. 
Figures for the survival function, S(a), for England and Wales were obtained from the 
Office for National Statistics (ONS) [316]  (Figure 9.2). These figures were available 
for males and females and presented for birth years of 1975, 2000 and 2010. The 
figures for 2000 were chosen as they represent a relatively central value of birth 
dates in the study cohort. These survival functions were for the general population, 
rather than people with congenital heart disease (CHD) who may have reduced life 
expectancy. The impact of an overestimation of survival is an overestimation of 
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radiation induced cancer risks. However, obtaining an equivalent S(a) function for 
CHD patients is challenging, as survival has only been studied up to 15-25 years of 
age, so far [214, 317]. The most complete source of information of survival of 
children born with congenital defects in the UK is that by Tennant et al [213], 
published in 2010 and based on data from the North of England. Survival to 20 years 
is quoted for a range of congenital heart conditions, including tetralogy of Fallot 
(TOF) and ventricular septal defect (VSD), as well as all CHD conditions combined 
(Figure 9.2) Another study was conducted by Olsen and colleagues [317] examining 
survival to 25 years for Danish children with CHD, again, for individual conditions 
along with all CHD conditions combined (Figure 9.2). These survival rates are 
considerably lower than the UK study at age 1 year (80%, rather than 92%), though 
the rate of change beyond this age is similar. The date range in the Danish study 
(1977 to 2005) was wider than that of the UK study (1985 to 2003)  
These limited data were used to estimate lifetime survival functions for people with 
CHD beyond 20-25 years. Two approaches were considered. The first involved 
simply reducing the ONS survival function by a factor equal to the difference at the 
last age for which CHD survival is known. For the Tennant et al data [213], CHD 
survival is around 10% lower than background at 20 years, therefore survival beyond 
20 years was extrapolated by reducing the ONS rate by 10%. The difference 
between background and CHD survival is not constant, however, tending to widen 
slightly with increasing age. The second approach involved establishing the 
relationship between CHD and background survival, fitting a linear model (Figure 
9.1), then using this model to adjust ONS rates for survival beyond 20 years. The 
effect of the modified extrapolation was a reduction in estimated survival. This 
methodology is admittedly fairly crude, therefore risk estimates obtained using all 3 
survival functions (ONS and 2 extrapolated CHD) will be presented. Furthermore, the 
estimated CHD survival functions are for all CHD conditions combined, when in 
reality survival varies between CHD subtypes [213, 317]. This should be unimportant 
where radiation associated cancer risks are calculated for the whole cohort, but 
would result in either over- or underestimation of risks for patients with specific 
conditions. This is especially so for patients undergoing transplants or with 
hypoplastic ventricles, in which survival is further reduced [211]. 
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Figure 9.1: Linear models describing relationship between survival for CHD and background 
UK rates (ONS) 
 
 
Figure 9.2: Extrapolated survival curves for people with congenital heart disease, based on 
data from two studies. 
 
Returning to Equation 9.23 used to calculate LAR, cancer incidence rates, m(a,s), for 
different regions of the UK population were obtained from Cancer Research UK 
[202]. These figures represent UK-wide rates, based on data from the Office for 
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National Statistics (England), Welsh Cancer Intelligence and Surveillance, 
Information Services Division Scotland and the Northern Ireland Cancer Registry. 
The dates of data provision for these registries were July 2013, May 2013, June 2013 
and June 2013, respectively. 
The results of the EAR and ERR transport methods were combined to produce a 
weighted sum, in linear space. These proportions, obtained from the BEIR VII 
committee report [3] and Berrington de Gonzalez et al [315] were 0.3 (EAR) and 0.7 
(ERR) for stomach, liver, oesophagus and the ‘all solid cancers’ groups, while for 
lung cancer, these proportions were reversed. No weighting was applied for breast 
(EAR only) and thyroid cancer (ERR only).  
 
9.3: Results 
Summaries of median estimated lifetime attributable risks using EAR and ERR 
transport methodologies are shown in Tables 9.3 and 9.4 for male and female 
patients respectively. Each table presents risks calculated using three different 
survival functions; UK general population rates (ONS) and CHD survival rates based 
on the data presented by Tennant et al [213] and Olsen et al [317]. These figures 
represent all procedure types and all hospitals and data collection eras combined. 
LAR based on relative risk transport was higher for lung and oesophageal cancer, 
leukaemia and the ‘all solid cancers’ group, while for cancers of the liver, stomach 
and breasts, the absolute risk transport method resulted in higher estimated LAR. 
Tables 9.5 and 9.6 present LAR estimates based on the weighted sum of EAR and 
ERR transports, for males and females, respectively. From now on, all analysis will 
focus on the weighted sum of these two transports, unless stated. The figures for the 
‘all solid cancers’ group are based on the mean whole body dose and the ‘all solid 
cancers’ BEIR VII risk coefficients from Tables 9.1 and 9.2, while the ‘summed solid’ 
group is the sum of individual risks for individual sites, excluding leukaemia. The 'all 
solid cancers' LAR was lower than the 'summed solid' LAR for females by around 
58%. For males, the central values for the ‘all solid’ and ‘summed solid’ groups were 
very similar, although the confidence intervals were more widely spaced for the latter. 
The ‘summed solid’ group includes thyroid cancer, while the ‘all solid’ model does 
not. The contribution from this site is minimal, however. 
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Estimated solid cancer risks were dominated by lung and breast cancer, with 
relatively small contributions from cancers of the oesophagus, stomach, liver or 
thyroid. Leukaemia risks were the fourth highest among individual sites, after 
oesophageal cancer. Estimated thyroid cancer risks were especially small, with 
central figures being close to zero. Omitting the exponential term from the BEIR VII 
models results in a reduction in lung cancer risks by a factor of around 2 for the ERR 
transport and almost 3 for the EAR transport. The overall effect of omitting the 
exponential term is a 40% and 29% reduction in the ‘summed solid’ cancer risk for 
males and females respectively. 
The median LAR for all sites combined was higher for females than for males by a 
factor of 3.3. Excluding breast cancer from the analysis, female summed LAR 
remained higher than for males by a reduced factor of around 1.7. The difference 
between the ‘all solid cancers’ estimate and the ‘summed solid’ figure was also 
greater for females than males. 
 
 
EAR transport ERR transport 
Organ ONS S(a) Tennant S(a) Olsen S(a) ONS S(a) Tennant S(a) Olsen S(a) 
Lung 38 [18 : 82] 34 [16 : 75] 30 [14 : 66] 54 [26 : 119] 50 [23 : 109] 44 [21 : 96] 
Lung* 14 [7 : 31] 13 [6 : 29] 11 [5 : 25] 21 [10 : 45] 19 [9 : 42] 17 [8 : 37] 
Stomach 8 [4 : 14] 7 [4 : 13] 6 [4 : 12] 1 [1 : 2] 1 [0 : 2] 1 [0 : 1] 
Liver 9 [8 : 22] 8 [7 : 20] 7 [6 : 18] 2 [1 : 4] 2 [1 : 4] 2 [1 : 3] 
Oesophagus 7 [1 : 16] 6 [1 : 15] 6 [1 : 13] 13 [0 : 29] 12 [0 : 27] 11 [0 : 24] 
Breast n/a n/a n/a n/a n/a n/a 
Thyroid n/a n/a n/a 1 [0 : 3] 1 [0 : 2] 1 [0 : 2] 
Leukaemia 8 [1 : 19] 8 [0 : 18] 8 [0 : 17] 4 [0 : 9] 4 [0 : 9] 3 [0 : 8] 
All 49 [33 : 66] 45 [30 : 61] 40 [27 : 54] 74 [54 : 105] 68 [49 : 97] 61 [44 : 87] 
 
Table 9.3: Median estimated LAR per 100,000 for all procedure types combined, for males. 
*figures produced using modified model omitting age adjustment. Figures in brackets 
represent 95% confidence intervals of risk estimates. Data are for all procedure types 
combined. 
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EAR transport ERR transport 
Organ ONS S(a) Tennant S(a) Olsen S(a) ONS S(a) Tennant S(a) Olsen S(a) 
Lung 65 [44 : 93] 59 [40 : 85] 51 [35 : 74] 163 [109 : 244] 149 [100 : 224] 133 [89 : 199] 
Lung* 25 [17 : 36] 22 [15 : 32] 20 [13 : 28] 62 [42 : 93] 57 [38 : 86] 51 [34 : 76] 
Stomach 9 [6 : 13] 8 [5 : 12] 7 [5 : 10] 1 [1 : 2] 1 [1 : 1] 1 [1 : 1] 
Liver 5 [2 : 12] 4 [2 : 11] 4 [1 : 9] 1 [0 : 3] 1 [0 : 3] 1 [0 : 2] 
Oesophagus 1 [0 : 5] 1 [0 : 5] 1 [0 : 4] 9 [0 : 33] 8 [0 : 30] 7 [0 : 27] 
Breast 93 [67 : 132] 86 [61 : 121] 77 [55 : 108] 59 [32 : 96] 55 [30 : 90] 50 [28 : 82] 
Thyroid n/a n/a n/a 1 [0 : 4] 1 [0 : 4] 1 [0 : 4] 
Leukaemia 4 [0 : 9] 4 [0 : 9] 4 [0 : 8] 4 [0 : 9] 3 [0 : 8] 3 [0 : 8] 
All 65 [51 : 84] 60 [47 : 77] 53 [42 : 68] 111 [85 : 144] 103 [79 : 133] 93 [72 : 120] 
 
Table 9.4: Median estimated LAR per 100,000 for all procedure types combined, for females. 
*figures produced using modified model omitting age adjustment. 
 
 
 
Survival function 
Organ ONS Tennant Olsen 
Lung 43 [20 : 93] 39 [19 : 85] 34 [16 : 75] 
Lung* 16 [8 : 36] 15 [7 : 32] 13 [6 : 29] 
Stomach 3 [2 : 6] 3 [2 : 5] 2 [1 : 5] 
Liver 4 [3 : 9] 4 [3 : 9] 3 [2 : 8] 
Oesophagus 11 [0 : 25] 10 [0 : 23] 9 [0 : 21] 
Breast n/a n/a n/a 
Thyroid 1 [0 : 3] 1 [0 : 2] 1 [0 : 2] 
Leukaemia 5 [0 : 12] 5 [0 : 11] 5 [0 : 11] 
All 66 [47 : 93] 61 [44 : 86] 55 [39 : 77] 
Summed solid 62 [25 : 136] 57 [24 : 124] 49 [19 : 111] 
Summed solid* 35 [13 : 79] 33 [12 : 71] 28 [9 : 65] 
 
Table 9.5: Median estimated LAR (per 100,000) for all procedure types combined, for males, 
based on the weighted sum of EAR and ERR transports. *figures produced using modified 
model omitting age adjustment. 
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Survival function 
Organ ONS Tennant Olsen 
Lung 94 [63 : 138] 86 [58 : 126] 76 [51 : 111] 
Lung* 36 [24 : 53] 33 [22 : 48] 29 [19 : 42] 
Stomach 3 [2 : 5] 3 [2 : 4] 3 [2 : 4] 
Liver 2 [1 : 6] 2 [1 : 5] 2 [1 : 4] 
Oesophagus 7 [0 : 25] 6 [0 : 23] 5 [0 : 20] 
Breast 93 [67 : 132] 86 [61 : 121] 77 [55 : 108] 
Thyroid 1 [0 : 4] 1 [0 : 4] 1 [0 : 4] 
Leukaemia 4 [0 : 9] 4 [0 : 8] 3 [0 : 8] 
All 97 [75 : 126] 90 [70 : 116] 81 [63 : 105] 
Summed solid 200 [133 : 310] 184 [122 : 283] 164 [109 : 251] 
Summed solid* 142 [94 : 225] 131 [86 : 205] 117 [77 : 182] 
 
Table 9.6: Median estimated LAR (per 100,000) for all procedure types combined, for 
females, based on the weighted sum of EAR and ERR transports. *figures produced using 
modified model omitting age adjustment. 
 
Comparison of the data in Tables 9.3 to 9.6 shows a reduction in estimated LAR 
where survival functions based on populations with congenital heart disease are 
used. The effect is relatively small, being around 8% lower where the figures based 
on UK CHD survival reported by Tennant et al [213] are used, and around 18% lower 
using the Danish CHD survival reported by Olsen [317]. 
Table 9.7 shows median LAR for procedures conducted using 3rd generation 
(Siemens Axiom Artis and Artis Zee) machines compared to those conducted on 
older 2nd and 3rd generation machines. These figures utilise ONS survival rates and 
standard BEIR VII risk models (i.e. retaining the age adjustment for lung cancer). 
Overall, there has been a fall of around 77% in estimated risk per examination 
between these eras. Table 9.8 shows median LAR for summed solid cancers and 
leukaemia, stratified by procedure type. Data are presented for 3rd generation 
equipment. Again, patterns are similar to those for PKA or organ doses. The highest 
risks were for pulmonary valve replacements with overall estimated cancer risks of 
213 per 100,000 (1 in 469) for males, and 746 (1 in 134) for females. Corresponding 
figures for ASD occlusions were 16 (1 in 6250) and 47 (1 in 2127) for males and 
females respectively. These figures were based on ONS survival statistics. More 
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accurate estimations would require survival functions specific to each specific 
condition. 
 
Sex and equipment era 
Organ Male 1
st, 2nd  Male 3rd  Female 1st, 2nd Female 3rd  
Lung 101 [48 : 220] 22 [10 : 47] 233 [157 : 344] 53 [36 : 78] 
Stomach 7 [4 : 13] 2 [1 : 3] 8 [5 : 12] 2 [1 : 3] 
Liver 9 [7 : 21] 2 [2 : 5] 5 [2 : 13] 1 [0 : 3] 
Oesophagus 25 [1 : 57] 6 [0 : 14] 15 [0 : 58] 4 [0 : 15] 
Breast n/a n/a 229 [164 : 324] 51 [36 : 72] 
Thyroid 2 [0 : 6] 0 [0 : 1] 3 [1 : 11] 1 [0 : 3] 
Leukaemia 12 [1 : 28] 3 [0 : 6] 9 [1 : 21] 2 [0 : 5] 
All solid 156 [112 : 220] 34 [25 : 49] 237 [184 : 307] 55 [43 : 71] 
Summed solid 144 [60 : 317] 32 [13 : 70] 493 [329 : 762] 112 [73 : 174] 
 
Table 9.7: Median LAR (weighted sum of EAR and ERR transports) for two generations of 
equipment: 3rd (Siemens Axiom Artis/Artis Zee) and 1st and 2nd (Siemens HIcor/BIcor, 
Philips Integris and Toshiba Infinix). Figures in brackets represent 95% confidence intervals. 
 
 
 
Males Females 
Procedure: Leukaemia Summed solid Leukaemia Summed solid 
ASD Occlusion 1 [0 : 3] 15 [6 : 33] 1 [0 : 3] 48 [33 : 78] 
PDA occlusion 2 [0 : 5] 35 [13 : 74] 2 [0 : 4] 144 [98 : 224] 
Pulm valvuloplasty 4 [0 : 10] 54 [21 : 118] 3 [0 : 6] 151 [101 : 233] 
Aortic valvuloplasty 4 [0 : 8] 42 [16 : 89] 3 [0 : 7] 177 [118 : 274] 
PA angioplasty 5 [0 : 11] 71 [29 : 157] 3 [0 : 7] 258 [173 : 396] 
COA angioplasty 5 [0 : 11] 53 [21 : 117] 3 [0 : 8] 199 [134 : 306] 
EPS/RFA 2 [0 : 5] 21 [8 : 45] 2 [0 : 4] 49 [30 : 76] 
EMBx 1 [0 : 1] 5 [2 : 13] 0 [0 : 1] 16 [10 : 25] 
Coronaries 3 [0 : 6] 24 [10 : 52] 3 [0 : 6] 63 [39 : 103] 
PVR/pressures 1 [0 : 3] 15 [6 : 33] 1 [0 : 2] 41 [28 : 65] 
Valve replacement 17 [1 : 39] 196 [83 : 431] 10 [1 : 24] 736 [501 : 1114] 
Pacemaker 0 [0 : 1] 1 [1 : 4] 0 [0 : 1] 7 [4 : 13] 
Atrial septostomy 1 [0 : 3] 13 [5 : 27] 1 [0 : 3] 72 [46 : 112] 
 
Table 9.8: Median LAR (weighted sum of EAR and ERR transports) for 3rd generation 
equipment (Siemens Axiom Artis/Artis Zee), stratified by procedure type. Figures in brackets 
represent 95% confidence intervals. 
 
As with PKA and organ doses, LAR displayed a right skewed distribution, with the 
majority of procedures associated with a risk of below 200 per 100,000 (i.e. 1 in 500). 
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Figure 9.3 shows this distribution for the whole cohort and for all procedure types. 
Fourteen examinations resulted in an estimated LAR of 10,000 or more (i.e. 1 in 10), 
all of which involved female patients. The mean heart dose in these 14 cases was 
746 mGy, while the mean age at exposure was 2.9 years.  
Where cumulative LAR was calculated, the median across the whole cohort was 229 
per 100,000 (IQR: 82, 592), or about 1 in 436 (1220, 169) for cancers of the lung, 
stomach, liver, oesophagus, thyroid, breast and leukaemia combined. There was a 
suggestion of a positive correlation between median combined LAR, and the number 
of procedures conducted (Spearman’s r=0.61, p=0.06). Despite this, of the patients 
with the five highest cumulative combined LAR estimates (all female), three 
underwent a single catheterization, typically at an early age. The maximum 
cumulative LAR was 33,727 per 100,000, or about 1 in 3.  
 
Figure 9.3: Distribution of estimated lifetime attributable risk of cancer incidence 
across the whole cohort, for all procedure types. 
 
9.4: Discussion 
Many of the patterns in the risk modelling results mirror those for organ doses. This 
was expected due to the linear relationship assumed between dose and risk. The 
finding that the highest estimated risks were for the breasts and lungs was expected 
given that both organs receive relatively high doses and that both appear to be 
sensitive to radiation induced cancer [45, 139, 291]. Although the thyroid gland is 
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also considered radiosensitive [45, 294], the low doses received by this organ result 
in very low estimated risk of thyroid cancer. Risks were not estimated for lymphoma 
as no EAR or ERR models are available. Nor were risks estimated for cancers of 
organs for which no doses were calculated, including the colon, bladder, brain or 
salivary glands. These organs, although apparently susceptible to radiation induced 
cancer [9, 45, 53], were sufficiently far from the irradiated field that doses and 
associated risks were assumed to be negligible. 
The higher LAR for female patients reflects both the higher risk per unit dose for 
stomach, lung and thyroid cancer, and the inclusion of breast cancer in the total LAR 
for females. There is some association between radiation and male breast cancer, 
but this is limited [318]. Difference in dose between males and females does not 
appear to be a factor in the discrepancy in LAR. Mean effective doses were 
approximately the same for male and female cohort members, while median effective 
dose was 15% higher for males. Previous studies led by Johnson [89], Ait Ali [13] 
and Beels [12] reported female/male LAR ratios of around 2, 2.4 and 2.7 respectively 
(these papers are discussed in greater depth below). The larger male/female 
difference in the current study is most likely due to the use of organ doses to 
calculate LAR, rather than effective dose. The potentially high risk of breast cancer 
highlights the importance of radiation protection techniques to reduce breast dose, 
such as close collimation and use of lung shuttering where appropriate [104]. 
Avoidance of laterally orientated beam projections may also reduce breast dose, 
although choice of projections is largely dictated by procedure type. 
Across the whole cohort, the combined estimated LAR from cardiac catheterizations 
for leukaemia and lung, breast, stomach, liver, oesophageal and thyroid cancer was 
approximately 1 in 1500 and 1 in 500 for males and females respectively, using UK 
ONS survival rates and retaining the age modifier in BEIR VII models. For recent 
examinations conducted using modern equipment, equivalent figures are 1 in 2900 
and 1 in 900 for males and females respectively. Where accounting for reduced 
survival of people with congenital heart disease, these risks were reduced by 
between 10 and 25%. These latter risks were estimated using alternative survival 
functions. An alternative methodology involves adjusting the upper limit of integration 
(amax) in equations 9.6 and 9.9, allowing the risk of cancer to be estimated up to a 
particular number of years following exposure. This may be more suitable for 
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conditions in which survival is especially reduced, such as hypoplastic ventricles 
[215] or transplantation [211]. LAR as a function of amax has a sigmoid form (Figure 
9.4), rising steeply between 40 and 70 years before levelling off. Thus reducing amax 
to 80 years results in a small decrease in LAR of around 10%. Reducing amax to 50 
years, leads to a decrease in LAR by 63%. Patients with a hypoplastic left heart 
(where the left ventricle fails to develop properly) are not expected to survive beyond 
their teens [215]. Setting amax to 20 years results in a decrease in LAR of around 95% 
relative to risks estimated using an amax of 100 years.  Figures 9.5 and 9.6 show 
estimated LAR for coronary angiography examinations, based on median dose for 3rd 
generation equipment, as amax is adjusted from 5 to 75 years from the age at 
exposure. Note that the risks at 5 years post exposure are entirely due to leukaemia 
(which has a 2 year latency period). 
 
Figure 9.4: Lifetime attributable risk of cancer from cardiac catheterizations 
conducted on children who underwent Norwood procedures, as a function of attained 
age. Error bars represent 95% confidence intervals of risk. 
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Figure 9.5: LAR as a function of aMAX (upper limit of integration in Equations 9.23 and 9.26) 
for coronary angiography examinations at six ages at exposure. Data are for male patients. 
 
 
Figure 9.6 LAR as a function of aMAX for coronary angiography examinations at six ages at 
exposure. Data are for female patients. 
  
As with other medical radiation exposures, these risks must be placed in the context 
of the potential benefits of the diagnostic information provided and the therapeutic 
benefits of trans-catheter interventions. Radiation protection involves both 
justification and optimisation [60, 104]. The former is related to decision of whether or 
not to go ahead with the exposure or nor, based on net benefit to the patient. If the 
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procedure is considered justified, the process of optimisation seeks to reduce doses 
to as low as reasonable practicable (ALARP) [16, 104]. The issue of the compromise 
between radiation dose and image quality has been discussed previously and will be 
discussed again, later.  
 
9.4.1: Uncertainties in risk estimates 
There are a number of sources of uncertainty in risk estimates derived from the 
modelling approach. The uncertainty in the value of ERR and EAR risk coefficients is 
reflected in 95% confidence intervals incorporated into these estimates. A linear 
relationship between radiation dose and excess risk is assumed, with no threshold 
dose below which there is no risk.  This approach remains controversial [58, 59, 
311]. There is currently insufficient evidence to confirm or refute alternative 
proposals. The risks estimated using data derived from nuclear bombing survivors’ 
data tend to be higher than those obtained from studies of children treated with 
radiotherapy [172] though lower than that suggested by recent studies of children 
undergoing computed tomography scans [9, 124].  
The usage and associated value of the ‘dose and dose rate effectiveness factor’ 
(DDREF) is also controversial [59]. Models presented in ICRP 103 [44] utilise a 
DDREF of 2.0, while those developed by the UNSCEAR 2006 committee [45] use a 
linear quadratic model, in which a DDREF is implicit (i.e. the models effectively have 
a DDREF of 1.0). In this study, a factor of 1.5 was applied. Changing this to 2.0 
results in a reduction in LAR by 25%. The use of a single DDREF for all cancer sites 
is a generalisation without adequate evidential support. In particular, in some studies, 
the risk of breast cancer does not appear to be reduced for fractionated exposures, 
compared to single acute exposures [158, 314]. Brenner [137] argues that the 
apparent lack of effect of fractionation in studies of patients receiving fluoroscopically 
guided pneumothorax therapy for tuberculosis is due to the increased radiobiological 
effectiveness (RBE) of low energy x-ray photos [138, 319]. The energy of 
fluoroscopic x-rays used in cardiac catheterizations is strongly dependent on 
filtration. The almost complete removal of photons below around 30 keV with around 
0.2 mm of copper and 2.5 mm of aluminium filtration would result in a lower RBE 
than apparent from studies of fluoroscopic exposures used for TB pneumothorax 
therapy [154]. It is possible, therefore, that risks for breast cancer have been 
274 
 
underestimated in cases where filtration was lower. Furthermore, recent studies of 
cancer mortality in nuclear workers [139, 145, 146] and other occupationally exposed 
groups do not suggest a reduction in risk for protracted exposures, implying a 
DDREF or 1.0 or less [320].  
The decision to use BEIR VII risk models, as opposed to others developed by the 
ICRP [44] or UNSCEAR [45] was arbitrary. There is currently little to suggest that any 
one model provides more accurate estimates of the risks at low doses. The 
differences in LAR estimates obtained using EAR and ERR transports are consistent 
with those previously reported [49, 321]. The decision to apply either multiplicative or 
additive transports or the weightings in the combined approach is also arbitrary and 
lacks common consensus [321]. The ICRP 103 risk models use equal ERR/EAR 
weightings for liver and stomach cancer and a purely additive model for leukaemia 
[44], while the current study, the BEIR VII committee [3] and the online risk 
calculation tool RadRat [322] all utilise 70/30 weightings for all three sites. Wakeford 
and Little [321] note that when using BEIR VII risk models, the difference in 
leukaemia risk estimates between EAR and ERR transports are small, but very large 
when using the alternative risk models reported in the 2006 UNSCEAR report [45]. 
Fortunately, the contribution of cancers in which EAR and ERR transports differ 
substantially to overall cancer risks from cardiac catheterizations (stomach and liver 
in particular) is relatively small.   
The BEIR VII risk models assume a monotonically decreasing risk of radiation 
induced cancer with increasing age at exposure, up to 30 years. As previously 
mentioned, evidence in support of such an assumption is mixed [129, 196, 197], 
most notably for organs exposed during cardiac catheterizations, such as the lungs 
and oesophagus. This is unfortunate given the impact that the exponential age 
modification term from Equation 9.18 has on estimated risks, as demonstrated by the 
large reduction in LAR for lung cancer following its omission. The lack of evidence 
supporting the higher risks among children for lung cancer suggests that these 
modified figures may be more realistic. For the ICRP 103 risk models, lung cancer 
risk increases with age at exposure by 17% per decade for the ERR approach and 
1% for the EAR approach [44]. 
Risk estimates based on relative risk transport are also affected by regional variation 
in background rates. The estimates presented in this study are based on UK-wide 
275 
 
rates and may differ from those obtained using rates specific to the region of 
residence of individual patients. Regional rates are published by the International 
Agency for Research on Cancer (IARC) [203]. There is relatively little geographical 
variation in breast cancer incidence throughout the UK (Figure 9.7), though large 
differences are apparent for lung cancer (Figure 9.8). It should be noted, however, 
that the hospital at which procedures are carried out does not necessarily represent 
the location of residence of the patient. There are no hospitals carrying out paediatric 
cardiac catheterizations in Wales, for example, meaning Welsh patients must travel 
to English hospitals such as Alder Hey for these procedures. A similar issue could 
arise due to differences in ethnicity, which can affect background risk of cancer [323-
325]. The impact of variation in the survival function is somewhat smaller, with risks 
being around 25% lower based on the more pessimistic figures quoted by Olsen and 
colleagues [317]. 
Finally, risk estimation must also take into account the uncertainty in dose estimates 
described in Chapter 8. The largest potential uncertainties are for breast dose, due to 
the difficulty in predicting the inclusion of breast tissue within the primary beam. As 
discussed in Chapters 4 and 8, this study has assumed a large increase in breast 
dose for laterally orientated projections. Thus the breast cancer risks estimated in 
this chapter may be overly pessimistic.  
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Figure 9.7: Female breast cancer incidence from four different UK regions. Data obtained 
from IARC [200] 
 
 
Figure 9.8: Lung cancer incidence for four different UK regions. Data obtained from IARC 
[203] and Cancer Research UK [202]. 
 
 
9.4.2: Implications for epidemiological analysis 
The risk estimates for leukaemia and thyroid cancer; the malignancies best suited to 
an epidemiological analysis of radiation associated risks from childhood exposures 
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with a relatively short follow-up time, are small. Based on an average UK background 
incidence rate in the 0-29 year age group of 33 per million people, per year, for 
leukaemia and 12 for thyroid cancer [202], the expected number of background 
cases of these two malignancies over a 10 year study period, for a sample of 13,000 
subjects, is around 6. The expected number of radiation induced cancers in the same 
cohort, over the same time period, in the study cohort, was calculated by adjusting 
the upper limits of integration (amax) in Equation 9.23 from 100 to the number of years 
of follow up. This resulted in a mean ‘study period attributable risk’ of 7.2 and 1.8 per 
100,000 for leukaemia and thyroid cancer respectively (95% CI: 0.6, 17.1 and 0.5, 
6.6). Thus, the expected number of radiation induced leukaemia and thyroid cancer 
cases combined during the study period is 1.17 (95% CI: 0.1, 3.1). Restricting 
analysis to recently conducted examinations in which doses are relatively low, the 
number of expected radiation-induced leukaemia and thyroid cancer cases is 0.3 
(95% CI: 0.1, 0.8).  
A significant increase in leukaemia or thyroid cancer incidence in the study cohort 
was not expected, based on excess risks predicted by the modelling approach. For 
other cancer sites, including lung, oesophagus and breast, a longer follow up time is 
required to enable cohort members to reach the ages at which such diseases 
become relatively common. 
 
9.4.3: Comparison with previous research 
A number of previous studies have estimated lifetime attributable risk of cancer from 
cardiac catheterizations in children. Ait Ali et al [13] estimated LAR for 59 patients 
undergoing 1548 x-ray procedures, including catheterizations, CT and chest 
radiographs. For male patients receiving a median cumulative effective dose of 7.1 
mSv, the estimated median LAR of cancer incidence was 1 in 804, while for female 
patients receiving a median effective dose of 9.4 mSv, the median LAR was 1 in 331. 
The quoted cumulative effective doses do not appear to correspond to the sum of 
doses for each procedure type. The methodology states that effective doses for 
catheterizations were estimated using the E/PKA conversion factor of 1.2 
mSv/Gy·cm2, which based on the quoted median PKA of 20 Gy·cm2, ought to result in 
effective doses for catheterizations alone of around 24 mSv. Moreover, the 
methodology for LAR estimation is unclear, appearing to involve using BEIR VII risk 
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models to estimate risks from effective dose, rather than individual organ doses. 
Such a methodology is regarded as improper [326], for the reasons outlined earlier in 
the chapter, though deserves further analysis. The LAR estimates obtained using the 
‘All solid cancers’ risk coefficients in Tables 9.1 and 9.2, and the mean whole body 
dose, were 58% lower for females than corresponding estimates obtained by 
summing LAR for individual sites obtained using respective organ doses, but almost 
identical for males. Based on the earlier finding that effective dose is, on average, 
higher than mean whole body dose by a factor of 1.7 (see Chapter 8, section 8.2), 
using effective dose rather than mean whole body dose with the ‘All solid cancers’ 
risk coefficients results in a higher LAR than that obtained by summing risks for 
individual sites by a factor of 1.7 for males, but brings these figures closer for 
females (28% lower rather than 58%). Thus, for analyses with both sexes combined, 
the use of effective dose in BEIR VII risk models results in a crudely similar risk 
estimate to that obtained using the ‘proper’ methodology. 
Johnson et al [89] estimated LAR for 337 children aged under 6 years, undergoing 
13,932 procedures, giving a median cumulative effective dose of 2.7 mSv (range 0.1-
76.9 mSv). The majority (72%) of exposures were chest radiographs, delivering 
effective doses of less than 0.03 mSv each. As with the study by Ait Ali et al [13], the 
authors chose to apply effective dose to BEIR VII risk models rather than use 
individual organ doses. For patients undergoing transplant and Norwood procedures, 
a separate ‘short term’ risk estimation was conducted to account for shorter life 
expectancy. This used an ERR of 0.035 mSv-1 derived from the epidemiological 
analysis of CT-associated risks performed by Mathews et al [124], background 
cancer rates for US adolescents (15-19 years) and assumed exposure at 5 years. 
The rationale for using this separate ERR, as opposed to using a different survival 
function, or value of amax is not made clear. The decision to use the ERR from the 
Mathews study is also questionable. As noted in the literature review, this analysis 
has drawn criticism, in particular related to the issue of confounding by indication 
[129, 177, 178]. Using an upwardly biased ERR for patients with shortened life 
expectancy would achieve the opposite effect to that desired. In reality, shorter life 
expectancy would mean less time to develop radiation induced cancers and hence 
lower risk, not higher. Whatever the thinking, the median estimated LAR for the 
whole cohort was 65 cases per 100,000, or 1 in 1538. For the Norwood and 
Transplant groups, these figures were 799 and 1677 respectively (1 in 125 and 1 in 
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60), based on median cumulative effective doses of 63.8 and 28.9 mSv respectively. 
The LAR estimates for the latter group are high, but then so are the dose estimates 
for cardiac catheterizations (effective dose of 13.8 and 9.1 mSv for interventional and 
diagnostic procedures respectively), based on physical measurements in 
anthropomorphic phantoms.  
Beels et al [12] estimated LAR for 49 patients aged from 0 to 11.8 years. Unlike Ait 
Ali et al [13] and Johnson et al [89], Beels used organ doses, calculated from Monte 
Carlo simulations (MCNP-X 2.5.0) rather than effective dose. The authors report 
median estimated LAR figures of 0.076% and 0.205% for males and females 
respectively (1 in 1316 and 1 in 488). The organ doses used for these estimates 
were not stated. The median effective dose, based on ICRP 103 weighting factors, 
was 6.4 mSv, ranging from 0.5 to 53.4 mSv. 
Yakoumakis et al [107] used the risk of exposure–induced death (REID) estimation 
tool built in to PCXMC v2.0. This utilises BEIR VII risk models and organ doses 
transferred from Monte Carlo simulations in the same program. The model uses 
three sets of background cancer rates; Euro-American, Asian and Finnish, although it 
is not clear which were used in this case. Aside from calculating REID as opposed to 
LAR, the upper limits of integration (i.e. amax) are set at 120, rather than 100. 
Yakoumakis’s team estimated risks for 53 cardiac catheterizations carried out on 
patients aged 3 months to 11 years. The median REID estimates for ASD, VSD and 
PDA occlusions were 0.110%, 0.126% and 0.067% respectively (i.e.1 in 909, 794 
and 1493). These risk estimates are quite low, considering the exceptionally high 
calculated doses (effective dose = 40, 22 and 17 mSv for ASD, VSD and PDA 
occlusions respectively). The discrepancy in the relative magnitudes of dose and 
REID between procedure types is striking, but not commented on by the authors.  
A number of older studies utilising simpler risk estimation methodologies are also 
worthy of mention. Bacher and colleagues [8] estimated a median risk of cancer 
mortality for 60 cardiac catheterizations conducted on patients aged  under 10 years 
of 0.08% (1 in 1250). These figures were derived by multiplying the effective dose, 
calculated using MCNP4b2 Monte Carlo code, by risk factors quoted in ICRP 60 [67] 
of 13%/Sv for boys and 16%/Sv for girls. These estimates are similar to those of 
Yakoumakis et al [107] despite the effective doses being 5-10 times lower (these 
were 4.6 and 6.0 mSv for ‘low dose’ and ‘standard’ techniques respectively). The 
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results of Bacher et al should be interpreted with caution, given the simplicity of the 
risk estimation methodology, which assumes all exposure to have occurred at 10 
years. A similar analysis appears to have been performed by Martinez et al [94], who 
arrive at a figure – which is presumably the LAR, though not explicitly stated as such - 
of 0.07% (1 in 1429) for fatal cancer, based on an estimated effective dose of 5 mSv 
for 137 patients aged up to 16 years. It is unclear how this estimate of effective dose 
was derived. The use of cancer mortality in the above studies, rather than incidence, 
is a further limitation. Although survival of lung and oesophageal cancer remains 
poor [327], the survival of leukaemia and breast cancer is now sufficiently high [328-
330], that risk estimates based on mortality may underestimate the burden 
associated with radiation exposures. 
A final comparison was made between LAR estimates calculated by the current 
author, those of the BEIR VII committee presented in Tables 12D-1 and 12D-2 of the 
BEIR VII report [3] and those produced by the RadRat online risk estimation tool 
developed by the National Cancer Institute (NCI) [315, 322]. The results of this 
comparison are presented in Table 9.9. The goal was primarily to identify potential 
errors in the LAR estimation process. All three sources utilise the same BEIR VII 
models previously described. The BEIR VII example tables and RadRat are based 
on US background rates and survival curves, rather than UK rates in this study. LAR 
estimates calculated by the current author are close to those of the BEIR VII report, 
while those calculated by RadRat are much higher than both. 
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Male Female 
Age Study Lung Stomach Liver Leukaemia Thyroid Lung Stomach Liver Leukaemia Thyroid Breast 
0 y 
This 322 182 105 401 192 787 221 61 335 346 1224 
BEIR VII 314 76 61 237 115 733 101 28 185 634 1171 
RadRat 523 272 175 377 297 1220 328 98 332 1650 1810 
5 y 
This 267 150 86 245 128 657 182 50 202 251 953 
BEIR VII 261 65 50 149 76 608 85 23 112 419 914 
RadRat 438 225 146 181 198 1020 271 81 149 1100 1420 
10 y 
This 222 123 71 179 83 549 150 41 151 165 742 
BEIR VII 216 55 43 120 50 504 72 20 86 275 712 
RadRat 364 184 120 138 130 856 222 45 106 723 1110 
15 y 
This 184 101 59 145 54 459 123 34 127 107 578 
BEIR VII 180 46 36 105 33 417 61 16 76 178 553 
RadRat 302 151 100 116 86 716 182 55 90 470 859 
20 y 
This 154 83 49 125 34 384 101 28 113 68 448 
BEIR VII 149 40 30 96 21 346 52 14 71 113 429 
RadRat 252 123 82 104 56 600 149 45 82 299 664 
30 y 
This 107 56 34 97 13 270 67 19 93 25 265 
BEIR VII 105 28 22 84 9 242 36 10 63 41 253 
RadRat 176 81 56 92 23 421 98 31 72 112 387 
 
Table 9.9: Comparison of three lifetime attributable risk estimates, calculated for an acute 
exposure of 100 mSv. 
 
9.5: Conclusions 
Risk modelling suggests a median lifetime attributable risk of radiation induced 
cancer from cardiac catheterizations across the whole cohort of around 1 in 1500 
and 1 in 500 for males and females respectively. For more recently conducted 
procedures with lower doses, these risks fall to around 1 in 2900 and 1 in 900 
respectively. These relatively low excess cancer risks ought not to be detectable by 
epidemiological analysis unless the sample size is especially large, or follow-up time 
sufficiently long to include breast and lung cancers. The following chapter will 
discuss the results of matching cohort members to cancer registry data to provide 
direct epidemiological assessment of cancer risks following cardiac catheterizations. 
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Chapter 10: Epidemiology 
Excess cancer risks estimated using existing risk models are subject to large 
uncertainties in the shape of the relationship between radiation dose and cancer. An 
epidemiological analysis, using empirical data, has the benefit of allowing direct 
assessment of cancer risks, though has the disadvantages of sensitivity to sample 
size and confounding factors. The following chapter describes an epidemiological 
analysis of around 13,000 cohort members. This should be seen as a pilot study, 
with the aim of evaluating the possibility of a larger scale study involving patients 
from more UK hospitals and, potentially, a pooled analysis with European studies 
[331]. Two analyses were carried out; (1) an overall assessment of cancer incidence 
in the study cohort, and (2) an assessment of the potential impact of radiation doses 
on these cancer risks. The latter analysis focused only on cancers developing more 
than 5 years following the first recorded catheterization (2 years for leukaemia). 
 
10.1: Methods 
Details of cancer diagnosis and deaths were obtained by linking the cohort with the 
National Health Service Central Register (NHSCR). This holds records of everyone 
in Great Britain registered with a general practitioner, and is continuously updated 
with details of cancer incidence from regional registries, along with births, deaths, 
marriages and names changes [9]. Some of the 13,564 patients in the cohort could 
not be matched. Patients at Hospital 6 (n=337) had no Christian name, while 48 
patients at other hospitals had no date of birth and 125 were over 22 years at the 
time of the first procedure (these latter patients were not included in organ dose 
estimations). A further 222 patients had procedures not considered to be true cardiac 
catheterizations, including pericardiocentesis and PICC/Hickman insertions. Finally 
78 patients were excluded because it was unclear what equipment was used, making 
dose estimation too unreliable. This left 12,754 patients, contributing 191,865 person 
years on the 1st of February 2014. The mean patient age on this date was 15.1 years 
(median = 14.7). 7,562 patients were born within the data collection period at the 
hospital at which they were first examined. These patients contributed 78,835 person 
years and had a mean follow-up of 10.4 years (median = 9.3). Details of the cohort 
are shown in Table 10.1. 
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Characteristic Whole cohort Transplant Cases 
Male 6335 (50%) 374 (51%) 63 (49%) 
Female 5685 (45%) 335 (46%) 62 (48%) 
Unknown 733 (6%) 21 (3%) 4 (3%) 
Total 12753 730 129 
Born within study period 5295 306 35 
Mean age 01/02/2014 15.1 years 13.4 years 23.3 
Born <1980 248 (2%) 59 (8%) 13 (10%) 
Born 1980-1989 1557 (12%) 203 (28%) 53 (41%) 
Born 1990-2009 4831 (38%) 307 (42%) 42 (33%) 
Born 2000-2009 4985 (39%) 144 (20%) 21 (16%) 
Born >2010 1132 (9%) 17 (2%) 0 (0%) 
Mean age at first procedure 6 years 5.1 years 11.3 
1 procedure 9663 (76%) 229 (30%) 65 (50%) 
2 procedures 1747 (14%) 121 (16%) 18 (14%) 
3 procedures 621 (5%) 77 (10%) 8 (6%) 
4 procedures 261 (2%) 56 (7%) 7 (5%) 
5 procedures 154 (1%) 61 (8%) 6 (5%) 
>5 procedures 326 (3%) 220 (29%) 26 (20%) 
 
Table 10.1: Details of the cohort 
 
The standardised incidence ratio (SIR) was calculated as the ratio of observed to 
expected cases. The expected number of cases was calculated as follows: the sex 
adjusted average risk of cancer, per 100,000, was obtained for each year, from birth 
up to the age of the patient on the 1st of February 2014. The mean of these yearly 
risks was calculated, and this figure multiplied by the patient’s age on the 1st of 
February 2014. If the patient died prior to this date, risks were calculated up to the 
age at which the patient died. The sum of risks for cohort members was then divided 
by 100,000 to obtain the expected number of cancer cases. Expected cancer 
incidence rates were obtained from Cancer Research UK [202]. As explained in 
Chapter 9, these figures represent UK-wide rates, combining 2013 data from the 
English, Scottish, Welsh and Northern Irish cancer registries. Confidence intervals 
for SIR were calculated using the method described by Vandenbroucke [332], 
defined as (√𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 − 1)
2
 for the lower limit of observed cases, 
and (√𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 + 1 + 1)
2
 for the upper limit.  
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Information on potentially confounding conditions was determined from clinical 
details, where recorded (Hospitals 1 and 2 only), cause of death if the patient had 
died, and examination type. Conditions searched for were Down syndrome (trisomy 
21), axaxia telangiectasia, Li Fraumeni syndrome, organ transplantation and 
neurofibromatosis.  Patients were considered to have a history consistent with heart 
transplant if they had undergone coronary angiography and/or endomyocardial heart 
biopsies, unless stated as having Kawasaki's disease (the other common indication 
for this procedure in young people). 
Survival was calculated for cohort members using the Kaplan Meier method, defined 
for n individuals and d deaths in each time interval i as: 
?̂?(𝑡) = ∏
𝑛𝑡𝑖 − 𝑑𝑡𝑖
𝑛𝑡𝑖
𝑡𝑖<𝑡
 
Analysis was censored at 40 years of age as data beyond this age was too sparse 
(39 cohort members (0.3%) had reached this age).  
The number of person-years contributed by the cohort to a range of cumulative 
cardiac dose categories (<5, 5-20, 20-40, 40-80, 80-100, 100-120, 120-140, 140-
160, 160-180 and 180-200 mSv) was calculated. Person years were contributed after 
5 years following each exposure, to take into account the latency period of radiation 
induced cancers. A dose response analysis was conducted by dividing the number of 
cases occurring in each cumulative dose category by the respective number of 
person years. Relative risk was calculated with respect to the lowest dose category 
(<5 mSv). Excess relative risks (ERR) was calculated as the relative risk, minus one. 
 
 
10.2: Results 
A total of 141 tumours were identified among eligible patients. The mean age at first 
procedure among these patients was 11.3 years, compared to 6.0 years for the 
cohort overall. Nine cohort members were diagnosed with 2 tumours. In 7 of these, 
the second event was of similar histology to the first, suggesting that the second was 
simply a reclassification or a transition rather than a second primary malignancy. 
Excluding these left 133 cases, of which 24 were classified as benign, ‘borderline 
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malignancy’ or non-melanoma skin cancers. These were not included in SIR 
calculations. However, three benign or borderline malignant brain tumours were 
classed as malignant tumours and included in SIR calculations. Of the 109 malignant 
events, 12 were classified as ‘in situ carcinoma’. The majority of tumours were of the 
haematopoietic and lymphoid tissues, including leukaemia and lymphoma (Table 
10.2). Among haematological tumours, including borderline malignancies, there were 
4 cases of myelodysplastic syndrome (D46, 3 borderline, 1 malignant), 3 
Polycythaemia Vera (D45, borderline) and 1 acute panmyelosis with myelofibrosis 
(C94.4, malignant). The remainder (n=30) were malignant leukaemias, 14 of which 
were acute myeloid leukaemia (AML), while 9 were acute lymphoblastic leukaemia 
(ALL). Of the 43 lymphatic tumours, 10 were lymphoproliferative diseases (all 
classed as borderline malignancies), 7 were Hodgkin lymphomas and 22 were non-
Hodgkin lymphomas (NHL), including 15 classified as diffuse large B-cell 
lymphomas. Of the 20 tumours classified as carcinomas, 11 were of the cervix or 
exocervix, all but one of which were in situ carcinomas. Of the remaining carcinomas, 
4 were of the skin (3 basal cell and 1 squamous cell). One papillary adenocarcinoma 
of the thyroid and one renal cell carcinoma were identified. Among the remaining 
malignancies were a number of embryonic cancers including 4 each of Wilm's 
tumours and neuroblastomas, and one hepatoblastoma. 
The expected number of malignancies, excluding non-melanoma skin cancer, was 
calculated as 36.64. The standardised incidence ratio, based on 109 observed 
malignancies, was 2.97 (95% CI: 2.43, 3.60) (Table 10.3). This figure represents the 
overall cancer incidence in the cohort, irrespective of radiation exposure. The overall 
SIR was higher for patients first examined between 2000 and 2010 (3.20, 95% CI: 
2.41, 4.17) than for those first examined between 1990 and 1999 (2.78, 95% CI: 
2.00, 3.75). For leukaemia, the SIR was 4.30 (95% CI: 2.87, 6.18) based on 30 cases 
verses 6.98 expected, while for lymphoma it was 5.92 (95% CI: 4.04, 8.38) based on 
33 cases verses 5.57 expected. Incidence was significantly raised for cervical cancer 
(SIR=9.32), but not brain tumours (0.64). The SIR was greater at hospitals carrying 
out transplants (3.24, 95% CI: 2.60, 3.99) compared to non-transplant hospitals, 
where SIR was still significantly raised (1.90, 95% CI: 1.09, 3.07). Sixty eight patients 
developing a malignancy or borderline malignancy (51%) had a clinical history 
consistent with organ transplantation. Where transplant patients were removed from 
the analysis, the overall cohort SIR for all malignancies was reduced to 1.67 [95% CI: 
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1.25, 2.18]. For leukaemia, SIR was reduced to 2.16 [95% CI: 1.16, 3.67], and for 
lymphoma, SIR was reduced to 1.60 [95% CI: 0.67, 3.19]. Transplant patients 
underwent more examinations (4.27 per patient) than non-transplant (1.35) and 
received a higher cumulative dose (median effective dose of 11.2 mSv, compared to 
7.7 mSv) (see Chapter 8, section 8.2). The SIR for all sites, where transplant patients 
were excluded, was slightly higher for patients first examined between 2000 and 
2010 (1.62, 95% CI: 1.05, 2.40) than for those first examined between 1990 and 
1999 (1.57, 95% CI: 9.97, 2.40). 
 
Classification Total Borderline/Benign Malignant 
Leukaemia 35 5 30 
Lymphoma 43 10 33 
Carcinoma 20 4 16 
Sarcoma 10 1 9 
Neuroblastoma 4 0 4 
Wilms tumour 4 0 4 
Brain 5 5* 
Germ cell 2 0 2 
Others 10 4 6 
Total 133 24 109 
 
Table 10.2: Classification of 169 malignancies and borderline malignancies diagnosed 
among cohort members. Note *three benign or borderline malignant brain tumours were 
included as ‘malignancies’ for the purpose of SIR calculations. 
 
 
Cancer type Expected Observed SIR [95% CI] 
Whole 
cohort 
All 37.04 109 2.94 [2.41, 3.56] 
Leukaemia 6.98 30 4.3 [2.87, 6.18] 
Lymphoma 5.57 33 5.92 [4.04, 8.38] 
CNS 7.87 5 0.64 [0.19, 1.51] 
Cervical 1.18 11 9.32 [4.55, 16.89] 
Excluding 
transplant 
patients 
All 32.94 55 1.67 [1.25, 2.18] 
Leukaemia 6.47 14 2.16 [1.16, 3.67] 
Lymphoma 5.01 8 1.6 [0.67, 3.19] 
CNS 7.22 3 0.42 [0.07, 1.25] 
Cervical 1.01 10 9.9 [4.63, 18.45] 
 
Table 10.3: Observed and expected cancer cases and associated standardised incidence 
ratio (SIR), for the whole cohort and after excluding patients with a history of transplant. 
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Of the 41 tumours with a clearly defined location (Table 10.4), the majority (n=25) 
were in the abdominal and pelvic region, driven by the 11 cervical carcinomas, 4 
neuroblastomas and 4 Wilm's tumours (kidneys). Four malignancies were listed as 
being in the thoracic region – one peripheral primitive neuroectodermal tumour 
(pPNET) of the pleura, two ganglioneuroblastomas and one rhabdomyosarcoma. 
There were no tumours of the lung, breasts, stomach, heart or oesophagus. A further 
3 tumours, one melanoma, one synovial sarcoma and one basal cell skin carcinoma, 
had locations simply listed as ‘trunk’, meaning chest or abdomen (or both).  
 
Location Total Borderline Malignant 
Head 5 0 4 
Neck 2 0 2 
Upper limbs 2 0 2 
Thorax 4 0 4 
Trunk 3 0 3 
Abdominal/pelvic 25 2 23 
Lower limbs 0 0 0 
 
Table 10.4: Location of tumours where defined. 
 
One cancer was diagnosed among patients with transposition of the great arteries, 
verses 1.09 expected. One cancer was diagnosed among patients with Down 
syndrome (leukaemia), verses 0.18 expected. No malignancies were diagnosed 
among patients identified as having Tetralogy of Fallot (1.03 expected), Hypoplastic 
left or right ventricles (0.14 expected), or having undergone Norwood or Fontan 
procedures (0.06 and 0.37 expected, respectively). The latter operation is associated 
with liver disease, including hepatocellular carcinoma [333], though no such tumours 
were identified among this group, or the cohort as a whole. One tumour was 
diagnosed in a patient identified as having neurofibromatosis. No cases of tuberous 
sclerosis, ataxia telangiectasia or Li Fraumeni syndrome were identified. 
 
Association with radiation exposure:  
Almost half of the cases (45%, n=61) were diagnosed before the date of the first 
recorded catheterization for that patient (maximum of 17.9 years prior). This does not 
necessarily imply the tumour could not be associated with a catheterization - 5499 
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patients were born before the earliest recorded procedure at their respective hospital, 
therefore could have undergone procedures not included within the study. 
Considering only patients born within the data collection period, 35 developed a 
malignancy (n=29, SIR=2.59, 95% CI: 1.72, 3.75) or borderline malignancy (n=6). Of 
these, 17 cases (49%) were still diagnosed before the first recorded catheterization – 
a similar proportion to the cohort as a whole. 
Forty nine patients in the total cohort developed a malignancy (n=36) or borderline 
malignancy (n=13, including 3 basal cell carcinomas) at least 5 years after the first 
recorded procedure (solid cancers and lymphoma) or 2 years after the first procedure 
(leukaemia) (Table 10.5). Of these, 23 (52%) had a history consistent with transplant. 
None had Down syndrome, tetralogy of Fallot, transposition or had undergone 
Norwood procedures. The median age at first recorded procedure was 13.3 years 
(interquartile range: 6.7, 15.9 years), while the mean age was 11.7 years (standard 
deviation: 6.2 years). The expected number of malignancies developing between 5 
years since the first recorded procedure and the 1st of February 2014 was 16.87. The 
SIR was 2.13 (95% CI: 1.48, 2.97). Fifty five percent of patients (n=27) developing a 
tumour after the minimum latency period were male. 
 
Site Total Borderline Malignant 
Leukaemia 8 3 5 
Lymphoma 18 6 12 
Carcinoma 15 6* 9 
Sarcoma 1 0 1 
Neuroblastoma 0 0 0 
Wilms tumour 0 0 0 
CNS 3 0 3 
Germ cell 2 0 2 
Others 2 1 1 
Total 49 10 39 
 
Table 10.5: Cases developing at least 5 years (solid tumours) or 2 years (leukaemia) 
following the first recorded procedure. *Note – includes 3 basal cell carcinomas. 
 
Of the 49 patients developing a malignancy or borderline malignancy after the 
minimum latency period, 38 were born before the earliest date of data collection at 
their respective hospital. These patients may have undergone further 
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catheterizations not captured by the study, thus cumulative dose estimates may be 
underestimates. In Chapter 3 (section 3.3.5), it was found that the mean number of 
procedures per patient was 1.5, with this figure remaining unchanged when analysis 
was restricted to patients born within the study period. Considering only patients born 
within the data collection period, 11 developed a malignancy (n=9) or borderline 
malignancy (n=2) after the minimum latency period, verses 4.33 malignancies 
expected. Five of these 11 patients (45%) had a history consistent with transplant. 
The SIR, excluding borderline cases, was 2.08 (95% CI: 0.92, 4.00). Thus, the 
standardised incidence ratios for the overall cohort (2.94), those developing 
malignancies after the minimum latency period (2.13) and the subset of this latter 
group who were born within the study period (2.08) are reasonably similar. Only the 
final figure is non-significantly raised. Likewise, the percentage of cases developing 
in transplant patients is similar in all three analyses - around 50%. As for the cohort 
as a whole, the SIR was higher for patients first examined between 2000 and 2010 
(3.21, 95% CI: 1.88, 5.31) than between 1990 and 2000 (2.31, 95% CI: 1.49, 3.42). 
Evidence of an association with radiation exposure is strengthened by a dose 
response - a proportionality between dose and excess risk. Only exposures occurring 
more than 5 years (solid cancers) or 2 years (leukaemia) prior to cancer diagnosis 
contributed toward cumulative dose. A summary of these doses for the 36 patients 
developing malignancies, not including non-melanoma skin cancer is shown in Table 
10.6. 
 
Median cumulative dose [IQR] 
Organ Cases after latency period Non-cases 
Bone marrow 5.8 [5.3 : 12.1] 3.8 [1.8 : 8.1] 
Breasts 28.9 [19.9 : 64] 16.6 [6 : 41.8] 
Heart 34.2 [24.9 : 61.5] 21.1 [10.2 : 43.1] 
Lungs 42.3 [34.1 : 81.5] 26.5 [13.6 : 56.7] 
Lymph nodes 8.9 [6.5 : 15.9] 5.4 [2.7 : 10.5] 
Oesophagus 32.4 [21.3 : 53] 19.3 [8.9 : 36.4] 
Thyroid 2.1 [1.3 : 3.3] 1 [0.5 : 2.2] 
Liver 13 [10.9 : 22.9] 7.5 [3.7 : 16.9] 
Stomach 7.6 [5 : 11.2] 4.1 [2.1 : 7.7] 
Whole body 8 [6 : 15.2] 5 [2.5 : 9.9] 
Effective dose 14.4 [11.2 : 25.4] 8.7 [4.4 : 18.7] 
 
Table 10.6. Median cumulative doses for cohort members developing malignancies after the 
minimum latency period of 5 years (solid tumours) or 2 years (leukaemia), compared to 
equivalent figures for non-cases. Borderline malignancies not included). 
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A plot of SIR against cumulative cardiac dose is shown in Figure 10.1 and 
demonstrates little suggestion of a pattern of increasing risk with increasing dose (p 
for trend = 0.48). SIR was significantly elevated for the 5-40 and 40-80 mSv dose 
categories, but not for any others. With the exception of the largest dose category, 
the percentage of cases developing in patients receiving a heart transplant, steadily 
increased, ranging from 0% for patients receiving less than 5 mSv to 100% for 
patients receiving 120-160 mSv (Figure 10.1). There were few cases among patients 
receiving especially high doses. Of the 191 patients receiving an estimated 
cumulative cardiac dose of over 250 mSv, none developed a malignancy after the 
latency period. 
 
Figure 10.1: Variation in standardized incidence ratio (SIR) with cumulative cardiac dose. 
Percentages represent the proportion of cases among transplant recipients. 
 
The risk of developing a tumour (malignant or borderline/benign, after the latency 
period) for different cumulative cardiac dose ranges relative to less than 5 mSv was 
calculated. There is a suggestion of a pattern of increasing risk with increasing dose, 
especially in the 0-120 mSv range, albeit with very wide confidence intervals (Figure 
10.2). Where transplant patients are removed from the analysis, this pattern was 
replaced by an apparently negative relationship. It should also be noted that many of 
the cases were of organs remote from the site of irradiation, most notably the 10 
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cervical cancer cases. Thus this suggestion of a ‘dose response’ should be 
interpreted with caution. 
 
Figure 10.2: Relative risk of developing a malignant tumour in relation to cumulative cardiac 
dose. 
 
 
Figure 10.3: Trend following removal of cases developing in patients receiving a 
transplanted organ. 
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This analysis does not include radiation exposures from other forms of medical 
imaging (general radiography, computed tomography and nuclear medicine). 
Information from these procedures was not obtained from participating hospitals as 
part of this study. Data on CT scans in the UK were gathered as part of a separate 
study [9]. Linkage was performed between the cardiac and CT cohorts to identify 
patients who have undergone both cardiac catheterizations and CT scans. Members 
of both cohorts were assigned non-anonymous identification codes based on the 
combination of name and date of birth (anonymous ID numbers were then derived 
from these). Patients with the same non-anonymous ID code were assumed to be 
the same person. Potentially, two distinct patients could have the same name and 
date of birth. Although unlikely, this could result in matching errors. Overall, 1848 
patients in the cardiac cohort were identified as having undergone at least one CT 
scan (14% of the total cohort). Of the 131 patients in the cardiac cohort developing a 
tumour, 70 (53%) had undergone at least one CT scan. Among the 49 patients 
developing a tumour after the minimum latency period, 23 have received at least one 
CT scan.  
 
10.2.1: Survival of cohort members 
Analysis of survival is largely outside the scope of this thesis. Details of cause of 
death were primarily analysed to obtain information on confounding conditions. 
Childhood mortality is a highly sensitive issue [334-336], therefore comparison of 
death rates between participating hospitals was avoided and only overall details 
described. In total, 1060 patients were recorded as having died. For 76% of these 
(n=805), the primary cause of death was listed as being cardiac related or due to 
congenital disease of the heart or blood vessels. Other causes included cystic 
fibrosis (n=20), infections (n=10), complications of surgery (n=10) or neoplasm 
(n=23). Thirty five patients who died had Down syndrome while 30 had Tetralogy of 
Fallot. Of 132 patients developing a tumour, 36 (27%) are recorded as having died. 
For these patients, the median number of years between cancer diagnosis and death 
was 1.8 years (range: 0 to 35 years).  
The calculated Kaplan Meier survival function is shown in Figure 10.4. Survival fell 
rapidly in the first and second years of life, with 361 and 105 deaths respectively, 
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before levelling off. At 40 years, the survival was just under 92%, compared to 98% 
in the general UK population. 
 
 
 
Figure 10.3: Kaplan Meier survival function for entire cohort, censored at 40 years. 
ONS=Office for National Statistics. 
 
10.3: Discussion 
Two findings are particularly striking; the significantly raised incidence of 
malignancies among cohort members compared to the general population and the 
large impact of organ transplantation on the results. Addressing the first point, the 
finding of elevated cancer incidence among people with heart disease is not 
unprecedented. In a recent study by Lee et al [337] focusing on 31,961 Taiwanese 
patients of all ages with CHD between 1998 and 2006, an overall SIR of 1.45 was 
found (95% CI: 1.25, 1.67). Around half of these patients had undergone a 
catheterization procedure (48.9%) while 18.9% had undergone a CT scan. The most 
common cancers were haematological (SIR=4.04) or of the CNS (3.51). In contrast 
to the current study, the number of cervical cancers was smaller than expected (8 
observed verses 15.1 expected) while brain tumour incidence was increased (14 
observed verses 4 expected). Lymphomas were not analysed separately. Heart 
transplants are carried out in Taiwan [338], though it is unclear how many patients in 
Lee’s analysis had undergone this procedure. The SIR in the Taiwanese study is 
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similar to the equivalent figure in the current study where transplant patients are 
excluded (1.35). 
Bjørge et al [233] studied cancer incidence among children born with a range of 
congenital defects in Scandinavia. The SIR associated with malformations of the 
heart and blood vessels was slightly raised in Sweden (1.2, 95% CI: 1.0, 1.6) and 
Norway (1.2, 95% CI: 0.7, 2.0). Carozza et al [339] studied 115,686 patients with 
congenital abnormalities born in Texas between 1996 and 2005, among whom 239 
cancer cases were diagnosed. Half of the cases in this group were leukaemia (n=74) 
and 15% were of the central nervous system (n=23), while only 3% (n=4) were 
lymphomas. The incident rate ratio (IRR) was 3.50 (95% CI: 2.81, 4.31). Fisher and 
his colleagues [340] analysed 222 patients in California with various birth defects, 
who developed cancer. Of these, 69 cancers developed in patients with 
malformations of the heart or circulatory system. Hazard ratios were significantly 
raised, ranging from 3.36 to 4.28. Thus cancer incidence is comparable, albeit 
somewhat higher among the current cohort than has been suggested in previous 
research. It should be noted that the current cohort was established from patients 
undergoing cardiac catheterizations, rather, as with the above mentioned studies, 
from registers of congenital malformations. 
The increased cancer risk among patients undergoing organ transplantation is well 
known [341], including among childhood recipients [211]. For example, Engels and 
colleagues studied cancer incidence among solid organ transplant recipients in the 
United States, using data from the US Scientific Registry of Transplant Recipients 
(1987-2008) and 13 regional cancer registries. For all ages, a significantly raised SIR 
of 2.10 was found (95% CI: 2.06, 2.14), while for non-Hodgkin lymphoma this figure 
was 7.79 (95% CI: 6.89, 8.79) [341]. The rate of malignancies in children receiving 
heart transplants recorded by the International Society for Heart and Lung 
Transplantation (ISHLT) is approximately 1% per year of survival, with the majority of 
these cases being lymphomas [211]. Consistent with the used of immunosuppressive 
agents, malignancies following organ transplantation tend to be virus-related, 
including lymphoma, certain skin cancers and cervical cancer [342, 343]. Most 
notably, there is a strong association between transplantation, Epstein-Barr virus and 
post-transplant lymphoproliferative disease (PTLD) [344, 345]. In this study, the 
impact of transplantation was especially pronounced for lymphoma, with the SIR 
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falling from 5.36 to 1.33 when transplant patients were removed from the analysis. 
This is an important finding, of relevance to studies examining the potential risks from 
other medical exposures, including CT scans. An infectious aetiology has long been 
suspected for leukaemia [346], although the exact infection/mechanism is yet to be 
identified. The effect of removing transplant patients from the analysis was smaller 
than for lymphoma, with the SIR falling from 4.07 to 1.92 and remaining significantly 
raised. Eleven cases of cervical cancer were identified among cohort members in the 
current study, though only one of these patients appeared to have undergone a 
transplant. This possibly suggests under-ascertainment of transplantation among the 
cohort. The identification of transplantation and other potentially confounding 
conditions was based principally on clinical details and death records. The former 
were only recorded at two hospitals, while the latter were only available for the cohort 
members that died. The limitations of this incomplete ascertainment of such 
confounding conditions is acknowledged, although the quality and completeness of 
this information is similar, if not better than for studies investigating the risks following 
CT scans [187, 190, 191]. For example, the German CT study by Krille et al [190] 
used the diagnosis of lymphoproliferative disease to identify cases developing in 
transplant recipients. This may be unreliable, considering that many of the cases 
among this group in the current study were B-cell lymphomas, rather than 
lymphoproliferative disease. 
The number of thyroid cancers (a single case) was very small, though expected 
given the limited sample size and low radiation dose to the thyroid. The absence of 
any cancers of the lung and oesophagus was also expected given the relatively short 
follow-up period. There is some evidence of relatively early onset (i.e. under age 35 
years) of breast cancer among young people exposed to radiation [129], although no 
suggestion that the disease can be induced in childhood. Only 189 female cohort 
members had reached the age of 35 by February 1st 2014, therefore the complete 
lack of breast cancer cases should not be regarded as a surprising finding at this 
stage of follow-up. Given the potentially high localised skin doses, potentially 
reaching several Gray, the small number of skin cancers (especially basal cell 
carcinoma) was surprising.  
More than half of the patients developing a tumour after the minimum latency period 
were male. The risk estimates described in Chapter 9 using existing risk models 
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suggested females were around three times more likely to develop radiation induced 
cancer. However, this gender difference was driven by the impact of breast cancer 
and the higher risk coefficients for lung cancer in females. Thus a difference in risk 
by gender ought not to be apparent at this early stage of follow up where lung and 
breast cancer have not had sufficient time to develop.  
Limitations of the cohort were discussed in Section 3.7. In particular, misspelling of 
names and dates of birth could potentially lead to under ascertainment of cancer 
rates in the study group. The overall cohort SIR was somewhat higher at hospitals 
who had provided data in electronic format (3.33) compared to those who provided 
hand-written log books (2.81), although this comparison ought to be interpreted with 
caution as these two groups may involve different patient characteristics and doses. 
A reanalysis of the first UK CT study [9] by Berrington-de-González et al [191] found 
a number of brain tumours, apparently occurring at least 5 years following the first 
CT scan, were in fact present at the time of the first scan. This suggests cancer 
registry matching may not be as reliable as could be hoped for. 
 
10.4: Conclusion 
Patients undergoing cardiac catheterizations for congenital heart disease are at a 
significantly increased risk of developing cancer, although it appears that this 
increase is mostly unrelated to radiation exposure. Future epidemiological analysis of 
cancer risks following cardiac catheterizations requires rigorous attention to clinical 
history, most notably transplantation. Ideally, linkage with both transplant and 
congenital anomaly registries, such as the British Isles Network of Congenital 
Anomaly Registers (BINOCAR) [347], should be carried out. 
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Chapter 11: Discussion 
Summary of main findings: 
This study has established a cohort of around 13,500 patients aged under 22 years 
who have undergone cardiac catheterizations in the UK, comprising around 20,000 
individual procedures. The doses from these procedures, as represented by kerma 
area product (PKA), have fallen by a factor up to twenty during the study period, and 
appear to be relatively low compared to equivalent figures quoted in recent large 
studies based in the United States. Effective dose and equivalent doses to individual 
organs were estimated based on a dosimetry system utilising data from Monte Carlo 
simulations. The results were compared to equivalent figures derived from physical 
measurements and previous publications. A number of discrepancies were found, 
which appear to be due to a combination of experimental error and differences in 
phantom anatomy. Uncertainties in dose estimates were also calculated. These are 
generally around ±30%, though do not account for uncertainties due to anatomical 
variation, which are difficult to quantify. The risk of cancer in relation to estimated 
doses was calculated based on BEIR VII risk models, suggesting an approximate 
risk of developing cancer of 1 in 1000, per examination, for the overall cohort. For 
examinations conducted using modern equipment, these risks are reduced to around 
1 in 1700, due to lower doses. Estimated risks were higher for females than males by 
a factor of around 3. This is due to the impact of breast cancer and higher risk per 
unit dose for other tissues. A number of modifications to the BEIR VII models were 
investigated, to account for the reduced survival of people with heart disease, and 
the uncertain relationship between risk and age at exposure. A small epidemiological 
analysis was performed, suggesting an almost threefold increased risk of cancer in 
the cohort, compared to the general UK population. There are a number of reasons 
to suggest that this increase was primarily not related to radiation exposure, most 
notably the large impact of transplantation and associated immunosuppressant use. 
Despite the high cancer incidence, the overall survival in the cohort was high, at 
around 91% after 30 years.  
 
Radiation doses: 
The radiation doses from cardiac catheterizations are higher than those of general 
radiography (i.e. ‘normal’ x-rays), approximately similar to CT and nuclear medicine 
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[52, 111, 164], and much lower than radiotherapy. The variation in doses from one 
procedure to the next is higher for cardiac catheterizations, with some procedures 
delivering organ doses of several hundred mSv. The use of CT as an alternative to 
cardiac catheterizations could result in an underestimation of collective doses to 
cohort members. Johnson et al [89] estimate proportional contributions to collective 
effective dose of 35.2, 20.5 and 6.8%, for interventional and diagnostic 
catheterizations and gated cardiac CT, respectively, based on respective doses per 
examination of 13.77, 9.10 and 18.28 mSv. These figures are based on an unusually 
high estimated CT dose relative to catheterizations, compared to that suggested by 
previous research [111, 167]. Potentially, the contribution to collective dose may be 
lower than 6.8%, therefore. Ait Ali et al [13], recorded 7 CT chest examinations 
carried out among their cohort of 59 patients, compared to 55 and 40 diagnostic and 
interventional catheterizations, respectively. Again, this suggests that 
catheterizations are the dominant source of medical radiation exposure in this patient 
group. The current study is being run alongside a larger study investigating the risks 
from CT scans [9], for which data on scans carried out at most UK hospitals are 
available. Future epidemiology-based risk estimates should incorporate these data. 
The large fall in doses over the study period appears to be mainly due to 
technological factors, including improved detector efficiency, ability to remove 
antiscatter grids, greater control over frame rates, use of added copper filtration and 
improved image processing. However, a large variation is also apparent for the same 
equipment, even when corrected for patient size and procedure type. An especially 
pronounced variation was apparent between the dose indicators presented in the 
current study and those of several large, multi-centre American studies [82, 83, 91, 
207], where doses appeared to be higher by a factor of between 2 and over 50, 
depending on procedure type. This was made clear in a paper from this thesis 
published in the British Journal of Radiology [348]. It is noted that these American 
studies formed part of multi-centre collaborations on cardiac outcomes, including 
radiation protection, namely the CCISC (Congenital Cardiovascular Interventional 
Study Consortium) and C3PO (Congenital Cardiac Catheterization Project on 
Outcomes). The fact that radiation doses are so much higher in spite of such 
initiatives is puzzling. The authors of these studies appear to be unaware of the 
discrepancies in doses, tending to conduct only limited comparisons with previous 
research.  
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Higher doses are not without benefits, however. Increased photon fluence is 
associated with improved image quality. It is currently unclear if such gains in image 
quality necessarily lead to better patient outcomes [95], such as increased survival or 
lower complication rates. Until such information is available, it is not possible to claim 
high doses are ‘too high’ – that would require proof of improved patient outcomes due 
to improved image quality failing to offset the increased risk of radiation induced 
cancer. This is an exceptionally difficult issue to research, partly because the cancer 
risks are uncertain, but also due to the difficulty in quantifying patient outcomes. The 
high survival rates among members of the UK cohort described in this study does not 
suggest any overt burden caused by the use of low radiation doses.    
One of the most interesting findings of the current study was the large increase in 
breast dose calculated using Monte Carlo simulations, as the beam is rotated 
towards laterally orientated projections, or where the central ray location is translated 
in the anterior-posterior direction. This ‘cliff’ in breast dose was present for all 
phantom sizes, and to some extent, for different field sizes. Previously published 
estimates of breast dose or effective dose per unit PKA did not exhibit this feature [88, 
92], nor did physical measurements using anthropomorphic phantoms. However, 
none of these previous studies appear to have investigated the same range of beam 
angles and field sizes of the current study and may have restricted their analyses to 
somewhat idealized conditions, i.e. close collimation, deliberately excluding the 
breasts from the primary field. Clearly, there is scope for large variation in breast 
dose depending on beam angle, centring point and field size, relating to the 
exclusion or inclusion of the breasts (in particular the glandular tissues) within the 
primary beam. It is very difficult to assess from clinical images whether the breasts 
were included within the primary beam or not. The size and shape of the breasts is 
also variable and cannot be predicted from patient size (i.e. BMI) alone. The major 
implication is that breast dose estimates are subject to much larger uncertainties 
than for other tissues. Techniques for limiting the size of the irradiated field in the 
lateral projection should be employed, where possible, including collimation and ‘lung 
shuttering’. It is recommended that the anterior chest wall should always be excluded 
from the primary field of irradiation. The use of lead or lead-free shielding materials to 
reduce breast dose is unlikely to be practical, as the region of interest would be 
obscured in other projections. 
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A further important finding was the potential impact of antiscatter grid usage on 
patient dose. This was associated with a striking difference in the variation in either 
organ doses, or PKA per kilogram, between hospitals depending on grid usage. 
Hospitals claiming to selectively remove grids, report doing so only for small patients 
below around 10 kg (approximately less than 1 year). However, the pattern of 
relatively lower doses for smaller patients extended well above 10 kg. This could be 
potentially explained by radiographers removing grids for larger patients, where they 
see this as appropriate, though it is likely that other factors are involved. Patterns of 
antiscatter grid usage are variable within the UK. McFadden et al [281] report that 
27% of UK hospitals remove grids - 18% for patients under 10 kg, and 9% for ‘small 
children’. The removal of grids for patients below around 10 kg is supported by 
evidence from a number of studies [217, 222]. The extension of this practice beyond 
such small patient sizes is more limited [224]. For examinations in which image 
quality is of less importance, grid removal may be warranted for all patients. Further 
research in this area would be beneficial.  
Organ dose estimates are affected by the phantom models - either physical or 
computational - upon which they are based. The mathematical phantoms used in 
PCXMX 2.0 are rather crude. In particular, changes to phantom mass for a given 
height are not adequately modelled - all organs inflate like a balloon. Some patients 
in the cohort are obese, with body mass indices of up to 40.0. In these cases, 
attenuation of the beam by adipose tissue would have the effect of reducing beam 
intensity before more radiosensitive organs such as the lungs are reached. Although 
x-ray output, and hence kerma area product, would increase in response to a greater 
patient thickness, it would be expected that organ doses per unit PKA would be lower. 
A study investigating the effect of obesity on doses from CT found a 59% decrease in 
dose for deep lying organs for obese patients (BMI up to 46.4) compared to normal 
sized patients (BMI of 23.5) [349]. There are two problems that need to be addressed 
when attempting to correct for changes to body habitus; (1) the level of attenuation 
provided by adipose tissue, and (2) the distribution of adipose tissue in the body. The 
first problem is relatively easy to overcome. The attenuation coefficient (µ) of fat can 
easily be obtained from published data [16] or derived from Hounsfield Units from 
computed tomography (CT) images. From these values, an estimated reduction in 
beam intensity per unit thickness of adipose tissue could be calculated analytically. 
The second problem is considerably more difficult to address; the thickness of 
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adipose tissue traversed by the beam needs to be determined. Little information on 
the distribution of fat around the body is available. Again, CT images may provide the 
best source of information. 
Organ dose estimates may also be affected by the administration of iodinated 
contrast agents. These are designed to increase the attenuation of blood relative to 
surrounding tissues, thereby increasing subject contrast. The impact of contrast 
agents on organ doses should not be underestimated. Blood vessels perfuse tissues; 
they branch into successively smaller arteries and arterioles and capillaries, before 
regrouping as veins, returning blood to the heart. Almost all tissues have an 
extensive vascular network (cartilage is avascular). Blood makes up around 60% of 
the mass of the heart and 43% of the lungs [296]. With the exception of the brain, the 
whole organ should thus be perfused by contrast agent containing blood following 
administration (the blood-brain barrier prevents enhancement of the brain in healthy 
individuals). This would have the effect of increasing x-ray attenuation by organs 
compared to that simulated by both Monte Carlo simulations and anthropomorphic 
phantoms in which non contrast enhanced organ densities are assumed. The thorax 
is the location for the largest arteries and veins in the body as well as the heart itself, 
therefore the impact of contrast agent administration on dose estimates may be 
especially important for cardiac catheterizations. The impact of contrast 
administration would vary between procedures types; almost no effect for 
electrophysiology studies where contrast is rarely used, small for coronary 
angiography (the coronary vessels are relatively small) but potentially large for 
investigations including the right side of the heart and pulmonary vessels. Contrast 
agents are very rarely used during fluoroscopic imaging and are mostly restricted to 
acquisitions.  
Correcting for contrast agent administration is even more challenging than for body 
fat. Neither PCXMC Monte Carlo software, nor ATOM anthropomorphic phantoms 
allow adjustment of the attenuating properties of organs. Furthermore, although 
whole organs may experience enhancement, this effect is often highly uneven, with 
greater enhancement occurring where blood vessel density is highest. The heart 
itself could reasonably be modelled as a single homogenous volume subject to 
uniform enhancement, but the blood vessel density in the lungs varies from 
tremendously high around the hilum to fairly low around the lung periphery. 
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The ideal solution to the issue of both contrast agents and fat distribution is the use 
of voxel phantoms derived from CT images. These could be specific to the patient for 
whom dose from a cardiac catheterization is to be calculated. However, such 
phantoms would represent a single level of contrast agent enhancement and a single 
level of lung inflation (CT scans are usually acquired on inspiration). The density and 
shape of organs may not necessarily reflect the respective density and shape during 
fluoroscopic exposures. Voxel phantoms of a range of patients, or patient specific 
voxel phantoms would improve central dose estimates and narrow, but not eliminate, 
associated uncertainties.  
This study did not assess doses to the operator in cardiac catheterizations (i.e. 
cardiologists, radiologists, nurses and radiographers). The risk of cancer and 
cataracts among operators should not be underestimated [350], especially 
considering recent findings of studies of nuclear workers suggesting risks are higher 
than previously supposed at low doses [145, 146]. To some extent, operator dose is 
related to patient dose [229]. Thus the fall in patient dose found in this study should 
have been accompanied by a corresponding fall in operator dose. 
 
 
Associated risks: 
Cardiac catheterizations are a vital procedure in the treatment and management of 
acquired and congenital heart diseases. In many cases, the procedure may be 
lifesaving. In others, quality of life may be significantly improved. Cardiac 
catheterizations are a proven alternative to surgery [2], with similar success rates 
and reduced complications [1]. The increased lifetime risk of developing cancer 
needs to be placed in the context of these benefits. The reduced survival of children 
with certain heart conditions is also an important factor in risk estimation. Some 
children, most notably those with a hypoplastic left heart, are unlikely to survive 
beyond their teens [214, 215], thus have limited time to develop radiation induced 
cancers. The fact that the lungs, stomach, oesophagus, liver and breasts receive the 
highest radiation doses from cardiac catheterizations is particularly significant in this 
sense, as cancers of these organs are all ‘adult’ diseases, tending to occur beyond 
30 or 40 years [202]. There is reasonably strong evidence that radiation induced 
cancers develop at the ages at which they normally occur (i.e. in an unexposed 
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population) [132]. Second cancers developing after radiotherapy for primary cancer 
in childhood tend to be other cancers normally occurring in childhood such as 
sarcomas, brain tumours or leukaemia, unless the follow-up time is long [199, 351]. 
Excess cancers of the lungs, stomach and oesophagus among atomic bombing 
survivors did not appear below attained ages of 35 years [169]. Unless patients are 
likely to survive to at least this age, the risk of radiation induced cancer may be very 
small and restricted mainly to leukaemia, regardless of how high the doses are. This 
does not excuse poor radiation protection, however. For many heart conditions, 
including isolated pulmonary valve stenosis, atrial septal defect or Wolf-Parkinson-
White syndrome, survival now approaches that of the general population [213, 214]. 
The reduction of radiation doses in these patients is especially important. It is 
pleasing, therefore, that doses for trans-catheter treatment of these conditions has 
fallen considerably over the last two decades, with the estimated lifetime risk of 
cancer being generally less than 1 in 1000. There is still scope for further dose 
reductions, however, such as the increased use of ultrasound or magnetic resonance 
imaging guidance [2].  
Although the epidemiological analysis was small and likely underpowered (in terms 
of ability to detect radiation induced excess cancers, at least), the work done in 
establishing the dosimetry system, including gathering data on projection angles and 
beam energy used in clinical practice, prepares the ground for further research. A 
number of studies are ongoing to assess the long term risks of diagnostic x-ray 
exposures [352-355]. These studies mostly focus on computed tomography (CT), 
with only one other – the French ‘Coccinelle’ cohort [331, 355] – focusing on cardiac 
catheterizations. Both the current and French studies have relatively small sample 
sizes (13,500 and 10,000 respectively), thus limiting statistical power. More 
European-based studies may follow, allowing the pooling of data.  
Studies of people undergoing cardiac catheterizations have a number of advantages 
for radiation epidemiology. Firstly, individualised dose estimation is possible using 
data recorded at the time of the examination (i.e. PKA). More complete versions of the 
structured dose reports used in this study, which include details on all exposure 
events including non-acquisition fluoroscopy are now available [356]. Utilisation of 
these data could improve central dose estimates by improving information on beam 
angles and energy used in clinical practice and provide improved information on 
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uncertainties. Such information may be difficult to acquire for large volumes of 
patients, and are not available for older examinations (i.e. pre-2011). Automatic 
recording of structured dose reports in a form suitable for retrospective dose 
reconstructions would be desirable and has been implemented for CT [357]. No 
epidemiological studies of cancer risks following CT scans published so far [9, 124, 
186, 187, 190] have utilised this methodology, instead using average dose values 
adjusted for patient size and date of examination. A second advantage is the wide 
range of doses delivered, per procedure. This allows the relationship between 
radiation dose and cancer risk to be determined (i.e. a ‘dose response’). This is 
preferable to simply using the number of procedures as a surrogate for radiation 
dose. A third advantage is the relatively homogenous patient group compared to 
those undergoing CT scans. This potentially means confounding factors are easier to 
identify and control for. Unlike CT, cardiac catheterizations are not used in the 
diagnosis and screening of cancer.  
A number of disadvantages of epidemiological studies of these patients must also be 
acknowledged. Firstly, estimating the radiation doses from cardiac catheterizations is 
difficult, with large uncertainties. These uncertainties, as indicated by the variation in 
dose estimates between different studies, appear to be larger than for CT [248]. 
Incorporation of uncertainties into epidemiological analysis is complex, though the 
approach used by Lee et al [358], in a study investigating the risks from CT scans, 
could also be applied to cardiac catheterizations. Shared and unshared errors among 
catheterizations with the same attributes (patient age, equipment type, year, etc.) 
could be accounted for using a 2 dimensional Monte Carlo (2DMC) approach. 
Probability density functions (PDFs) could be calculated for scan parameters, based 
on a sample of examinations with structured dose reports [358]. These could be used 
to produce multiple realizations of cumulative doses for each cohort member. The 
concept of multiple dose realizations has been used previously in ‘ecological’ 
analyses, such as the study of thyroid cancer incidence among residents of the 
Semipalatinsk region of Kazakhstan [359] where dose estimates are highly 
uncertain. 
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Such uncertainty analysis is hindered by the variable availability of dose indicators 
over the study period. Much more complete information is available for beam energy 
and projection angles for recently conducted examinations, where structured dose 
reports are available. Thus, the increased uncertainty in dose estimates for older 
examinations should be taken into account. This is partly reflected in the current 
study in the wider uncertainty limits for beam energy for older equipment. 
Secondly, while there may be a narrower range of confounding factors, the impact of 
these conditions appears to be especially severe. Even a small number of transplant 
patients in a cohort may result in greatly increased risk of cancer. It is essential 
therefore that such patients are identified. Although a range of methodologies were 
utilised in this study (clinical details, examination type, cause of death), it is possible 
that some transplant cases were missed. Linkage with a transplant registry may be 
the best solution, although no previous radiation epidemiology studies have achieved 
this. An alternative source of information is the National Institute for Cardiovascular 
Outcomes Research (NICOR) [360], who hold data on cardiac catheterizations 
carried out at all 13 paediatric cardiology centres in the UK, or the British and Irish 
Network of Congenital Anomaly Researchers (BINOCAR) [347], who hold registers 
of congenital diseases throughout most of the UK and Ireland. This would allow 
identification of conditions such as Down syndrome or neurofibromatosis.  
Analysis of cancer by individual site may also provide evidence of potential 
confounding effects. In particular, the large incidence of cervical cancer, a disease 
not normally associated with radiation exposure [45], and other diseases remote from 
the site of irradiation, raises suspicions of confounding effects. It may also be 
possible to take advantage of knowledge of the location of tumours within large 
organs. For example, the distal oesophagus and lower lobes of the lungs receive 
higher doses than the proximal oesophagus or upper lung lobes. Likewise, the right 
breast receives a higher dose than the left. A higher proportion of tumours in the 
regions of these organs receiving the higher dose may strengthen the association 
with radiation exposure. No known condition predisposes individual specifically to 
right sided breast cancer or lower lobe lung cancer. 
A third difficulty is the smaller number of cardiac catheterizations carried out 
compared to CT, which limits sample size. A collaboration with NICOR represents 
the best opportunity for expanding the study. Even acquiring data from all hospitals 
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carrying out these procedures in the UK over the last 10-15 years, the sample size is 
unlikely to exceed around 30,000 patients. Doses have decreased to low levels in 
recent years, at least in the UK, lowering risks and reducing statistical power for a 
given sample size. Thus multinational collaboration may be essential to achieve 
further progress. 
Patients receiving the highest doses tended to be examined earlier in the study 
period, using older equipment, thus accruing a greater number of years of follow-up, 
compared to recently examined patients receiving smaller doses. Despite this, even 
accounting for transplantation, the SIR was higher for patients examined in more 
recent years, with little suggestion of lower statistical power (i.e. in terms of the width 
of confidence intervals). This unusual finding reinforces the impression that higher 
cancer rates in this patient group are due to factors other than radiation exposure. 
Ongoing research investigating the long term cancer risks from ionising radiation, 
including the above mentioned medical studies, updates of the Life Span Study, and 
analysis of occupational and background exposures, will enable risk models such as 
those described in the BEIR VII report to be refined. This risk projection approach, 
free from the limitations of small sample sizes, remains the most viable method of 
calculating excess cancer risks from cardiac catheterizations.  
 
 
 
 
 
 
 
 
 
 
307 
 
Appendix 1: 
Nature of x-rays: 
X-rays, like visible light, are a form of electromagnetic radiation (ER) and can be 
described to a layperson as a different colour of light, not visible to the human eye. X-
rays generally behave in similar ways to other forms of ER, such as infrared or 
microwaves, though the energy is sufficiently high to cause ionisation of atoms and 
molecules, including DNA molecules and water. It is this property that means that x-
rays are potentially harmful to human health [3]. X-rays are a form of indirectly 
ionising radiation. They transfer energy to a so-called secondary electron, which, 
depending on the amount of energy it receives, may have sufficient energy to cause 
hundreds or thousands of further, direct, ionisations via Coulombic interactions with 
other electrons.  
The nature of electromagnetic radiation was predicted by Maxwell, building on the 
work of Faraday, Ampere and others. Maxwell developed equations demonstrating 
that a time varying magnetic field (?⃗? ) produces a circulating electric field (?⃗? ) [361]: 
∇⃗  X E⃗ =  −
𝜕?⃗? 
𝜕𝑡
 
And that a circulating magnetic field is produced by an electric current or a time 
varying electric field [361]: 
∇⃗  X 𝐵⃗⃗  ⃗ = 𝜇0 (𝐽 + 𝜀0
𝜕?⃗? 
𝜕𝑡
) 
Where the vector 𝐽   is the current density, μ0 is the magnetic permeability of free 
space and ε0 is the electric permittivity of free space. Thus the electric and magnetic 
fields sustain each other, allowing a disturbance to propagate as a wave, without the 
need for any medium, or ‘aether’. The electric and magnetic components of ER are 
each described by a wave equation, which can be derived from the above using the 
Divergence theorem and Stoke's theorem [361]. In three dimensions, the 
electromagnetic wave equations for electric and magnetic components respectively, 
are: 
∇2E⃗ = μ0ε0
∂2E⃗ 
∂t2
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∇2B⃗ = μ0ε0
∂2B⃗ 
∂t2
 
[362] 
Along with other forms of ER, x-rays have properties of both waves and particles. 
The energy of a particle of ER, known as a photon, is given by hf, where h is Plank’s 
constant and f is the frequency (s-1). Photons belong to the class of particles known 
as Bosons, thus do not obey the Pauli Exclusion Principle (i.e. they ‘pile on’). They 
have a rest mass of zero and propagate at the speed of light (3x108 ms-1). 
 
Exposure factors: 
Radiation doses from cardiac catheterizations are modified by a range of factors, 
many of which also impact image quality. The term ‘exposure factors’ is generally 
used to describe the peak tube potential, measured in kilovolts (kV), and tube 
current, measured in milliamps (mA). The latter parameter determines x-ray intensity 
in a similar way to a dimmer switch for a lightbulb. The peak tube potential defines 
the maximum kinetic energy (E, in Joules, J) of electrons as they arrive at the anode:  
𝐸 = 𝑒 ∙ 𝑉 
Where e is the charge of a single electron (1.602 x 10-19 C). X-rays are produced by 
two mechanisms; (1) Bremsstrahlung, and (2) characteristic interactions. In the 
former, an electron is deflected off course and decelerated (Bremsstrahlung is 
German for ‘Breaking radiation’) by the Coulombic field of target material nuclei, as 
predicted by Maxwell’s general theory of electromagnetic radiation [43]. The strength 
of this field is proportional to Z/r2, (where Z is the atomic number and r is the 
proximity of the electron to the nucleus). A portion of the electron’s kinetic energy is 
lost and radiated away as electromagnetic radiation. The proportion of kinetic energy 
radiated as EM is dependent on the proximity of the electron to the nucleus, up to a 
maximum of nearly 100% for a direct hit. As accelerating potential is increased, a 
greater proportion of input energy is converted to x-rays as opposed to heat, such 
that: 
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 9 x 10−10 ∙ 𝑉 ∙ 𝑍 
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[16]. Where V is the accelerating potential and Z is the target material atomic 
number. For a tungsten anode (Z=74), the efficiency ranges from 3.33 x 10-3 at 50 
kV, to 5.33 x 10-3 at 80 kV. Alongside increased production efficiency, high-energy x-
rays are more likely to pass through the tube filtration (both added and inherent). 
Thus increasing tube potential increases both the energy of x-rays produced and 
also the intensity.  
With regard to the second process of x-ray production - characteristic emissions - the 
K-edge for tungsten is 73.9 keV [16]. For tube potentials below 74 kV, x-ray output is 
essentially entirely due to Bremsstrahlung. Due to the impact of inherent (i.e. the 
tube housing materials) and added filtration of at least 2.5 mm Al equivalent, photons 
below around 15 keV are entirely removed from the beam [16] and thus play no role 
in patient interactions. This is desirable, and indeed mandatory, as such low energy 
photons would add to patient skin dose while contributing nothing to image formation 
[16]. With further filtration, often with copper (Cu), higher energy photons are 
removed from the beam, restricting the spectrum to 30 keV or above.  
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Projection terminology 
The beam angles used in x-ray imaging are known as projections, and are described 
by a particular vocabulary, which will be described here: 
 
For example, the heart is deep to the skin, while the wrist is distal to the elbow, the 
knee is proximal to the ankle. The words Cranial and caudal (literally towards the tail) 
refer to the direction of the beam from source to detector.  
The diagram below shows rotational beam angle notation as used in PCXMC, 
Cardiodose and in Figures showing variation in dose with beam angle in Chapter 4. 
The arrows denote the direction the x-rays travel in. Thus a 90° rotational angle 
denotes x-rays entering the posterior and exiting the anterior of the patient, i.e. a 
posterior-anterior (PA) projection. 
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AP=anterior-posterior, LPO=left posterior oblique, RPO=right posterior oblique, 
RAO=right anterior oblique, LAO=left anterior oblique. The diagram below shows 
angulation in the cranio-caudal direction. In PCXMC, negative cranio-caudal 
angulation refers to what is widely regarded as ‘cranial’ angulation, though in 
PCXMC, this is referred to as ‘caudal x-ray tube’. Likewise, what is widely referred to 
as ‘caudal angulation’ is called ‘cranial x-ray tube’ in PCXMC. This discrepancy has 
been accounted for in dose calculations. 
 
 
Rotational and cranio-caudal beam angulations can be combined. For example, the 
‘LAO 40, CAU 25’ projection, used in coronary angiography implies a rotational angle 
of 130° (i.e. 90° plus 40°), combined with 25° degrees of angulation in the caudal 
direction (i.e. +25° in PCXMC and Cardiodose).  
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